<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008245790
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Aceda 500mg F.C.Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Capecitabine
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        658.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="INTAS PHARMACEUTICALS LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            INTAS PHARMACEUTICALS LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Accord Healthcare Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC06 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Aceda belongs to the group of medicines called &quot;cytostatic medicines&quot;, which stop the growth<br />of cancer cells. Aceda contains Capecitabine, which itself is not a cytostatic medicine. Only<br />after being absorbed by the body is it changed into an active anticancer medicine (more in<br />tumour tissue than in normal tissue).<br />Aceda is used in the treatment of colon, rectal, gastric, or breast cancers. Furthermore, Aceda<br />is used to prevent new occurrence of colon cancer after complete removal of the tumour by<br />surgery.<br />Aceda may be used either alone or in combination with other medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Aceda<br />&bull; if you are allergic to Capecitabine or any of the other ingredients of this medicine (listed in<br />section 6). You must inform your doctor if you know that you have an allergy or<br />overreaction to this medicine<br />&bull; if you previously have had severe reactions to Fluoropyrimidine therapy (a group of<br />anticancer medicines such as Fluorouracil)<br />&bull; if you are pregnant or breastfeeding<br />&bull; if you have severely low levels of white cells or platelets in the blood (leucopenia,<br />neutropenia or thrombocytopenia)<br />&bull; if you have severe liver or kidney problems<br />&bull; if you know that you do not have any activity of the enzyme Dihydropyrimidine<br />Dehydrogenase (DPD)<br />&bull; if you are being treated now or have been treated in the last 4 weeks with Brivudine as part<br />of herpes zoster (chickenpox or shingles) therapy<br />Warnings and Precautions<br />Talk to your doctor before taking Aceda, if you<br />&bull; know that you have a partial deficiency in the activity of the enzyme Dihydropyrimidine<br />Dehydrogenase (DPD)<br />&bull; have liver or kidney diseases<br />&bull; have or had heart problems (for example an irregular heart beat) or pains to the chest, jaw<br />and back, brought on by physical effort and due to problems with the blood flow to the<br />heart<br />&bull; have brain diseases (for example cancer that has spread to the brain) or nerve damage<br />(neuropathy)<br />&bull; have calcium imbalances (seen in blood tests)<br />&bull; have diabetes<br />&bull; have diarrhoea<br />&bull; are or become dehydrated<br />&bull; have imbalances of ions in your blood (electrolyte imbalances, seen in test)<br />&bull; have a history of eye problems as you may need extra monitoring of your eyes or<br />&bull; have severe skin reaction<br />&bull; cannot keep your food or water in your body because of severe nausea and vomiting<br />DPD deficiency: DPD deficiency is a rare condition present at birth that is not usually<br />associated with health problems unless you receive certain medicines. If you have an<br />unrecognized DPD deficiency and take Aceda, you are at an increased risk of acute<br />early-onset of severe forms of the side effects listed under section 4 Possible side effects.<br />Children and Adolescents<br />Aceda is not indicated in children and adolescents. Do not give Aceda to children and<br />adolescents.<br />Other medicines and Aceda<br />Before starting treatment, tell your doctor or pharmacist if you are taking, have recently taken<br />or might take any other medicines, including medicines obtained without a prescription. This<br />is extremely important, as taking more than one medicine at the same time can strengthen or<br />weaken the effect of the medicines.<br />You must not take Brivudine (an antiviral medicines for treatment of shingles or<br />chickenpox) at the same time as Capecitabine treatment (including during any rest<br />periods when you are not taking any Capecitabine tablets).<br />If you have taken Brivudine you must wait for at least 4 weeks after stopping<br />Brivudine before starting to take Capecitabine. See also section &ldquo;Do not take<br />Aceda&rdquo;.<br />Also you need to be particularly careful if you are taking any of the following:<br />&bull; gout medicines (Allopurinol)<br />&bull; blood thinning medicines (Coumarin, Warfarin)<br />&bull; medicines for seizures or tremors (Phenytoin)<br />&bull; Interferon alpha<br />&bull; radiotherapy and certain medicines used to treat cancer (Folinic Acid, Oxaliplatin,<br />Bevacizumab, Cisplatin, Irinotecan)<br />&bull; Medicines used to treat Folic Acid deficiency.<br />Aceda with food and drink<br />You should take Aceda no later than 30 minutes after meals.<br />Pregnancy, Breastfeeding and Fertility<br />If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a<br />baby, ask your doctor or pharmacist for advice before taking this medicine. You must not take<br />Aceda if you are pregnant or think you might be.<br />You must not breastfeed if you are taking Acedaand for 2 weeks after the last dose.<br />If you are a woman who could become pregnant you should use effective contraception<br />during treatment with Aceda and for 6 months after the last dose.<br />If you are a male patient and your female partner could become pregnant, you should use<br />effective contraception during treatment with Aceda and for 3 months after the last dose.<br />Driving and using machines<br />Aceda may make you feel dizzy, nauseous or tired. It is therefore possible that Aceda could<br />affect your ability to drive a car or operate machines. Do not drive if you feel dizzy, nauseous<br />or tired after taking this medicine.<br />Aceda contains lactose<br />This medicine contains lactose. If you have been told by your doctor that you have an<br />intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. You should<br />check with your doctor or pharmacist if you are not sure.<br />Aceda should only be prescribed by a doctor experienced in the use of anticancer medicines.<br />Your doctor will prescribe a dose and treatment regimen that is right for you. The dose of<br />Aceda is based on your body surface area. This is calculated from your height and weight.<br />The usual dose for adults is 1250mg/m2 of body surface area taken two times daily (morning<br />and evening). Two examples are provided here: A person whose body weight is 64kg and<br />height is 1.64m has a body surface area of 1.7m2 and should take 4 tablets of 500mg and 1<br />tablet of 150mg two times daily. A person whose body weight is 80kg and height is 1.80m<br />has a body surface area of 2.00m2 and should take 5 tablets of 500mg two times daily.<br />Your doctor will tell you what dose you need to take, when to take it and for how long<br />you need to take it.<br />Your doctor may want you to take a combination of 150mg, 300mg and 500mg tablets for<br />each dose.<br />&bull; Take the tablets in the morning and evening as prescribed by your doctor.<br />&bull; Take the tablets within 30 minutes after the end of a meal (breakfast and dinner) and<br />swallow them whole with water.<br />&bull; It is important that you take all your medicine as prescribed by your doctor.<br />Aceda tablets are usually taken for 14 days followed by a 7 day rest period (when no tablets<br />are taken). This 21 day period is one treatment cycle.<br />In combination with other medicines the usual dose for adults may be less than 1250mg/m2 of<br />body surface area, and you may need to take the tablets over a different time period (e.g.<br />every day, with no rest period).<br />If you take more Aceda than you should<br />If you take more Aceda than you should, contact your doctor as soon as possible before taking<br />the next dose.<br />You might get the following side effects if you take a lot more Capecitabine than you should,<br />feeling or being sick, diarrhoea, inflammation or ulceration of the gut or mouth, pain or<br />bleeding from the intestine or stomach, or bone marrow depression (reduction in certain kinds<br />of blood cells). Tell your doctor immediately if you experience any of these symptoms.<br />If you forget to take Aceda<br />Do not take the missed dose at all and do not double the next one. Instead, continue your<br />regular dosing schedule and check with your doctor.<br />If you stop taking Aceda<br />There are no side effects caused by stopping treatment with Capecitabine. In case you are<br />using Coumarin anticoagulants (containing e.g. Phenprocoumon), stopping Capecitabine<br />might require that your doctor adjusts your anticoagulant dose.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Aceda can cause side effects, although not everybody gets them.<br />STOP taking Aceda immediately and contact your doctor if any of these symptoms occur:<br />&bull; Diarrhoea: if you have an increase of 4 or more bowel movements compared to your<br />normal bowel movements each day or any diarrhoea at night.<br />&bull; Vomiting: if you vomit more than once in a 24-hour time period.<br />&bull; Nausea: if you lose your appetite, and the amount of food you eat each day is much less<br />than usual.<br />&bull; Stomatitis: if you have pain, redness, swelling or sores in your mouth.<br />&bull; Hand-and-foot skin-reaction: if you have pain, swelling, redness or tingling of hands<br />and/or feet.<br />&bull; Fever: if you have a temperature of 38&deg;C or greater.<br />&bull; Infection: if you experience signs of infection caused by bacteria or virus, or other<br />organisms.<br />&bull; Chest pain: if you experience pain localized to the centre of the chest, especially if it<br />occurs during exercise.<br />&bull; Steven-Johnson syndrome: if you experience painful red or purplish rash that spreads and<br />blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips),<br />in particular if you had before light sensitivity, infections of the respiratory system (e.g.<br />bronchitis) and/or fever.<br />&bull; DPD Deficiency: if you have a known DPD deficiency, you are at an increased risk of<br />acute early-onset of toxicity and severe, life threatening, or fatal adverse reactions caused<br />by Aceda (e.g. stomatitis, mucosal inflammation, diarrhoea, neutropenia, and<br />neurotoxicity)<br />If caught early, these side effects usually improve within 2 to 3 days after treatment<br />discontinuation. If these side effects continue, contact your doctor immediately. Your doctor<br />may instruct you to restart treatment at a lower dose.<br />Hand and foot skin-reaction can lead to loss of fingerprint, which could impact your<br />identification by fingerprint scan.<br />In addition to the above, when Capecitabine is used alone, the very common side effects<br />which may affect more than 1 person in 10 are:<br />&bull; abdominal pain<br />&bull; rash, dry or itchy skin<br />&bull; tiredness<br />&bull; loss of appetite (anorexia)<br />These side effects can become severe; therefore, it is important that you always contact your<br />doctor immediately when you start to experience a side effect. Your doctor may instruct you<br />to decrease the dose and/or temporarily discontinue treatment with Aceda. This will help<br />reduce the likelihood that the side effect continues or becomes severe.<br />Other side effects are:<br />Common side effects (may affect up to 1 in 10 people) include:<br />&bull; decreases in the number of white blood cells or red blood cells (seen in tests)<br />&bull; dehydration, weight loss<br />&bull; sleeplessness (insomnia), depression<br />&bull; headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling<br />sensation), taste changes<br />&bull; eye irritation, increased tears, eye redness (conjunctivitis)<br />&bull; inflammation of the veins (thrombophlebitis)<br />&bull; shortness of breath, nose bleeds, cough, runny nose<br />&bull; cold sores or other herpes infections<br />&bull; infections of the lungs or respiratory tract system (e.g. pneumonia or bronchitis)<br />&bull; bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind, dry<br />mouth<br />&bull; skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin<br />discolouration, skin loss, skin inflammation, nail disorder<br />&bull; pain in the joints or in the limbs (extremities), chest or back<br />&bull; fever, swelling in the limbs, feeling ill<br />&bull; problems with liver function (seen in blood tests) and increased blood bilirubin (excreted<br />by the liver)<br />Uncommon side effects (may affect up to 1 in 100 people) include:<br />&bull; blood infection, urinary tract infection, infection of the skin, infections in the nose and<br />throat, fungal infections (including those of the mouth), influenza, gastroenteritis, tooth<br />abscess<br />&bull; lumps under the skin (lipoma)<br />&bull; decreases in blood cells including platelets, thinning of blood (seen in tests)<br />&bull; allergy<br />&bull; diabetes, decrease in blood potassium, malnutrition, increased blood triglycerides<br />&bull; confusional state, panic attacks, depressed mood, decreased libido<br />&bull; difficulty speaking, impaired memory, loss of movement coordination, balance disorder,<br />fainting, nerve damage (neuropathy) and problems with sensation<br />&bull; blurred or double vision<br />&bull; vertigo, ear pain<br />&bull; irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction)<br />&bull; blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs<br />(extremities), purple spots on the skin<br />&bull; blood clots in the veins in the lung (pulmonary embolism), collapsed lung, coughing up<br />blood, asthma, shortness of breath on exertion<br />&bull; bowel obstruction, collection of fluid in the abdomen, inflammation of the small or large<br />intestine, the stomach or the oesophagus, pain in the lower abdomen, abdominal<br />discomfort, heartburn (reflux of food from the stomach), blood in the stool<br />&bull; jaundice (yellowing of skin and eyes)<br />&bull; skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling or<br />pain of the face<br />&bull; joint swelling or stiffness, bone pain, muscle weakness or stiffness<br />&bull; fluid collection in the kidneys, increased frequency of urination during the night,<br />incontinence, blood in the urine, increase in blood creatinine (sign of kidney dysfunction)<br />&bull; unusual bleeding from the vagina<br />&bull; swelling (oedema), chills and rigors<br />Some of these side effects are more common when Capecitabine is used with other medicines<br />for the treatment of cancer. Other side effects seen in this setting are the following:<br />Common side effects (may affect up to 1 in 10 people) include:<br />&bull; decrease in blood sodium, magnesium or calcium, increase in blood sugar<br />&bull; nerve pain<br />&bull; ringing or buzzing in the ears (tinnitus), loss of hearing<br />&bull; vein inflammation<br />&bull; hiccups, change in voice<br />&bull; pain or altered/abnormal sensation in the mouth, pain in the jaw<br />&bull; sweating, night sweats<br />&bull; muscle spasm<br />&bull; difficulty in urination, blood or protein in the urine<br />&bull; bruising or reaction at the injection site (caused by medicines given by injection at the same<br />time)<br />Rare side effects (may affect up to 1 in 1,000 people) include:<br />&bull; narrowing or blockage of tear duct (lacrimal duct stenosis)<br />&bull; liver failure<br />&bull; inflammation leading to dysfunction or obstruction in bile secretion (cholestatic hepatitis)<br />&bull; specific changes in the electrocardiogram (QT prolongation)<br />&bull; certain types of arrhythmias (including ventricular fibrillation, torsade de pointes, and<br />bradycardia)<br />&bull; eye inflammation causing eye pain and possibly eyesight problems<br />&bull; inflammation of the skin causing red scaly patches due to an immune system illness<br />Very rare side effects (may affect up to 1 in 10,000 people) include:<br />&bull; severe skin reaction such as skin rash, ulceration and blistering which<br />may involve ulcers of the mouth, nose, genitalia, hands, feet and eyes<br />(red and swollen eyes).<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist or nurse. This<br />includes any possible side effects not listed in this. You can also report the<br />side effects directly to the National Pharmacovigilance Centre (NPC) (See<br />Section 6). By reporting side effects, you can help provide more<br />information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />Do not store above 30&deg;C. Store in the original pack.<br />Do not use this medicine after the expiry date which is stated on the pack. The expiry date<br />refers to the last day of that month.<br />Do not use Aceda if you notice any visible signs of deterioration.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required. These measures will help to protect the<br />environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Capecitabine.<br />Each film-coated tablet contains 150mg or 300mg or 500mg of Capecitabine.<br />The other ingredients are:<br />Tablet core: Anhydrous lactose, croscarmellose sodium, hypromellose, microcrystalline<br />cellulose, magnesium stearate<br />Tablet coating (for 150mg): Hypromellose, titanium dioxide (E171), yellow iron oxide, red<br />iron oxide (E172), talc<br />Tablet coating (for 300mg): Hypromellose, titanium dioxide (E171), talc<br />Tablet coating (for 500mg): Hypromellose, titanium dioxide (E171), yellow iron oxide, red<br />iron oxide (E172), talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Aceda 150mg film-coated tablets are light peach coloured, oblong shaped, biconvex, 11.4mm
in length and 5.3mm in width, debossed with ‘150’ on one side and plain on other side.
Aceda 300mg film-coated tablets are white to off white, oblong shaped, biconvex, 14.6mm in
length and 6.7mm in width, debossed with ‘300’ on one side and plain on other side.
Aceda 500mg film-coated tablets are peach coloured, oblong shaped, biconvex, 15.9mm in
length and 8.4mm in width, debossed with ‘500’ on one side and plain on other side.
Aceda is packed in blisters and is available in different pack sizes
(30, 60 or 120 tablets per pack).
Not all strengths may be marketed.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder (MAH):<br />Accord Healthcare Limited<br />Sage House, 319 Pinner Road, North Harrow,<br />Middlesex HA1 4HF, United Kingdom<br />Manufactured for Accord Healthcare Limited by<br />Intas Pharmaceuticals Limited, Ahmedabad, Gujarat state, India<br />For any information about this medicinal product, please contact the local representative of<br />the MAH:<br />Accord Healthcare KSA Scientific Office<br />At Zimmo Trading Company Ltd.<br />Riyadh, Olaya, Al-Arfaj Street,<br />branched from Abdulmalik Bin Marwan Street,<br />Behind Ministry of Interior, Atlas building, office No. 1<br />Tel: +966-11-217-0140<br />E-mail: mena-pv@accord-healthcare.com<br />This leaflet was last approved in 09/2019, version number SA-04.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2340.<br />SFDA Call Centre: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa/</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2019, version number SA-04.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي أسيدا إلى مجموعة الأدوية التي يطلق عليها &quot;أدوية تثبيط الخلايا&quot;، والتي توقف نمو<br />الخلايا السرطانية. يحتوي أسيدا على كابيسيتابين، التي لا تعد بحد ذاتها من الأدوية المثبطة<br />للخلايا. ولكن بعد أن يمتصها الجسم تتحول إلى دواء نشط في مكافحة السرطان (لأنسجة<br />الورم أكثر من الأنسجة العادية).<br />يستخدم أسيدا في علاج سرطان القولون أو المستقيم أو المعدة أو الثدي.<br />كما أن أسيدا يستخدم أيضًا لمنع حدوث سرطان القولون مجددًا بعد الاستئصال الكامل للورم<br />بالجراحة.<br />كما يمكن استخدام أسيدا وحدة أو مع مجموعة أخرى من الأدوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أسيدا<br />&bull;إذا كنت تعاني من حساسية من كابيسيتابين أو أي مكون آخر من مكونات هذا الدواء (التي<br />تم ذكرها في القسم ٦). يجب إبلاغ الطبيب إذا كنت تعرف أنك تعاني من حساسية أو رد<br />فعل متزايد من هذا الدواء<br />&bull; إذا كنت تعاني من قبل من بعض ردود الأفعال الحادة للعلاج بالفلوروبيرميدين (وهي<br />مجموعة من الأدوية المكافحة للسرطان مثل فلورويوراسيل)<br />&bull; في حال الحمل أو الرضاعة<br />&bull;إذا كنت تعاني من انخفاض حاد من انخفاض في كرات الدم البيضاء أو الصفائح في الدم<br />(نقص الكريات الدم البيضاء، قلة العدلات أو قلة الصفائح الدموية)<br />&bull; إذا كنت تعاني من مشاكل خطيرة بالكبد أو الكُلى<br />دايهدروبيراميدين دايهدروجيناز DPD &bull; إذا كنت تعاني من نقص غيرمعروف في إنزيم<br />المطلوب في أيض اليوراسيل والثايمين، أو<br />&bull; إذا كان يتم علاجك الآن أو من قبل في آخر ٤ أسابيع باستخدام بروفيدين أو سوروفيدين أو<br />أي فئات مشابهة من المواد كجزء من علاج الهربس النطاقي (الجديري المائي أو القوباء)</p><p>التحذيرات والاحتياطات<br />تحدث إلى الطبيب قبل تناول أسيدا إذا كنت<br />&bull; تعاني من أمراض الكلى أو الكبد<br />&bull; تعاني أو كنت تعاني من مشكلات بالقلب (على سبيل المثال، عدم انتظام نبضات القلب) أو<br />آلام الصدر والفك والظهر، والتي تظهر بسبب المجهود البدني وبسبب المشكلات التي<br />تتعلق بتدفق الدم إلى القلب<br />&bull; تعاني من أمراض بالمخ (مثل السرطان الذي ينتشر إلى المخ) أو تلف الأعصاب<br />(الاعتلال العصبي)<br />&bull; تعاني من عدم توازن في مستويات الكالسيوم (الظاهرة في اختبارات الدم)<br />&bull; تعاني من داء السكري<br />&bull; تعاني من الإسهال<br />&bull; كنت تعاني أو أصبحت تعاني من الجفاف<br />&bull; تعاني من وجود عدم توازن في أيونات الدم (عدم توازن الإلكتروليت، تظهر في<br />الاختبارات)<br />&bull; كان لديك تاريخ لوجود مشكلات بالعين حيث إنك ستحتاج إلى المزيد من المراقبة لعينيك<br />أو<br />&bull; تعاني من تحسس جلدي شديد<br />&bull; لا تستطيع إبقاء الطعام أو الماء في جسمك بسبب شدة الغثيان والتقيؤ.<br />من الحالات النادرة التي DPD يعد نقص :(DPD) نقص دايهدروبيراميدين دايهدروجيناز<br />توجد مع الولادة والتي عادةً لا تكون مصحوبة بأي مشكلات صحية إلا في حال تناول بعض<br />وتتناول أسيدا، فقد تعاني من DPD الأدوية المحددة. إذا كان لديك نقص غير معروف في<br />بعض الأشكال الحادة من الأعراض الجانبية المذكورة في القسم ٤ &quot;الأعراض الجانبية<br />المحتملة&quot;. اتصل بالطبيب على الفور إذا كنت تشعر بأي من الأعراض الجانبية أو إذا<br />لاحظت وجود أي أعراض جانبية&nbsp;إضافية غير مذكورة في هذه النشرة (راجع القسم ٤<br />&quot;الأعراض الجانبية المحتملة&quot;).</p><p>لأطفال والمراهقون<br />دواء أسيدا غير موصوف للأطفال والمراهقين. لا تعطي أسيدا الأطفال والمراهقين.<br />أسيدا والأدوية الأخرى<br />قبل بدء العلاج، أخبر طبيبك أو الصيدلي إذا تناولت أو تتناول أدوية أخرى، بما في ذلك<br />الأدوية التي يتم الحصول عليها دون وصفة طبية. هذا الأمر مهم للغاية، حيث إن تناول أكثر<br />من دواء واحد في نفس الوقت يمكن أن يؤدي إلى تقوية أو إضعاف تأثير الأدوية. يجب<br />الحرص التام إذا كنت تتناول أيًّا مما يلي:<br />&bull; أدوية النقرس الوبيورينول<br />&bull; الأدوية المرققة للدم كوكمارين، ورافارين<br />&bull; بعض الأدوية المضادة للفيروسات بروفيدين، سوروفيدين<br />&bull; الأدوية الخاصة بالصرع أو الارتجاف فينيتوين<br />&bull;إنترفيرون ألفا<br />&bull; العلاج الإشعاعي وبعض الأدوية المستخدمة لعلاج السرطان (حمض الفولنيك،<br />أوكزاليبلاتين، بيفاسيزاماب).<br />&bull; الأدوية المستخدمة لعلاج نقص حمض الفوليك<br />أسيدا مع الطعام والشراب<br />لا يجب تناول أسيدا بعد مرور أكثر من ۳۰ دقيقة بعد الوجبات.<br />الحمل، الرضاعة الطبيعية، الخصوبة<br />قبل بدء العلاج، يجب إخبار الطبيب إذا كانت المريضة حاملًا، أو إذا كانت تعتقد أنها حامل<br />أو إذا كانت تنوي أن تكون حاملًا.<br />يجب عدم تناول أسيدا في حال الحمل أو التفكير في الحمل.<br />يجب تجنب الرضاعة الطبيعية في حال تناول أسيدا.<br />يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء.<br />القيادة واستخدام الآلات<br />قد يجعلك أسيدا تشعر بالدوار أو الدوخة أو الإرهاق لذا فمن الممكن أن يؤثر أسيدا في<br />قدرتك على قيادة السيارة أو تشغيل الآلات. لا تقم بالقيادة إذا كنت تشعر بالدوار أو الغثيان أو<br />الإرهاق بعد تناول هذا الدواء.<br />أسيدا يحتوي على اللاكتوز<br />هذا الدواء يحتوي على اللاكتوز. استشر طبيبك قبل تناول هذا الدواء إذا كان قد أخبرك<br />مسبقا من مشكلة تتمثل في عدم تحمل بعض أنواع السكريات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب الالتزام التام بالطريقة التي وصفها لك الطبيب أو الصيدلي لتناول هذا الدواء. يجب<br />مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا.<br />يجب وصف أسيدا فقط بواسطة طبيب خبير في استخدام الأدوية المضادة للسرطان.<br />يجب ابتلاع أقراص أسيدا دون تقسيمها مع شرب الماء وخلال ۳۰ دقيقة من تناول<br />الوجبة.<br />سيقوم طبيبك بوصف نظام الجرعات والعلاج الصحيح بالنسبة لك. وتعتمد جرعة أسيدا على<br />منطقة سطح جسمك. ويتم حسابها من الارتفاع والوزن. الجرعة المعتادة للبالغين هي<br />1250 ملغم/م ۲ من منطقة مسطح الجسم ويتم التناول مرتين يوميًّا (صباحًا ومساءً). ويتم<br />توفير مثالين هنا: شخص وزن جسمه هو ٦٤ كغم و طوله هو ۱٫٦٤ م يكون لديه منطقة<br />مسطح جسم ۱٫۷۰ م ۲ ويجب أن يتناول ٤ أقراص من تركيز ٥۰۰ ملغم وقرص واحد من<br />تركيز ۱٥۰ ملغم مرتين يوميًّا. شخص وزن جسمه هو ۸۰ كغم وطوله هو ۱٫۸۰ م<br />يكون لديه منطقة مسطح جسم ۲٫۰۰ م ۲ ويجب أن يتناول ٥ أقراص من تركيز ٥۰۰<br />ملغم مرتين يوميًّا.<br />عادة يتم تناول أقراص أسيدا لمدة 14 يومًا، ثم تتبع بفترة راحة تصل إلى ۷ أيام (لا يتم<br />خلالها تناول أي أقراص). وتعد فترة ال 21 يومًا هذه دورة علاجية.</p><p>عند الجمع مع الأدوية الأخرى قد تكون الجرعة المعتادة للبالغين أقل من 1250 ملغم/م ۲<br />من منطقة مسطح الجسم، وقد تحتاج إلى تناول الأقراص خلال فترات زمنية مختلفة<br />(على سبيل المثال، يوميًّا بلا فترات راحة).<br />سيخبرك طبيبك بالجرعة التي تحتاج إليها ومتى يجب تناولها وإلى متى ستظل تتناولها.<br />قد يطلب منك الطبيب تناول خليط من أقراص ۱٥۰ ملغم و ۳۰۰ ملغم و ٥۰۰ ملغم مع كل<br />جرعة.<br />&bull; تناول الأقراص في الصباح والمساء كما حدد لك الطبيب.<br />&bull; تناول الأقراص خلال ۳۰ دقيقة من نهاية تناول الوجبة (الإفطار والعشاء).<br />&bull; من المهم أن تلتزم بالطريقة التي وصفها لك الطبيب لتناول الأدويةز<br />في حال تناول كمية أكبر من اللازم من أسيدا<br />في حال تناول كمية أكبر من المفروض من أسيدا، اتصل بالطبيب في أقرب فرصة قبل<br />تناول الجرعة التالية.<br />قد تعاني من الأعراض الجانبية التالية في حال تناول كمية كبيرة من كابيسيتابين أكثر من<br />المفروض: الشعور بالغثيان أو الإسهال أو الالتهابات أو التقرحات في الأمعاء أو الفم أو<br />الألم أو النزيف من الأمعاء أو المعدة أو تخميد النخاع الشوكي ( نقص في بعض أنواع خلايا<br />الدم)<br />في حال نسيان تناول أسيدا<br />لا تتناول الجرعة المفقودة على الإطلاق ولا تتناول جرعة مضاعفة في المرة التالية. ولكن<br />استمر في جدول الجرعات المعتاد الخاص بك وراجع طبيبك.<br />في حال التوقف عن تناول أسيدا<br />لا توجد أي أعراض جانبية ناتجة عن التوقف عن العلاج باستخدام كابيسيتابين. في حال<br />استخدامك للكومارين المضاد للتجلط (الذي يحتوي على فينبروكومون، على سبيل المثال)،<br />فقد يحتاج التوقف عن تناول كابيسيتابين إلى أن يقوم طبيبك بضبط جرعة مضاد التجلط<br />الخاصة بك.<br />إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، فاطرحها على الطبيب أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية، قد يتسبب أسيدا في ظهور بعض الأعراض الجانبية، على<br />الرغم من أنها قد لا تظهر مع الجميع.<br />توقف عن تناول أسيدا على الفور واتصل بالطبيب في حال ظهور أي من الأعراض التالية:<br />&bull;الإسهال: إذا عانيت وجود عدد أكبر من ٤ مرات لحركة الأمعاء مقارنةً بالحركة الطبيعية<br />الخاصة بك يوميًّا أو في حال وجود أي إسهال ليلًا.<br />&bull;القيء: في حال القيء لأكثر من مرة خلال فترة مدتها ۲٤ ساعة.<br />&bull;الغثيان: في حال فقدان الشهية لتصبح كمية الطعام التي تتناولها يوميًّا أقل من المعتاد.<br />&bull;التهاب الفم: في حال شعورك بالألم أو الإحمرار أو التورم أو الالتهاب في الفم.<br />&bull;تحسس جلدي في منطقة اليدين أو القدمين: إذا كنت تشعر بالألم، التورم، الإحمرار،<br />الوخز في اليدين و/أو القدمين.<br />&bull;الحمى: إذا كانت درجة حرارتك ۳۸ درجة أو أكثر.<br />&bull;العدوى: إذا كنت تعاني من أي علامات للإصابة بالعدوى بسبب البكتريا أو الفيروسات أو<br />أي كائنات أخرى.</p><p>&bull;آلام الصدر: إذا كنت تعاني من ألم متمركز في وسط الصدر، خاصة في حال حدوثه أثناء<br />ممارسة التمارين الرياضية.</p><p>&bull;متلازمة ستيفن جونسون: إذا كنت تعاني من ألم مصاحبا لطفح جلدي أحمر أو أرجواني<br />يمكن أن ينتشر وبثور و/أو تقرحات تبدأ في الظهور في الأغشية المخاطية (مثل الفم و<br />الشفتين)، وبخاصة إذا كان لديك حساسية للضوء، والتهابات في الجهاز التنفسي (مثل التهاب<br />الشعب الهوائية) و/أو الحمى.</p><p>في حال اكتشاف هذه الأعراض مبكرًا، فإنها عادة ما تتحسن خلال يومين أو ۳ أيام بعد<br />توقف العلاج. أما في حال استمرار ظهور هذه الأعراض، فاتصل بالطبيب على الفور. قد<br />ينصحك طبيبك ببدء العلاج بجرعة أقل.</p><p>وإضافة إلى ما سبق، فعند استخدام كابيسيتابين وحده، تكون الأعراض الجانبية الأكثر<br />شيوعًا والتي تؤثر في أكثر من شخص واحد من بين كل ۱۰ أشخاص هي:<br />&bull;آلام البطن</p><p>&bull;الطفح الجلدي أو جفاف البشرة أو الإحساس بالحكة.</p><p>&bull;الإرهاق</p><p>فقدان الشهية</p><p>قد تصبح هذه الأعراض الجانبية خطيرة، لذا، فمن المهم أن يتم الاتصال بالطبيب على الفور<br />عندما تبدأ في المعاناة من أي من هذه الأعراض الجانبية. قد ينصحك طبيبك بتخفيض<br />الجرعة و/أو التوقف المؤقت عن العلاج باستخدام أسيدا. سيساعد هذا الأمر في تقليل<br />احتمالية استمرار هذا العرض الجانبي أو تفاقمه</p><p>الأعراض الجانبية الأخرى هي:<br />الأعراض الجانبية الشائعة (التي يمكن أن تؤثر في واحد من كل ۱۰ أشخاص) تتضمن:<br />&bull;نقص عدد كرات الدم البيضاء أو كرات الدم الحمراء (التي تظهر في الاختبارات)<br />&bull;الجفاف، فقدان الوزن<br />&bull;عدم النوم (الأرق)، الاكتئاب<br />&bull;الصداع والنوم والدوار والشعور&nbsp;غير الطبيعي بالجلد (التنميل أو الوخز) وتغير المذاق<br />&bull;تهيج العينين وزيادة الدموع واحمرار العين (التهاب الملتحمة)</p><p>&bull;التهاب الأوردة (التهاب الوريد الخثاري)</p><p>&bull;قصر التنفس ونزيف الأنف والكحة والزكام</p><p>&bull;تقرحات البرد أو أي عدوى هربس أخرى</p><p>&bull;عدوى الرئتين أو جهاز المسار التنفسي (الالتهاب الرئوي أو التهاب الشعب الهوائية)</p><p>&bull;نزيف الأمعاء والإمساك، ألم الجزء العلوي من البطن وعسر الهضم والانتفاخ وجفاف الفم</p><p>الطفح الجلدي وفقدان الشعر (الصلع) واحمرار البشرة وجفاف البشرة والشعور بالحكة<br />و تغيير لون البشرة وسقوط الجلد والتهاب الجلد واضطرابات الأظافر</p><p>&bull;آلام المفاصل أو الأطراف (أطراف الجسم)، أو الصدر أو الظهر</p><p>&bull;الحمى أو تورم الأطراف أو الشعور بالمرض</p><p>&bull;المشكلات المتعلقة بوظائف الكبد (تظهر في اختبارات الدم) وزيادة نسبة الصفراء بالدم&nbsp;&nbsp;التي تفرزهاالكبد)</p><p>الأعراض الجانبية غير الشائعة (التي يمكن أن تؤثر في واحد من كل ۱۰۰ شخص)</p><p>تتضمن:<br />&bull;عدوى الدم وعدوى المسار البولي وعدوى الجلد والعدوى التي تصيب الأنف والحلق و<br />العدوى الفطرية (بما في ذلك تلك التي تصيب الفم)، والأنفلونزا والتهاب المعدة والأمعاء<br />وخراج الأسنان<br />&bull;تورمات تحت الجلد&nbsp;(الورم الشحمي)</p><p>&bull;نقص عدد خلايا الدم بما في ذلك الصفائح الدموية وترقق الدم (تظهر في الاختبارات)<br />&bull;الحساسية</p><p>&bull;داء السكري ونقص في بوتاسيوم الدم وسوء التغذية وزيادة نسبة الدهون الثلاثية بالدم<br />&bull;الارتباك ونوبات الهلع والشعور بالاكتئاب ونقص الرغبة الجنسية</p><p>&bull;صعوبة التحدث وضعف الذاكرة وفقدان اتزان الحركة واضطرابات التوازن والإغماء<br />وتلف الأعصاب (الاعتلال العصبي) والمشكلات الخاصة بالإحساس<br />&bull;الرؤية المشوشة أو المزدوجة</p><p>&bull;الدوار وآلام الأذن<br />&bull;عدم انتظام نبضات القلب والخفقان وآلام الصدر والأزمات القلبية (الاحتشاء)<br />&bull;تجلطات الدم في الأوردة العميقة وارتفاع أو انخفاض ضغط الدم أو نوبات الحرارة<br />وبرودة الأطراف (أطراف الجسم) والبقع القرمزية على البشرة<br />&bull;تجلطات الدم في أوردة الرئة (الانسداد الرئوي)، وانقباض الرئة والكحة بالدم وأزمة الربو<br />وضيق التنفس عند بذل مجهود<br />&bull;إنسداد الأمعاء وتجميع السوائل في البطن ،التهاب الأمعاء الدقيقة أو الغليظة أو المعدة أو<br />المريء، آلام الجزء السفلي من البطن والحرقة (ارتجاع الطعام من المعدة) والشعور بعدم<br />الراحة في البطن ودم في البراز<br />&bull;اليرقان (اصفرار البشرة والعينين)<br />&bull;تقرحات وبثور البشرة وتفاعل البشرة مع ضوء الشمس واحمرار الكفين وتورم أو آلام<br />االوجه<br />&bull;تورم المفاصل أو خشونتها وآلام العظام وضعف أو خشونة العضلات<br />&bull;تجمع السوائل في الكليتين وزيادة معدل التبول ليلاً والسلس البولي ووجود دم في البول<br />وزيادة نسبة كرياتينين الدم (علامة على خلل وظائف الكليتين)<br />&bull;نزيف غير عادي من المهبل<br />&bull;تورم (وذمة)، القشعريرة وتيبس الأعضاء<br />بعض هذه الأعراض الجانبية تكون شائعة عند استخدام كابيسيتابين مع أدوية أخرى لعلاج<br />السرطان. تتمثل<br />الأعراض الجانبية الأخرى التي تظهر في هذه الحالة<br />الأعراض الجانبية الشائعة (التي يمكن أن تؤثر في واحد من كل ۱۰ أشخاص) تتضمن:<br />&bull;انخفاض نسبة الصوديوم أو المغناسيوم أو الكالسيوم في الدم، وزيادة نسبة السكر في الدم<br />&bull;آلام الأعصاب<br />&bull;رنينًا أو طنينًا في&nbsp;الأذنين (طنين) وفقدان السمع<br />&bull;التهاب الأوردة</p><p>الفواق، تغيير في الصوت<br />&bull;آلام أو تبديل أو شعور غير طبيعي في الفم وآلام في المفاصل<br />&bull;التعرق، أو العرض الليلي<br />&bull;التشنج العضلي<br />&bull;صعوبة التبول ووجود دم أو بروتين في البول<br />&bull;كدمات أو تحسس عند موقع الحقن (بسبب الأدوية التي يتم تناولها عن طريق الحقن في<br />نفس الوقت)<br />الأعراض الجانبية النادرة (التي يمكن أن تؤثر في واحد من كل ۱,۰۰۰ شخص) تتضمن:<br />&bull;ضيق أو انسداد المسار الدمعي (ضيق القناة الدمعية)<br />&bull;الفشل الكبدي<br />&bull;الالتهاب الذي يؤدي إلى سوء عمل أو إعاقة إفراز العصارة الصفراء (الالتهاب الكبدي<br />الركودي)<br />(QT &bull; تغييرات محددة في الصورة البيانية الكهربائية للقلب (إطالة<br />&bull;بعض أنواع عدم انتظام ضربات القلب (بما في ذلك الرجفان البطيني، ظاهرة<br />وبطء القلب) torsade de pointes<br />&bull;التهاب العين المسبب لألم العين والمشاكل المحتملة الخاصة بالرؤية<br />&bull;التهاب البشرة الذي يسبب وجود بقع متقشرة بسبب ضعف الجهاز المناعي<br />الأعراض الجانبية الشديدة الندرة (التي يمكن أن تؤثر في واحد من كل ۱۰,۰۰۰ شخص)<br />تتضمن:<br />&bull; تحسس جلدي شديد مثل الطفح الجلدي، تقرحات وبثور والتي قد تشتمل على تقرح الفم و<br />الأنف والأعضاء التناسلية واليدين والقدمين والعينين (احمرار وتورم العينين).</p><p>في حال زيادة حدة أي من هذه الأعراض الجانبية، أو إذا لاحظت أي أعراض جانبية<br />أخرى ليست مذكورة في هذه النشرة، يرجى الإتصال بالطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدًا عن متناول أيدي الأطفال.<br />يجب عدم تخزين الدواء فوق ۳۰ درجة مئوية. يجب التخزين في العبوة الأصلية.<br />لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة. يشير تاريخ انتهاء<br />الصلاحية إلى آخر يوم من الشهر المذكور.<br />لا تستخدم أسيدا إذا لاحظت وجود أي علامات ظاهرة من التلف.<br />يجب عدم التخلص من الأدوية مع مياه الصرف الصحي أو المخلفات المنزلية. اطلب من<br />الصيدلي معرفة كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات<br />ستساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما هي محتويات أسيدا<br />المادة الفعالة هي كابيسيتابين.<br />كل قرص مغلف يحتوي على ۱٥۰ ملغم أو ۳۰۰ ملغم أو ٥۰۰ ملغم من كابيسيتابين.<br />المكونات الأخرى هي:<br />أساس القرص: اللاكتوز اللامائي والصوديوم والهيبروميلوز والميكروكريستالين و<br />السيلولوز، وستيرات المغنيسيوم<br />أوكسيد ،E الطبقة المغلفة للقرص (ل ۱٥۰ ملغم): هيبروميلوز، تيتانيوم دايوكسيد 171<br />تلك ،E الحديد الأصفر،أكسيد الحديد الأحمر 172<br />تلك ،E الطبقة المغلفة للقرص (ل ۳۰۰ ملغم): هيبروميلوز، تيتانيوم دايوكسيد 171<br />أوكسيد ،E الطبقة المغلفة للقرص (ل ٥۰۰ ملغم): هيبروميلوز، تيتانيوم دايوكسيد 171<br />تلك ،E الحديد الأصفر،أكسيد الحديد الأحمر 172<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ما هو شكل أسيدا ومحتويات العبوة<br />أسيدا ۱٥۰ ملغم أقراص مغلفة ذات لون خوخي فاتح، مستطيله الشكل، محدبة من<br />٥ملم، محفور على أحد جانبيها &quot; ۱٥۰ &quot; وفارغة , الجانبين، طولها ۱۱,٤ ملم وعرضها ۳<br />على الجانب الاخر.<br />أسيدا ۳۰۰ ملغم أقراص مغلفة ذات لون أبيض مائل للاصفرار، مستطيله الشكل، محدبة<br />٦ملم، محفور على أحد جانبيها &quot; ۳۰۰ &quot; وفارغة , من الجانبين، طولها ۱٤,٦ ملم وعرضها ۷<br />على الجانب الاخر.<br />أسيدا ٥۰۰ ملغم أقراص مغلفة ذات لون خوخي، مستطيله الشكل، محدبة من الجانبين،<br />۱٥ ملم وعرضها ۸,٤ ملم، محفور على أحد جانبيها &quot; ٥۰۰ &quot; وفارغة على , طولها ۹<br />الجانب الاخر.</p><p>تتوفر أسيدا في شرائط وعبوات بأحجام مختلفة ( ۳۰ أو ٦۰ أو ۱۲۰ قرص لكل عبوة).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل التصريح بالتسويق والمُصنِع<br />حامل التصريح بالتسويق<br />شركة أكورد هيلثكير ليميتد<br />٤ اتش اف ساج هاوس, ۳۱۹ بينر رود، نورث هارو، ميدلسيكس اتش أيه ۱<br />المملكة المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
              رقم الإصدار  تم الموافقة على هذه النشرة 08/2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aceda 500mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500mg of Capecitabine.
Excipient(s) with known effect
Each film-coated tablet contains 25mg anhydrous lactose
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Aceda 500mg film-coated tablets are peach colored, oblong shaped, biconvex, film-coated tablets of 15.9mm in length and 8.4mm in width, debossed with ‘500’ on one side and plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aceda is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes&rsquo; stage C) colon cancer (see section 5.1).<br />Aceda is indicated for the treatment of metastatic colorectal cancer (see section 5.1).<br />Aceda is indicated for first-line treatment of advanced gastric cancer in combination with a platinum based regimen (see section 5.1).<br />Aceda in combination with Docetaxel (see section 5.1) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy&nbsp;should have included an Anthracycline.<br />Aceda is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of Taxanes and an Anthracycline containing chemotherapy regimen or for whom further Anthracycline therapy is not indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aceda should only be prescribed by a qualified physician experienced in the utilisation of antineoplastic medicinal products. Careful monitoring during the first cycle of treatment is recommended for all patients.<br />Treatment should be discontinued if progressive disease or intolerable toxicity is observed. Standard and reduced dose calculations according to body surface area for starting doses of Aceda of 1250mg/m2 and 1000mg/m2 are provided in Tables 1 and 2, respectively.</p><p>Posology<br />Recommended posology (see section 5.1)<br />Monotherapy<br />Colon, colorectal and breast cancer<br />Given as monotherapy, the recommended starting dose for Capecitabine in the adjuvant treatment of colon cancer, in the treatment of metastatic colorectal cancer or of locally advanced or metastatic breast cancer is 1250mg/m2 administered twice daily (morning and evening; equivalent to 2500mg/m2 total daily dose) for 14 days followed by a 7-day rest period. Adjuvant treatment in patients with stage III colon cancer is recommended for a total of 6 months.<br />Combination therapy<br />Colon, colorectal and gastric cancer<br />In combination treatment, the recommended starting dose of Capecitabine should be reduced to 800 &ndash; 1000mg/m2 when administered twice daily for 14 days followed by a 7-day rest period, or to 625mg/m2 twice daily when administered continuously (see section 5.1). For combination with Irinotecan, the recommended starting dose is 800mg/m2 when administered twice daily for 14 days followed by a 7-day rest period combined with Irinotecan 200mg/m2 on day 1. The inclusion of Bevacizumab in a combination regimen has no effect on the starting dose of Capecitabine. Premedication to maintain adequate hydration and antiemesis according to the Cisplatin summary of product characteristics should be started prior to Cisplatin administration for patients receiving the Capecitabine plus Cisplatin combination. Premedication with antiemetics according to the Oxaliplatin summary of product characteristics is recommended for patients receiving the Capecitabine plus Oxaliplatin combination.<br />Adjuvant treatment in patients with stage III colon cancer is recommended for a duration of 6 months.<br />Breast cancer<br />In combination with Docetaxel, the recommended starting dose of Capecitabine in the treatment of metastatic breast cancer is 1250mg/m2 twice daily for 14 days followed by a 7-day rest period, combined with Docetaxel at 75mg/m2 as a 1 hour intravenous infusion every 3 weeks. Pre-medication with an oral Corticosteroid such as Dexamethasone according to the Docetaxel summary of product characteristics should be started prior to Docetaxel administration for patients receiving the Capecitabine plus Docetaxel combination.</p><p>Aceda dose calculations<br />Table 1 Standard and reduced dose calculations according to body surface area for a starting dose of Capecitabine of 1250mg/m2.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="11" style="vertical-align:top"><p>Dose level 1250mg/m2 (twice daily)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Full dose</p><p>1250mg/m2</p></td><td colspan="3" style="vertical-align:top"><p>Number of 150mg tablets, 300mg tablets and/or 500mg tablets per administration (each administration to be given morning and evening)</p></td><td colspan="3" style="vertical-align:top"><p>Reduced dose (75%)</p><p>950mg/m2</p></td><td colspan="3" style="vertical-align:top"><p>Reduced dose (50%)</p><p>625mg/m2</p></td></tr><tr><td style="vertical-align:top"><p>Body Surface Area (m2 )</p></td><td colspan="2" style="vertical-align:top"><p>Dose per administration (mg)</p></td><td style="vertical-align:top"><p>150mg</p></td><td colspan="2" style="vertical-align:top"><p>300mg</p></td><td style="vertical-align:top"><p>500mg</p></td><td colspan="2" style="vertical-align:top"><p>Dose per administration (mg)</p></td><td style="vertical-align:top"><p>Dose per administration (mg)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.26</p></td><td colspan="2" style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>1150</p></td><td style="vertical-align:top"><p>800</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.27 - 1.38</p></td><td colspan="2" style="vertical-align:top"><p>1650</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>800</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.39 - 1.52</p></td><td colspan="2" style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>1450</p></td><td style="vertical-align:top"><p>950</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.53 - 1.66</p></td><td colspan="2" style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>1000</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.67 - 1.78</p></td><td colspan="2" style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>1650</p></td><td style="vertical-align:top"><p>1000</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.79 - 1.92</p></td><td colspan="2" style="vertical-align:top"><p>2300</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>1150</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>1.93 - 2.06</p></td><td colspan="2" style="vertical-align:top"><p>2500</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>5</p></td><td colspan="2" style="vertical-align:top"><p>1950</p></td><td style="vertical-align:top"><p>1300</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2.07 - 2.18</p></td><td colspan="2" style="vertical-align:top"><p>2650</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>5</p></td><td colspan="2" style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>1300</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>2.19</p></td><td colspan="2" style="vertical-align:top"><p>2800</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>5</p></td><td colspan="2" style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1450</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>Table 2 Standard and reduced dose calculations according to body surface area for a starting dose of Capecitabine of 1000mg/m2</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="10" style="vertical-align:top"><p>Dose level 1000mg/m2 (twice daily)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Full dose</p><p>1000mg/m2</p></td><td colspan="3" style="vertical-align:top"><p>Number of 150mg tablets, 300mg tablets and/or 500mg tablets per administration (each administration to be given morning and evening)</p></td><td colspan="3" style="vertical-align:top"><p>Reduced dose (75%)</p><p>750mg/m2</p></td><td colspan="2" style="vertical-align:top"><p>Reduced dose (50%)</p><p>500mg/m2</p></td></tr><tr><td style="vertical-align:top"><p>Body Surface Area (m2 )</p></td><td colspan="2" style="vertical-align:top"><p>Dose per administration (mg)</p></td><td style="vertical-align:top"><p>150mg</p></td><td colspan="2" style="vertical-align:top"><p>300mg</p></td><td style="vertical-align:top"><p>500mg</p></td><td colspan="2" style="vertical-align:top"><p>Dose per administration (mg)</p></td><td style="vertical-align:top"><p>Dose per administration (mg)</p></td></tr><tr><td style="vertical-align:top"><p>1.26</p></td><td colspan="2" style="vertical-align:top"><p>1150</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>800</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>1.27 - 1.38</p></td><td colspan="2" style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>1000</p></td><td style="vertical-align:top"><p>600</p></td></tr><tr><td style="vertical-align:top"><p>1.39 - 1.52</p></td><td colspan="2" style="vertical-align:top"><p>1450</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>1100</p></td><td style="vertical-align:top"><p>750</p></td></tr><tr><td style="vertical-align:top"><p>1.53 - 1.66</p></td><td colspan="2" style="vertical-align:top"><p>1600</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>1200</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.67 - 1.78</p></td><td colspan="2" style="vertical-align:top"><p>1750</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>1300</p></td><td style="vertical-align:top"><p>800</p></td></tr><tr><td style="vertical-align:top"><p>1.79 - 1.92</p></td><td colspan="2" style="vertical-align:top"><p>1800</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>1400</p></td><td style="vertical-align:top"><p>900</p></td></tr><tr><td style="vertical-align:top"><p>1.93 - 2.06</p></td><td colspan="2" style="vertical-align:top"><p>2000</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>1500</p></td><td style="vertical-align:top"><p>1000</p></td></tr><tr><td style="vertical-align:top"><p>2.07 - 2.18</p></td><td colspan="2" style="vertical-align:top"><p>2150</p></td><td style="vertical-align:top"><p>1</p></td><td colspan="2" style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>1600</p></td><td style="vertical-align:top"><p>1050</p></td></tr><tr><td style="vertical-align:top"><p>2.19</p></td><td colspan="2" style="vertical-align:top"><p>2300</p></td><td style="vertical-align:top"><p>-</p></td><td colspan="2" style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>4</p></td><td colspan="2" style="vertical-align:top"><p>1750</p></td><td style="vertical-align:top"><p>1100</p></td></tr></tbody></table><p>Posology adjustments during treatment<br />General<br />Toxicity due to Capecitabine administration may be managed by symptomatic treatment and/or modification of the dose (treatment interruption or dose reduction). Once the dose has been reduced, it should not be increased at a later time. For those toxicities considered by the treating physician to be unlikely to become serious or life threatening, e.g. alopecia, altered taste, nail changes, treatment can be continued at the same dose without reduction or interruption. Patients taking Capecitabine should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs. Doses of Capecitabine omitted for toxicity are not replaced. The following are the recommended dose modifications for toxicity:</p><p>Table 3 Capecitabine Dose Reduction Schedule (3-weekly Cycle or Continuous Treatment).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity grades* </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Dose changes within a treatment cycle </strong></p></td><td style="vertical-align:top"><p><strong>Dose adjustment for next cycle/dose </strong></p><p><strong>(% of starting dose) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&bull; Grade 1</p></td><td colspan="2" style="vertical-align:top"><p>Maintain dose level</p></td><td style="vertical-align:top"><p>Maintain dose level</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&bull; Grade 2</p></td></tr><tr><td style="vertical-align:top"><p>-1st appearance</p></td><td colspan="2" style="vertical-align:top"><p>Interrupt until resolved to grade 0-1</p></td><td style="vertical-align:top"><p>100%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>-2nd appearance</p></td><td colspan="2" style="vertical-align:top"><p>75%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>-3rd appearance</p></td><td colspan="2" style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-4th appearance</p></td><td colspan="2" style="vertical-align:top"><p>Discontinue treatment permanently</p></td><td style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&bull; Grade 3</p></td></tr><tr><td style="vertical-align:top"><p>-1st appearance</p></td><td colspan="2" style="vertical-align:top"><p>Interrupt until resolved to grade 0-1</p></td><td style="vertical-align:top"><p>75%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>-2nd appearance</p></td><td colspan="2" style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-3rd appearance</p></td><td colspan="2" style="vertical-align:top"><p>Discontinue treatment permanently</p></td><td style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&bull; Grade 4</p></td></tr><tr><td style="vertical-align:top"><p>-1st appearance</p></td><td colspan="2" style="vertical-align:top"><p>Discontinue permanently</p><p><em>or </em></p><p>If physician deems it to be in the patient&#39;s best interest to continue, interrupt until resolved to grade 0-1</p></td><td style="vertical-align:top"><p>50%</p></td></tr><tr><td style="vertical-align:top"><p>-2nd appearance</p></td><td colspan="2" style="vertical-align:top"><p>Discontinue permanently</p></td><td style="vertical-align:top"><p>Not applicable</p></td></tr></tbody></table><p>&nbsp;</p><p>According to the National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) Common Toxicity Criteria (version 1) or the Common Terminology Criteria for Adverse Events (CTCAE) of the Cancer Therapy Evaluation Program, US National Cancer Institute, version 4.0. For hand-foot syndrome and hyperbilirubinemia, see section 4.4.<br />Haematology<br />Patients with baseline neutrophil counts of &lt;1.5 x 109/l and/or thrombocyte counts of &lt;100 x 109/l should not be treated with Capecitabine. If unscheduled laboratory assessments during a treatment cycle show that the neutrophil count drops below 1.0 x 109/L or that the platelet count drops below 75 x 109/l, treatment with Capecitabine should be interrupted.</p><p>Dose modifications for toxicity when Capecitabine is used as a 3 weekly cycle in combination with other medicinal products<br />Dose modifications for toxicity when Capecitabine is used as a 3 weekly cycle in combination with other medicinal products should be made according to Table 3 above for Capecitabine and according to the appropriate summary of product characteristics for the other medicinal product (s).<br />At the beginning of a treatment cycle, if a treatment delay is indicated for either Capecitabine or the other medicinal product(s), then administration of all therapy should be delayed until the requirements for restarting all medicinal products are met.<br />During a treatment cycle for those toxicities considered by the treating physician not to be related to Capecitabine, Capecitabine should be continued and the dose of the other medicinal product should be adjusted according to the appropriate Prescribing Information.<br />If the other medicinal product(s) have to be discontinued permanently, Capecitabine treatment can be resumed when the requirements for restarting Capecitabine are met.<br />This advice is applicable to all indications and to all special populations.</p><p>Dose modifications for toxicity when Capecitabine is used continuously in combination with other agents<br />Dose modifications for toxicity when Capecitabine is used continuously in combination with other medicinal products should be made according to Table 3 above for Capecitabine and according to the appropriate summary of product characteristics for the other medicinal product(s).<br />Posology adjustments for special populations<br />Hepatic impairment<br />Insufficient safety and efficacy data are available in patients with hepatic impairment to provide a dose adjustment recommendation. No information is available on hepatic impairment due to cirrhosis or hepatitis.</p><p>Renal impairment<br />Capecitabine is contraindicated in patients with severe renal impairment (creatinine clearance below 30ml/min [Cockcroft and Gault] at baseline). The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50ml/min at baseline) is increased compared to the overall population. In patients with moderate renal impairment at baseline, a dose reduction to 75% for a starting dose of 1250mg/m2 is recommended. In patients with moderate renal impairment at baseline, no dose reduction is required for a starting dose of 1000mg/m2. In patients with mild renal impairment (creatinine clearance 51-80ml/min at baseline) no adjustment of the starting dose is recommended. Careful monitoring and prompt treatment interruption is recommended if the patient develops a grade 2, 3 or 4 adverse event during treatment and subsequent dose adjustment as outlined in Table 3 above. If the calculated creatinine clearance decreases during treatment to a value below 30ml/min, Aceda should be discontinued. These dose adjustment recommendations for renal impairment apply both to monotherapy and combination use (see also section &ldquo;Elderly&rdquo; below).</p><p>Elderly<br />During Capecitabine monotherapy, no adjustment of the starting dose is needed. However, grade 3 or 4 treatment-related adverse reactions were more frequent in patients &ge;60 years of age compared to younger patients.<br />When Capecitabine was used in combination with other medicinal products, elderly patients (&ge;65 years) experienced more grade 3 and grade 4 adverse drug reactions, including those leading to discontinuation, compared to younger patients. Careful monitoring of patients &ge;60 years of age is advisable.<br />- In combination with Docetaxel: an increased incidence of grade 3 or 4 treatment-related adverse reactions and treatment-related serious adverse reactions were observed in patients 60 years of age or more (see section 5.1). For patients 60 years of age or more, a starting dose reduction of Capecitabine to 75% (950mg/m2 twice daily) is recommended. If no toxicity is observed in patients &ge;60 years of age treated with a reduced Capecitabine starting dose in combination with Docetaxel, the dose of Capecitabine may be cautiously escalated to 1250mg/m2 twice daily.<br />Paediatric population<br />There is no relevant use of Capecitabine in the paediatric population in the indications colon, colorectal, gastric and breast cancer.<br />Method of administration<br />Aceda film-coated tablets should be swallowed with water within 30 minutes after a meal.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                History of severe and unexpected reactions to Fluoropyrimidine therapy,
• Hypersensitivity to Capecitabine or to any of the excipients listed in section 6.1 or Fluorouracil,
• In patients with known Dihydropyrimidine Dehydrogenase (DPD) deficiency (see section 4.4),
• During pregnancy and lactation,
• In patients with severe leukopenia, neutropenia, or thrombocytopenia,
• In patients with severe hepatic impairment,
• In patients with severe renal impairment (creatinine clearance below 30ml/min),
• Treatment with Sorivudine or its chemically related analogues, such as Brivudine (see section 4.5),
• If contraindications exist to any of the medicinal products in the combination regimen, that medicinal product should not be used.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dose limiting toxicities include diarrhoea, abdominal pain, nausea, stomatitis and hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia). Most adverse reactions are reversible and do not require permanent discontinuation of therapy, although doses may need to be withheld or reduced.</p><p>Diarrhoea<br />Patients with severe diarrhoea should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated. Standard antidiarrhoeal treatments (e.g. Loperamide) may be used. NCIC CTC grade 2 diarrhoea is defined as an increase of 4 to 6 stools/day or nocturnal stools, grade 3 diarrhoea as an increase of 7 to 9 stools/day or incontinence and malabsorption. Grade 4 diarrhoea is an increase of &ge;10 stools/day or grossly bloody diarrhoea or the need for parenteral support. Dose reduction should be applied as necessary (see section 4.2).<br />Dehydration<br />Dehydration should be prevented or corrected at the onset. Patients with anorexia, asthenia, nausea, vomiting or diarrhoea may rapidly become dehydrated. Dehydration may cause acute renal failure,especially in patients with pre-existing compromised renal function or when Capecitabine is given concomitantly with known nephrotoxic drugs. Acute renal failure secondary to dehydration might be potentially fatal.<br />If grade 2 (or higher) dehydration occurs, Capecitabine treatment should be immediately interrupted and the dehydration corrected. Treatment should not be restarted until the<br />patient is rehydrated and any precipitating causes have been corrected or controlled. Dose modifications applied should be applied for the precipitating adverse event as necessary (see section 4.2).</p><p>Hand-foot syndrome<br />(also known as hand-foot skin reaction or palmar-plantar erythrodysesthesia or chemotherapy induced acral erythema).<br />Grade 1 hand-foot syndrome is defined as numbness, dysesthesia/paresthesia, tingling, painless swelling or erythema of the hands and/or feet and/or discomfort which does not disrupt the patient&rsquo;s normal activities.<br />Grade 2 hand-foot syndrome is painful erythema and swelling of the hands and/or feet and/or discomfort affecting the patient&rsquo;s activities of daily living.<br />Grade 3 hand-foot syndrome is moist desquamation, ulceration, blistering and severe pain of the hands and/or feet and/or severe discomfort that causes the patient to be unable to work or perform activities of daily living. If grade 2 or 3 hand-foot syndrome occurs, administration of Capecitabine should be interrupted until the event resolves or decreases in intensity to grade 1. Following grade 3 hand-foot syndrome, subsequent doses of Aceda should be decreased. When Capecitabine and Cisplatin are used in combination, the use of Vitamin B6 (Pyridoxine) is not advised for symptomatic or secondary prophylactic treatment of hand-foot syndrome, because of published reports that it may decrease the efficacy of Cisplatin. There is some evidence that Dexpanthenol is effective for hand-foot syndrome prophylaxis in patients treated with Aceda.</p><p>Cardiotoxicity<br />Cardiotoxicity has been associated with Fluoropyrimidine therapy, including myocardial infarction, angina, dysrhythmias, cardiogenic shock, sudden death and electrocardiographic changes (including very rare cases of QT prolongation). These adverse reactions may be more common in patients with a prior history of coronary artery disease. Cardiac arrhythmias (including ventricular fibrillation, torsade de pointes, and bradycardia), angina pectoris, myocardial infarction, heart failure and cardiomyopathy have been reported in patients receiving Capecitabine. Caution must be exercised in patients with history of significant cardiac disease, arrhythmias and angina pectoris (see section 4.8).<br />Hypo- or hypercalcaemia<br />Hypo- or hypercalcaemia has been reported during Capecitabine treatment. Caution must be exercised in patients with pre-existing hypo- or hypercalcaemia (see section 4.8).<br />Central or peripheral nervous system disease<br />Caution must be exercised in patients with central or peripheral nervous system disease, e.g. brain metastasis or neuropathy (see section 4.8).<br />Diabetes mellitus or electrolyte disturbances<br />Caution must be exercised in patients with diabetes mellitus or electrolyte disturbances, as these may be aggravated during Capecitabine treatment.</p><p>Coumarin-derivative anticoagulation<br />In a drug interaction study with single-dose Warfarin administration, there was a significant increase in the mean AUC (+57%) of S-Warfarin. These results suggest an interaction, probably due to an inhibition of the cytochrome P450 2C9 isoenzyme system by Capecitabine. Patients receiving concomitant Capecitabine and oral Coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely and the anticoagulant dose adjusted accordingly (see section 4.5).<br />Hepatic impairment<br />In the absence of safety and efficacy data in patients with hepatic impairment, Capecitabine use should be carefully monitored in patients with mild to moderate liver dysfunction, regardless of the presence or absence of liver metastasis. Administration of Capecitabine should be interrupted if treatment-related elevations in Bilirubin of &gt;3.0 x ULN or treatment-related elevations in hepatic Aminotransferases (ALT, AST) of &gt;2.5 x ULN occur. Treatment with Capecitabine monotherapy may be resumed when Bilirubin decreases to &le;3.0 x ULN or hepatic Aminotransferases decrease to &le; 2.5 x ULN.</p><p>Renal impairment<br />The incidence of grade 3 or 4 adverse reactions in patients with moderate renal impairment (creatinine clearance 30-50ml/min) is increased compared to the overall population (see sections 4.2 and 4.3).<br />DPD deficiency<br />Rarely, unexpected, severe toxicity (e.g. stomatitis, diarrhoea, neutropenia and neurotoxicity) associated with 5-FU has been attributed to a deficiency of DPD activity. A link between decreased levels of DPD and increased, potentially fatal toxic effects of 5-FU therefore cannot be excluded.<br />Patients with known DPD deficiency should not be treated with Capecitabine (see section 4.3). In patients with unrecognised DPD deficiency treated with Capecitabine, life threatening<br />toxicities manifesting as acute overdose may occur (see section 4.9). In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately until observed toxicity resolves. Permanent discontinuation should be considered based on clinical assessment of the onset, duration and severity of the observed toxicities.<br />Ophthalmologic Complications<br />Patients should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders, especially if they have a prior history of eye disorders. Treatment of eye disorders should be initiated as clinically appropriate.<br />Severe skin reactions<br />Capecitabine can induce severe skin reactions such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis. Capecitabine should be permanently discontinued in patients who experience a severe skin reaction during treatment.<br />As this medicinal product contains anhydrous lactose as an excipient, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.<br />Interaction with other medicinal products<br />Cytochrome P-450 2C9 substrates<br />Other than Warfarin, no formal drug-drug interaction studies between Capecitabine and other CYP2C9 substrates have been conducted. Care should be exercised when Capecitabine is co-administered with 2C9 substrates (e.g., phenytoin). See also interaction with Coumarin-derivative anticoagulants below, and section 4.4.</p><p>Coumarin-derivative anticoagulants<br />Altered coagulation parameters and/or bleeding have been reported in patients taking Capecitabine concomitantly with Coumarin-derivative anticoagulants such as warfarin and Phenprocoumon. These reactions occurred within several days and up to several months after initiating Capecitabine therapy and, in a few cases, within one month after stopping Capecitabine. In a clinical pharmacokinetic interaction study, after a single 20mg dose of Warfarin, Capecitabine treatment increased the AUC of S-Warfarin by 57% with a 91% increase in INR value. Since metabolism of R-warfarin was not affected, these results indicate that Capecitabine down-regulates isozyme 2C9, but has no effect on isozymes 1A2 and 3A4. Patients taking Coumarin-derivative anticoagulants concomitantly with Capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR) and the anti-coagulant dose adjusted accordingly.</p><p>Phenytoin<br />Increased Phenytoin plasma concentrations resulting in symptoms of Phenytoin intoxication in single cases have been reported during concomitant use of Capecitabine with Phenytoin. Patients taking Phenytoin concomitantly with Capecitabine should be regularly monitored for increased Phenytoin plasma concentrations.<br />Folinic Acid/Folic Acid<br />A combination study with Capecitabine and Folinic Acid indicated that Folinic Acid has no major effect on the pharmacokinetics of Capecitabine and its metabolites. However, Folinic Acid has an effect on the pharmacodynamics of Capecitabine and its toxicity may be enhanced by Folinic Acid: the maximum tolerated dose (MTD) of Capecitabine alone using the intermittent regimen is 3000mg/m2 per day whereas it is only 2000mg/m2 per day when Capecitabine was combined with Folinic Acid (30mg orally bid). The enhanced toxicity may be relevant when switching from 5-FU/LV to a Capecitabine regimen. This may also be relevant with Folic Acid supplementation for folate deficiency due to the similarity between Folinic acid and Folic Acid.<br />Sorivudine and analogues<br />A clinically significant drug-drug interaction between Sorivudine and 5-FU, resulting from the inhibition of Dihydropyrimidine Dehydrogenase by Sorivudine, has been described.<br />This interaction, which leads to increased Fluoropyrimidine toxicity, is potentially fatal. Therefore, Capecitabine must not be administered concomitantly with Sorivudine or its chemically related analogues, such as Brivudine (see section 4.3). There must be at least a 4-week waiting period between end of treatment with Sorivudine or its chemically related analogues such as Brivudine and start of Capecitabine therapy.</p><p>Antacid<br />The effect of an aluminium hydroxide and magnesium hydroxide-containing antacid on the pharmacokinetics of Capecitabine was investigated. There was a small increase in plasma concentrations of Capecitabine and one metabolite (5&rsquo;-DFCR); there was no effect on the 3 major metabolites (5&rsquo;-DFUR, 5-FU and FBAL).<br />Allopurinol<br />Interactions with Allopurinol have been observed for 5-FU; with possible decreased efficacy of 5-FU. Concomitant use of Allopurinol with Capecitabine should be avoided.<br />Interferon alpha<br />The MTD of Capecitabine was 2000mg/m2 per day when combined with interferon alpha- 2a (3 MIU/m2 per day) compared to 3000mg/m2 per day when Capecitabine was used alone.<br />Radiotherapy<br />The MTD of Capecitabine alone using the intermittent regimen is 3000mg/m2 per day, whereas, when combined with radiotherapy for rectal cancer, the MTD of Capecitabine is 2000mg/m2 per day using either a continuous schedule or given daily Monday through Friday during a 6-week course of radiotherapy.<br />Oxaliplatin<br />No clinically significant differences in exposure to Capecitabine or its metabolites, free platinum or total platinum occurred when Capecitabine was administered in combination with Oxaliplatin or in combination with Oxaliplatin and Bevacizumab.<br />Bevacizumab<br />There was no clinically significant effect of Bevacizumab on the pharmacokinetic parameters of Capecitabine or its metabolites in the presence of Oxaliplatin.<br />Food interaction<br />In all clinical trials, patients were instructed to administer Capecitabine within 30 minutes after a meal. Since current safety and efficacy data are based upon administration with food, it is recommended that Capecitabine be administered with food. Administration with food decreases the rate of Capecitabine absorption (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential/Contraception in males and females<br />Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Capecitabine. If the patient becomes pregnant while receiving Capecitabine, the potential hazard to the foetus must be explained. An effective method of contraception should be used during treatment.<br />Pregnancy<br />Pregnancy Category (D).<br />There are no studies in pregnant women using Capecitabine; however, it should be assumed that Capecitabine may cause foetal harm if administered to pregnant women. In reproductive toxicity studies</p><p>in animals, Capecitabine administration caused embryolethality and teratogenicity. These findings are expected effects of Fluoropyrimidine derivatives. Capecitabine is contraindicated during pregnancy.<br />Breastfeeding<br />It is not known whether Capecitabine is excreted in human breast milk. In lactating mice, considerable amounts of Capecitabine and its metabolites were found in milk. Breast-feeding should be discontinued while receiving treatment with Capecitabine.<br />Fertility<br />There is no data on Capecitabine and impact on fertility. The Capecitabine pivotal studies included females of childbearing potential and males only if they agreed to use an acceptable method of birth control to avoid pregnancy for the duration of the study and for a reasonable period thereafter.<br />In animal studies effects on fertility were observed (see section 5.3)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capecitabine has minor or moderate influence on the ability to drive and use machines. Capecitabine may cause dizziness, fatigue and nausea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The overall safety profile of Capecitabine is based on data from over 3,000 patients treated with Capecitabine as monotherapy or Capecitabine in combination with different chemotherapy regimens in multiple indications. The safety profiles of Capecitabine monotherapy for the metastatic breast cancer, metastatic colorectal cancer and adjuvant colon cancer populations are comparable. See section 5.1 for details of major studies, including study designs and major efficacy results.<br />The most commonly reported and/or clinically relevant treatment-related adverse drug reactions (ADRs) were gastrointestinal disorders (especially diarrhoea, nausea, vomiting, abdominal pain, stomatitis), hand-foot syndrome (palmar-plantar erythrodysesthesia), fatigue, asthenia, anorexia, cardiotoxicity, increased renal dysfunction on those with pre-existing compromised renal function, and thrombosis/embolism.</p><p>Tabulated summary of adverse reactions<br />ADRs considered by the investigator to be possibly, probably, or remotely related to the administration of Capecitabine are listed in Table 4 for Capecitabine given as monotherapy and in Table 5 for Capecitabine given in combination with different chemotherapy regimens in multiple indications. The following headings are used to rank the ADRs by frequency: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10) uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000) and very rare (&lt; 1/10,000). Within each frequency grouping, ADRs are presented in order of decreasing seriousness.</p><p>Capecitabine monotherapy<br />Table 4 lists ADRs associated with the use of Capecitabine monotherapy based on a pooled analysis of safety data from three major studies including over 1900 patients (studies M66001, SO14695, and SO14796). ADRs are added to the appropriate frequency grouping according to the overall incidence from the pooled analysis.</p><p>Table 4 Summary of related ADRs reported in patients treated with Capecitabine monotherapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Body System</p></td><td style="vertical-align:top"><p>Very Common</p><p><em>All grades </em></p></td><td style="vertical-align:top"><p>Common</p><p><em>All grades </em></p></td><td style="vertical-align:top"><p>Uncommon</p><p><em>Severe and/or Life threatening (grade 3-4) or considered medically relevant </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Herpes viral infection, Nasopharyngitis, Lower respiratory tract infection</p></td><td style="vertical-align:top"><p>Sepsis, Urinary tract infection, Cellulitis, Tonsillitis, Pharyngitis, Oral candidiasis, Influenza, Gastroenteritis, Fungal infection, Infection, Tooth abscess</p></td></tr><tr><td style="vertical-align:top"><p><em>Neoplasm benign, malignant and unspecified </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Lipoma</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Neutropenia, Anaemia</p></td><td style="vertical-align:top"><p>Febrile neutropenia, Pancytopenia, Granulocytopenia, Thrombocytopenia, Leukopenia, Haemolytic anaemia, International Normalised Ratio (INR) increased/Prothrombin time prolonged</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders </em></p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Dehydration, Weight decreased</p></td><td style="vertical-align:top"><p>Diabetes, Hypokalaemia, Appetite disorder, Malnutrition, Hypertriglyceridaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Insomnia, Depression</p></td><td style="vertical-align:top"><p>Confusional state, Panic attack, Depressed mood, Libido decreased</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Headache, Lethargy Dizziness, Parasthesia, Dysgeusia</p></td><td style="vertical-align:top"><p>Aphasia, Memory impairment, Ataxia, Syncope, Balance disorder, Sensory disorder, Neuropathy peripheral</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Lacrimation increased, Conjunctivitis, Eye irritation</p></td><td style="vertical-align:top"><p>Visual acuity reduced, Diplopia</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear and labyrinth disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Vertigo, Ear pain</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Cardiac disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Angina unstable, Angina pectoris, Myocardial ischaemia, Atrial fibrillation, Arrhythmia, Tachycardia, Sinus tachycardia, Palpitations</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p></td><td style="vertical-align:top"><p>Deep vein thrombosis, Hypertension, Petechiae, Hypotension, Hot flush, Peripheral coldness</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Dyspnoea, Epistaxis, Cough, Rhinorrhoea</p></td><td style="vertical-align:top"><p>Pulmonary embolism, Pneumothorax, Haemoptysis, Asthma, Dyspnoea exertional</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders </em></p></td><td style="vertical-align:top"><p>Diarrhoea, Vomiting, Nausea, Stomatitis, Abdominal pain</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage, Constipation, Upper abdominal pain, Dyspepsia, Flatulence, Dry mouth</p></td><td style="vertical-align:top"><p>Intestinal obstruction, Ascites, Enteritis, Gastritis, Dysphagia, Abdominal pain lower, Oesophagitis, Abdominal discomfort, Gastrooesophageal reflux disease, Colitis, Blood in stool</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hyperbilirubinemia, Liver function test abnormalities</p></td><td style="vertical-align:top"><p>Jaundice</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders </em></p></td><td style="vertical-align:top"><p>Palmar-plantar erythrodysaesthesia syndrome</p></td><td style="vertical-align:top"><p>Rash, Alopecia, Erythema, Dry skin, Pruritus, Skin hyper-pigmentation, Rash macular, Skin desquamation, Dermatitis, Pigmentation disorder, Nail disorder</p></td><td style="vertical-align:top"><p>Blister, Skin ulcer, Rash, Urticaria, Photosensitivity reaction, Palmar erythema, Swelling face, Purpura, Radiation recall syndrome</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Pain in extremity, Back pain, Arthralgia</p></td><td style="vertical-align:top"><p>Joint swelling, Bone pain, Facial pain, Musculoskeletal stiffness, Muscular weakness</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hydronephrosis, Urinary incontinence, Haematuria, Nocturia, Blood creatinine increased</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Vaginal haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions </em></p></td><td style="vertical-align:top"><p>Fatigue, Asthenia</p></td><td style="vertical-align:top"><p>Pyrexia, Oedema peripheral, Malaise, Chest pain</p></td><td style="vertical-align:top"><p>Oedema, Chills, Influenza like illness, Rigors, Body temperature increased</p></td></tr></tbody></table><p>Capecitabine in combination therapy<br />Table 5 lists ADRs associated with the use of Capecitabine in combination with different chemotherapy regimens in multiple indications based on safety data from over 3000 patients. ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen in addition to those seen with Capecitabine monotherapy or seen at a higher frequency grouping compared to Capecitabine monotherapy (see Table 4). Uncommon ADRs reported for Capecitabine in combination therapy are consistent with the ADRs reported for Capecitabine monotherapy or reported for monotherapy with the combination agent (in literature and/or respective summary of product characteristics).<br />Some of the ADRs are reactions commonly seen with the combination medicinal product (e.g. peripheral sensory neuropathy with Docetaxel or Oxaliplatin, hypertension seen with Bevacizumab); however an exacerbation by Capecitabine therapy cannot be excluded.<br />Table 5 Summary of related ADRs reported in patients treated with Capecitabine in combination treatment in addition to those seen with Capecitabine monotherapy or seen at a higher frequency grouping compared to Capecitabine monotherapy</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System </strong></p></td><td style="vertical-align:top"><p><strong>Very Common </strong></p><p><strong><em>All grades </em></strong></p></td><td style="vertical-align:top"><p><strong>Common </strong></p><p><strong><em>All grades </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Infections and infestations </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Herpes zoster, Urinary tract infection, Oral candidiasis, Upper respiratory tract infection , Rhinitis, Influenza, +Infection, Oral herpes</p></td></tr><tr><td style="vertical-align:top"><p><em>Blood and lymphatic system disorders </em></p></td><td style="vertical-align:top"><p>+Neutropenia, +Leucopenia, +Anaemia, +Neutropenic fever, Thrombocytopenia</p></td><td style="vertical-align:top"><p>Bone marrow depression, +Febrile Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune system disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td></tr><tr><td style="vertical-align:top"><p><em>Metabolism and nutrition disorders </em></p></td><td style="vertical-align:top"><p>Appetite decreased</p></td><td style="vertical-align:top"><p>Hypokalaemia, Hyponatraemia, Hypomagnesaemia, Hypocalcaemia, Hyperglycaemia</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Sleep disorder, Anxiety</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous system disorders </em></p></td><td style="vertical-align:top"><p>Parasthesia, Dysaesthesia, Peripheral neuropathy, Peripheral sensory neuropathy, Dysgeusia, Headache</p></td><td style="vertical-align:top"><p>Neurotoxicity, Tremor, Neuralgia, Hypersensitivity reaction, Hypoaesthesia</p></td></tr><tr><td style="vertical-align:top"><p><em>Eye disorders </em></p></td><td style="vertical-align:top"><p>Lacrimation increased</p></td><td style="vertical-align:top"><p>Visual disorders, Dry eye, Eye pain, Visual impairment, Vision blurred</p></td></tr><tr><td style="vertical-align:top"><p><em>Ear and labyrinth disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Tinnitus, Hypoacusis</p></td></tr><tr><td style="vertical-align:top"><p><em>Cardiac disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Atrial fibrillation, Cardiac ischemia/infarction</p></td></tr><tr><td style="vertical-align:top"><p><em>Vascular disorders </em></p></td><td style="vertical-align:top"><p>Lower limb oedema, Hypertension, +Embolism and thrombosis</p></td><td style="vertical-align:top"><p>Flushing, Hypotension, Hypertensive crisis, Hot flush, Phlebitis</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal system disorders </em></p></td><td style="vertical-align:top"><p>Sore throat, Dysaesthesia pharynx</p></td><td style="vertical-align:top"><p>Hiccups, Pharyngolaryngeal pain, Dysphonia</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal disorders </em></p></td><td style="vertical-align:top"><p>Constipation, Dyspepsia</p></td><td style="vertical-align:top"><p>Upper gastrointestinal haemorrhage, Mouth ulceration</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Gastritis, Abdominal distension, Gastroesophageal reflux disease, Oral pain, Dysphagia, Rectal haemorrhage, Abdominal pain lower, Oral dysaesthesia, Parasthesia oral, Hypoaesthesia oral, Abdominal discomfort</p></td></tr><tr><td style="vertical-align:top"><p><strong>Body System </strong></p></td><td style="vertical-align:top"><p><strong>Very Common </strong></p><p><strong><em>All grades </em></strong></p></td><td style="vertical-align:top"><p><strong>Common </strong></p><p><strong><em>All grades </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Hepatic function abnormal</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders </em></p></td><td style="vertical-align:top"><p>Alopecia, Nail disorder</p></td><td style="vertical-align:top"><p>Hyperhidrosis, Rash erythematous, Urticaria, Night sweats</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders </em></p></td><td style="vertical-align:top"><p>Myalgia, Arthralgia, Pain in extremity</p></td><td style="vertical-align:top"><p>Pain in jaw , Muscle spasms, Trismus, Muscular weakness</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Haematuria, Proteinuria, Creatinine renal clearance decreased, Dysuria</p></td></tr><tr><td style="vertical-align:top"><p><em>General disorders and administration site conditions </em></p></td><td style="vertical-align:top"><p>Pyrexia, Weakness, +Lethargy, Temperature intolerance</p></td><td style="vertical-align:top"><p>Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain</p></td></tr><tr><td style="vertical-align:top"><p><em>Injury, poisoning and procedural complications </em></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>Contusion</p></td></tr></tbody></table><p>+ For each term, the frequency count was based on ADRs of all grades. For terms marked with a &ldquo;+&rdquo;, the frequency count was based on grade 3-4 ADRs. ADRs are added according to the highest incidence seen in any of the major combination trials.<br />Post-marketing experience<br />The following additional serious adverse reactions have been identified during post-marketing exposure:<br />Table 6 Summary of events reported with Capecitabine in the post-marketing setting</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Rare </strong></p></td><td style="vertical-align:top"><p><strong>Very rare </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Eye disorders </em></p></td><td colspan="2" style="vertical-align:top"><p>Lacrimal duct stenosis, corneal disorders, keratitis, punctate keratitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Cardiac disorders </em></p></td><td colspan="2" style="vertical-align:top"><p>Ventricular fibrillation, QT prolongation, Torsade de pointes, Bradycardia, Vasospasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Hepatobiliary disorders </em></p></td><td colspan="2" style="vertical-align:top"><p>Hepatic failure, cholestatic hepatitis</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin and subcutaneous disorders </em></p></td><td colspan="2" style="vertical-align:top"><p>Cutaneous lupus erythematosus</p></td><td style="vertical-align:top"><p>Severe skin reactions such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (see section 4.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Renal and urinary disorders </em></p></td><td colspan="2" style="vertical-align:top"><p>Acute renal failure secondary to dehydration</p></td></tr></tbody></table><p>&nbsp;</p><p>Description of selected adverse reactions<br />Hand-foot syndrome (HFS) (see section 4.4)<br />For the Capecitabine dose of 1250mg/m2 twice daily on days 1 to 14 every 3 weeks, a frequency of 53% to 60% of all-grades HFS was observed in Capecitabine monotherapy trials (comprising studies in adjuvant therapy in colon cancer, treatment of metastatic colorectal cancer, and treatment of breast cancer) and a frequency of 63% was observed in the Capecitabine/Docetaxel arm for the treatment of metastatic breast cancer. For the Capecitabine dose of 1000mg/m2 twice daily on days 1 to 14 every 3 weeks, a frequency of 22% to 30% of all-grade HFS was observed in Capecitabine combination therapy.<br />A meta-analysis of 14 clinical trials with data from over 4700 patients treated with Capecitabine monotherapy or Capecitabine in combination with different chemotherapy regimens in multiple indications (colon, colorectal, gastric and breast cancer) showed that HFS (all grades) occurred in 2066 (43%) patients after a median time of 239 [95% CI 201, 288] days after starting treatment with Capecitabine. In all studies combined, the following covariates were statistically significantly associated with an increased risk of developing HFS: increasing Capecitabine starting dose (gram), decreasing cumulative Capecitabine dose (0.1*kg), increasing relative dose intensity in the first six weeks, increasing duration of study treatment (weeks), increasing age (by 10 year increments), female gender, and good ECOG performance status at baseline (0 versus &ge;1).</p><p>Diarrhoea (see section 4.4)<br />Capecitabine can induce the occurrence of diarrhoea, which has been observed in up to 50% of patients.<br />The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with Capecitabine showed that in all studies combined, the following covariates were statistically significantly associated with an increased risk of developing diarrhea: increasing Capecitabine starting dose (gram), increasing duration of study treatment (weeks), increasing age (by 10 year increments), and female gender. The following covariates were statistically significantly associated with a decreased risk of developing diarrhoea: increasing cumulative Capecitabine dose (0.1*kg) and increasing relative dose intensity in the first six weeks.<br />Cardiotoxicity (see section 4.4)<br />In addition to the ADRs described in Tables 4 and 5, the following ADRs with an incidence of less than 0.1% were associated with the use of Capecitabine monotherapy based on a pooled analysis from clinical safety data from 7 clinical trials including 949 patients (2 phase III and 5 phase II clinical trials in metastatic colorectal cancer and metastatic breast cancer): cardiomyopathy, cardiac failure, sudden death, and ventricular extrasystoles.</p><p>Encephalopathy<br />In addition to the ADRs described in Tables 4 and 5, and based on the above pooled analysis from clinical safety data from 7 clinical trials, encephalopathy was also associated with the use of Capecitabine monotherapy with an incidence of less than 0.1%.</p><p>Special populations<br />Elderly patients (see section 4.2)<br />An analysis of safety data in patients &ge; 60 years of age treated with Capecitabine monotherapy and an analysis of patients treated with Capecitabine plus Docetaxel combination therapy showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions and treatment-related serious adverse reactions compared to patients &lt; 60 years of age. Patients &ge; 60 years of age treated with</p><p>Capecitabine<br />plus Docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients &lt; 60 years of age.<br />The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with Capecitabine showed that in all studies combined, increasing age (by 10 year increments) was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.<br />Gender<br />The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with Capecitabine showed that in all studies combined, female gender was statistically significantly associated with an increased risk of developing HFS and diarrhoea and with a decreased risk of developing neutropenia.<br />Patients with renal impairment (see section 4.2, 4.4, and 5.2)<br />An analysis of safety data in patients treated with Capecitabine monotherapy (colorectal cancer) with baseline renal impairment showed an increase in the incidence of treatment-related grade 3 and 4 adverse reactions compared to patients with normal renal function (36% in patients without renal impairment n=268, vs. 41% in mild n=257 and 54% in moderate n=59, respectively) (see section 5.2). Patients with moderately impaired renal function show an increased rate of dose reduction (44%) vs. 33% and 32% in patients with no or mild renal impairment and an increase in early withdrawals from treatment (21% withdrawals during the first two cycles) vs. 5% and 8% in patients with no or mild renal impairment.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />To report any side effect(s) in Saudi Arabia, please contact:<br />The National Pharmacovigilance and Drug Safety Centre (NPC) Fax: +966-11-205-7662 Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340. Toll free phone: 8002490000 E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The manifestations of acute overdose include nausea, vomiting, diarrhoea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management of overdose should include customary therapeutic and supportive medical interventions aimed at correcting the presenting clinical manifestations and preventing their possible complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group<br />Cytostatics (antimetabolites), ATC code: L01BC06<br />Capecitabine is a non-cytotoxic Fluoropyrimidine Carbamate, which functions as an orally administered precursor of the cytotoxic moiety 5-Fluorouracil (5-FU). Capecitabine is activated via several enzymatic steps (see section 5.2). The enzyme involved in the final conversion to 5-FU, Thymidine Phosphorylase (ThyPase), is found in tumour tissues, but also in normal tissues, albeit usually at lower levels. In human cancer xenograft models Capecitabine demonstrated a synergistic effect in combination with Docetaxel, which may be related to the upregulation of Thymidine Phosphorylase by Docetaxel.<br />There is evidence that the metabolism of 5-FU in the anabolic pathway blocks the methylation reaction of Deoxyuridylic Acid to Thymidylic Acid, thereby interfering with the synthesis of Deoxyribonucleic Acid (DNA). The incorporation of 5-FU also leads to inhibition of RNA and protein synthesis. Since DNA and RNA are essential for cell division and growth, the effect of 5-FU may be to create a Thymidine deficiency that provokes unbalanced growth and death of a cell. The effects of DNA and RNA deprivation are most marked on those cells which proliferate more rapidly and which metabolize 5-FU at a more rapid rate.</p><p>Colon and colorectal cancer<br />Monotherapy with Capecitabine in adjuvant colon cancer<br />Data from one multicentre, randomized, controlled phase III clinical trial in patients with stage III (Dukes&#39; C) colon cancer supports the use of Capecitabine for the adjuvant treatment of patients with colon cancer (XACT Study; M66001). In this trial, 1987 patients were randomized to treatment with Capecitabine (1250mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles for 24 weeks) or 5-FU and Leucovorin (Mayo Clinic regimen: 20mg/m2 Leucovorin intravenous followed by 425mg/m2 intravenous bolus 5-FU, on days 1 to 5, every 28 days for 24 weeks). Capecitabine was at least equivalent to intravenous 5-FU/LV in disease-free survival in per protocol population (hazard ratio 0.92; 95% CI 0.80-1.06). In the all-randomized population, tests for difference of Capecitabine vs 5-FU/LV in disease-free and overall survival showed hazard ratios of 0.88 (95% CI 0.77 &ndash; 1.01; p = 0.068) and 0.86 (95% CI 0.74 &ndash; 1.01; p = 0.060), respectively. The median follow up at the time of the analysis was 6.9 years. In a preplanned multivariate Cox analysis, superiority of Capecitabine compared with bolus 5-FU/LV was demonstrated. The following factors were pre-specified in the statistical analysis plan for inclusion in the model: age, time from surgery to randomization, gender, CEA levels at baseline, lymph nodes at baseline, and country. In the all-randomized population, Capecitabine was shown to be superior to 5-FU/LV for disease-free survival (hazard ratio 0.849; 95% CI 0.739 - 0.976; p = 0.0212), as well as for overall survival (hazard ratio 0.828; 95% CI 0.705 - 0.971; p = 0.0203).</p><p>Combination therapy in adjuvant colon cancer<br />Data from one multicentre, randomized, controlled phase 3 clinical trial in patients with stage III (Dukes&#39; C) colon cancer supports the use of Capecitabine in combination with Oxaliplatin (XELOX) for the adjuvant treatment of patients with colon cancer (NO16968 study). In this trial, 944 patients were randomized to 3-week cycles for 24 weeks with Capecitabine (1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period) in combination with Oxaliplatin (130mg/m2 intravenous infusion over 2-hours on day 1 every 3 weeks); 942 patients were randomized to bolus 5-FU and Leucovorin. In the primary analysis for DFS in the ITT population, XELOX was shown to be significantly superior to 5-FU/LV (HR=0.80, 95% CI=[0.69; 0.93]; p=0.0045). The 3 year DFS rate was 71% for XELOX versus 67% for 5-FU/LV. The analysis for the secondary endpoint of RFS supports these results with a HR of 0.78 (95% CI=[0.67; 0.92]; p=0.0024) for XELOX vs. 5-FU/LV. XELOX showed a trend towards superior OS with a HR of 0.87 (95% CI=[0.72; 1.05]; p=0.1486) which translates into a 13% reduction in risk of death. The 5 year OS rate was 78% for XELOX versus 74% for 5-FU/LV. The efficacy data is based on a median observation time of 59 months for OS and 57 months for DFS. The rate of withdrawal due to adverse events was higher in the XELOX combination therapy arm (21 %) as compared with that of the 5-FU/LV monotherapy arm (9 %) in the ITT population.</p><p>Monotherapy with Capecitabine in metastatic colorectal cancer<br />Data from two identically-designed, multicentre, randomized, controlled phase III clinical trials (SO14695; SO14796) support the use of Capecitabine for first line treatment of metastatic colorectal cancer. In these trials, 603 patients were randomized to treatment with Capecitabine (1250mg/m2 twice daily for 2 weeks followed by a 1-week rest period and given as 3-week cycles). 604 patients were randomized to treatment with 5-FU and Leucovorin (Mayo regimen: 20mg/m2 Leucovorin IV followed by 425mg/m2 IV bolus 5-FU, on days 1 to 5, every 28 days). The overall objective response rates in the all- randomized population (investigator assessment) were 25.7% (Capecitabine) vs. 16.7% (Mayo regimen); p &lt;0.0002. The median time to progression was 140 days (Capecitabine) vs. 144 days (Mayo regimen). Median survival was 392 days (Capecitabine) vs. 391 days (Mayo regimen). Currently, no comparative data are available on Capecitabine monotherapy in colorectal cancer in comparison with first line combination regimens.</p><p>Combination therapy in first-line treatment of metastatic colorectal cancer<br />Data from a multicentre, randomized, controlled phase III clinical study (NO16966) support the use of Capecitabine in combination with Oxaliplatin or in combination with Oxaliplatin and Bevacizumab for the first-line treatment of metastatic colorectal cancer. The study contained two parts: an initial 2-arm part in which 634 patients were randomized to two different treatment groups, including XELOX or FOLFOX-4, and a subsequent 2x2 factorial part in which 1401 patients were randomized to four different treatment groups, including XELOX plus placebo, FOLFOX-4 plus placebo, XELOX plus Bevacizumab, and FOLFOX-4 plus Bevacizumab. See Table 7 for treatment regimens.</p><p>Table 7 Treatment Regimens in Study NO16966 (mCRC)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Treatment </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Starting Dose </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Schedule </strong></p></td></tr><tr><td style="vertical-align:top"><p>FOLFOX-4</p><p>or</p><p>FOLFOX-4 + Bevacizumab</p></td><td colspan="2" style="vertical-align:top"><p>Oxaliplatin</p></td><td colspan="2" style="vertical-align:top"><p>85mg/m2 IV 2 hr</p></td><td style="vertical-align:top"><p>Oxaliplatin on Day 1, every 2 weeks</p><p>Leucovorin on Days 1 and 2, every 2 weeks</p><p>5-Fluorouracil IV bolus/infusion, each on Days 1 and 2, every 2 weeks</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Leucovorin</p></td><td colspan="3" style="vertical-align:top"><p>200mg/m2 IV 2 hr</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>5-Fluorouracil</p></td><td colspan="3" style="vertical-align:top"><p>400mg/m2 IV bolus, followed by 600mg/m2 IV 22 hr</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Placebo or Bevacizumab</p></td><td colspan="2" style="vertical-align:top"><p>5mg/kg IV 30-90 mins</p></td><td colspan="2" style="vertical-align:top"><p>Day 1, prior to FOLFOX-4, every 2 weeks</p></td></tr><tr><td style="vertical-align:top"><p>XELOX</p><p>or</p><p>XELOX+ Bevacizumab</p></td><td colspan="2" style="vertical-align:top"><p>Oxaliplatin</p></td><td colspan="2" style="vertical-align:top"><p>130mg/m2 IV 2 hr</p></td><td style="vertical-align:top"><p>Oxaliplatin on Day 1, every 3 weeks</p><p>Capecitabine oral twice daily for 2 weeks (followed by 1 week off- treatment)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Capecitabine</p></td><td colspan="3" style="vertical-align:top"><p>1000mg/m2 oral twice daily</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Placebo or Bevacizumab</p></td><td colspan="2" style="vertical-align:top"><p>7.5mg/kg IV 30-90 mins</p></td><td colspan="2" style="vertical-align:top"><p>Day 1, prior to XELOX, every 3 weeks</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>5-Fluorouracil: IV bolus injection immediately after Leucovorin</p></td></tr></tbody></table><p>Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival in the eligible patient population and the intent-to-treat population (see Table 8). The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see Table 8). A comparison of XELOX plus Bevacizumab versus FOLFOX-4 plus Bevacizumab was a pre-specified exploratory analysis. In this treatment subgroup comparison, XELOX plus Bevacizumab was similar compared to FOLFOX-4 plus Bevacizumab in terms of progression-free survival (hazard ratio 1.01; 97.5% CI 0.84 - 1.22). The median follow up at the time of the primary analyses in the intent-to-treat population was 1.5 years; data from analyses following an additional 1 year of follow up are also included in Table 8. However, the on-treatment PFS analysis did not confirm the results of the general PFS and OS analysis: the hazard ratio of XELOX versus FOLFOX-4 was 1.24 with 97.5% CI 1.07 - 1.44. Although sensitivity analyses show that differences in regimen schedules and timing of tumour assessments impact the on-treatment PFS analysis, a full explanation for this result has not been found.</p><p>Table 8 Key efficacy results for the non-inferiority analysis of Study NO16966</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>PRIMARY ANALYSIS </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>XELOX/ XELOX+P/ </strong></p><p><strong>XELOX+BV </strong></p><p><strong>(EPP*: N=967; ITT**: N=1017) </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>FOLFOX-4/ FOLFOX-4+P </strong></p><p><strong>/FOLFOX-4+BV </strong></p><p><strong>(EPP*: N = 937; ITT**: N= 1017) </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Population </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Median Time to Event (Days) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HR (97.5% CI) </strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>241</p><p>244</p></td><td colspan="2" style="vertical-align:top"><p>259</p><p>259</p></td><td style="vertical-align:top"><p>1.05 (0.94; 1.18)</p><p>1.04 (0.93; 1.16)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Overall Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>577</p><p>581</p></td><td colspan="2" style="vertical-align:top"><p>549</p><p>553</p></td><td style="vertical-align:top"><p>0.97 (0.84; 1.14)</p><p>0.96 (0.83; 1.12)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>ADDITIONAL 1 YEAR OF FOLLOW UP </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Population </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Median Time to Event (Days) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HR (97.5% CI) </strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>242</p><p>244</p></td><td colspan="2" style="vertical-align:top"><p>259</p><p>259</p></td><td style="vertical-align:top"><p>1.02 (0.92; 1.14)</p><p>1.01 (0.91; 1.12)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Overall Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>EPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>600</p><p>602</p></td><td colspan="2" style="vertical-align:top"><p>594</p><p>596</p></td><td style="vertical-align:top"><p>1.00 (0.88; 1.13)</p></td></tr></tbody></table><p>*EPP=eligible patient population; **ITT=intent-to-treat population.<br />In a randomized, controlled phase III study (CAIRO), the effect of using Capecitabine at a starting dose of 1000mg/m2 for 2 weeks every 3 weeks in combination with Irinotecan for the first-line treatment of patients with metastatic colorectal cancer was studied. 820 Patients were randomized to receive either sequential treatment (n=410) or combination treatment (n=410). Sequential treatment consisted of first-line Capecitabine (1250mg/m2 twice daily for 14 days), second-line Irinotecan (350mg/m2 on day 1), and third-line combination of Capecitabine (1000mg/m2 twice daily for 14 days) with Oxaliplatin (130mg/m2 on day 1). Combination treatment consisted of first-line Capecitabine (1000mg/m2 twice daily for 14 days) combined with Irinotecan (250mg/m2 on day 1) (XELIRI) and second-line Capecitabine (1000mg/m2 twice daily for 14 days) plus Oxaliplatin (130mg/m2 on day 1). All treatment cycles were administered at intervals of 3 weeks. In first-line treatment the median progression-free survival in the&nbsp;intent-to-treat population was 5.8 months (95%CI 5.1 - 6.2 months) for Capecitabine monotherapy and 7.8 months (95%CI 7.0 - 8.3 months; p=0.0002) for XELIRI. However this was associated with an increased incidence of gastrointestinal toxicity and neutropenia during first-line treatment with XELIRI (26% and 11% for XELIRI and first line Capecitabine respectively).</p><p>The XELIRI has been compared with 5-FU + Irinotecan (FOLFIRI) in three randomised studies in patients with metastatic colorectal cancer. The XELIRI regimens included Capecitabine 1000mg/m2 twice daily on days 1 to 14 of a three-week cycle combined with Irinotecan 250mg/m2 on day1. In the largest study (BICC-C), patients were randomised to receive either open label FOLFIRI (n=144), bolus 5-FU (mIFL) (n=145) or XELIRI (n=141) and were additionally randomised to receive either double-blind treatment with Celecoxib or placebo. Median PFS was 7.6 months for FOLFIRI, 5.9 months for mIFL (p=0.004) for the comparison with FOLFIRI), and 5.8 months for XELIRI (p=0.015). Median OS was 23.1 months for FOLFIRI, 17.6 months for mIFL (p=0.09), and 18.9 months for XELIRI (p=0.27). Patients treated with XELIRI experienced excessive gastrointestinal toxicity compared with FOLFIRI (diarrhoea 48% and 14% for XELIRI and FLFIRI respectively).</p><p>In the EORTC study patients were randomised to receive either open label FOLFIRI (n=41) or XELIRI (n=44) with additional randomisation to either double-blind treatment with Celecoxib or placebo. Median PFS and overall survival (OS) times were shorter for XELIRI versus FOLFIRI (PFS 5.9 versus 9.6 months and OS 14.8 versus 19.9 months), in addition to which excessive rates of diarrhoea were reported in patients receiving the XELIRI regimen (41% XELIRI, 5.1% FOFIRI).<br />In the study published by Skof et al, patients were randomised to receive either FOLFIRI or XELIRI . Overall response rate was 49% in the XELIRI and 48% in the FOLFIRI arm (p=0.76). At the end of treatment, 37% of patients in the XELIRI and 26% of patients in the FOLFIRI arm were without evidence of the disease (p=0.56). Toxicity was similar between treatments with the exception of neutropenia reported more commonly in patients treated with FOLFIRI.<br />Montagnani et al used the results from the above three studies to provide an overall analysis of randomized studies comparing FOLFIRI and XELIRI treatment regimens in the treatment of mCRC. A significant reduction in the risk of progression was associated with FOLFIRI (HR, 0.76; 95%CI, 0.62-0.95; P &lt;0.01), a result partly due to poor tolerance to the XELIRI regimens used.<br />Data from a randomized clinical study (Souglakos et al, 2012) comparing FOLFIRI + Bevacizumab with XELIRI + Bevacizumab showed no significant differences in PFS or OS between treatments. Patients were randomized to receive either FOLFIRI plus Bevacizumab (Arm-A, n=167) or XELIRI plus Bevacizumab (Arm-B, n-166). For Arm B, the XELIRI regimen used Capecitabine 1000mg/m2 twice daily for 14 days +Irinotecan 250mg/m2 on day 1. Median progression-free survival (PFS) was 10.0 and 8.9 months; p=0.64, overall survival 25.7 and 27.5 months; p=0.55 and response rates 45.5 and 39.8%; p=0.32 for FOLFIRI-Bev and XELIRI-Bev, respectively. Patients treated with XELIRI + Bevacizumab reported a significantly higher incidence of diarrhoea, febrile neutropenia and hand-foot skin reactions than patients treated with FOLFIRI + Bevacizumab with significantly increased treatment delays, dose reductions and treatment discontinuations.Data from a multicentre, randomized, controlled phase II study (AIO KRK 0604) supports the use of Capecitabine at a starting dose of 800mg/m2 for 2 weeks every 3 weeks in combination with Irinotecan and Bevacizumab for the first-line treatment of patients with metastatic colorectal cancer. 120 Patients were randomized to a modified XELIRI regimen with Capecitabine 800mg/m2 twice daily for two weeks followed by a 7-day rest period), Irinotecan (200mg/m2 as a 30 minute infusion on day 1 every 3 weeks), and Bevacizumab (7.5mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks) ; 127 patients were randomized to treatment with Capecitabine (1000mg/m2 twice daily for two weeks followed by a 7-day rest period), Oxaliplatin (130mg/m2 as a 2 hour infusion on day 1 every 3 weeks), and Bevacizumab (7.5mg/kg as a 30 to 90&nbsp;minute infusion on day 1 every 3 weeks). Following a mean duration of follow-up for the study population of 26.2 months, treatment responses were as shown below:</p><p>Table 9 Key efficacy results for AIO KRK study</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong><em>XELOX + Bevacizumab </em></strong></p><p><strong><em>(ITT: N=127) </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Modified XELIRI+ Bevacizumab </em></strong></p><p><strong><em>(ITT: N= 120) </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Hazard ratio </em></strong></p><p><strong><em>95% CI </em></strong></p><p><strong><em>P value </em></strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><em>Progression-free Survival after 6 months </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ITT </em></strong></p><p><strong><em>95% CI </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>76% </em></strong></p><p><strong><em>69 - 84% </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>84% </em></strong></p><p><strong><em>77 - 90% </em></strong></p></td><td style="vertical-align:top"><p><strong><em>- </em></strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><em>Median progression-free survival </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ITT </em></strong></p><p><strong><em>95% CI </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>10.4 months </em></strong></p><p><strong><em>9.0 - 12.0 </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>12.1 months </em></strong></p><p><strong><em>10.8 - 13.2 </em></strong></p></td><td style="vertical-align:top"><p><strong><em>0.93 </em></strong></p><p><strong><em>0.82 - 1.07 </em></strong></p><p><strong><em>P=0.30 </em></strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong><em>Median overall survival </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ITT </em></strong></p><p><strong><em>95% CI </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>24.4 months </em></strong></p><p><strong><em>19.3 - 30.7 </em></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>25.5 months </em></strong></p><p><strong><em>21.0 - 31.0 </em></strong></p></td><td style="vertical-align:top"><p><strong><em>0.90 </em></strong></p><p><strong><em>0.68 - 1.19 </em></strong></p><p><strong><em>P=0.45 </em></strong></p></td></tr></tbody></table><p>Combination therapy in second-line treatment of metastatic colorectal cancer<br />Data from a multicentre, randomized, controlled phase III clinical study (NO16967) support the use of Capecitabine in combination with Oxaliplatin for the second-line treatment of metastatic colorectal cancer. In this trial, 627 patients with metastatic colorectal carcinoma who have received prior treatment with Irinotecan in combination with a Fluoropyrimidine regimen as first line therapy were randomized to treatment with XELOX or FOLFOX-4. For the dosing schedule of XELOX and FOLFOX-4 (without addition of placebo or Bevacizumab), refer to Table 7. XELOX was demonstrated to be non-inferior to FOLFOX-4 in terms of progression-free survival in the per-protocol population and intent-to-treat population (see Table 10). The results indicate that XELOX is equivalent to FOLFOX-4 in terms of overall survival (see Table 10). The median follow up at the time of the primary analyses in the intent-to-treat population was 2.1 years; data from analyses following an additional 6 months of follow up are also included in Table 10.</p><p>Table 10 Key efficacy results for the non-inferiority analysis of Study NO16967</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>PRIMARY ANALYSIS </strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>XELOX </strong></p><p><strong>(PPP*: N=251; ITT**: N=313) </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>FOLFOX-4 </strong></p><p><strong>(PPP*: N = 252; ITT**: N= 314) </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Population </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Median Time to Event (Days) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HR (95% CI) </strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>154</p><p>144</p></td><td colspan="2" style="vertical-align:top"><p>168</p><p>146</p></td><td style="vertical-align:top"><p>1.03 (0.87; 1.24)</p><p>0.97 (0.83; 1.14)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Overall Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>388</p><p>363</p></td><td colspan="2" style="vertical-align:top"><p>401</p><p>382</p></td><td style="vertical-align:top"><p>1.07 (0.88; 1.31)</p><p>1.03 (0.87; 1.23)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>ADDITIONAL 6 MONTHS OF FOLLOW UP </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Population </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Median Time to Event (Days) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HR (95% CI) </strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Progression-free Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>154</p><p>143</p></td><td colspan="2" style="vertical-align:top"><p>166</p><p>146</p></td><td style="vertical-align:top"><p>1.04 (0.87; 1.24)</p><p>0.97 (0.83; 1.14)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Parameter: Overall Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>PPP</p><p>ITT</p></td><td colspan="2" style="vertical-align:top"><p>393</p><p>363</p></td><td colspan="2" style="vertical-align:top"><p>402</p><p>382</p></td><td style="vertical-align:top"><p>1.05 (0.88; 1.27)</p><p>1.02 (0.86; 1.21)</p></td></tr></tbody></table><p>*PPP=per-protocol population; **ITT=intent-to-treat population.</p><p>Advanced gastric cancer<br />Data from a multicentre, randomized, controlled phase III clinical trial in patients with advanced gastric cancer supports the use of Capecitabine for the first-line treatment of advanced gastric cancer (ML17032). In this trial, 160 patients were randomised to treatment with Capecitabine (1000mg/m2 twice daily for 2 weeks followed by a 7-day rest period) and Cisplatin (80mg/m2 as a 2-hour infusion every 3 weeks). A total of 156 patients were randomised to treatment with 5-FU (800mg/m2 per day, continuous infusion on days 1 to 5 every 3 weeks) and Cisplatin (80mg/m2 as a 2-hour infusion on day 1, every 3 weeks). Capecitabine in combination with Cisplatin was non-inferior to 5-FU in combination with Cisplatin in terms of progression-free survival in the per protocol analysis (hazard ratio 0.81; 95% CI 0.63 - 1.04). The median progression-free survival was 5.6 months (Capecitabine + Cisplatin) versus 5.0 months (5-FU + Cisplatin). The hazard ratio for duration of survival (overall survival) was similar to the hazard ratio for progression-free survival (hazard ratio 0.85; 95% CI 0.64 - 1.13). The median duration of survival was 10.5 months (Capecitabine + Cisplatin) versus 9.3 months (5-FU + Cisplatin).<br />Data from a randomized multicentre, phase III study comparing Capecitabine to 5-FU and Oxaliplatin to Cisplatin in patients with advanced gastric cancer supports the use of Capecitabine for the first-line treatment of advanced gastric cancer (REAL-2). In this trial, 1002 patients were randomised in a 2x2 factorial design to one of the following 4 arms:<br />- ECF: Epirubicin (50mg/ m2 as a bolus on day 1 every 3 weeks), Cisplatin (60mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200mg/m2 daily given by continuous infusion via a central line).<br />- ECX: Epirubicin (50mg/m2 as a bolus on day 1 every 3 weeks), Cisplatin (60mg/m2 as a two hour infusion on day 1 every 3 weeks), and Capecitabine (625mg/m2 twice daily continuously).<br />- EOF: Epirubicin (50mg/m2 as a bolus on day 1 every 3 weeks), Oxaliplatin (130mg/m2 given as a 2 hour infusion on day 1 every three weeks), and 5-FU (200mg/m2 daily given by continuous infusion via a central line).</p><p>- EOX: Epirubicin (50mg/m2 as a bolus on day 1 every 3 weeks), Oxaliplatin (130mg/m2 given as a 2 hour infusion on day 1 every three weeks), and Capecitabine (625mg/m2 twice daily continuously).<br />The primary efficacy analyses in the per protocol population demonstrated non-inferiority in overall survival for Capecitabine - vs 5-FU-based regimens (hazard ratio 0.86; 95% CI 0.8 - 0.99) and for Oxaliplatin- vs Cisplatin -based regimens (hazard ratio 0.92; 95% CI 0.80 - 1.1). The median overall survival was 10.9 months in Capecitabine -based regimens and 9.6 months in 5-FU based regimens. The median overall survival was 10.0 months in Cisplatin -based regimens and 10.4 months in Oxaliplatin-based regimens.<br />Capecitabine has also been used in combination with Oxaliplatin for the treatment of advanced gastric cancer. Studies with Capecitabine monotherapy indicate that Capecitabine has activity in advanced gastric cancer.</p><p>Colon, colorectal and advanced gastric cancer<br />Meta-analysis<br />A meta-analysis of six clinical trials (studies SO14695, SO14796, M66001, NO16966, NO16967, M17032) supports Capecitabine replacing 5-FU in mono- and combination treatment in gastrointestinal cancer. The pooled analysis includes 3097 patients treated with Capecitabine -containing regimens and 3074 patients treated with 5-FU-containing regimens. Median overall survival time was 703 days (95% CI: 671; 745) in patients treated with Capecitabine -containing regimens and 683 days (95% CI: 646; 715) in patients treated with 5-FU-containing regimens. The hazard ratio for overall survival was 0.94 (95% CI: 0.89; 1.00, p=0.0489) indicating that Capecitabine -containing regimens are non-inferior to 5-FU-containing regimens.<br />Breast cancer<br />Combination therapy with Capecitabine and Docetaxel in locally advanced or metastatic breast cancer<br />Data from one multicentre, randomised, controlled phase III clinical trial support the use of Capecitabine in combination with Docetaxel for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an Anthracycline. In this trial, 255 patients were randomised to treatment with Capecitabine (1250mg/m2 twice daily for 2 weeks followed by 1-week rest period and Docetaxel 75mg/m2 as a 1 hour intravenous infusion every 3 weeks). 256 patients were randomised to treatment with Docetaxel alone (100mg/m2 as a 1 hour intravenous infusion every 3 weeks). Survival was superior in the Capecitabine + Docetaxel combination arm (p=0.0126). Median survival was 442 days (Capecitabine + Docetaxel) vs. 352 days (Docetaxel alone). The overall objective response rates in the all-randomized population (investigator assessment) were 41.6% (Capecitabine + Docetaxel) vs. 29.7% (Docetaxel alone); p = 0.0058. Time to progressive disease was superior in the Capecitabine + Docetaxel combination arm (p&lt;0.0001). The median time to progression was 186 days (Capecitabine + Docetaxel) vs. 128 days (Docetaxel alone).</p><p>Monotherapy with Capecitabine after failure of Taxanes, Anthracycline containing chemotherapy, and for whom Anthracycline therapy is not indicated<br />Data from two multicentre phase II clinical trials support the use of Capecitabine monotherapy for treatment of patients after failure of Taxanes and an Anthracycline-containing chemotherapy regimen or for whom further Anthracycline therapy is not indicated. In these trials, a total of 236 patients were treated with Capecitabine (1250mg/m2 twice daily for 2 weeks followed by 1-week rest period). The overall objective response rates (investigator assessment) were 20% (first trial) and 25% (second trial). The median time to progression was 93 and 98 days. Median survival was 384 and 373 days.</p><p>All indications<br />A meta-analysis of 14 clinical trials with data from over 4700 patients treated with Capecitabine monotherapy or Capecitabine in combination with different chemotherapy regimens in multiple indications (colon, colorectal, gastric and breast cancer) showed that patients on Capecitabine who developed hand-foot syndrome (HFS) had a longer overall survival compared to patients who did not develop HFS: median overall survival 1100 days (95% CI 1007;1200) vs 691 days (95% CI 638;754) with a hazard ratio of 0.61 (95% CI 0.56; 0.66).<br />Paediatric population<br />The European Medicines Agency has waived the obligation to conduct studies with Aceda in all subsets of the paediatric population in adenocarcinoma of the colon and rectum, gastric adenocarcinoma and breast carcinoma (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of Capecitabine have been evaluated over a dose range of 502-3514 mg/m2/day. The parameters of Capecitabine, 5&#39;-Deoxy-5-Fluorocytidine (5&#39;-DFCR) and 5&#39;-Deoxy-5-Fluorouridine (5&#39;-DFUR) measured on days 1 and 14 were similar. The AUC of 5-FU was 30%-35% higher on day 14. Capecitabine dose reduction decreases systemic exposure to 5-FU more than dose-proportionally, due to non-linear pharmacokinetics for the active metabolite.<br />Absorption<br />After oral administration, Capecitabine is rapidly and extensively absorbed, followed by extensive conversion to the metabolites, 5&#39;-DFCR and 5&#39;-DFUR. Administration with food decreases the rate of Capecitabine absorption, but only results in a minor effect on the AUC of 5&#39;-DFUR, and on the AUC of the subsequent metabolite 5-FU. At the dose of 1250mg/m2 on day 14 with administration after food intake, the peak plasma concentrations (Cmax in &mu;g/ml) for Capecitabine, 5&#39;-DFCR, 5&#39;-DFUR, 5-FU and FBAL were 4.67, 3.05, 12.1, 0.95 and 5.46 respectively. The time to peak plasma concentrations (Tmax in hours) were 1.50, 2.00, 2.00, 2.00 and 3.34. The AUC0-&infin; values in &mu;g&bull;h/ml were 7.75, 7.24, 24.6, 2.03 and 36.3.</p><p>Distribution<br />In vitro human plasma studies have determined that Capecitabine, 5&#39;-DFCR, 5&#39;-DFUR and 5-FU are 54%, 10%, 62% and 10% protein bound, mainly to albumin.<br />Biotransformation<br />Capecitabine is first metabolised by hepatic Carboxylesterase to 5&#39;-DFCR, which is then converted to 5&#39;-DFUR by Cytidine Deaminase, principally located in the liver and tumour tissues. Further catalytic activation of 5&#39;-DFUR then occurs by Thymidine Phosphorylase (ThyPase). The enzymes involved in the catalytic activation are found in tumour tissues but also in normal tissues, albeit usually at lower levels. The sequential enzymatic biotransformation of Capecitabine to 5-FU leads to higher concentrations within tumour tissues. In the case of colorectal tumours, 5-FU generation appears to be in large part localized in tumour stromal cells. Following oral administration of Capecitabine to patients with colorectal cancer, the ratio of 5-FU concentration in colorectal tumours to adjacent tissues was 3.2 (ranged from 0.9 to 8.0). The ratio of 5-FU concentration in tumour to plasma was 21.4 (ranged from 3.9 to 59.9, n=8) whereas the ratio in healthy tissues to plasma was 8.9 (ranged from 3.0 to 25.8, n=8). Thymidine Phosphorylase activity was measured and found to be 4 times greater in primary colorectal tumour than in adjacent normal tissue. According to immunohistochemical studies, Thymidine Phosphorylase appears to be in large part localized in tumour stromal cells.</p><p>5-FU is further catabolized by the enzyme Dihydropyrimidine Dehydrogenase (DPD) to the much less toxic Dihydro-5-Fluorouracil (FUH2). Dihydropyrimidinase cleaves the Pyrimidine ring to yield 5-Fluoro-Ureidopropionic Acid (FUPA). Finally, &beta;-Ureido-Propionase cleaves FUPA to &alpha;-Fluoro-&beta;-Alanine (FBAL) which is cleared in the urine. Dihydropyrimidine Dehydrogenase (DPD) activity is the rate limiting step. Deficiency of DPD may lead to increased toxicity of Capecitabine (see section 4.3 and 4.4).<br />Elimination<br />The elimination half-life (t1/2 in hours) of Capecitabine, 5&#39;-DFCR, 5&#39;-DFUR, 5-FU and FBAL were 0.85, 1.11, 0.66, 0.76 and 3.23 respectively. Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered Capecitabine dose is recovered in urine. Faecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL, which represents 57% of the administered dose. About 3% of the administered dose is excreted in urine as unchanged drug.<br />Combination therapy<br />Phase I studies evaluating the effect of Capecitabine on the pharmacokinetics of either Docetaxel or Paclitaxel and vice versa showed no effect by Capecitabine on the pharmacokinetics of Docetaxel or Paclitaxel (Cmax and AUC) and no effect by Docetaxel or Paclitaxel on the pharmacokinetics of 5&#39;-DFUR.<br />Pharmacokinetics in special populations<br />A population pharmacokinetic analysis was carried out after Capecitabine treatment of 505 patients with colorectal cancer dosed at 1250mg/m2 twice daily. Gender, presence or absence of liver metastasis at baseline, Karnofsky Performance Status, total Bilirubin, serum albumin, ASAT and ALAT had no statistically significant effect on the pharmacokinetics of 5&#39;-DFUR, 5-FU and FBAL.</p><p>Patients with hepatic impairment due to liver metastases<br />According to a pharmacokinetic study in cancer patients with mild to moderate liver impairment due to liver metastases, the bioavailability of Capecitabine and exposure to 5-FU may increase compared to patients with no liver impairment. There are no pharmacokinetic data on patients with severe hepatic impairment.<br />Patients with renal impairment<br />Based on a pharmacokinetic study in cancer patients with mild to severe renal impairment, there is no evidence for an effect of creatinine clearance on the pharmacokinetics of intact drug and 5-FU. Creatinine clearance was found to influence the systemic exposure to 5&#39;-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%). FBAL is a metabolite without antiproliferative activity.<br />Elderly<br />Based on the population pharmacokinetic analysis, which included patients with a wide range of ages (27 to 86 years) and included 234 (46%) patients greater or equal to 65, age has no influence on the pharmacokinetics of 5&#39;-DFUR and 5-FU. The AUC of FBAL increased with age (20% increase in age results in a 15% increase in the AUC of FBAL). This increase is likely due to a change in renal function.</p><p>Ethnic factors<br />Following oral administration of 825mg/m2 Capecitabine twice daily for 14 days, Japanese patients (n=18) had about 36% lower Cmax and 24% lower AUC for Capecitabine than Caucasian patients (n=22). Japanese patients had also about 25% lower Cmax and 34% lower AUC for FBAL than Caucasian patients.</p><p>The clinical relevance of these differences is unknown. No significant differences occurred in the exposure to other metabolites (5&#39;-DFCR, 5&#39;-DFUR, and 5-FU).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat-dose toxicity studies, daily oral administration of Capecitabine to cynomolgus monkeys and mice produced toxic effects on the gastrointestinal, lymphoid and haemopoietic systems, typical for Fluoropyrimidine. These toxicities were reversible. Skin toxicity, characterised by degenerative/regressive changes, was observed with Capecitabine. Capecitabine was devoid of hepatic and CNS toxicities. Cardiovascular toxicity (e.g. PR- and QT-interval prolongation) was detectable in cynomolgus monkeys after intravenous administration (100mg/kg) but not after repeated oral dosing (1379mg/m2/day).<br />A two-year mouse carcinogenicity study produced no evidence of carcinogenicity by Capecitabine.<br />During standard fertility studies, impairment of fertility was observed in female mice receiving Capecitabine; however, this effect was reversible after a drug-free period. In addition, during a 13-week study, atrophic and degenerative changes occurred in reproductive organs of male mice; however these effects were reversible after a drug-free period (see section 4.6).<br />In embryotoxicity and teratogenicity studies in mice, dose-related increases in foetal resorption and teratogenicity were observed. In monkeys, abortion and embryolethality were observed at high doses, but there was no evidence of teratogenicity.<br />Capecitabine was not mutagenic in vitro to bacteria (Ames test) or mammalian cells (Chinese hamster V79/HPRT gene mutation assay). However, similar to other nucleoside analogues (ie, 5-FU), Capecitabine was clastogenic in human lymphocytes (in vitro) and a positive trend occurred in mouse bone marrow micronucleus tests (in vivo).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />Tablet core<br />Anhydrous lactose<br />Microcrystalline cellulose (E460)<br />Croscarmellose sodium<br />Hypromellose<br />Magnesium stearate<br />Tablet coating<br />Hypromellose<br />Talc<br />Titanium dioxide (E171)<br />Iron oxide red (E172)<br />Iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.<br />Do not store above 30&deg;C. Store in the original pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aceda 500mg film-coated tablets are peach coloured, oblong shaped, biconvex, film-coated tablets of 15.9mm in length and 8.4mm in width, debossed with &lsquo;500&rsquo; on one side and plain on other side.<br />Aceda is packed in blisters and is available in different pack sizes (30, 60 or 120 tablets per pack).<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Accord Healthcare Limited
Sage House, 319, Pinner Road
North Harrow
Middlesex HA1 4HF
United Kingdom
Tel: +44 208 863 1427
Fax: +44 208 863 1426
E-mail: mena-info@accord-healthcare.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2015 (SA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="data:image/png; base64,iVBORw0KGgoAAAANSUhEUgAACSMAAAZ2CAIAAADVZbb1AAAKQ2lDQ1BJQ0MgUHJvZmlsZQAAeJydU3dYk/cWPt/3ZQ9WQtjwsZdsgQAiI6wIyBBZohCSAGGEEBJAxYWIClYUFRGcSFXEgtUKSJ2I4qAouGdBiohai1VcOO4f3Ke1fXrv7e371/u855zn/M55zw&#x2B;AERImkeaiagA5UoU8Otgfj09IxMm9gAIVSOAEIBDmy8JnBcUAAPADeXh&#x2B;dLA//AGvbwACAHDVLiQSx&#x2B;H/g7pQJlcAIJEA4CIS5wsBkFIAyC5UyBQAyBgAsFOzZAoAlAAAbHl8QiIAqg0A7PRJPgUA2KmT3BcA2KIcqQgAjQEAmShHJAJAuwBgVYFSLALAwgCgrEAiLgTArgGAWbYyRwKAvQUAdo5YkA9AYACAmUIszAAgOAIAQx4TzQMgTAOgMNK/4KlfcIW4SAEAwMuVzZdL0jMUuJXQGnfy8ODiIeLCbLFCYRcpEGYJ5CKcl5sjE0jnA0zODAAAGvnRwf44P5Dn5uTh5mbnbO/0xaL&#x2B;a/BvIj4h8d/&#x2B;vIwCBAAQTs/v2l/l5dYDcMcBsHW/a6lbANpWAGjf&#x2B;V0z2wmgWgrQevmLeTj8QB6eoVDIPB0cCgsL7SViob0w44s&#x2B;/zPhb&#x2B;CLfvb8QB7&#x2B;23rwAHGaQJmtwKOD/XFhbnauUo7nywRCMW735yP&#x2B;x4V//Y4p0eI0sVwsFYrxWIm4UCJNx3m5UpFEIcmV4hLpfzLxH5b9CZN3DQCshk/ATrYHtctswH7uAQKLDljSdgBAfvMtjBoLkQAQZzQyefcAAJO/&#x2B;Y9AKwEAzZek4wAAvOgYXKiUF0zGCAAARKCBKrBBBwzBFKzADpzBHbzAFwJhBkRADCTAPBBCBuSAHAqhGJZBGVTAOtgEtbADGqARmuEQtMExOA3n4BJcgetwFwZgGJ7CGLyGCQRByAgTYSE6iBFijtgizggXmY4EImFINJKApCDpiBRRIsXIcqQCqUJqkV1II/ItchQ5jVxA&#x2B;pDbyCAyivyKvEcxlIGyUQPUAnVAuagfGorGoHPRdDQPXYCWomvRGrQePYC2oqfRS&#x2B;h1dAB9io5jgNExDmaM2WFcjIdFYIlYGibHFmPlWDVWjzVjHVg3dhUbwJ5h7wgkAouAE&#x2B;wIXoQQwmyCkJBHWExYQ6gl7CO0EroIVwmDhDHCJyKTqE&#x2B;0JXoS&#x2B;cR4YjqxkFhGrCbuIR4hniVeJw4TX5NIJA7JkuROCiElkDJJC0lrSNtILaRTpD7SEGmcTCbrkG3J3uQIsoCsIJeRt5APkE&#x2B;S&#x2B;8nD5LcUOsWI4kwJoiRSpJQSSjVlP&#x2B;UEpZ8yQpmgqlHNqZ7UCKqIOp9aSW2gdlAvU4epEzR1miXNmxZDy6Qto9XQmmlnafdoL&#x2B;l0ugndgx5Fl9CX0mvoB&#x2B;nn6YP0dwwNhg2Dx0hiKBlrGXsZpxi3GS&#x2B;ZTKYF05eZyFQw1zIbmWeYD5hvVVgq9ip8FZHKEpU6lVaVfpXnqlRVc1U/1XmqC1SrVQ&#x2B;rXlZ9pkZVs1DjqQnUFqvVqR1Vu6k2rs5Sd1KPUM9RX6O&#x2B;X/2C&#x2B;mMNsoaFRqCGSKNUY7fGGY0hFsYyZfFYQtZyVgPrLGuYTWJbsvnsTHYF&#x2B;xt2L3tMU0NzqmasZpFmneZxzQEOxrHg8DnZnErOIc4NznstAy0/LbHWaq1mrX6tN9p62r7aYu1y7Rbt69rvdXCdQJ0snfU6bTr3dQm6NrpRuoW623XP6j7TY&#x2B;t56Qn1yvUO6d3RR/Vt9KP1F&#x2B;rv1u/RHzcwNAg2kBlsMThj8MyQY&#x2B;hrmGm40fCE4agRy2i6kcRoo9FJoye4Ju6HZ&#x2B;M1eBc&#x2B;ZqxvHGKsNN5l3Gs8YWJpMtukxKTF5L4pzZRrmma60bTTdMzMyCzcrNisyeyOOdWca55hvtm82/yNhaVFnMVKizaLx5balnzLBZZNlvesmFY&#x2B;VnlW9VbXrEnWXOss623WV2xQG1ebDJs6m8u2qK2brcR2m23fFOIUjynSKfVTbtox7PzsCuya7AbtOfZh9iX2bfbPHcwcEh3WO3Q7fHJ0dcx2bHC866ThNMOpxKnD6VdnG2ehc53zNRemS5DLEpd2lxdTbaeKp26fesuV5RruutK10/Wjm7ub3K3ZbdTdzD3Ffav7TS6bG8ldwz3vQfTw91jicczjnaebp8LzkOcvXnZeWV77vR5Ps5wmntYwbcjbxFvgvct7YDo&#x2B;PWX6zukDPsY&#x2B;Ap96n4e&#x2B;pr4i3z2&#x2B;I37Wfpl&#x2B;B/ye&#x2B;zv6y/2P&#x2B;L/hefIW8U4FYAHBAeUBvYEagbMDawMfBJkEpQc1BY0FuwYvDD4VQgwJDVkfcpNvwBfyG/ljM9xnLJrRFcoInRVaG/owzCZMHtYRjobPCN8Qfm&#x2B;m&#x2B;UzpzLYIiOBHbIi4H2kZmRf5fRQpKjKqLupRtFN0cXT3LNas5Fn7Z72O8Y&#x2B;pjLk722q2cnZnrGpsUmxj7Ju4gLiquIF4h/hF8ZcSdBMkCe2J5MTYxD2J43MC52yaM5zkmlSWdGOu5dyiuRfm6c7Lnnc8WTVZkHw4hZgSl7I/5YMgQlAvGE/lp25NHRPyhJuFT0W&#x2B;oo2iUbG3uEo8kuadVpX2ON07fUP6aIZPRnXGMwlPUit5kRmSuSPzTVZE1t6sz9lx2S05lJyUnKNSDWmWtCvXMLcot09mKyuTDeR55m3KG5OHyvfkI/lz89sVbIVM0aO0Uq5QDhZML6greFsYW3i4SL1IWtQz32b&#x2B;6vkjC4IWfL2QsFC4sLPYuHhZ8eAiv0W7FiOLUxd3LjFdUrpkeGnw0n3LaMuylv1Q4lhSVfJqedzyjlKD0qWlQyuCVzSVqZTJy26u9Fq5YxVhlWRV72qX1VtWfyoXlV&#x2B;scKyorviwRrjm4ldOX9V89Xlt2treSrfK7etI66Trbqz3Wb&#x2B;vSr1qQdXQhvANrRvxjeUbX21K3nShemr1js20zcrNAzVhNe1bzLas2/KhNqP2ep1/XctW/a2rt77ZJtrWv913e/MOgx0VO97vlOy8tSt4V2u9RX31btLugt2PGmIbur/mft24R3dPxZ6Pe6V7B/ZF7&#x2B;tqdG9s3K&#x2B;/v7IJbVI2jR5IOnDlm4Bv2pvtmne1cFoqDsJB5cEn36Z8e&#x2B;NQ6KHOw9zDzd&#x2B;Zf7f1COtIeSvSOr91rC2jbaA9ob3v6IyjnR1eHUe&#x2B;t/9&#x2B;7zHjY3XHNY9XnqCdKD3x&#x2B;eSCk&#x2B;OnZKeenU4/PdSZ3Hn3TPyZa11RXb1nQ8&#x2B;ePxd07ky3X/fJ897nj13wvHD0Ivdi2yW3S609rj1HfnD94UivW2/rZffL7Vc8rnT0Tes70e/Tf/pqwNVz1/jXLl2feb3vxuwbt24m3Ry4Jbr1&#x2B;Hb27Rd3Cu5M3F16j3iv/L7a/eoH&#x2B;g/qf7T&#x2B;sWXAbeD4YMBgz8NZD&#x2B;8OCYee/pT/04fh0kfMR9UjRiONj50fHxsNGr3yZM6T4aeypxPPyn5W/3nrc6vn3/3i&#x2B;0vPWPzY8Av5i8&#x2B;/rnmp83Lvq6mvOscjxx&#x2B;8znk98ab8rc7bfe&#x2B;477rfx70fmSj8QP5Q89H6Y8en0E/3Pud8/vwv94Tz&#x2B;5fBhlYAAAAJcEhZcwAAHsMAAB7DAbyXl9oAACAASURBVHic7N3LqizZfeDhlBH4NRohUdgPUAhDjxqs1qDmAnE4CHpi3AhNNDY91qQQGA9FUQg0V0PZBo8MRtQDtBE2xq/hUfUgu9OhuOWKf6xYt/g&#x2B;anDqnL1z52VnRK74xVrxrW&#x2B;&#x2B;&#x2B;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&#x2B;NY333xT&#x2B;z4AEPF2lPWzT37&#x2B;P//3/yhzZwAAADgvkNP&#x2B;9V9&#x2B;f8U9AQASKW0ArdsfaP327366/Mt/&#x2B;Okff/77X6x&#x2B;vfwGAABQXWCgt/TZD365&#x2B;vfaGwCUpLQBtCLLQGvH1hjsIb8BAABc4&#x2B;qB3pL8BgCFKW0ApZUfaG3Zmfr2kN8AAADStDPKW7Vz2qX8BgDnKW0AV2l8rLVFfgMAAFjV6ShvlfwGALkobQBnjTTW2iK/AQAA93GHUd4q&#x2B;Q0AApQ2gFS3HWttkd8AAICuGeWlkN8AYJ/SBjBnrHWG/AYAALTGKC87&#x2B;Q0AXpQ24L6MtYqR3wAAgAKM8uqS3wC4J6UNGJ&#x2B;xVpvkNwAAIKadUd5PfvTF1j/96jcfi92NlslvAAxPaQPGsTPWktN6Ib8BAAAv7RS1VTuZbYv89iS/ATASpQ3oTOMDLa6wn98MwwAAoHdtDvQCIS2d5LYkvwHQKaUNaFSbAy3asZPfTH0DAIA2NTXQ21/4MXtmk9Zi5DcA2qe0AZU1NdCid/IbAAC0oM2B3qVz1J7ktDLkNwCaorQBhbQ50OIOdsZg8hsAAJzRxUDP7LTCZk94sadLfgOgFqUNyKyLgRY3t3/hN/kNAACmWh7lXT1NTVSLSXxdCjy98hsABShtQFDLYy0IkN8AALi5Zkd5h3LaNN4c7XC6Wl7hF&#x2B;5q8hsAeSltwBvNjrWgAPkNAIDxdDTKe5tqfvWbj3JaC16vwuvpTXldmnot5DcAwpQ24P/paKwFdclvAAB0od9R3pk1IZuKN0O61auzld&#x2B;0NwCmlDa4nX7HWtAy&#x2B;Q0AgFraH&#x2B;Wdv5ra25lS3SWcWpaTz7a&#x2B;4IyxXw75DYAZpQ2G1f5YC4YnvwEAkFH1Ud60wcxSSiDPPG9h5xvHrjXZZSlkT4fW5Nz64lu9fFaeBLg5pQ26V32sBRwivwEAsK/uKC9jsJnajzfTKvP8slt1mpiMqzgm3pQX5RD5DeA&#x2B;lDbohqIGA5PfAABuqMFR3kWZbUqtuc7s5fNUN0h&#x2B;AxiS0gbNaXCsBVQhvwEAjKGvUV722Kb3XOQnP/rCczsG&#x2B;Q2gd0obVNPXWAtohPwGANCsuqO8P/nOX8a&#x2B;8Z//7a9TvmyrwM0ut6b9lLF8OTzzg5HfADqitMHlFDXgajv5TXsDAMiu8aL2Z3/&#x2B;N4/H45/&#x2B;/i/2v2bnCxLbG9kFrlHnsna3Ir8BtElpgzzkNKA18hsAwEmdFrX9ipZ4U2JbeauzBiU03pLfAKpT2uAYRQ3ol5UnAQCW9kd5j4aL2qWUtoD0S9zt9zPT1DhPfgMoSWmDdYoacBPyGwBwE9VHeeHrqAVMp7U9Q93jXauT1s5LL20PIY0a5DeAiyht3F31sRZAg&#x2B;Q3AKBf1Ud5JYvayyunPRS1ZszCm7RGm&#x2B;Q3gPOUNu6i&#x2B;lgLoHfyGwDQlEZGeYldLXDttJ2bev7h7Q2KaudtTVOTzRib/AZwiNLGaBoZawHchPwGAFyt5VHeK7Nlv5Ra&#x2B;hy1h6KWZn9px61ylrIgpOrGTchvAFuUNnrV8lgL4ObkNwAgoPoob9pUEtvJ1oS2xBls05z2UNRyWIaxnZfy0GXVUm4Qbkh&#x2B;A3gobbSv&#x2B;lgLgCzkNwDgqfoobyvGxOY8TeW6QpuiFhaLZ/ukNThKfgPuRmmjFdXHWgCUJ78BwMDqjvIaKS777U1Ry&#x2B;j8K66owaW28pv2BgxAaaM0RQ2AffIbAPSlwVFeenRZnc2muBRzaLHHoze1xesL7ZDfgDEobVylwbEWAP2S3wCguvZHeW9byyuxBC7JRtjW6/LKnL/6zcf01y72s9JvAajLypNAj5Q2zmp/rAXAqOQ3ALhCU6O81XAySybhZQOllzJWpwyeWezxTHXzokOP5DegcUobqZoaawHAlp38pr0BwFT7o7wrrrW2Sn0p5kwWfX3vRa&#x2B;XMgd9kd&#x2B;AdihtzLU/1gKAQ0x9A&#x2B;DO9od4j4ZHeTtX8DpZ4LST885cX636BdX8/sDA5DegCqXtvhQ1AO5MfgNgML0M8bqepra6CuJtpbyUb5&#x2B;iM8Vu9daW3573V&#x2B;7mLzp0Sn4Drqa0Da7fsxcBoDz5DYD2dVHUdlbhi2WP/e8Nx4/pDa7eSODeDlxizl8P7&#x2B;0tZHkpY6arU56/P0D75DcgI6VtEF2MtQCgR/IbAFV0N8pLTB2rPSPlu47fo/f270nsrj5GzDONvGTXTYgc7yUDYuQ3IEZp60x3Yy0AGJL8BkAurY3y0oNZyje&#x2B;/bIyhSNLoUkPb/1mmwbLYpbJatPb6ffVAWqR34C3lLYOrI67RDUAaI38BkDA6ojvZ5/8/L/98j/K35mnXi6lltL2zix4&#x2B;HbGW&#x2B;yWq0tpTtkX6nxr69U889vY72sEtE9&#x2B;A6aUtm60dp4jAJBCfgPgrbcX2K4S3nL1tqtrx0VdcOBIszWtMOWZPPO0vL0K2vnrwAHUJb/BbSlt3fju9z6Z5rSdDfdDeAOAtslvAEy9hnv7A72XkuEtcU3IS39cSX01m52na/&#x2B;BHHqeszwnGVcl7es1ApDf4A6Utm7MStuM8AYAvZPfAG5ra7jXTngrc3G16aqGR1du3CmCzaaak3eswYvG9TIPEqA6&#x2B;Q0Go7R1Y7&#x2B;0zQhvADAG&#x2B;Q3gDhKHe&#x2B;2Et7eexSVwGbCMmqo1JefqVVmu0wXVAM6T36BfSls3DpW2GeENAEYivwEMJjbcaza8pUxHm37NyUgzvdm6duaoXVfaursMXguvFEBH5DfogtLWjTOlbUZ4A4DxyG8A/coy3GsqvKXkmaMV6hXkCqea9JUz&#x2B;81pj2vuvKgGcBH5DVqjtHUjY2mbEd4AYEj/8NM/fjweW/ntZ5/8/PF4yG8ALbhiuNdUeHsKtJy6qebMhdBaXkpxyAmFAGzt&#x2B;rU3KEBp68Z1pW1GeAOAgZn6BtCgAsO9BsPbU5VpamfknftV7IHv3O302NbRywTAw9Q3KEhp60ax0jYjvAHA8OQ3gLrKD/fSw9vj8Sjc3hoXK221GlV38wgBuJr8BldQ2rpRq7TNCG8AcBPyG0Ax1Yd7wtshFefhnZxRp6IBsEp&#x2B;g5OUtm5UH3qtEt4A4FbkN4ArtDbcE94Ke/Wz1YUcXUoNgCrkN0intHWjtaHXKuENAG5IfgM4qfHhnvB2hezXe5veoK4GwEXkN1iltHWj8aHXKuENAGqpfrhNfgNI19dwT3jL5fxSkBXXsQSAF/kNlLZu9DX0WiW8AcBFAitNPY/KTZeruui&#x2B;TclvAKu6Hu4Jby/p5Wx1t7v67SarAdAp&#x2B;Y1bUdq60fXQa5XwBgBnvD2cl34Ub&#x2B;frC5DfAEYa7o0d3mKz0GZntyz/CQBuQn5jVEpbN0Yaeq0S3gBgR&#x2B;KhveVUttchvLd/39TBPvkNuJWBh3udhretnePW9LLl36fvuM/cTwAYgPzGAJS2bgw89FolvAHA1NYBu7erRG591&#x2B;l7VIH8BozqPsO9LsJbYP53bKI5ALBFfqMvSls37jP0WiW8ATCqlE62c0L90e8dj/wGDOC2w702w9tsglpKeFu9YOoV9w0A7kx&#x2B;o1lKWzduO/RaJbwB0KnnkbjYRLQpx&#x2B;92/MNP//jxeMhvQEcM957aDG9LW2tIAgDlyW&#x2B;0QGnrhqHXDuENgGadLGr7HN1L93bq2&#x2B;PxkN&#x2B;AWgz3VvUS3gCA1shvFKa0dcPQK53wBkBFl6a1J4EtF/kNaIThXorE8PZ4PH72yc&#x2B;FNwBgRn7jOkpbNwy9woQ3AAoLxzYJrQUu/AaUZ7gXILwBAOfJb2ShtHXD0CsX4Q2AMwIV7dnPVr&#x2B;xTFqb/ejXD915LJrfjPwGXMpw7zzhDQDIRX7jKKWtG4ZeFxHeAFiVUtSmCe1Xv/m4FbTKO7&#x2B;CpdKWQn4DcjHcy054AwAy0t7Yp7R1w9CrDOEN4J6WkWw1mx0qWMVi1dGuNrtj&#x2B;9&#x2B;&#x2B;9cAbTHEpD6QA&#x2B;Q0IMNy7mvAGAGQnv/GitHXD0KsK4Q1gVOdnfU2VzE657nnKfW55ecksz4P8BjTCcK8w4Q0AuIj8dk9KWzcMvVogvAH0q&#x2B;sFFWN3fjkzL&#x2B;VbAj&#x2B;ojLdT1nauhNfmZET5DXgx3KtLeAMALiW/DU9p64ahV4OEN4Bm5Z2y9mh4KciY9teEzDhlLXBTFZ8H&#x2B;Q3uyXCvKcIbAFCA/DYSpa0bhl7tE94AqsgyWW3rRsoUl8SHEO5GO7fWmgKhsc0Hvk9&#x2B;g&#x2B;EZ7rVMeAMAipHfOqW0dcPQqzvCG8ClMiaZKukl/f4funs7Kyi2ZnVGXXryTHkCK14/r8CPlt9gJIZ7HRHeAIDC5Lf2KW3dMPTqnfAGcIWLelXen77/o9/eSJud7JAyS2K&#x2B;dekzufMYS1747fF4yG/QI8O9fglvAEAV8ltTlLZuGHoNRngDWHUoyawGjEuDx8liNEAzO6RYYNt5Yp/3IftLv3WDDXZT&#x2B;Q26YLg3DOENAKhIfqtFaeuGodfYhDfgttKnhYVXC8zVWh7RtRmn3zVqbFt9jIfWh1yVfmm67E9slky4/3gr/jK8XXny8XjIb1CS4d6ohDcAoDr5rQClrRuGXrcivAGjyjXJ6RUwZiXj6nSRZbnIweRtpcvvSvy5uZ7zWgtdtvA7s5XfDL2gAMO9mxDeAICKlh9FDPdyUdq6Yeh1Z8Ib0KllC1mtI&#x2B;dXjLyItSKnjlbGM89emafuTDfd&#x2B;t70NJj&#x2B;jQU4wxGqM9y7J&#x2B;ENALjU2w8bRny5KG3dMPTiRXgD2lRgMlAjU9ZmBitqW8pM9mrzJX4cmZPXxe9D4meJz37wS&#x2B;MuKMNwj4fwBgCclvhx4rd/99PnVxrx5fLt2ncAOGw2CJ9tQGf/a8QOlJFxWcjzN/L2zmSZdzW7qeEFJiCu3sJMrdUan9IfVJVrxWXkNB2A9u0P9KY&#x2B;//0vPv/Bf/6v8AYAt5We1q6&#x2B;JzdnTls3nORIIofSgCvkzSGzIJH3glvZl/Xb0nJWKS&#x2B;9bta9G&#x2B;f18rpn&#x2B;TxgThsUY7jHW2a8AQCPfGnNnLa8lLZuGHoRI7wBZ2TpFoXLxPI&#x2B;B&#x2B;5A7xOY7iY9r7Z/9biwK/b4ShsUY7jHUcIbANzERbPWlLa8lLZuGHqRhfAGHNVLbDt6P2N3afpTGu8uQ8q7SOnqrXX0shbYpyttUIzhHicJbwAwjDILQipteSlt3TD04grCGxAQWJ4x&#x2B;x3IdaG1jrLKPe28vtPXbmsB0jL9tZjye22lDYox3CMv4Q0AOlLlWmtKW15KWzcMvShAeAOu9iof4aSR8UJcy4lNjYeWewq84ltT1hILXDu/BtX3y0obFGO4x6WENwBoSpW0tnofjPhyUdq6YehFedUP8AHjyXj9s4zJLfDTqSv26u&#x2B;/uM/brPsL0NqeV2mDYgz3KEl4A4DCWkhrM0pbXkpbNwy9qK61w3/AMDJeLuvtXKVXTen9Gl23tbVQ5PKfHj28oI3vW5U2KMZwj4qENwDIrsG0NqO05aW0dcPQi9Y0fnAQaFn5q2f12GB4bL9wics/Nrg0aF97T6UNijHcox3CGwAEtJ/WZpS2vJS2bhh60bi&#x2B;Dh0CtVyx6B/D&#x2B;MmPvtiabrgjpb096v0Wdb1/VNqgGMM9miW8AcCq7tLajNKWl9LWDUMv&#x2B;tL1gUXgjPOXT9PVWvMn3/nLwHf987/99aGvz37hPWntPKUNijHcoxfCGwC31Xtam1Ha8lLaumHoRddGOuwIzKQHksB0pYfwVsNOWvuzP/&#x2B;bnW/8p7//i51/PdTeDs1Re11&#x2B;L/32Mxp4H6e0QTGGe3RKeANgYIOltRmlLS&#x2B;lrRuGXoxk4IOScB8XXWtt62b1tksF0tp&#x2B;VJt&#x2B;185XnmlvFX8l7rMXU9qgGMO9F5dW7ZrwBkDXxk5rM0pbXkpbNwy9GNh9DllCjw5NWcvyjRSwldZWu9oylf3Zn//Nfmnbv/Hl9x5darKw2&#x2B;6nlDYoxnDvyQk3gxHeAGjcrdLajNKWl9LWDUMv7uO2BzShQYcmrqUcBdu5QQfRLnUorb0Eclqi58993X5rpc2e6Elpg2IM9x7vPnX4nDAA4Q2A6u6c1maUtryUtm4YenFbDndCa5xv3r6jq0FeV9QSVS9tb4db99zdKG1QjOHeY/IB4/WJop11g7mC8AZAAdLaFqUtr2/XvgMAb8x2dbMd5Ox/b7hfhPIc52pQIK3trOWYxWzW2lLjdc0OBaC650eO/blualy/9gd6U5///hef/&#x2B;A//1d4A2CHtEYVShvQGeENzkhZDdIhqi7EZq1Nr6&#x2B;WJbDtXLCtwYuxSWsA7dv5HPKTH33x9lOK8NYv4Q2AmPRJ0gZ9XEdpA/o23Ucu96zCGzwdutzacu0mWnD0QmvLtPYovkqktAZAov0ruR76JLN6sz7VdEd4A2CHiWu0RmkDxvF2MCa8cVtnDlFRy86stalpPFsu2Hgyrb29qNvs9qU1AAqbJrSjn3ZSJsnRCOEN4OakNRqntAHDEt4Y3urhpK0DRqt/v3VAylGnpqRfUO2KrrZzs9W72kNaAxjU8yPK6wNJ4jlDgepmtclOCW8Aw5PW6IvSBtyF8MZNHDo72&#x2B;GkLrzWgVxOWTtq2tL&#x2B;6e//QloDoBHh&#x2B;fdb60PGPuQIb50S3gAGIK3RNaUNuCnhjQG8jv5Mjwo5JDSMZ9Z6rSG5rF/pc91mX7/8X2kNgN5d8XHI8pKdEt4AuiCtMRKlDeDxEN5owPI8blPTBjZbFGvHrHVNL96W0t7MWgOgL6txK3ABtucf9ne1s391UdtRCW8AjZDWGNi3vvnmm9r3gSTf/d4ntjJQy9uPAt6enOeSaTexfxQv8HJP21uAtMaOz37wy3/9l9/XvhdwC4Z7j&#x2B;2zjlImq&#x2B;X6HHXmzCc6lXjY9yG8ARwnrbXs&#x2B;eoY8eWitHXD0AvaIbxxHVcHGcxOV1sePdz5ssFIa71Q2qAYw72n5Qeho2tCBj5KZT8Jhq4JbwBnSGsdUdrysnokwGGWmuQ6jub0Ln3hqdWz5pd/uXqD3f2eSGsAlJF4IstTsfNdViegtzCtnCVLTQIcIq3Bk9IGcJbwRkDi5UNo3M5aVYFrvQQqXbO/P9IaAAGv/dp0T5d&#x2B;cdO89yGXrXWeZ38vvLVJeAOYkdZgldUju2E5EeiUpSYHkKVqzNY&#x2B;Sl9UsNmUcjf7q1GlnBQfaG9vtfPrIa0NyeqRUIzhXnYpfe7o0pQBscupqm69sNQkcAfS2qisHpmX0tYNQy8Yg/DWhVnlelvFdm4h0U6GaSel3NzRBaau6GqrP6gWae0OlDYoxnDvsbGu8tHvOnTG0tXXx41ltiXhrRfCGzAGae0mlLa8lLZuGHrBkIS3q6UcskksIulzkk7OXmqko9xWelg939JSbrCd3wdprVNnJsgqbVCM4d4jdG7T/nftf&#x2B;PqLeTd7eYqbU96W3eEN6AX0loX/v2v/nb6v//lf/33kzeotOWltHXD0AvuQHjLKMuMosCZ1KvfHjtHm7pSfoWmr&#x2B;PRr2&#x2B;ftNapjBNklTYokRysjAAAIABJREFUxnDvUa&#x2B;0LW8ky/46b2Z7Etu6JrwB7ZDWujBLa6vO9DalLS&#x2B;lrRuGXnBDwttJFy3fdyi/9VVWeCqWaVsjrfXrotCrtEExhnvLz06BqWZngln22HZFaXuIbQMR3oCSpLUupKS1pXBsU9ryUtq6YegFCG&#x2B;HBK6Uln4LPUaUG8qYWg9dkK&#x2B;jXw9pbQDpv&#x2B;dKG7TMcO/x/zdoJXej&#x2B;3nv5J1R2jhEeAPyktZ6EatrM7HYprTl9e3adwCAVLMPQMuPTbO/uckHpkM15Xm4ZPVbfvKjL2YHUzrqJSy9XbHz7W9Oyi9Ad78kgv2t7GzxAIa3/Gi3/8Xnb2Tf9z/9dPq/v/v669jt/Ml3/lJsG9Lbsd7L57//xec/&#x2B;M//Fd6AJ2mtF1nSGg1S2gB6dc/wdttl/Vg6&#x2B;sswO1j2dhZjxoNrFUlrtyKtAfe0dXpNxV35bELbLLO9/ibW28S2OxDegLektV4USGv//ld/e&#x2B;aCbWShtAEMYrDw9nYxnx0D1BF2nKkIryNuA6cIae1ubPGAwRxdQ3JrrYLXH3ZuavhPBQxDeAMeR5aZNeirzsS1G1LaAMY0THhbXi3D0RBm9g/GLWeqnbzB1khrXct4QSCATq3GsIybx7cz246uL33UckLb9J9e09rOzHJLtzybjR4Jb3AT0lpHqqc109qqU9oAbqG78LY1lW3n2IfjBQOIHdvavyTbVp3t9xdGWuuacwUApp5bxSzLPAYWQph&#x2B;5evbp/ek/EY7sbedX0DSqR4jEd5gGNJaX6rXNZqitAHcUUfhLf0s46NrDdGC/QNY&#x2B;4e6dg6ovT0u1tfvibTWO3UNIEUglT3WTqlZrgmZUvKeX/P2qq7ZTae1VSS8jUR4g45Ia32R1tihtAHQcXh7mh1JSfkWWvD2ONrbKYwDv9z7Iy6jrMEM83sLcNSrk00TV2w5x9WTrgIb2CwT7E66Lr&#x2B;5NN0NCW/QFGmtL32lNQtI1qW0ATDXUXh7qrvID28lviiHDv2M90JLa/dU/WAuQDtW13J8HN9UJq5zML1i2av2vf7puu3z777&#x2B;eufKbWX48HxnwhsUJq11p6&#x2B;6RjuUNgDe6Cu8OWxdUfqRmtVrp61OUDt0m4lf2Qhp7W5iq6Kd/3EAPdqqbvtf&#x2B;ThXyw598Ih5zlRLiW2NrCq5ahop694TzhPeIDtprTvSGlkobQAc01d4o4yjh6XeXk9l62a7PqAjrd3WcimzS6dNnF85DaCkt5Pa06vb0Z&#x2B;7rHQFYlsLzjzGOzw/dya8QYC01i&#x2B;NjYyUNgBOEd5YFVsKMv1YWxfxQFrr3UWtd/XA7vmbBejayfUMpx8hVq/91prptLbn9LUyq0qmPLc7T9rWtx&#x2B;ag9jsi8KS8AarpLUBaGxkp7QBkJPwNpjwactb35hyHG3r&#x2B;Ev751BLawO4&#x2B;tds9fZzHXZcnS0K0J3Z5itly3xmQ9rOB4xZbCu2gGTsqdtaFfntayG29Ut447aktcHIbFxBaQPgQsJbd6pkhqe3x1waPCgjrQ2g4gHWjMtIXhrwAMrYmhe1vylbXe&#x2B;xzUUgW7vu2pl9xMmW9pp9GL4DtEB4Y2DS2sBkNi6itAE9cbZ&#x2B;74S3ARxdUGiw96m0xhn7i2uFw1iDR5MBTqq1XvSlW9SUOWpl1pB8ynJCxmzXdugJdEbIYIQ3epdY1wz6gFVKG9Cxi66OTjHCW4NWj/7v/O/wpLV7Cixc9tbqPiv7rIvZxQ4dxAR6sXMBsJTZUat/YGm5m3hkGkkl3shsx2dy28CEN9onrd1QIxPafvjlb6f/&#x2B;9WHz2rdEzJS2oBBmO42AOGtTWeSQ4/vRGntti79dd05NSRjbLsu4AEUs9yCXXfSwNaVxnr8AHPIMncdesg7X5yyAyr5EtMO4Y0WSGudynWefSOZbekV3iS3riltQJdmJ2Mu3W20PCThrU2HwlsX5ylLa1zt7cjwTBirtcAaQF7LLWHJkwZuuAk9M7ntfBhbjubEtrsR3ihDWuvXzmT35x&#x2B;G3GtM57qpbt1R2oCOpR/xt87kAIS3Nr1dbbJB0hoNsm8CWEqcIPX689GT7cY&#x2B;Wrdq9pBPTm7L&#x2B;6kvsfbd8FW7A&#x2B;GNXKS1MaTsX47us5qd0LbFRLfuKG3AOHaG2VOmu41BeGtWg&#x2B;8paY1GlH93NPh&#x2B;BLjImUlRNxwgzM5EPDq5bfZsb63DmSJc&#x2B;5xMObDp5/P9T/LCG9LaYA7tR/qdD/3Vh89ml2rbYaJbL5Q2YEymu92N8MbU2&#x2B;GWXwDKWx6FvG6n0/7UUoAt0&#x2B;QTKC657kPGTfTvvv76&#x2B;59&#x2B;mv735aU/gcsmF7udnZt9hJ7/G7bS&#x2B;0if7vYQ3u5BWhvYrUYx02Z2tLrpbW1S2oBbSAxvRmjDEN7uRloj7O3SZFnC2OpPyXsk91bjUuAmAlu2Qxvtt9d&#x2B;zu77n376u6&#x2B;/Lvbjlq67&#x2B;t3Jm02PbSkPwQqTAxPebkhau4mdbfvOzOnEIVXjS0cemuJGs5Q24I6sM3k3wtt4pDWyWx2kZTkcuXNM8Hxs27lxuy3gDmZ5ZvrnxM1g4tBgGCcf73K/s3yeYzug9Ap4t5eMHcLbkBLT2sOgb3Rb&#x2B;5fht/yvKWvyW1&#x2B;UNuDurDN5Q8Jbj6Q1Cpgdlu16CGc/BQwjPZjNttsdXb6l1ly39KHQzneddH4yXK6bYgDCW6ekNQ6d6X7d/OzWxFaYpBalDeAPvHbY&#x2B;3tu091GIry1SVqjiivmh63eZsbx4ezUTrskoFMtbL4uOng3vSRb3QUk90cxhy6MF/ve1btxxk0OthIjvDVLWmMqcIRtdt3QFj5CXEdj64XSBrApNt1t&#x2B;Y30RXirRVq7gz/9xx8&#x2B;//B//utXde/JIbm26peefbl6Ur/9EdCR1X4Tk7i9rXVsrvrV2l6OLtoRW59z6xZWHb0bkE54q0haG0CZnabxy4zM1hGlDSCVdSbvSXi7jrR2E6&#x2B;61qz9A7IZM1uW29nisCMwhvMfpMOTq647H&#x2B;I1oW3nb6p7HkI91DsD37Il/duztDp4CG8Xk9YGMMz44t//6m9r34WgZWabridJa5Q2gKDESwKY7jYY4e0Mae0m2k9rS8tra/eyuR5mAAywlDJD91V6ZtOtzvy4vBKjWpn29nomsz/Y2FyHXFMYz98ICG8nSWtjKD&#x2B;46HEIVsDqVDaZrXFKG0AGprvdlvC2T1q7jx7r2lLJzbJCBjCTa0qZDWyK9PHL1veeeZ4z7nDrDqkyLnlKa4S3t6S1MdhpNkhm65TSBpCf6W63JbxJa/cRSGvffPzOt774tyvuTC7LLXbGLXOBCxss9z7DXx4cGEzip&#x2B;jld01nv6Vfq3Lrx4295Vwdg7we8qWXFH3keG5nna&#x2B;F1mVYdwfC20Nag3pkti4obQDXik13W34jPbpDeJPW7iM2a&#x2B;2bj9/Jfk&#x2B;uUOZczitKnp0FMKpDyWe6MXx&#x2B;49HN4002p8undFmqjl7obrqAZ8r3rr6sgddrtl5oO6/gfartnZ0Mb4/Ho4v2Jq3d3HULDpNOY&#x2B;uI0gZQlHUm72yY8LY/4mr2bhMQm7h2xT2p5dIjdwW27XYfwD2lb/1a/sj9u6&#x2B;/LvazDu3vzuwct4Y/4Tja1OS2pZZ/wcjoaHh7PB6v9tZUeJPW7qx6V7ORXJLZ&#x2B;qK0AdT39lIHprsNqaPwJq3dx9gT17asbmMzjjBXp2XYkgOsKjk5abZxLhNFfvf119//9NOLbjxdbGd36dqSsZe&#x2B;7uS22HqnDK&#x2B;j8Cat8dTd2GSk8xhWr8r2kNk6pLQBtMJ0t5trKrxJa7di4trLcvGxK265DHsHoDvTyUmjbsSe09Smk9W2qtsVE9qWV7Cb9raUp302geyM8OSJ5VCokclt6aM57qap8Cat0ayB9/47VjObxtYppQ2gUYknSJruNqrC4U1au5V7TlzbsjzsWOBnvdhoA6wqsHGe/YhaXaTkEpEXzUgL3ObWqS1HD7Puj5Kq7GQFNt4qHN6kNcYzzJZWZhuM0gbQgdh0t&#x2B;U30q/s4U1auxVprQWrm&#x2B;57nrkJsJTx8l0xd14GMFeBC79S1yXAKqfRwCHZw5u0xtjGOOplxcghKW0A/bHOJIHwJq3djTUhT8p74MxhOIBEy&#x2B;hyUS/ZqTt5f9x01toXX/569Ws&#x2B;fvhxxp/4VvgpzdUjz7ymdecgzqTcDaMwDjkT3o7eOLTm7d6hkY3/RWS23iltAN07tM6kkd6Qjoa35bcwABPXmjX2gBAgi2X3umieU0Vbme31TyV72/RoZuLzPDsAWndY0fJF0Qy4yOhQeHv77VTkgMyW2e7&#x2B;0KkYwzyfGtsYlDaAobQ85qSYrfGYgdZ4TFzL6DWou27LOR1GjncEGSC7lE3l&#x2B;VWkyqwxuJPZpl9TOLbFvjLLyl2B1Le8D69baGHxz2EO&#x2B;NKyt&#x2B;HNiK9xlh1KkXit1mGeQJltGEobwMhaGHMCGZm4lt30MO5yOznM&#x2B;A3gJmIHMRMP6hVQOLbNrD4P&#x2B;5ntcXCiRpYTTWY77tmPLvkiLj9FVP8V4laeXc2JlZ1S3QJeW91hnrFpZltevE2E64vSBgDQLmmtorzjt6tHgzIhMIZptzi5HQscxLwouaVMaJt&#x2B;8XWx7eTs7Syn7p28Qt7q91Y88Hpm3TOAp3ZO&#x2B;HgpuVzw0ZMw2nmWzthvbK&#x2B;/F9s6orQBALRFXStsdWhXPoxlvzUH&#x2B;4DepWwqzyzhcNuFfGMLzs&#x2B;erlm0O39lnfA&#x2B;K2OdjVk&#x2B;FY9RDgQDW462scT1cltIbi2ctbBzN8bYur762VZjexHbOqK0AQBUJq1VV2DAdt3hv3seJgZYmi4qlV6PXn&#x2B;&#x2B;aHN6aELb61suXUNydiQ38CRML5B29HnLdXbL6o&#x2B;ueJaJyW1AiquvDN2vGz4zbzPb68vEti4obQAAFQTqmrTWuwLjxtnZsg7zAX3JOMk4cfbA&#x2B;R8UMKtogRR3xqwGPf8wLWdHb/D1qqXsdC5a&#x2B;7HW9MTZPTe5DW5if0N6SGBvldfq3a67JG/5H9qUrz58lljgaI3SBgBQgolrLGUcSRqUAr1bzq&#x2B;62urh0asPLy4nqz3/ZtbbLprW1vJcgcDZIdPAVnEt0Nmimia3wXhSNi9dv9m3doj9PqL2zXLadNba8896W3eUNgCAq5i4xmP72F&#x2B;WgWvLx0wBemFbunM4dTplLeNPrD6N4yIXTdqraHlxPriJklunilvC2Y&#x2B;e7Q5aiG132AqtLg5pclt3lDYAgGxMXGPV7KT7uncGoE2zg33ThfjCW87wscuL0sjONLWPH35cbBnJ1QuzHTqcevLY6/R7j85FO7RYJWesXgZv&#x2B;r&#x2B;ef3icnlCba83kAaRsYYbZ8k8TmmuwDUNpAwCIk9ZINBsTlglvYwxEgXs6eeAyZQM4u6pW&#x2B;HZ2HIpns9iWfQHJrQnWb5/q1a/JeHQ4fKW36vPhVpvlfdxhognMXD0ft4W30mtTXHdW3zBRjftQ2gAAjlHXiCkzWL3hkT5geJcuvnefWHJm4kXeq6BlP37awgu3dUpNp47ef8fEGVXJX&#x2B;zyb6LZyX8tXO1y9vfL52SwrY0JbSNR2gAA3pDW7inLgd1i49Xej&#x2B;gBPOU62Jd&#x2B;JG76lXl7UrNmT07iox71ymrnrU7tGqngjvRYIN3&#x2B;TmS2FT10y1aMPKRuBYR0ShsA5bhMER1R1&#x2B;4p1xCu2FBw5/CoLS3Qr9WokxLPplvFt5vinUuU1boYWMmrtb0c3Wdl6S5nntimjrrO7sbqaTpd75H3H0sjrwIUcz6SNZXZWji/ZHl5tup3qRHTa7nRBaUNgHJcwJyWSWu3VXIsV2xCgG0s0J2dDdfJbVrKtz8/na4mtzM/ulknd0OvnnT0&#x2B;Um85Nv&#x2B;Lcz&#x2B;UNGhFc&#x2B;GdJOHyc1ddypey&#x2B;&#x2B;gKrnr&#x2B;YSs7inuVuCmmc0Kk71Q2gDI7NILaUBG0hqFrS7Vdf5gnO0tMLC3m7jlJ8/ECU9bvec&#x2B;jWQp5bHPZhk&#x2B;/3DoGTs5G7uXRTLu/IsEI7lJZntusqYjlPL3oaknpJgffvnbZUgzm61TShsAl1iuAPD6g6MYVKSu8VaWNanSV9bKviVcvVoMwNiWm770DeAy/LwOOGa8h414Oydg/5y5XFO4skxNqL6/m92B1XY75G8R3MfOluq6U&#x2B;Vqnbu8&#x2B;mBtxAp4dbXVuWsmtHVEaQOghNUPbQafFCCtkWK5Lcq&#x2B;Psmlm7tbLaUCsC8xwCy381esTFXlumv7slxlbenQB/vZnInzu8i61W3rIn9A17bOHj5peTu2GDAGpQ0AGI26xiFlDsnNDkFetxANwK3sV41DLed1qbZsd649s53R7GlJf&#x2B;xnnqitdTsTd8fDv0atcXIkPC7IbI1vx9p514&#x2B;6Cfrqw2ezJSKnc9ee/2o2W3eUNgAyO3QoedSPTRQmrdGRxsfVAN25aJLWqHamf6W3riw/PcwrXoCiCS8ZD1m0/LZq/MhMy09dzDK2zf615J0hC6UNgAuFz5OFfbG09lDXSHbF9urSC6Gvbm&#x2B;dzQD05fzFaQLX2iw5le2LL3/98cOPC/ygRFnWRotdhnn5SsX2WRUniOw88MEyVa2rRsGtVHyLrZ6&#x2B;UOVCca8fOtuKjrRFnXrmtJ3eRl&#x2B;UNgDKcf4pZ5i4RgFXbJq2DrdlGb467AUM46It8KEfffMPqIkHWM&#x2B;fxjE9lvoY4mmfPYQBHtFj90i3jx/wyHd2SF1b5ysUS&#x2B;zTTc3q/uWiC&#x2B;a1Y7&#x2B;3mdzWEaUNgDrG&#x2B;3hEdtIaZewcDst4SYYqQ0RbWqBTjulfpM3z3mKz4prVzhN73tbZQsMf&#x2B;Iap16bp/Lu7zTfL/uVOC9/nkTahifbntLlgW0eUNgAyG2OETC3qGqMqvGG0HQZuov0m9/HDj7/48tev/91fQHL6lVc7U90qHgltaqwx2CqRq1Ieo&#x2B;UlGdJsrtX5W1v9&#x2B;4qrNbYjfVs63rNk6ciRKG3AUC69BA7pjLVIJ63RoB43X9MjjzbCQHemhxqXC1gdXQQy0dYVha/efta9WtvqbKTE6rZ6MDTwvJ2sZVsPoUr02vm5w&#x2B;yIK14MDyq69LLNua5VmfEuPc6dgZHlDuwbZqP6kpjZTGvrhdIGjGNnXYvx9sddaOqEU5qirtGgrrdXr0W3Hn94OKzrBwVQuJ0U22ZuZbYCE9q2Otn0se8/Dw3O4qo&#x2B;r3EZokbd/7a5&#x2B;iiUF3uPN35Bx9mDamprP&#x2B;RGdSezffXhM3PdeqS0AYPY/wSgt9Wycz3bIV&#x2B;OgR/aSdIaLds6U7uX93I7Y2CAsPARvZ3ZNimb8TJb/tcCkofWjSw57&#x2B;3QyRmrL1bit08vyfZYm9VxUpXqVj31XWT/cY30SOGtMr/wFc&#x2B;Ta/Ad3eBdutSsroltPVLaAKhj4MkWAz&#x2B;0dLG09lDXqGf1NP/238tbd/t1HLP9hwCw6ujmK7C5S5nglUvF5SJXnZyskOspCpTO9GlVZXaCq5NURt35Dj9pD6be/p6H3&#x2B;&#x2B;zLXDF2WM7P7fWerzlf2gLVheHFNu680e17wBAOc76r6K1j25l/ORHXwz86Lb86T/&#x2B;8PVf&#x2B;nd98/E70/&#x2B;uu3uwY&#x2B;sN29Eb&#x2B;bbjUmAws4vWJH7L67/L7tflSqa41V1GsWcv4w6r&#x2B;r5vgM8PW3YuyLf6r3AH093N0XfBVqiuvh1rxK9&#x2B;8/FWT8Vs&#x2B;lrFe0JG5rQBI0j/iOPs/ipu&#x2B;7QP/8BNXGMMqyfUO4QEUFd6Zlv9m8S5CNOvfP3NpR/hdlaJfC0y&#x2B;bgmvK0&#x2B;pVXmUqzuao8&#x2B;5zsrWLawEx9pILCVZod5gLCjhe3JdbZWwmjtIqmdLvKfQmYbidIGjKap8dXNbY3bp38//Aht4AVkjk5cu&#x2B;6eQC7Tt&#x2B;pFRx5HvZQLwHnT&#x2B;rL8c6IzHzILNKdlZnv95TOtTWNbdhUXKHuZvqZn9oP7D6TYFZVWf&#x2B;JgIx1nIHFbKb/2Wd7jjazLurrJqniXbHbojtUjgfENMLwZwMCnIE1tPa4bfka0JiS9KDayXS4yk32hM&#x2B;eaAAOYrh9Vfi2pS3/cfkKbzmYrfFG38p/Mzyz4ufNdtXZ/t1oLbvqu9HkDzr8LWn4f9bV3gOqUNmAEb3f/Y492WnbDZ34ntg3/YVFagy3Xvf33j3bdcCMM3NOszz3/0MK0p5eUmWrXzWabWZ75Uebnrjp5XHWWY1tb8QwYw3NTM/0vfFPTzV0Lm5HV&#x2B;zBr6pfWL3Vty/RabnTB6pHAaMZYo2NIs5emheVrLrKzxMqQv5&#x2B;6GkPqcQPV430GeFm97Fb6RdfCH7EKfDxLT2hffPnrMhPapiscFvhxiY6&#x2B;FtO8WvGBLO/2wCMduI&#x2B;RJlUf/dFXb8HO3P54R1RWTTOba7n1QmkDBmRU05Stq7IN/zJtDbAHvnIbsOrtdVxy3fiM7QzQu5TrXa1&#x2B;4jraOZ6338in00tjW/WHmWs/uHoxoUZewcdYI52RHgvkEpiUtnMZ&#x2B;2x365wyb/ajP2X5vA12&#x2B;vIPv/ztMqSZzdYppQ24BcODumaxre6dKeluk9uga693ZYGVHi9l2wIM6e1np8DWu0ybKbYmZKLno14&#x2B;9pTdx9a5I&#x2B;F7srzZ9O9qynjn0mVp2DCq13vh0Lh&#x2B;9g5qZIuR&#x2B;KauOMPv6jFadaux7cWEto4obcAgfOinO2IbtGD/VICMb9Kr3&#x2B;&#x2B;rt9/gYB5g39H6svyyo9nm0o3/lumstWWKu3oNydUJYUdvJOMuJjCUW82E1YeEdxuQ&#x2B;mgBj4Pz22YXP1v&#x2B;fYMaWUWz&#x2B;hb&#x2B;UvuxjV4obcA4xt7vdmTrgrpenaXxzn6FkXTx3ix/WQWAiyyvdPX4w23aRWcpTa/1lf3GV80q2scPPy457y2w6Fn6bea92ZQfN/2bX/3mY2v77iue7WJm78EeHwJkd/6TduNr3pS83sfyZzXyJBTw1YfPUpaIlN/6orQBQ4mtgkIZq1P&#x2B;7/YCrRbHdj5Vwz3tr4900dsz79hVXQMGsFNrim2Kr974PxaZ7fWXs9h20bS25dVunn9IfLwpS3hVPJOs/Ifq9EPS/X7gX74Z&#x2B;30sEJPxk/bOTdV6Z1WfsmYgs0pj65HSBoxm/1NC9s8Q5iTtWD1c4rnaim0PTw7Uk3Ltn5Pv0Ongucxw/cmGBehU4rZ39gUnJ1dVPN5XeGbb48R8welXBp6xk8t1zl7iRg7R7vwe9m75nvLRgvvIew2zvrYM5Tewd9u2bE1r09j6pbQBQ9kakF&#x2B;xw54NTS/6KZ3av2CGJ2rrdGDnh0I7di7edv42Xy56y9uSAL2bboTfngwx/YJcG8CLPt5fevW1Q5aHUE9&#x2B;EE08Jru1bNrrRg79xNWbKrkTTBl&#x2B;9nVsfcrZgZAi9o5Y3Uo0dUCgtW1Xa/cni1lU09h6p7QB48g7VozdgXY&#x2B;FVWUsnbKwwjN5DZoT&#x2B;/jN5sOoF/T1nJ0a3zyjK6dCcfnP94fmqY2m9aWfQHJqy&#x2B;Ec/JmC3S&#x2B;i&#x2B;z/Bo63dzbs5Sb2T5I7s81ZXZQ1fGtXaO3&#x2B;3MRyipv21helDRjEztmRhc9qNOpI5Ll6mNwGbUgZSWY//JfrPW5bAYxh9XLLz7859LnoTHVLuQhZ17YO5lY5yLsMnGUm1V1tmItSv70aX78PDY7a&#x2B;m1fhred98XV5zrkUvesha0nZ/hFklaXkXz&#x2B;vdjWEaUNGF&#x2B;B3jYdlht1vLy91K3n6qmR4wLAqiybqZ1Bo80gwBk7n6PebmN3/nX4jXM7x3yH/yTczlMd49RAWHXFtqvWe2rngbTwNh97H/HYzmyvfxXbeqG0AXdxXW973ebwo8QU&#x2B;yPJ4c8UPspTAdXtnHt&#x2B;0TvUGx8gUeKn653lH/etTjiue1RxtoDkRarvibZWTjs6f7H6IeDZHaj&#x2B;xBZgzMvNXfH7X/c91VRmmx6425qEXfguXW0/s72&#x2B;RmzrgtIG3MvV47Hx9vpHpQy9pl/Twgi5JONSaNbO&#x2B;QFZePsDpDjzKfH8SV29Tz&#x2B;KKb&#x2B;HOjME2BputLCfLXC&#x2B;TgvENm4ifBrHIW2&#x2B;m0ruBJeblDafkyukZDY6orQBI6i7ZPPdWlGi/afF8Axon8wGUFds4&#x2B;lz5iGHnqtmS2Q7M0Km6528/jDqL6SBMGNLfOcefRe83jitbRnafzu3fw8PWWa22cQ1Ha47ShsAdYw95jx5C4N9goT2XfqmW12d7LofB0CKZTS64qNpmdUg080&#x2B;gU//99C&#x2B;6fxzdWZt/3bGEatXL3usLY9Z7j4BBaW/u2dL&#x2B;5y5qbxa2EC93aq3cCcvtbo45FcfPhPb&#x2B;qK0AcNqZwB2W/vj5yFfnTMPavjPjtCmwkujFPtZD2eaA/cQnmW1HCzcZJt50WrJsXIWfgm2vrKRF3GAXXDs4nkwsNXrMuZ6g3iXbR3BG/WZmSY012AbhtIGjGB1l7x1tiZXmz3bzS4y0wLPCZCd/R3Qqa1rXCV&#x2B;XvLhP9GZvvj2iT35yT/w7c1&#x2B;nB4pUK0O7mB42d/Cq5vQYTYU53kq6J3SBoym2Ef/2dx/nwmm3rbPO/OrAvd09XvfNhYYyclt5tFrj93n49nqR/SjsW3n1tK//W2x27lXZ1aezGirCw4zSLSeG2TnXcOMCW0jUdoA8jAImXEq8dQNfwGAFFmOwdnYAmNY7RZvm8rzn05uCYsVkS&#x2B;&#x2B;/PXHDz8u8IMOCT/8M9Ut/L2rFzqa/hpU/&#x2B;BtHARwxtYmtPrmvTAXaeuO0gYMosp4Jv2H9n4&#x2B;Y0zKgY&#x2B;Bn5aBHxrwf9m7e1VLjjTf/4nMcw8Dh3GGcWQWhUCuoIzyBc1GSJ7oezjG3EMjT43YDLRfRoFcgSjKlNP8nWbgfw9jHyPPJNHxlpERT0Q88cT3g2h271p7rVy5VkZGxC9eKlw3ggF3K8ofAEtrmSlV9&#x2B;dHen6SVeF67&#x2B;VvPLr&#x2B;5JTUrfGvcCszB3GTKwWIoszppGW6s2HnvDe2dtOPpA2AfZ3uxOc9nrDt1lbveqs3CxjWaVB87zY5RRAAqx4Vy40j8MRvAd&#x2B;9/OmX1/&#x2B;8/m9&#x2B;Wpv7yH6i766wtVKy/mTL2ROc6t37tpj5ptmb1kYdAzj2i5wHTxQuKTb36VhzczUmt62CpA2AHSPbM&#x2B;cLXWFb/mGnTWoDALBjD60eAAAgAElEQVSocM6ZkkWo8nabhAEAggr3DBM3aw3J6Nt81IZKPXJK1&#x2B;esjy8UVhimHxIAKVzOY5ob257nd68fwglqRGuLImkDYErYUOzd5Mu3Kq/joQN0T/SAA6u4xk&#x2B;MeTnKBABIeRpXRKtbT0fgKclsek9oExyYGK6HPHGeQerjm3VI2/YXA8bcXstWq/SqBlUcbcsdL4FczQySNgDWzLrjpjIVYzUAlIguqnP9zFcC0GZWwNZ7KIa9VigA28Iiyx219v23v&#x2B;SLtYrCPKzAdyo23QUkU7PZxqwbGVWdwA3bfzT10k//qcdhkKsBuzFZwZ5blIUj5m9/s7qPL&#x2B;/rAjZ2aNOMpA2AHfkwQ7Yy5E1W88bXRB8v&#x2B;OrQ7Lb&#x2B;xzRHQC23CSc&#x2B;8D&#x2B;lcfJrOMaz4kkAQInM6hTDFq3q&#x2B;kKPFo3st8Jk41CMcGTh&#x2B;LuPnnFs9vp/AYQMt9&#x2B;1lWCpU22ssH0Us5GurYKkDYAR4VIhx5DKUOGdnokFm3i0ywVfCUCD8au8dmoiWmp5AthTdFWA28JZfFpVp3bEbWzmznsboGWURupz0bBa4&#x2B;ADyO/bTW0fWFqqoEv90yOD9z2p4E0r7/dCekZOqEK6tiKSNgDGcc&#x2B;GWoRtgFo9rs2SCa8Vr0vABsC2wrIxurvb&#x2B;JSu0YCwLewwHfz2ew9wOb8wI9eQCNub1PABewTHdkdLXSUr32wyn0wzAralkbQBsGz8ntjRPXjC32MT0U4fF2EboEqnZRjzT9WjEKBgAbCu9u686xmepnTDuhHdOM2b63aFbf2Wjkyd4Uf3jvZKbHVD6baC7f7r&#x2B;Clu18/ciwEbMuVMRSGjMK/KvwVtQ1JMIl0zg6QNACqV9ALs2b7KjMayHSzl138Y34kDoFrv67RHk9Vw6QpgB2GR&#x2B;DQwazdgzH44Ze36jRut9d6hLbwNFZ5h9xRdn0vjSWtJp8pTt/HcVdfWvUdHL8wpRwIYoK2Yyht8Cz6KN7e2gXTNJJI2ABZ4zTPZMUeok2ozK1kVobfMG/S&#x2B;onwnASXaB/jfGjN9jQH1ALYSnRpVnZl1DdvyK0P&#x2B;8vqfZ8DWL2Y7XZVPhfsMldzCUo&#x2B;ZcssrHEu3aAtI8xp3wBipBkI45uCp6HpI0zsHjKVZS3v3&#x2B;uH8gUxuISRtAAwas4Q0VZBynCsPq5wDeoTX4zVCv3fMJvj8Y7YrB4B&#x2B;oiXYo2JNpACcFbNdj&#x2B;kds51a7nGN9xrZWWh6UjfNs&#x2B;t6mJ4HAIN5RZ9gSThd&#x2B;RuZeNiGhxJeidqRCNXevX4gbFsFSRsAm9x6T9eeR7o16zAWEoByV/Guv6RiJjcASzptmVnycke3un1JzHY9ckrY9uiWF100suJ2I7uW8pQdslNTKocdQD80cgHZUmVKGdVOag50iVTLxXBx5MZshxOqeb/HKkjaAFhw2yQmDxtJ8y7levCdBPTIT2JrbxVvW9ABwAAtaU34V&#x2B;e9YG4lrWvYFi56Vv1mxe9uhSsx9tjrtF1mvsXq1YDoGnfH3k05oBMl15SSw4jSfGxPReO06Aw2prWtgqQNgDVjmsdMICh0m7pZOl3VXzxLJwFY16LrPkUnf0zvJgaAdo/KMa8Mb6lZma&#x2B;YeWHb0z8X35stVPKcmu/ahlc5O6hjAB1ouKZKtsbMPEzKKmuK9Pbx5T3T2lb0xewDAAB5XlVgZK3l2sZWQ1VJm61qS3wBgBWdpfei1&#x2B;9WZSwAk1Ll2G35dpXedT104eNlbwSppSMzE9fKV5sUVHLeorMAp989//q372bdBPe8&#x2B;RbOPgQME1wKcvp1FC1CRxbs5efQUpF7G6R9fHnPPLblMKcNwBam1122UlLp3GEspPkB0YAZJcXRopfzoocNYFvhwoAlMVv0NxV/OMyVsZ0/TMnVPNwvqmmeXQdARHRjy5ZnO2Kl7vRyWHkJNv389OPtzcZakesiaQNgxKzk5qpyDZ5Tv4R8L4nJsM17U5mOHnvvHbBqxfKcEgbAQsL6UuPajy0HM6CCGk5li&#x2B;ZtnXZrk3p3CjdL09C4UHha2jF8EDgS1/WjSyNfRk28yjQMOlR7cgYgVLOEpA0AZNi&#x2B;97ezvV3BU&#x2B;SygB6Z67FfT1mPTis2aQOwqLPUElyJ63Rb0lJauh7dmK5HVtw02&#x2B;&#x2B;A4l8VcTa&#x2B;WjbeBdBiTPyjuSgb/HLh2VZ7coAokjYAdoQ35n7NA28jcW7/rtvTfp4xqy23krc/7GAAlBuwhEvhnFcp3JsA7MOdS3RVxgpr6SPrZplpat&#x2B;9/GnkMpLiW22V33SkRuB5z0Mdux8v3dQfdgK91X3586MTlFxQEw9Danb7oj6&#x2B;vL/dvA3KkbQBMOV2icIN79ZTbL5dAU19YGmd&#x2B;o&#x2B;ixUL7WA2GfwIwoL3uJDX0TbwK9yg8Gxa2pdY2LzyHggMNpU74rLp36lTYaA6E78LAmwIe8YZxiDxn6jqaNYY786IDhgZmsBQQlkPSBsC&#x2B;Tvfj6LQ25reF9kzdyjdp4AsDaBDtEVPYkxjlHjxFCoBFVRdfqQEHhdUwzbXTHlu1Se2d3HsZ5MzDtH1q0WGdqo6whbazDUzhFUotCdASF9T0g0yNUDw2a&#x2B;wwxW05JG0AIMNN3Y7Nbv&#x2B;ezCTC3U7L7fvd7YQACuVzcZGexFSpKNiIvd4F07gBbGt6z&#x2B;C6qsO24/m9piSLun3mzM107r3P5JcwVVOimoGtiFzd1eNCBljlMOyNbn/3&#x2B;uHjy/vo78cfDBqRtAFAvUytyN7tv862qVv0i3G&#x2B;ZdtvHFjRsIZlv8u/09KUAKBfdEZy&#x2B;Z9HU4SJhefg3dou1b291SM8KqZ/RSe9cafrxMs7Oc/YUO9FKdwfHm0vKiv/Nkcej5K0TwMvZotGcVCIpA0AmjDEr9w&#x2B;My0y&#x2B;eth/b0Dq7O37hMAII8a2qnkDPSYflE429uL2ZS0v/LVBgNfqn1acECduutioatpWPj3aNTFQicw5ePL&#x2B;ytOY/qaGSRtACDAwG1eUMkWZYbbbCXLHRzm3jVggzdGXrYzcfCEtuufKG0AIMUtP6mhFWpfBjkTkhWef4UzuXf45hhuwQHlvO6O8pJniW2VOy10X0fVwUzEhLaFkLQBALrYs1a02zgswIBZjd4eBeOVDurZ8gEAepPdsou87ZGWFSDDX2ZOe&#x2B;HNenwFe9vwiSsFWwm/6p0q23Pn5oa/H9aguL19b9u6ScVsqd3dMBdJGwCguz1Tt1uEbcBW3EtesCRcYngsAIxBSTjA9M3SwnBLSfvCWN2eFhww7IrWeYnNOioNyd8AtytGZoI0VptUi6QNACAsP7Rzqzbbba&#x2B;6sQY5YEmPAkrJpjIAYExd6RpNjM5fCtbQvnv50y&#x2B;v/ynyVBp4p7pltEfYZ/r0tHtrTop/dhXOV7c334tdbAGP4Fg3nZfVyKPadnJwiGlqqyNpAwB0VJ66GVCyYJGxcViAVWauU2PFLAAUYjBTSqcQ6OnT2vh0bveltvE2XaomEQITtVzdV&#x2B;HQvuJxD1zg4xGwmfHF7AMAAOzi&#x2B;29/uf6bfSzdZWrJ3j/tcDaAJUTLKJEW7/glUChYAKyorpaYWTkg/4epQVFPD2BF7dVy2VvY7ZQp9wGZu6rU8Tz11799F311q7fjTS4TQJY3f1pV&#x2B;ZC5KYy83jcsWz6&#x2B;vCdms4SkDQAgLNXUxIXzA&#x2B;hRnos3voq7yNX5n2wDW1VzHQCqVSdAV&#x2B;na46ikKFxJsiJ1807y4KUFr1eZfuNLpWvKv4QAFJq77O2sl35kleMsRMZmEkkbAKCLq7ODpiaAFfUou6JFYvusgop/AgD9quddPQ1&#x2B;3Jcw1pEXyt8ahq0/UZek5p/H/Gc3WMmXgXMOPJKaS6250q7kMldyGNO9e/3w7vXD7KNAEvu0AQC681Yh11yPHIYN2wA9BpdRmYXOZGfRST0VAIyRqR0NKKKHVcx&#x2B;ef3P717&#x2B;lPnX3gfQPgVN5IYldcI11KjDE2Kpqh&#x2B;uqm3mrQHjpQrPTptoPjJ9n4vUzUXnhnbDEK0thKQNADDI1eC0uqZKdYva6gkB1uLtnRD9fbWuLVVGMwAwY/A6hBmC1bPvXv6kcNHIoy01kd3grfDZLMVXi9q8vxuQpaRAG7&#x2B;lNEoQsK2IpA0AAHmEZ8CKOjUm808r1Yg9yxxKHgA2lEduLWO58lFTvxkG&#x2B;WltUxSe8PCeJdsVe3u29WSxHu94tB1eBTrZgR4WuqymHOrt2MFNGjuZmO3jy3tCOLVI2gAAwsTngiyKsA1YxfhmZDgLbaFWNwB0Eu1fS004LnmeQhUv0S4atmmY&#x2B;tZSfS38W5G73pRPrZC246mm&#x2B;SQDqpSsLbHWRTTyaMtvCjt3sHx8eT/7EHCPpA0A0NFatUlxmbBt8zMDbKhrw5toH4AlqWFbA1a46jRlKrqA5PmbK2/TELOVcM929a0nOpuw8dlO1LE7oZoBuKwOL9ZchGa6Vix9BC7SteWQtAEAIKauo8dqvRBYUY8&#x2B;1tvFT1oKAc3tYQBoV7iEY7QONmB6VrtMwKZthclL9OSUn7GuG4sOrlerXc2yndUgAajWtXUwtwzJvPqYyz/fkbLh8GUytkWRtAEAhLVsrm5Avo647WkBlKMLCQCmawktrq3avKfSIzqtbVFeBvPobLt/e01EMDAjwTv&#x2B;fpv8TUHqhm2V34/Kt5nMv9z4S2x6zOa&#x2B;VmFfCgURdCJpAwB0kVnFhVoRAFUolABAlafDtsJH6kxuHoVtnSa0tSdA3tlufMLVw7ZUuLvieylEZzf2cXsbElmgQqGJb0fbbD&#x2B;dmPGmFkkbAKC73Wa5PXq/xirlgBmCu/50RRkCwKrGcnjR5GaM6sl/qU9E5GwXPonO6WKa51PWKWnRkLphQz2&#x2B;6koKED1X8RKtsFnevX44fyBvU4ikDQAwyNVdsknHR8l73OE8AGuhzwgA1rJWf1zhtLZhO7RdZ&#x2B;9p/TzMQR89Q/s4PLUNCmMVicw6JR61nwjQrut3e/pdLHqZq1rEMmWfMudK16AcSRsAAN2FnRH7VAqBVayy&#x2B;BgAWBXOVXo0ra0x&#x2B;xnmTNEyeduwmM0zMSKqG5Cn4fMt36F5&#x2B;qGWyHeyl6dugA2py1akac9FdHl6KpYoTkUQsC2HpA0AIGy5JuUYnApAs67LYeVflMIBAFxuX39dR2T5H0ZzhTGFcypvGxCzXW&#x2B;tup833JNs1uw0DXfSwvxJQy4oiNQNG2r/quefwVIRIW63k0PGtiiSNgBAR9umbtE69FZnAFjI3B4iJRszAIA2Iwvnrq/19s2b84dPnz97/zRl&#x2B;toV&#x2B;bRHbqlnFnxkKFx5Uk&#x2B;IJX5K1XIzTiUnH&#x2B;hB8FomZqvAabl8fHnvxm9s0qYTSRsAYBDzDc5LZnLMQWURWEHj8Pxb&#x2B;5SHAFCud9n7SI/w5orcjljqNpL37p7OT2rMya6FIuuewXue9kPqYfUpX&#x2B;H5XPFdAI1KvvaNJY9XVqgqx2bJnIQNRyieidq71w/EbEsgaQOANSwU0qjqJRnv9r0v9FECu3GLL/GirKRw6FQyUOwAWEV0SlC&#x2B;&#x2B;GpJbsLZUa6uhWdmotsYqXfX&#x2B;2YheG8Nw7ZD5c1O4SGluKd05wYdkJG/cZQ/g0fz0IEBKt6v7dTNzdK8lSSJ2TQjaQMAyMuP4jRZEzqVV7g3rD0DOo1ppI1fLoYOMgCLas9LnhaAc6cfDZ7o1jgVLJpr9t676OlTUccGICs6KOEqDAvLnJKHuVH3PkVZS8ymwZWEiWdgZGzLIWkDgAWoqkY8tU8F8amtas/AzlIbN/YYfb/0/QLA5qrnJ6VmIVcUsHPXZhgz0a3fuotKarbUsVvcztfh3GIfC83xtS1/orqW&#x2B;Y9StHevHwTDMGK2FZG0AcAyVmzV2J7R7/Hqf&#x2B;FbDiuIdAQAanVq&#x2B;nZdHxIAjHk0V6CuJEzV32xHbi1hW&#x2B;OZye/&#x2B;1b792/W01LFbhJ8y5xOQornefmXt00tRbWfpzL2GxV3EbIsiaQMAQF60Vtq&#x2B;pDuAMcbEbGGZIL52yuYbZwIwQHZhrvDJoy&#x2B;3Q2bTsslZtE5b&#x2B;Lfe&#x2B;RQ8t6ts27YKzieQITK2I6Qq3Jpy1VdvuTpGOGvNjcTIw0DSBgDAUJt03wDLkVp5LCU/il8cBQuAtYQLITza/tb9v40FoHgU5M5Lc3dlUyhTLw3/qfrMNA4xyRgzrK3f8WsTnk9aLoD4dE8l43FTBzDsqn90BiYWRLJLRJa/qPcbUj2dSNoAQLs9N8W1jVkmgB6Z61E8Zut64Vf0TQOAZlf5/LQO/HT18rD8PF&#x2B;xR8X7St30RG7lg8B6JExSS83PuvftkLoxuQ04JAoZzcXF9OZDyQHo7EX5&#x2B;PL&#x2B;isFGhnBTAj/cImkDAGACndVEYHPuhSnbAL5d47H6mbU11AGgjtRGa94/ZQrJ8A9HVs9URW4aVlyo6IPWVpc2vEF1eGkwBhQ76LTYY2aniSlSs/SUlLFzp6&#x2B;lfu&#x2B;mXD3CtvBJUgcDVUjaAEA7IplVtPQQ0VIFJnInnI2/GLn8AcBVXS9SsgDXU2fkNj1vuz17Uk2Skj7c/B25/DA63WFvz5XmmSvVWEkS8MhO7dVwNYVLBI&#x2B;5pUYHvgx4XSkDMjBitlWQtAHASmjPrIJPCljOmGvWfZXluoMBYIyWelT5YPxoH&#x2B;KsIW6fPn&#x2B;eFbY9Da6kzk&#x2B;nG&#x2B;KwGviiyW4jxoBic9GC61Gxk1pCY3repqT74vYwJh6nN3ct9RiplyNdWxFJGwAAYtx6M2EbgNPIooD&#x2B;LwA2tJdm5WWvzjrbtbykuMZz2&#x2B;NcNS5WpuHj07beWj97RozYmVQJo3NiaOH0XCUGny43WjvGRl&#x2B;Z12J7Ns1I2gBgAevmNwsdqojyDQxMrioDYK6w6a6whQwAFTJ1KpGyTkMFe8y0tpJz1fVU5DcEKn/p6Z/XkZjRssnNd5O3ic1V7BmZ/xOuGmPc0Kt3DkfAtgSSNgBYj9d/qqGd6YnWIBUe5wDTV4EAsImw4CXRB7CW/KygVJ2qZTiaN5rt0d/29vbNm37T2kKzbhPlw9Qu&#x2B;u9om6RQ&#x2B;j8IQFzLpZ26tblz3TQM&#x2B;zipKsQmNmq8aW3u729/I/Lq4s&#x2B;JrkjaACxpw/TCa7BpW3PAlaqTaTvOkVTVUwFMR5kAABnVC/FpHohWYvBubTrPUkmTITUxbrCrgbZzMwcwT7zermoJVrccO2LF6cTNL6MvPbK8HbAZWwoZ26JI2gAsbPW29FMGRkfSCg1xQoB99CvDvUapki5IAHgk7F8bELlFK9hKis0e09qUvLW8fJOBOdwAxii89RjoqEkZU6Kmose53UeFU9kAF0kbAAv2aVxp7gsIRTtHbIdtFcPTdguMgQ1lygSRCz/aN03ZAmBpXiGWKcqq07jjf&#x2B;qllJPjeedcsIN1VlvDdhsHgEvVpLRONBdoA8rbMGYjY0MJkjYAS8rUbDbsW1TVrkttDO7&#x2B;k6oD7sF9d&#x2B;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&#x2B;I0tQfbp8&#x2B;fu77uZfo4jNvzfNtGc5dcm97W8GoO049HUL4iNP2LBAwjdV/IPM/cSyk6RGBK1kWRgtWRtAHYgvmJbmq5DeAdOoIbe9L5&#x2B;gFz9WtSdi0AdyhdAZjXPmNApAzv2reYitnOfzrDtsxjBFU3f/In52muWfKc&#x2B;WPQELZdFh3HmVHyMdGUxuZaSqHUH85Ksr1XZGIZ8BRJG4C9lE90Q7VohWzzExsmjjREgX0M22ngek5V4/0B4JGW4lHzUgG3EdoVtg32dD2GU&#x2B;YxT289jTdEhUmPwkNqt9XoSeCSuZxFblXeE05ftlEhzc2Zd68fzh8&#x2B;vryfeyRQgqQNwL6Y6NbPnqOfbgf5er0/fK8AzXoUYl3LRooUAEsLS0iRQQPnk5Q/w9wa7ICZbSV3okeLn7t/1X5UjXHO&#x2B;AFthtdwTn0NqG9gT&#x2B;3ffPGSU0T5NqjTTTyeK1E7hbnau9cP4mGb&#x2B;6IkeasgaQOAVXd0U55mZVYeUHUa&#x2B;7n9gAjbAA1Wn4a70KECQFepqubI&#x2B;VUp5cnZGbZ1ndwmOzkput1pdS33&#x2B;sPMnyucuWh1vtftbB5jW9MBnn49GMbKCimZe4eemO3ok6ulXsv9PXmbfiRtAPBPSnZ&#x2B;vh455IhyNBxDVGqptPFHMsvVR0DYBqyid8HFxQ4AT9XlXo19o9OL62HLSFZHVpnZTiUT5sJXr6Yt4rI9xe36efo1AqyosGRQcn1NL8e80RveP804on&#x2B;SisS6Plu/hA9SSNoAIG7RiW4atG9ob4nyqYcAZulaMnCHArCup/OiMtnGbWE4pnbabylIQeMjq06Rmwbm6/&#x2B;23x1QwkwJ5i7UnHrAsGM4nPvyDuVMPmD76pufzh9&#x2B;//VH908I2zQjaQOAezp3dFsxuFrxmAWdb99re29&#x2B;TgC1eqwSw8UOAI&#x2B;Ud7TdVtfnhm0eb8paGMUNm9YWKt/QrnpaW/hUjx5/pNtf4/dpM6wkfGVkD/YkFQLpv3CmHGH&#x2B;9Oo8aRXpVypmuwI27zdu3ga1SNoA4AEmuj0SbZ4Z7msu71kwP9AVWFdYQAkOpwgvfMHyMCxdrRa2AJBRMTdrcO00jNA&#x2B;ff68xLy3I7uc13kab097&#x2B;2SF8HWrn0qQ7TbO9TOLl2BP7je8sczJ70Om6joaeTD6e0g&#x2B;vrwXXDEyfKowYMOKSNoAoJLOiW56uO96n&#x2B;n/5fRXJYGt5AM2zShMACA6juFRr&#x2B;j0nCAM2yZOa8vL3Hfa5yCKfAqDP81U9GhS5rKafhEBXbXv6Ky2uRF21wy&#x2B;lpfYwS7Mxs55bBXxm/sn5QHbV9/8dE5rYwFJzUjaAKDV4Ilu0TWs9chUktwVwLUdNoCdlQzWbnz&#x2B;rrPZwuenjAWwIq/saqlCu7XNzJ&#x2B;Pr1dnwrOFZrYJ6nTOh80OUdJRPgvDfWBb/hteXcLovGqit&#x2B;DpbYrpB5ByZV1PQ6&#x2B;6mA2rIGkDAEkDJrpF12mpe6oeaG6dvP6d/DnR9iECuykptRov0qsc6HSxl3QoA8BayjcMS/2&#x2B;5BnC5RApSG9FT1F5S0dq9EnvgTLtdvgu0fqDbalveN0QEIkj6iU6umXWbbH8FaccYfWUssaY7ZrWBrVI2gCgi/KJblbtmR4pn3EIIFS4o0y73gVCdAMJSiEA&#x2B;6jeRMfrSJ1YhVt6WltLMvronEcfGV2svvdHGQ0XzbfyTlQwsI/Mt93M&#x2B;AwlN8HGETZjiKzcyGw2q0jaAKC7fu0uhhBqo3zGIYASK24tea3Ne5ho7QNAi/YVywWrcC3Jmdqt2nooP&#x2B;e3k&#x2B;fmTr9g4B1gm1QbIbVg8nhKWj23paWG4&#x2B;wXs/3&#x2B;64/n71Oz1gjnlkDSBgDj9FjhRHPjjbblQfYGLGXRyzNzQ6HMAYA65svP6W8wHNdScUjeHG4lwxCVHMYwu71f7Kn9S15Svk0vmb3DGHNp384aVKIxZnOXjvSwJqQZJG0AMEd7xUVDDSwq3O7ioAEWENm0D0C71A5qq5Ra4UGebeMlDh4AVPHq5yI9nk8XhBy5gKTgTOinT&#x2B;VtL9p&#x2B;z&#x2B;KuNxfNGZg0YC9nPVSt6qHkME6pgO1Kzh4lcOHUNGI2S76YfQAAgEqqKh&#x2B;esLqp&#x2B;WgH&#x2B;/7bXzgbgB6p63G569RMOx8AHhFfp73HKhSbqD5djz7Ev/7tu/wt76xsD/jsMofNTRnYhEhRM3GLZVW3uUel93kvuL0jDPDu9UNmvloeMZsxJG0AgC4y1Z3pNSEAAABYparfUL9HpyvVB1q96mO1kj5W9j0SwTBB4NIj2uH6ejo8Qkm6Jv74MHVjb7blsHokAKCX6PoD06tEXenZ1hhAiwEXr5JtGADAAKklc7etuT29JWWmX0y5u2lY9ExwKU49tr0iAFf0um6/7yi5vjJvRMkRhuY2o6KZWeMWbqczV/vqm5&#x2B;Y6LYukjYAWJjajlo2ITuVrD608/kBVBEZpH/7EuFOloIvcT35xCVoAGCKaF/hbRmothtxvLpmRcsJ7NeQGblZqfdalr5R0fdCBQNb6TFlNvOHcy&#x2B;rs0wOWxMTKRzHXL1K5Mmbo&#x2B;Ymakxfs4GkDQDWpjBs8ypACo9wCk4CoFOmP07wsu3XMnTbw5QzAPbkjmAQXFRqh0LVG/9x&#x2B;5ZLQqz880SfQeQu6T7zyM9uTEVCAy9TNPbugDrlF0K&#x2B;oNNwQQ0Yd1hIw9nwZDI2kQltFya0LY2kDQAwiMk1VQBYtWJhpWGkJwAMlopt6orxFQv/R6Iz/x7dPq5TlPmrirDNe/IMhdOqNCxf2U/qPBO2YWdSY924iI7gppA6JyPnK7sa57E9Qsy2OpI2AFjYKtUyxj8C0MztIOtRQEXXlRqwqxCFLYANPZqhdepdWn76/Pntmzfnz2/fvPn0&#x2B;XPXl3skXC6s/GyURG6Zv22/CXqR2/Sgy/Ztd/rpBZSQmoPb/iS9MZstSnYG24WMzQaSNgBYmMJZYtpavABQ6Oz180ot2QJ2zEhMVTcFANCMAvOQWPi9ZGfi6AOu12r8IOa2OCo2CFwarTxsqGu6pmqebnRrtN4HtlB50ilmi2LnthV9MfsAAACtVNVLMjP9r59VHTAAnKJFk&#x2B;DTnsQAACAASURBVGB51buNek5K0NBEB4Dx3ALw0Vyrc4zF9V/HQ/wf1/y2in9t92h5xrrnr7gZ1S1fqUGq8rBJe2eTt4ltldwaKkok9zmjS19MkSm6h90i8ydz7vn5&#x2B;PJePGYrydK&#x2B;&#x2B;uan8z/Zl0YnJG0AgI7cqpKqVjEAuMa33GRf8RpgPri/GACUqCv0Unu8iVO1YqSqYRnR7uZbV56n542EzNyIzbwRQAM90dolWpZGWxNKDniwM2B79/rh/O/6ffgbQURri2L1SABYleaG5cF&#x2B;bA1ULR8B7CC6YmTXlqTgMpKZo6UcBrCDaInaUsyKF57hNLXC3doG5HMVe62J1FSjH1DdmZ94p3PfQsuudTq5n5GZNwW0iK6s&#x2B;KjgSl1KdZtlitN8pUfLWyXOsK1uxttX3/zk7dBGxrY0kjYAwDhj9igCgDreNFzZ8ir6bNoaigCwrqeFdpgYublC7/I5Grb1XjrS5d3mCoOi/BSHRyet8T7bdV/Vp1L1B3tDXmjNYUOdrmJVl9LtwYwpylJlpqpz9e71g&#x2B;wykl605gVv0cdALVaPBAD0Eq4/rqqGNAWrugFqje8Lk3pFr5fTXQGG0gaAedHsp670E7wR/P0ff7l9zNs3b9xobUzMdhuMPVqS0TvPdWfe7Vot/HPBD71FyQbVS7t9I2beKRAlu0Rtqvidfh1lZtp5P4w/mLBsH3&#x2B;6StaHFMnefv/1x2jMdiTiNyjEnDYAACbQvPoBsJVZHXPR9WcaSwMKEwAoJ77sZJ1UwNZv6UiRWmjmD0smcrVM9sp8QLPmkNmbu3Zxrwir7xGo0HKnyFxKGq6y6cewxEhB2e3ZCNLMIGkDgFVl6h/T60ZRS1SYpiB1AxQSLLLcrdTca/z6jcjyWZQeAICn6m4ieu44ahczVHtgFbyP&#x2B;3xrer4DwGA9plgpKS7C9zLmSi8vME2WPIUx2&#x2B;&#x2B;//sgakvqRtAGAQTR&#x2B;1HI73KOUVLIBiJuyomMq5AMAM6JThKP/lKKz5hzdyK2fisitcaO79ruhO0d8&#x2B;tZo3uuaqdJHQwWF1wvQW7&#x2B;LWklxof&#x2B;6HnaEH1/e305Zcx/TsnRkPmb76pufmO62FpI2ALBpYpdBpr8j&#x2B;oANsYUSoFmnaaYjdxr39sgEAMO8vKeuLL1qzqqKzWthScHI7bYWWjI44zxd4SyE6olcIqnb9M9u&#x2B;gGIi&#x2B;6Hd9CawzYGpGuqFmiNvl8N09pKbkkdDurGGbDJLiN5HAcT15ZG0gYAi8lvilDysMH0HIlCJoe&#x2B;AouaOFJVtpykMAGwp4rOSq9rT7b8/Ps//vLv//rnw8nJUluy3XL/UCp1axz4pXAioIawzRKF&#x2B;&#x2B;EBNkwMtKLyA02GXe/hYQyYG51SMq3teqTUi5KxGUDSBgArKRxFSMtnRUx0A6bIdMx1LUulnvw6/nzRwX0BwD4eRW4j45n2yK2fwvMQfZjbD3v7PPku3eXuVuUrwy/31vII27CncKRs&#x2B;bWQKh41XEp6uiAK07XeJ018plqUuzJkNGa7fQC0IWkDgPWk6hYaqmhHdrlIq01NAEuLtnuvXwqWVz2KPgI2AJvLRB0lNU9vfy/Z/OCa1ubRGbk9HfXlTQd8tPxmy7oO7hATJbe5krej52ifSn2y674j4JF&#x2B;33MlV1Aq/9MTv&#x2B;k5kkN0ElsG27MtiqQNAFa10FBQVRUjAAiFJadgwZXpgOtUYiu8EQBAV/mUKBUJeA8eX2V1l4LUk7rlbyKp7tdH&#x2B;Zz7Ei33LPeTVdLi0HY84lT1vwNdideolVfRtV3dsw5mzIS2EOmaASRtAEwxP2WqZKzoEqMLlzhIANvq0a571PlbgUIVwLbcJkB7zjFmWltI50S3qPbe2Mbtpd0DmN4vnHovhiM3bd3xwHg7XAKzrvRHLzqgBeTu2dZvQls&#x2B;ZmPpyFWQtAGwyXaQc1vjUfL288c5Zn1tbRq7FQAMINuk7F0gU5IAQNSjnENVcrBE5Ca43drSYyUz0yLdveuGHtNASlqdwGAmG/Vz30jdLXjYMXcK2L765qeSeWzEbAshaQNglu16v/fW9HQNXM4jNDyWs53JCjqwNPGlHaMj7h/tZAMAyEtFHbc5h/dIt3CeNa3N0yNyk31r0ap&#x2B;3eKTx8NxeKmb6chK9e3Yx8NEJd92sxooZLXqfjs2eu4xuDYsiMjYlkPSBsCyfVoFqt5m9GDYSTsvuuoRgJFGxmyH09VIMQgAIrwIR1XpWh22nWQjtx5zyB49VeNQPDfB0vMR26NqiU5glvyX33ARpOeqN3ySj/S0NjK2RZG0AQC6yLfht53ScduzwEQ3YArxmC0qUx4CAMTlw7bo5Kp&#x2B;y0j&#x2B;/R9/OY6jJW87nMhNxPSqeEuLQNWak/qXGxFk&#x2B;90Brh1ittvBf7Pepo3TW4JQzRKSNgDGqRrNug9vQPH5wzlbiyTpxLqagB49Yja36OMyBwDNRrYXzrztaI7crueRMnGpw8YReBMbF6lbvJk2zm0dxsw7BQoN&#x2B;M5PHEagoc1CqZLauY1AbgkkbQDsI2wbTGTrhX1sO70P2Fzvq54iF8DOno5yGN9ecKOyxtTtkXzNU9VEsRSpnd5QggFDwDE2YFNlTHFa&#x2B;CrmB22nMjYshKQNwBYI26CEzgo0ANeAlSTHbzDOTRCAVe7KV9dvnv7taVY97elEt/YJbasvrqDt&#x2B;G03NlPprOG3DJxSX3KpyEdJCZZaS3nKwYSUnKWuSjK233/9kWlt&#x2B;pG0ATBi5C4LKBRtldluiAJAxviADQD2tGgxWBK5ya4bOSWyEuzS1bM4hNU2DkN2APFBeBqKLM9Vluq50hWepU6YymYJSRsAy9ywbUClgeVKjnRjbPBnsSLOCTCLe/WJN&#x2B;rm9l26/0QhA2ATjwpet456/Ty9wExFbu0xW6auHj6m/M8rDsD75Xny655WSd5mLJRiuCRwFBQs5ZdGSRk19yqbPrltejE&#x2B;XiZmO2ewkcOthaQNgFnhTXpM84BGSAqzDEN8VQBtvKuya6klVQLkD5JyBoB50bTsKCgAw6UjtZWZsjPYXJmzVHISxPfLsdSGsrqZ0BWIHrbeF/CIeyFI0XBBZfa/HDNmvdD4c/Xu9cPHl/fDXo4lIpf2xewDAACDds6TNNQRNRvZiQ&#x2B;gXeN6Vql/Ov&#x2B;7fvP9t7&#x2B;c/9W9Vt1hAIAlbtHq/u9TG9bN2u9Bdc8QfkCFz6DqM/Ju6PtQ9SkAnWRSc5ELP2wUzLLQFT3gUMNc7d3rh94vehzHV9/8RMy2Oua0AdjLsMGSlkZl1uEMpHjr2zAsFFBFcCcGb7hrdZdiXuqAF2owA4C4ltLbdiU2MxWjZCZWfp3G8tmEjWdY26Qx2zff1HfG9pUCuGS/6sovHFUFWnRl4ymFzxm2yU5uc1eGjGZstw&#x2B;ANiRtAIxQvjLhnmkKra8M7xvLuQKm69GLFP3bTner6EhbbX2RAKBHGAttsqlwey/q7TM8PYFXxbjizEcXDp2l686vE7kf0OxjASBMYXth&#x2B;mF8fHk/Zh5bFHuzrYukDYAdGhpXrrChaLvRjhLud4DJbYAevW8ft88ve&#x2B;2ruhsCwCq0tSZ6M/Z&#x2B;Z72X8HVb1i/Vz9jXBsAlHLc3&#x2B;GLPF5sjjycVs/Xbsy2frjGhbRXs0wbALCULXh/79Xim5nDsdh5Srq0sotEaZwkYb27MJnK3upJ7ClsAKBQte5U0H8Zr3C7o6Z&#x2B;33KpKXmvY3TA1IX7AS0&#x2B;kanE5YBirk1ZPJQvd91uZQ0/3HdCCpA2AcWPu2fRseqgkFYp&#x2B;c/g6AbN4U04HvJDUU2XKDdquAIBhBoRt17CS2xvcxBq1gco8cRpw8a4ChcstViu5wBnM10nhTDUmtC2E1SMBmJKp5UypAF2TljaslGTe9eqV0TFYaxQYbMB6Ke5LSD3/7YS59pcAANuodI0Uvf3V3RCvD07DRJNwe9TVv1fee5l4JMAsbnkVvQqWvsY9XpGl8KpXeEi9kbEth6QNgCnerXdMvef2fr9hheDkNn3ZhOykvPIKbGjAlTiy6PNGoK/ezQcAt65ivKW4u0pLqmdzSS2nPGakY/jdC7dh5i4MQDOvtOQmmCe&#x2B;SdtX3/wU3aGNjG1RJG0AjMgskT&#x2B;li9M7Bvf/7tDcSm0MDhdLsgCarXVhUsYCQEXkdjtfAT0IxmDRSRjhRLfBbK9oYvitAZ7dFunJXN3T37KlFTs9hGqWkLQBsG/ubCpvYKOxOkGUktRzIUx0A7QZORC&#x2B;EeUqAHgeVbxthyKXTlXx8OwVnszoDMK6w9tkIKNOnHlsxfvCu/caqwWRhjc1/h797vVD9PfiE9pS3Flu5HBrIWkDsIu5VZ9N2vC3rFZABXF&#x2B;AFV6XJLcDgBgjMLILayoW62P9Rv8V1fJX/08X9&#x2B;c8O0baP2lQgVgN7clVeOa7QqHZU8/EoUFzoCYLbqMJNZC0gZgI9PDtlkvPVF0oOuepwKAcr1bdMP2UTe8uAoAZGQ2WkvVPxX2b3aSCn4E3/jEjlEN7YvoOpaWTD/DwHj5G0fds33/7S&#x2B;pWw8dViXndvxx9s7YCNgsIWkDYIG9lsy6wh5etpcHoFlm1LlUQ27YHg&#x2B;UtABQtw/uDpGbgVlWHm&#x2B;bvSmfXfSs2jjPm0z0BAqJXNc6RyFPP4byczv4UJnHhqdI2gBYk1/mQklVZgeZFVT4FADodJVUvcsotyO4/bV2260dAEoQuYV6DICLRk3Dzp69&#x2B;FAt25cGkHFbyDReFJRjJUaWPMP2Y7vFJm3LIWkDYBwTqgazvV0BAJPcwqprKy46FqSx64qYDQDyMuXhni2F213rMv8aXaB4biXfbX3MPYBNELlhK5ma9tMLP7O4caYXZXObn43ff/2RsG0tJG0ALLidLzWx/TNmegQAQC3ZPR4qXgsAkLFn3tbOTVw2v/uk3v7Sp&#x2B;V2Vij7wsK8ThN2uenc2rNIcUM1VpVcFEkbAIMmjgPKtEM2rCvs&#x2B;a4BICPTqG4pM90/ZIQHAFSg67Pa9ElO00dVXofh/mDmu1SyECt1D9gW/W6H1e/UI1Fi21PHrDVLSNoA2KSworNn7LTnuwaAUL7HrT1jC/clbXlaANjTbisBPlU4zylz92lvpqV2hpv&#x2B;wYWpm7GmUN3eh4BVPTqdtJUYg3ewjr56ySPXFY3ZmNC2LpI2AEakGlc0A6bjIwCwuU4ZW/lLAIBh9vrdlpAPXUoSppa1B8&#x2B;mn&#x2B;Ycy/Z9OTqVB9hEj&#x2B;&#x2B;88uto/ED2bReLImNbHUkbAEjy7vosXg8ACMmuK9VpRUoAWELjiHuvuq68u3O6sL9VZJ7T027c6BbdEz&#x2B;&#x2B;zEsrXGpFltX3BVzK6&#x2B;35y&#x2B;EqKM6Cy/2/QkcqbMqB3b6oydYNAZsZJG0A7FDYNr4OyV5VIKN8Kf/D3Jn593/9s/t///6Pv8w6EgAiZAsr70n6FYAKb4gA0FVdcR1ddxclUpFb4w2o5HMMPzUNbS5WVgSsKlmd4mnhE31OJX0jE8fwbVh&#x2B;5jM2tnBbDkkbAFMU7j6tpLY0Rcm6ImZGJHkZm/dLIjdgde2F1YCyjoANAERGSNionY6RmeWWl2&#x2B;4PbrtRqe4jRG&#x2B;HJEbsAMlt4mff/vD/b8/fP1l9VPdFlm933J5mWmmEwn2kLQBMCjTbBt/P6YScLLd5ozGbKkHkLoBOk0fDl/H6hRhACiU3625ZGqU7WqqrEw7q67V03Lyox&#x2B;9tsaXt17c7MMB0KTlKk6VctXP6cVs528qwrbpGdsthUPqx/j91x&#x2B;Z1rYWkjYAZk2pDdS187diry8jjNnOylBqHQAmugEKlZRI1X1kGhazAgDDMtXLR8MRCEUK9ajP22sjXPguAUvzLmGp7p3GZwhjtuv3LTPbLoPDLe&#x2B;Ftl2oI9&#x2B;VBP1I2gBgEFrsHpNnwx1w5P4crSoRuQH6LTqCcrkDBoBqbqfno7Rm2468sEOz&#x2B;ql63CUfHY&#x2B;7Q5u2T9NkYwfYSmY7jJZVJdoLh1TM1k5DwZU6BoXlvBRv4tpX3/xE2LYokjYAAOq5E9oy8/qvf0pFboRtwESpORAampoAgBJep2f1BCnDHXmnxml/UYNPWurlzH92g7knkxoRNidSttxuYz/3Qou&#x2B;&#x2B;vhD2q20YXFIY0jaAEBSdGGB6D/BmMIaUmqiG2EboMHSBXU4c3rptwMAdVKRW/5PKDCPBTf&#x2B;5IMbZrnvBiAoH7NVFESpJ1RVpo286vUMknj3&#x2B;iH85ceX9yOPgdlsS/ti9gEAwPIyQ5Ouf9JTYYIeX33zkxu8hfu9ARhg9c6jzPoqg48EAKZIFXfff/tLeefd9WA9/X29ZW4TmZNwnqhMN7HAkd1xX2Wfz0uJ6wvAmccmwh6e8z&#x2B;pJ6zQaenI1KU9eMrysNcKRWO28/epfxL0&#x2B;68/nv/1fiF0xZw2ABDmrTlGX&#x2B;cOWqb8u2twM7MNUEVwJ5vok/e7QXDrAbCV6rUiPfuEB41rbB76xqns89kNc7sJn6r5N0Bv4dIRLSWn95zX76dcVt57UXtpdy3nb7O0d68fekxuy0drrC25HJI2AAAmI2wDVOnUigs7JaV2g3P7wnQ2jAFgjNtsIHx8fnqWsUI19WZFIrdCxk7poS90lHX73WC7BBjWL9oRye2kLDdSYUBRc4VqA2azwRKSNgDownaL65baYVCDuQOU8sOR3LANwES3vZDtT9upNUupCwCnR12W&#x2B;SBhtzrt7ZvNn9vCXfEKH3n7Khp6hzUcwxiZHRMA80RuBAtdONe9T88xjzwSd&#x2B;7a&#x2B;XOnCW15TGhbEUkbALQS3yB3deEuF2F7eIdzEk3Ofv/1x1SF6QrbmNYGTBEu5yJVZIW3ibkDVwHAEtn5wYemjkVxIncfkRMlcoeNHsncVoaeIxGRejsG3howUeYKmnhxaYjWUr1nvY/qduLayJiNgG1pJG0AgO4Md1hUOOM06k&#x2B;AEplux65tXcI2ABAkOJxrh8itmptryk7yEIncBsvnaqsPuMwsFxmmblws2I3sGGLBK&#x2B;iHr7&#x2B;c9dJjLF2uZtBBZANJGwD0ZbUe0Gj1luet26Ugo3kba0gCSnQqoEjXAKA3wWLWcGW1sSre0sWcuhU&#x2B;ek5t62Sk0iZjTZ7rDYYTSS29TeCWbH1ebetgyoHl56mP3KFtDK9HqHz/EehE0gYAHW3e5Mj3KZvcZ/6p1Pw2FpAERvIKq2h/meAkicNc1xsATMQghjoid6K6xOt2b7z8c6a2Pr2&#x2B;CdPvsMa&#x2B;k5kPYvqpBsaQXQAjde1MuaBuRz9MPIbwYQMOZpZwyHVm5xGo9cXsAwAA2HStKnP&#x2B;N/twZvrqm5/yNaTff/2RqWzAXG5h9f23v0SHpc84LgDAPSqc5bxhH1J3t7qnkv3guFN3xenFhvKlk8jM4AqZ9SGfLh3pUjJSIUXtgYlIdQfRTbQc5rQBQKvoABzb9YC8zPgs82uqtDiHLLGAJDBRvtErW1517bHStqwWAIzhVTgpA0s86l1t38QuureZl//VPXP4DL2/APmtXommAMME1869/qmxrdESs52ihzfmTjpr5&#x2B;yJrvWN6P&#x2B;xhKQNAAREVx7bVsmSa9tunU1FCtBpQE/ZgIEFGxaqABC6im5GdEVFb21P06n2yC31ouXNBJFjEDH9AEZyPyAuMZgXFpgt3/nbUdqF3UpnqPbzb394vxE38gLfqlft6hSid8gYkjYAkGG7HtAi0wDb5KSl1tcmdQPU8rr8GnvQ3D7fzAtV26qDDwA8LQtebTv7LZNmPT2fIkNSwg8icwDhP&#x2B;mJ3I6NBxQCVkWLo&#x2B;pMKHxwdXHRKV07pY6z6&#x2B;1yk3txphfo7Diim2hdJG0AgEGUL/wty0vRrrDNqzMRtgEa9B4&#x2B;2WktFHrxAODiRTVP4589IzepgOrR2c4HUSVzpG4/rJGTGvMTBJeWGScEbEvwctB5ZQkGgXjqGp9NN9G6SNoAAJIyY2Ovn7fqwrhQVQL0G7YPQfuT3KZ3LOsEYE&#x2B;NfYLmR4ZlFmw8Cs5e/rZSftPpt/hk6jf9uGGb4W&#x2B;Oi553bEX2C3/7bLOKEe91ucwHiy6DhOWQtAEAumDhFAYiAUu47R0T7D6LtmAFm9ObdPABgKtl9cLU3&#x2B;4QnOQjt6d/WE2kyTD987K6VH50h6p9NlICHm0YKfKEU66p1EZx6C3VZXT9kvhtOSRtAABJqQ4L9/f7zLEgbANWJ9Xa7NeCvUrXTcpVAAi1TJDK/&#x2B;0OtdbqmErwdvboXia4yZyI8EUtfWc2nLEH3BLZn/J6qvOHuRGXzghQiXevH66fP768b3y22w6i6C4kWAVJGwCgI69ttuEIqVTYRoUJ0E&#x2B;2CS0esJ0/5J9251YxgE24Vc2WQm&#x2B;Tmmo&#x2B;phpw18iHYVLrTw4Lh9yhhOGx2WB1xh7wiPeFr9gPMl9KTLygiNlc714/uHGaG7OF/yqIIdo2kLQBALrYYQhwoTNUc2tOxGyAQleplZqY2/LM9Ye1yCsCwHSC85nMr4JePYsi/4flJ7/Hysx6Pi/bk8BMvikgqtO3XflFpLBQncWL2Q6JOW0tSOP0I2kDAIyzyWDhKNI1QL9UAaW8PezZtpgFgKPn5pomVWeKUl2x1X8e7h82/vO6PXiGHgJICQsQDcWFhmOY7py4NiBmIzmzh6QNANCLW3c825lb9f9mqk1u6sZebsBc&#x2B;aJJvLXZb8M2nc11AOgtlRWxh2U/LSt2irQIbj/uwbMSmQIC7Kb6Ys&#x2B;UgdOz&#x2B;dQKmRvqF7M96v&#x2B;JDteeO68OeSRtAACMdlWtzpoT092AucJmpGwrt2ubOdUGpnMZwFbyedtBqZj1qDvVG0t3PD&#x2B;3mVyq5Kkyh&#x2B;r1U/f&#x2B;0DP1h227p4Ed1O3LqHxd4vCNqD1UcdEZbN4Dhh3MkeggYnz2EkjaAACD7FNRO4qrQb//&#x2B;iMxG6BBppGsv5e2d1IIAKt4mnNMn0AwXuNNLXpiq6cPNvY7a461dvteATvoMR/XKwY3vCspkQnbhsVsdA0ZQNIGABCmfKyWNmcmR6UK0ClcBbfHM7fzDoxWOoCthOlReQajfzhFJ&#x2B;4bn1tvbz8A9xmm3AG57QKGdVpn3puAO6scThWeG/bnXIlafn5bu3ABydvuoOvxLB2pHEkbAKCLxmVhjGEzNmBFnVqYXZ/WK3s3LG8B7CZczPBwei3Li8ENexVPdW887BduSZuuZ6t&#x2B;kul5IWEbYE&#x2B;&#x2B;VJGK2eaKFubeA8YekTrvXj&#x2B;I51uPRlrTlbQQkjYAgLDBGyTo523GFq0nsYwkoJbgPN1&#x2B;nYCsOQMArsby1nBZKnJTazk5dfsbldAQth20fQDrqq9x/VOoGSTdW0W3j9t9xIQ2/UjaACzJcOvXhn5NaANSkRthG2BVpzVnSp6f2yWAzeXDj0zspL9LtEV08YnxM9JMnmRLb4pud4z3829/XD//8PWXE4/E0/XLr7PcCA9m25ZFj2ltJYjZlkPSBmBVOusiCPFJpSI0lpQEVtFjjHy/IvFsA2&#x2B;7DBqAbZXvzSb1hyvyose6m5F4Z&#x2B;ujM9&#x2B;&#x2B;1KSgzA139SluGybQmMvN2NzfTMzbNvmeh&#x2B;VYuAP02CMy6OPL&#x2B;0fbv3k9RcRsqyBpA7A8qvur2OqT8lK062cvciNsA&#x2B;qMLE9kX0v8gMNNiQBgK2G5Gs5Uy0cyVyKyT&#x2B;Q2sVouuCbz8c&#x2B;f7KxPbfoBTLF6jghtwphtHxqKjui1rOHA9JCa1pZfyijaO0TMthCSNgBLivYnbhXkLG3nTyoVuQGwLdUNt2ExCAA9pFZBzI9C8NK462/3yU6eVsvd&#x2B;WQtr9t4W3Q/Vj2fkdWvjWw4Cjz1829/qFpGsl1q/Qkl7QIu9pR&#x2B;YVtm&#x2B;DUx21pI2gCsKtOS2TnIUeW2tWl7LGR&#x2B;vhpT2QD93DZwS0mVv2FZLQMBYBivdG0Z0&#x2B;AVy/aK6FT02FItf9Qt691YVz/D0Yh39TcVZTVHhAaaJ7QJdi7lhwhMLzfyl/b0wzPAXUDytjuIgG1RJG0Alkfkpkr0nG87EJLFIYHpGhN9wdvHgDIwnGrA7Q&#x2B;AeanStboAND8GIh&#x2B;Z3N43M9MEn4aaFX/lvZaq3upNbr5EbtjHsC/53EIj8zZtl2YVGqe13e7WRsC2OpI2AHYQuWmQb3tv2B47lwUgbwO6ShXyesqccIKF1LFJLeQFAKvzitbbwCyzz6X5sO1UHZmI77XmHU/54923oOcj26TtafvdYRjNE9rEhbcbndeRzqOyIRW2kbHZQNIGwCAiNw3yzd3dzn9J3sbObcAjmY27tZUwqaWlemdj2s4DAGC6zPoT5X/esvBjJqV7ehOPRm6qLN32dIfyrHj8gE7h1aSnoJh&#x2B;ADrdTkSreELBZ4MqJG0ALCNygypXlhZGbsRswCNPi&#x2B;6nnUSdRpv2uOOIL5sGAKsrTAiiIx72WYPBaw1dKVfJ7aO9JXWbtz16cg3jbPLz/DQc4VOPZogCJnX62rsFgoYLLbMoCBd&#x2B;qHEBSdhG0gZgC7eRGxWIHmiSRSexffXNT&#x2B;RqQFdX4VPRYZrq9etdmgnejLw&#x2B;0/YnBAAY1pIsiuy19vQYUjf38SMpw1c0vDs1A1UBEV60NvFIQtHuMi55oBxJG4C9pBo/tBwEua3fnbt6U2tFXr8nbwP6qWu4Zv6qvZ2ZGi4quGFb&#x2B;EvubgDMa5&#x2B;apq2vc6Lbqns&#x2B;5Xq00Vpq&#x2B;cqSj6N6h7kxbM&#x2B;MpGoBVLstGSYmW5kpuVzsQCGSNgA7KllVEi3CHeknHswU&#x2B;S3Z3MeQtwFK9G76un8uXipmVn0JXx0ATBKpfG5Sa225HzXey8KBJt5QyEfTwuZGbiXrlK578709t1QtACnT4/lN7n1AbyRtALbGRm79TK8sruL3X38kbAN6kNqYTbYoyzxb49JbPZ4cAFZUXm5vWF/1bgfRWKswQZFaKTH6DE9vW9o&#x2B;Sm3H00L5DEKY98PXX84&#x2B;BBne/md6epxShTCXPPDUF7MPAABUOHf/Ti29df43/qhWFz2fhRutb6VkAhyAci3lTPi3gkVW6lbSXjBm7lOUugDMaynl9iwhvbuGqhNY3ewavz1b5pcGGo9h1SLTZAZQLr9C78gjyb86FzvwFHPaAOCfbXQqEQAAIABJREFUZEbu6BlzpJx7ojhXR7A&#x2B;ZDRXY2YbUC0zHa3uGYaRKiGZygYA0flVhWVgWP83XHhG19i83m/17OrbRRTDPwmPxz2wzPNo2Af6OsLoBtUGYrZLtAls&#x2B;AKBNmYmtOVZKjTseff6wf2/H1/ezzoS6EfSBgBxLCzZjhMVdSZqzGMDREgNyZd6humvEr15aeiUBIABnhZ0sjeRdY3ccMsLolJtrttD0tPQ2GSDaj0nHMb88PWXP//2x&#x2B;AXDV9xYqSnpNAIL20lBwYshKQNAG4QubXb/ERF56uFeRvT2oAW&#x2B;mO2Ts&#x2B;fKmDZVQXAPsKCrm5&#x2B;85411dPgsE3w2TTc5ozNY8vbvGWHkTqlX9Fg7&#x2B;ff/hgZtonsT9nvSJDChDbkkbQBQCkit0KswHkcx1ff/OSlaEewjGT4MACPiLQMBzQvx5d4&#x2B;xS2ABBVkhtldtsyX3hGF9uUetpb&#x2B;WR0lZPvfVXCU7rKG0m5HbKzeTgNQdFpbSNjtsG8gkJn1kVrIjQlZrvWriTkWwJJGwA8RuR2q6Rh5j1yB1eoxtw1AD3obKgDQFftMYC7zZjkkemTf4MtwUn5H1ZszJZ6LQ2fl9eoMdm0UXXCYZWG/dh6T2tLhWpzy42KjTZ3E0Zc7NyGFJI2AKhH5HZr57GQmflqzGMDFqK8PL/tINZ52AAg7mkeEHZ6mu9wjPbzKplRUXHOo5/4gA8uesaU1xZEdJoKCQyjYUKbS1txIbIUsyXRCM2L2c7fDAjbiPeWQNIGAAKI3EKpAZ5btc1YHBJYnf4ii4ANADzVgZn&#x2B;Mt&#x2B;SMK&#x2B;qDjjH3/IymZP51p&#x2B;SaBbwnCmahrlxGe7l4xUjCkuM6wgVHltXqRArzNjyj2&#x2B;XekWoRdIGAJKI3E7u2988ciNsA8R1Kj3yzchViu5VjhMAdNokRfBueePftY27Vb5dY3jPv00uE6zCnamWyduUTGi74iupoQYihxTO8D5/uH5vuEArMThjKwnYxkykw1MkbQDQxc6RW&#x2B;FCkVbffujcle02b2PzNqBEpmenroHqti1TbcglyivvvrPEMQNAu/YVEffMDKID4wr/SvwWs/q6nSWR27HarZnqBPRLhWe9d1xrpHBnjfzr7nmXPGVCL/GgixlsBpC0AUBfJZHbPhZtPFdwc7UzQruCtGjkRswGNHL3KpMtZzqVWlL9bqm7DB1kADbhjpbYbe2ECtE1G58&#x2B;yaLR0QD2voH5PfD2adwBUpYoHBRmgYPlQ68pGdv5oqRxypG0AcAgG85yi25gsE/l7HJFa17kBqAH5TFbv6UvezwtAKylvTCkOH2kuhVjqUUQXXXNzLtzcXVAFSWrQT4SvYi8BTYmlh75a9xksRa6jbIEYzZiM3tI2gBgNNuRm4G30I8XuQGo0GNrkOiwAFmzOqcsdWUCQFTmvkABGJVqjLScroqJ1DZim1SDLlwzf7n3W1Lj4hKDWsoXkPSur&#x2B;l7H5KxlZCdylYY6ZHGrYWkDQCmsR25edwWJj2/RG5AD1LLMIrr3XJu3KAIAFaXSjJua9T21vp75Dpv5XfA9g3JNrlDhWd1xebP5hcIpnBnqmWish4T2jQnc12lZtql/sm2jy/vvXBLfK3I2wMQfBgGI2kDgPkylZjlIrdNGs8AVFmlhDz167eiBAawGzfPyA9ii94prt97f7vWbeUpkalst5Fbv/ltetpH&#x2B;SkplgYXErlhgDA8O39jJgArHIsw6nCUHoAGU0Ks8oCNWW6akbQBgBbtQ0RVsdS2rOBOVrtmsAHHcbx98&#x2B;Y4jk&#x2B;fP88&#x2B;kIVdnVnLFTI9Dni5uwMASLkWSzgaFuvzSlHzZWnJaocVHg31kFrwU88dcPoB9BA9vSbfKXDMzvNaMuzCWYAlwgucS36AfMbm/Ssxm3IkbQCgjpnIbfOw7XKlbkRuOzsDNujUO7ebWBJSCAMwzA1sMov11UVueOpRwBl9cPWZ1/bZXd9MG60hbacXJmVWg5Tace2Hr7/sseZku&#x2B;qYLToLsPpccYEPVjiJ7YrWWC5yCSRtAKBXSeRGfWghZ&#x2B;RG3rYVArYezKxc1G&#x2B;xRzOnCADaPa0tb1LH9rIuqUyo8Nbmrbso9RKbfHazELmhk&#x2B;mbrilZoPLRlaUzNVzamWnpCbSYvrYikjYAWEB&#x2B;2wnvMdNFW7&#x2B;7dfuecZq7huTlq29&#x2B;ImwzLx&#x2B;wsXSkCD2F3lNuub3uuwAADR7No0r9efQZFNax24VvKj8vsPwJW/6qIh5TsgRIfhnM1Zs/t4nmYevqwA6i09rGx2xdC4eKaW1cyKqUBGx64kB4SNoAYCWrdAcYaFuKuBK1aOQGewjYkNfet5h/8tTKaQBgW3tx15jYrSJaRa&#x2B;ut8v&#x2B;Vd2kutvIbcytcO4qkZ2agY/mJlLlQLXBc7PcsG1wxpYvbJnQNtf0CWSFB0DGphxJGwAsSX/kJrXVuQ2pyO33X38khCvkhViqUisCtrnad3kZ1g3X42lThe2GJS0APOWNeHi6tdu2OD&#x2B;h6GAaG9waBet2wgAla0VeuHD0GJ9jEbAZQ9IGAGvTHLmdr&#x2B;v1Am9ej2TdyApqtzqrCNiuPyF&#x2B;q&#x2B;YtchUt&#x2B;hSWM4N73BSeAQBQy6szu5mBpbzEVX2vFJyRFrZi2u/g47PS3ZbNt31dwAxtWdrFLTGqizsmtNnAKpEmkbQBgBElkdswXjuZPl9Y0hKwARfBVXbDruHw/wIAbkVXVpxyJAPMHZjitRTEWysj39rOy&#x2B;bv/N6hltqY7WT4trKu6UtHhjIZ23m0hHA6kbQBsINexdP0dW/O143OY9vnMzrXhLydwcbSkZ4zkdI534uATaFVOnfcsav9jplh5gAgSOcMaVnttwz3vpaaa5566WjYtuhpn7uS8/gzJjIvB2jhbrcGcVzgs9wGbFCOpA2ANZksZ5&#x2B;Y5zQ9cruE&#x2B;xZs8ilcQRqLRor49Pnz&#x2B;OxKPGDTmSMu5LYXb5PiJTS9qAeAKdpr&#x2B;KmRCiarrFJjPtzN7dywrf2ZFxW2vAZ8ebou0V8Sf5q8RrCKMGxTPptNv03ugwrlJ6iRsS2EpA2ATfn2wLFZVywTHaaLRm5MaNOMgG1Rmsv2TsdG2Q4AR21vYHS1c7dcNdnJ2LLNs&#x2B;DZaNkrTtWH4p3GYccWjmXs9&#x2B;razjm2ksnP1orWlO9eL7gNJwoRsNlD0gbALCoE02XGzG67HMFX3/x0hW2///ojYVvU2zdvZuVSBGxLmLtGkxQSMgCQVVH537ZGepIajRfelwvPZ3U4pOeDS6WV0w9MBBMWARH6Lx/9R9jPrEArFbMRsC2NpA2AZYRtE51nXs8KloNl5q65YRvKdY2sCNiWE3YO6i/tB9yS3OdfesMbAKjTMk3qSExxM&#x2B;9pdT0aqrWcrpa7udomRu/7b3jS3Pu&#x2B;YAUpv9zoPpcJZllr1lrU4GKq4oylhkqoLWD7eff6IT/PrPer3z5m4uGhBEkbADuizQA6GceLnvCtNsDwXLkaM9gqdN2YjYDNKj1D3T1hGdh&#x2B;hNreIwAM5jUBWuqWam8fY5T0rrZP4cpPpGucEDaxZRE2RcccTLhhnvhhSO3tB0SF260ZUz3rdzzvwLj2T14AJp51EbBZQtIGwJRoy22HLEebkj0eNqy0hVPZWEAy5VxAslPMRsAGJbg3AYCI6rAtMxTs2LiUrlvO8dFf5VO9/Pkvyeoyfy7Ie63pe2P3a2FF39q2FwiGMTCh7TTsYjFzxiZ6Oq3tzMkqkrDCVSLJ2NZC0gbAoFkjCnEqbODxiSDkpmtuuHVFWS2ZFgGbbZrD&#x2B;2jP15hFpShpAWzCSwIeVf7J2yqEJ62uwVWdTt3OwJv18YVrOQ4&#x2B;APdIWg4jXIKSawGdRKe1ERqlpGYBNp6x8ALX3LwS9PHlvRd6uWFb4YS26rwtc1RST4WRSNoA2BQN22YdDNbaSwnGELBtS1Vpc92Veh8VNzsAONXNsqIULeGuWHhInLSWbYF23lIoFG7SJnJaGMGD3sjVHgnDtuoTeDs/eE9n2NZ73cgQAdvqSNoAmLXn&#x2B;oQK7Tm/8FoTMlwxMvowXMJFI&#x2B;uSLZ0B2/USxHX9qC1hvAMT77TilgcAnk2qndMJNrvKY7PMjKthN8TMpDGrTVEiN0AJsklBYah2lK3uWLgCZOEx5F&#x2B;IEG4JJG0ALLPawtGM1penMHKDqzqFut3XbXrAht40lzxu8Sh4b8o8leazAQD9uMVsPmzLBCRWi1CR9DH1JILRZv55oouXiM&#x2B;0e8RerFuyH56xtwxsyB0xcMQuai7zo2yqWV0SdhuwVTwnJiJpA2AcYZtC9hqiFzdO8&#x2B;arMX2tHwI2HOobgd5ONl1f6&#x2B;oaM1zYAkDeo7DtUH8TkbX6wLhM9uO&#x2B;o7nvbmILVLb9y&#x2B;KcwM4WvU1UiE5ru/7piIVeXkj2dNpZ5sEEbOsiaQNgH2HbSN7Z7rFPgFphzBbOYyNvE0TAhlWERV&#x2B;n4faZncz3aScDwKk8bDt2TRFa7hFKBnOETY/BRxVt4Cj5OsmeDSI3YCsaSvjBUola5pfen7Sv8UjGtjqSNgBbMJ/xKKSk&#x2B;T1RdLnI85fkbS0I2LCuHjej1Ppd4W82L5MB7INq/1PlE/se5Ze9uduzTTyqKS3Nic1bWtaAuLlj4zKjpY/9IrfM5LZ&#x2B;CNjMIGkDAPQSblSO0&#x2B;&#x2B;//kjY9hQBG1Y3phik8wvAblrKvSkbes2VecuFXb1e2CZ9gJXmxj&#x2B;pM6ahBaThGABEqSpCj/9ZfN77p&#x2B;mDKqbLxGCNCVn5nzdOlcMwJG0AdsHgO4wUndDmPYCwrYS9gE3k1XFSNbL&#x2B;EfGjzdzgFjotADBFuCye&#x2B;ZIzHzFW36TMn7dQdGTh9PMwrOW7Vu0LuPz82x/eb374&#x2B;sthr66zY0rnUWnjzXgL/2/5Uz1K6drXpcQYJG0AbIq2kwnbxkidZ9sn39uk7TZpOwjbstQGbLev0vvVkVG&#x2B;&#x2B;JUGgkUiMRsAeMpLv53XYKhuHOmcCzi9ree1QHtXS6bMld/tGoFJYcx2/rJ32KatzHRpPjZVwnhMfLVJN1FjVcnlkLQB2AttgzG8hu4Opz2frp2JWkn8hjwbAdvbN28I3jY0bNy3zg5QAOiqroD1isq1RmyIK0yqps/8u45T7YSqwbfg6HkQOTPRdeQO5yPQef6BjGjMpsfTYs17O3VhYarrhtZEIanZZuHzTNk0Di1I2gAAXWQqiDs0ydzg7Zq4Rt5WzUzA1nw4uKe23&#x2B;2ItVfbDzXV46n2JABAD4KFv&#x2B;b7SG&#x2B;3b9y9kWk4URqOIa/3EfbrCs888/mm6IWHMQOmtbnaM60wNWx8C2Frgss8o1/AhnWRtAEABlHeDBZUviwkC0jmLRewRQ&#x2B;AgA00UwFggJZJNhsW1NHpSk/Pnpu4jKzqexu1DnvdlHCrP5eB6V/hdHn9GScQ0jChLX/hlF9WqfcyOC/cQXRiWXs8RsBmEkkbAADy3IlrXpxWuIvb5p7mVQRsuCjs94n2uyk8TgAwoHxtQ&#x2B;&#x2B;RXnhjuJTWEE2ZkZpQbukkX2/Ky9tsXyaAOOXXS3h4lsoxYAySNgAAoJexgI3t2XpT3oI9uh2h/jcOAJ2kNqesmEi0w8y21OCPRzufRc/54NxF&#x2B;aak4XfJTC61w2UCkzRMaEt5WjgIvhcu51u3E9rcB8jOVGOTtuWQtAEAICMzWe38fbhPG0tHptxGXyKRFQHb6ryWofIOrOg49/ZjVv6uAWCMfN52xErLaGCwW4oQncSg/M7iZqje567wyE3OcgMgQnNbRnO5OtGwJR/J2BZF0gYAQKtrfcj8ypAsGtlOW8B2&#x2B;2zen1wPJnsTp7kRmOll09&#x2B;hCQALqZvntG1R7L7rRxGje8bcrdpGnkm3F1jnx5daWNKAKZ84YElqT8eSC0p2cl54OTMsIMWN2a4kLJzf1pjGRTM2NnVbBUkbAACS2IatBzMBG2St1bkzsdVasYQaAKyrYl7aboFB/s1mzobCOX9MvOiEOA3oRFspeonO855yJKqEKZcbhklNPmMSmw0kbQCscdtaamswMOPv//jLv//rnw9nWtsRWyUSdVYP2FpeHcaEi8MMuEO58wwAYE/5EfpeIblDgZnpNi25ZVwPmHiuUse5c&#x2B;TWOwwjbAOkLHSj2fyqj04j65GHkbFZQtIGwBTN61xjN1fwRuRWoT1jI2CDTteNqWsGtlAbHgAaRTe/9MpYGgWX/CznVcZn5Dc/23kmd7&#x2B;40T2rS3xJgKd&#x2B;&#x2B;PrL3i8RvXbcy2pKqh2W/HuWn5fUUo2pSOzjy/vznx6t8fgoYGtflBJjkLQBsCO1BfrmtQT0Fp3W5iJyG4mADQoNG2Wf6fniVghgB1flvzAJ8MrnVXKmdrI3prnz21IHsElL0F3j0f29SH99eEXQHQ&#x2B;I0Ha7Ca9lRqu4Mhmb94OU8wmZ7rYckjYA9ilsZe28tsnOiNwqRLMrwYiLgM08hbcAcfmGuu33DgChiu7LK5bYrcwM75K3/b9KOoijvcAaDkyPTmEbYNKsCW0KrXKcY2Syrh6TzLznvGbLYRUkbQB2oWdx&#x2B;XA3CCUHhmq309o8JY9BJr56&#x2B;&#x2B;bNGXcRsOGUKktVNRS9w5M6tszmQyLPDwDKSaUs196WtsvPaHBSPgrQyyNnzXCKTrT669&#x2B;&#x2B;Gx&#x2B;5aZj20TsMS00ctH2lwJ4fvv7y59/&#x2B;mH0Ux3G3X2bjk1dHhqraTdPl860BGRsWRdIGYCNqYy3zTfqtFIZtyChMsCqCLgI229QW8qF&#x2B;Tdkl3j4A9BDmAfkiMVUUm6&#x2B;Zl2xyVvFUs2I29/fuRn1jDsY7gCM4vWOOpEfYFq6tKvv8gB4DJrTlzU25yNhcgzM2AjZjSNoAGHTbqFbYTtB5VCh3TWs7/mdxyLq8jYUlMznWp8&#x2B;fBSexEbBZFS1ONZSx0WMQPCr3qVijGMA&#x2B;vGitvNy7wolwpysNd41OwjjqaR9rdG6TktOl4YOb1Wfdb2YblQqYEZ3WtlzMlpmcJ/Ve6u4OtpGxoQRJGwDLUu0NDW2wk3uEeo4Kddyw7WjL23CJzkJr&#x2B;fPpAVvjO0IJd7sdVU3ETDlfPfK906KUALCixllE2u4anaTmKpW8d1VtqyW2Z5tycjq9IpEbDDizqJ9/&#x2B;2NiwJYqFhqvrPZ35B3AJvdET7g12sRIjE3alkPSBgDTuI3bDWswJnlh2&#x2B;HMUSuJ3JjQ5sZa0USqcFqbwlUiCdgGU16oincOKn&#x2B;/ADBSdR5wbdXW4aA0ElwecO6QQbc9NTfZyizIuVw6lbkWiNywOoXz2B5dTeG0tsZ3xLXsUjLbjJhtRSRtAAxKrdC1T7MZE/39H385jsPL246CyM2N2c4n2Vkql3qallX8CQEbxEVvQGRsACAiE3IUhi4UpG4UVNjfGg4W3HN9jnAKyPmDjS/V7dshcgPKZbqkKq4gwbAwv&#x2B;QGxgszNiXhH26RtAGwabmW3lpHi1tXVFYYuTGbzfU0nSJgQ5SqcrWk603qgKcP7QeAKVgookR7MBk&#x2B;m5JzrmpgZXgwI&#x2B;/I4q91e24XnbcHaMCFgwvz2FZH0gbADq8BoKehlUIH6A5KIrfUn8DjhWEEbMjQVroOC9gAYHOqsh/NBE/UrIhLSWMqvwqcjS&#x2B;kd/yqQk1gIW6B4I570FCUubjAB8sHbExoWwhJGwAAI2Qit&#x2B;jD4MlHYgsFbOdLk8kJCnt/Zh1JStfGqsL3CwDr2q17UTYHGt9f7HZYz0r7or/869&#x2B;&#x2B;c&#x2B;Oo8Tdrqc8i8wYzDwCQEV6bShZijV7OtDW6up3ERsy2FpI2AKYwvA76pSI3MrbL2zdvriAqGonl/zV8mPvMEgeYe4kU8ZfGSX/MFqJzCgAEuWXp0osfoprCT/AK2&#x2B;Yew/lDWPEQ3L9wiaoXoIfCxsuAtTcQImMziaQNAEYjDsSJaC0jk0vdxmwEbHtaoh04coOWwa8IABrUbRa11QCI6CmqaJ5M3JdLTz4aprzeXgZK7sIie/Kdrq&#x2B;KnncHLERDwVWIC3wWAralkbQBsONq7&#x2B;XXyleFJgrwSCbiWihgY&#x2B;lIKas0VscHbACws/LC0BuXsE&#x2B;1XConmzg5I5O3jR9ucr2QnhTwkB7fGV3vbp9LBujkuo70ZNjuAXidbNOPzTYyNgNI2gBY460ar7AqcB7V1exJ5YJUZVpw9uxJpVPR38/aho2ADbOwrQKAbYnMSNuz6lhxxrQtzpH/9Gc1BpVM/ApfvSKDDB&#x2B;p7TsArEL5hZMpFpQf&#x2B;eoI2CwhaQNg0NWoUNhavhpdt4&#x2B;5flb4LlbB2VvOp8&#x2B;fvbBq4iQ2Ajb0I9heTT0VpR&#x2B;A3YTTiZ6WhCy9W0LJZDLvg56yBKjazCl1YI8OOPMhqn3jwBJUTX49EjNWo4&#x2B;kg0VQGLC5O7cRvy2KpA3ARrRVaApRm2nB2VtORS41K2DLv3R&#x2B;sh3xWw9LzEgYcA9iYjSAnVVkCYK7WOlXnUh552TuZDLvRd1b3pQWX/h&#x2B;1WZRVr/YAERkCi5KD&#x2B;AWSRsAm6JrZaid6HbE1sJGtbDtrfNDR6OFtmETP1RkqL3key/wGH2qlrkdALCop2v3LToa75FwtlnFFMDolLXxk8lKJltwyzs1VooyVRe1USKwoukzqvOXMyUqUIikDcBGNHS/unvJZpb8om9UloaPHmoRsKG3rgs83gZsAGCbVLXZcN4WnQF2qjtj0ar1lBPotZsm1vm9qeQmv0gn5QNYgeVMLy4KO6YA3CJpA2BWtKGlJ3G5HTTEwl&#x2B;y9Hz0UIKADbP0K4toDAPYHPXnW5l1F/MKu1xHnvzUWJPBx&#x2B;BFfcNeOkPkMDJPQsMK2vz82x/nDz98/eXcI8nw5lurzbG4uoFqJG0AtrNKw2CJgwSW0y9gu/0TdKWzpeoZn7GpbcMDQD8t5Z7tYjP17sqX2VR7ciYem&#x2B;bTIiV8j6u0qWHelbG5/1dz3nbqvap8ndRkZQCFSNoAWHY1AMw3flAiNc3xoAa5jivKKg/MKh6fCcwI2DRY7rLteqi3N7gdegAB7KxxvT5vKUXDBaZ3M6pbd3Ghm&#x2B;9IqW/O9NPVb53qg7ANCngxm/t7/WGbZ/rV5B3Acg0uEe9eP7j/9&#x2B;PL&#x2B;1lHgkWRtAHYgqpmc/Rg9qzHdFLxcdNQ1Kwlx5IK2KJPRcA2V9fNz9aV6nHe/LQA2EE4wO626MtsYGaPW91199ky867ntvjC&#x2B;6/VO6&#x2B;qljWwEJ15fN5W/VRezBb&#x2B;huANt0jaABjn7th81WzUxipb1WOGybQGleygDnEEbNhQOFkh9U8AYM&#x2B;jgO3WVsWmt3XQ7MO5p/yANRxS72MgbIMGqQltq9BQVrhkb6PLCWO26GMI25BH0gYAExgbQKqQF6xev&#x2B;/dICcrbff2zZunK0O6&#x2B;m3DJhiwtbxBUHJ6oiu9RP8JAKyq20HKnXu0yc1F/7hDiBg2r44vEtTSvIAkS1BoUxKzASVI2gDYtMQMtqiFDlUhJb0k5heN6ec2/Uo9YImALfr8kLXzRRddl3jnEwJgE9HqX2MBaKz8vI0SDWSNqx9/J&#x2B;43&#x2B;em3WvncQWxuxQlt7nUkdefyzoNUuHgdifmiNczYPr68d3/p/V8g74vZBwAAI&#x2B;ivH/z1b9&#x2B;d/80&#x2B;kIUVfsrff/vLyGGemaPS/7VU7tPnz9d/tw9&#x2B;&#x2B;&#x2B;bN&#x2B;V/&#x2B;qcI/kT1UkWfbXOay3bkIpTwBAA8FY5636sPEI6mw8x3/KZEPerlvCKCZ1AUVxo2NAeRuRWu4DVu4OOT4mC16GFgFSRsAszILas1VsmcYegvDtn7VyjNvSw1b43PvrS5gE8nYCNg6WX1owlUmSF3&#x2B;mZVnKGEA7OPpfSH6&#x2B;HVvLnnR97X0PWLpmsBEjz701Ndm6W8OMFd4&#x2B;dRV3VOhWnXYtluJGsZss47EPYZzCp333&#x2B;zjwgOsHgkAE6SWBWBpjpG8sz3g5LOqZKHGrdquJ8n8K9uw2bPEZdV7gUd36AC9YAC24palT1e926TAjC4FtuJ79/ZFdm95S1QGLOGEA49IbagsuHjmincBcRpitiM9f&#x2B;7d6wclR4hbJG0A7Ahbjwq7Gt3d41IPoMUiIjyN0T5u7/82nvzC1cy1fS01uwKwwviKgA1q9b7wuXcA2BlV6EJmtt5x07WJH70X&#x2B;2l2No0rpn4a&#x2B;LZgQ1I7lnXiXYnXhaaqMLF97VdkV/3iLiaumUHSBsCOaNUk2jZQVX3BMMOWzXE3Hi95PH1DKeUx2MSALfr8Ue6LEsvtJlzgsdPSkQCwm1Rtv6R4DB&#x2B;2SaH6tLJ60dwXPD1vm3sMtx5N9Dyczzr1bdH8ZgGFHpW3w7oIvPugOyl8wKvjKIvZmNa2CpI2ANaENRIG4iGj69ejvBdjifb5SIVJ2NOArfyZS5SnZbLBHo6VL5nBCzwud34AoJpbqFL5z/NClLXyttQNVEMKqOEYZA/AfUfT3xdgQ2b1nZLSWHDpyOgxeLjwT52CLmazGUPSBsCgTNg2vZaQbxnCqkeR2/Rv6USfPn&#x2B;OhlJXpuWGW6n4ioBtH6tcLONzQe4pAHb2qAw0s5pioWgeWXd7mjjqJVO11lCX1jkeqGWIj853BKQoXzrSs88NCCXcSI8cbjkkbQB2oa1VwEw7PUYGsSWRm4YOgkUp2YatYqYdHqHwzOP8ANhNe73azds2rIY1Vj6nR24Tb3z5uv2sWn3qddsPhsgNkKW53h6de7fntZ&#x2B;a0HYmYdXT3bwgLXyejy/vCdvWQtIGwKawBqCnTqDkMOCSCj7LO2iIWlO8aW0luZTCbdiqnwTllitLex8wm5IC2JnI3sw7F5uFbaXbYOnYMm87yobTDTgGwVfX&#x2B;VkDt/RPaLu9TudeWcO2t1&#x2B;FF3ddedj1y8a8zXtaLI2kDYBZ0bDtmF1rgVqd9jMofGmv5qonGJ6iMJRSErDlXzd1kARvkGqvprrVdi5DAOzJi1soBkPhyam&#x2B;GWXCrc3bXEqG0wm2JjQEmYDnh6&#x2B;/jG5Xpjlmuy0cpheb0Q608Pebe/f6QSQVi6Z3WB1JGwDoQiXGjEcVU1qwjbStEtl7rzisrvfFzq0EwFa8QpUyMCXs53WroBXZjIaJXBclEdeh6UgEqfqsgSMWtmnm7Tw9AAAgAElEQVSO2Y7stSN426o7CamMDYWIynAiaQNgWbS5qHm2kNoDQwvGgvWjLWCLPg8Bm6x1G379Zp5F73SCzw8Aa9l8TtW2ptQQVH3ZxiySYTJHxKKUR2u3lBQdJTm6kkPVQ3D7tExKxyZtyyFpA7AFGgMbUji62ev7Zh5bI5EEi4BtXV7/0YrZUo9DpUgBsBvKvQqCGQzn/1izEgJgln4FRV30qHxNy&#x2B;mIu1COpA2AcWczcomRd9Rguhozl7EwPHNb43zus3Tdhg1jXNe18hI&#x2B;eg&#x2B;6filSCCg/AwAwgHdHKKn7aV7rQr/UrWfWKdVQJdB2O275hmdqKUs0rgFtpMrG1B51srg5luu0dCQbua2IpA3ALtz2gMJGtbbjMWnY516&#x2B;jYGqBWc2wTZsq/M6d1bp6HEPO7MRQkVpkD8DCu93ANDV07hl28pYyxvXlrFNPAbzmVN&#x2B;uh7VDEAPqbU0uag/vry/ncd2Rl/9prsxkW5RJG0A7KMBgMvgL8OjncNtt9IFnYFWeWB2UrVK5NODRznNpf2wncY1DOoHAA3KK37brv739GahOWOb5VGFfzDBz8W9RhS&#x2B;U2Ar4bS29piNjZ8riEw1e/f6If88TGhbCEkbAJtoAODWyCHMmlvgS6ieLkbAZlJqMcYpB/NU74ANAHYjW&#x2B;03P8VNfDSG4XP1VHhux0&#x2B;wk3226PeE5gyggdQMtmPgcECkXDPYwlCNmG0tJG0AtsC0tm2FTcTzy9BpKdHbYV9EbhXqYjY927ARsPWQurRnHU&#x2B;JTld9/l0rPycA0K5HpW7bvI0ZDO0sjfi8zWX5ngBmmCm4bDhXsCRmWw5JGwCz9O/lY6kZptasM3zbQcPybp0wiW0fC11E&#x2B;YPs9Ea4xQDYUF1Clo&#x2B;dDGcJIiPAzJ&#x2B;lCtctWP8woBKMFAQGmFiWcmk/IpV&#x2B;hbvBec9MzLYikjYAUMFGM2wVw6bClE9xw6luD7ZHf0LAZsnEBZoaeb264u1bGswA9hGd5Vz3PC1/vhDvDf71b9&#x2B;Vj/lgMpxnqze&#x2B;w3sE5tLTumHQ3lxnCEfYthySNgB2hBUR5ZWD5ZY&#x2B;M6z3yS9phC80QWeWT58/e7kXARs8elqnUdH7VPT3dShAAOwpU4mqqOPZrpJFQzLvZnT73vMn/FB5C&#x2B;7NXuRm7x0Baum547jXu/L&#x2B;tH7CqWaZfdRanM/mvpz30uRtyyFpA2BctHKgtrVA2DbLsNPOLDdBhclW723Yyo8EvaltCg643tW&#x2B;dwAYRnYRyK2qZF4bpPC9Z5K5nRs14&#x2B;/IO59tYGl6KvCUIXlds64rb/Nitgsbti2EpA2ANWGSscRInCUO0oau45TLxwIzSjTj7Zs37dkVk9g2t8&#x2B;Vxb0DANxq1T6LQLYIz1J5WtOy&#x2B;KQ909/7nqcdWFrJFs4jpV6R4mWYVMbmPoCwbQkkbQBMSVUFluhyXeIgF5I/n2602ePME7lJuQKw9hls0ScZH7BV70WHPOXrRo7k9voxzh2AeW757xZ60yMQhaJLfTw6RZkpgztnnCa/bIwEBcQVrs2LrdzGbFgISRsAO2gJ4JExrcenkRt16zqrBGwYYNuLaNs3DgAubwwTZaMrta5&#x2B;&#x2B;&#x2B;CMMOPcUFjtX/1UrH78wBIURvWqDkatcDu39ifxnooQbjkkbQB2wbh&#x2B;hEZ&#x2B;JQojNzMt80bnApIl6dSjbdjyj3/0POXI2Eba8MLZ8C0DQImSyj9FaDUmPF1Sy2kCQEZYUHiR25SSJDoaY/xhbMuL6z6&#x2B;vCdsWwtJG4CNELaht5JqscIxazq5AdWVdbmh16OMTVXAxtKR4ijbPWT2AHZTV7/adkUBr1n0NDZz5wtW7PRmSWY5zSmvDkCtfP187vCFpfdhGU8q/XKfh23YbCBpA7AXVS1Aty6l6sDQ7rabe&#x2B;etLDIK57Fl/tz7jaqArf3J4aHYDFGkANiTt3rho&#x2B;UQ98zbpFofTG6LonEHoND0IpSY7ZH8eo/YHEkbAIPyFQK1zR61B4YWt303RG6eMGy7TadEAraSF8pjEhsKuRe7YLFPGQJgT1JJzyazgaND/SrmAkanxO3WnPFu6N5p3O1sAHgkX/BOLD0ouFJSU9nad2gjqDODpA2AZcobzPSKTjS46Vu&#x2B;quTBF6M4l9K/DVsmAiR721N0janGsogSAwBO&#x2B;dgjKvqwraa4cRMRMevbwoRC4PLzb38cx/HD11/OPpCkkvb&#x2B;3FuP&#x2B;&#x2B;pb3QpLsF8aSpC0AYAijHwUdNvsnFJ3fBS5oZyqgC188pYlMWHGsL4wd4ICtxUA5jUOYshM6rJahIrEM1ZPjqxhZ4mPAzs7Mzb3Z515W0nB676XY9QbCUsPd&#x2B;pz9AG76RqzZSa0Ee8th6QNgEHRlobyTdG0Hc8&#x2B;ZL8M5fPSlE&#x2B;4XIXygO328diHVyZ0GoROeQIAp8Iy9upDTFXhFLYaGp3vKJovlrxT5U0qJZhqBgzjRVPXL3WGbSG3NP6Xr//N&#x2B;9eRb&#x2B;S6IVJ8eby4a8pKjywvuQqSNgA2eQ0//e1AxgpN1OPr8Shy43Ov8zTEmrJKpPhhoITmJPs6JNl2rMJ3CgCrcOvhdfuWrUXwLmn7RN3KbFA3rLd6203ygCMRsy0hLDH&#x2B;z18&#x2B;HcfxX3/89//&#x2B;8n&#x2B;5/zQmbNu8MC83MvFiQtuKSNoA2OG1Z1asK9BAEqRkNBa7r02nJGBrPxJUUFKodk3&#x2B;NLxBAJgo3FemTpi3mVc31C9Tx97kvAHQYNGYLVpOzn0vmSKdTozL4FllxGyLImkDsAuqCNvy6rKzvgk7DJFWRc8qkdEHk7pJUZKlqeKWM5wcAOZlZqTdloFhN6L7t5sUoRV5G92vodQXaQCmtaGH8Du81rdL4QKSmRP4X3/89/mDN6FtMLdsX&#x2B;vj7q1rzPbu9YP7/GHGxtKRCyFpA2DKuq0&#x2B;6jH9eG1O70sy&#x2B;MyTtw2gZBIbe7YNEL2U1F5fA1J/te8dAHqrTsh2q5ul3m9h3hZ2wm7eLRttfg7&#x2B;OnnLusxt7MCwzBd7/Nds0QltUUreC2VFyoCgKzODjZhtLSRtAKARAxJl5cO28RgsVsGLqcIcS0nAVvF41LkuohULTNkiiFW8AOBSvSLisV/edjS85es8c6&#x2B;Z27KYnvMBaPH9t7/8y9f/NvcAKv4JQNQXsw8AAISFW8vePkaba/WP2QeytvwSLnq&#x2B;A3zQt96&#x2B;eZOPwc7/Wp489fzhM98&#x2B;2H18/snRIj&#x2B;oVs8F7ooec/uhpp5W50kAAHHR4u77b3&#x2B;pqGJtWHI2vuXzPFObTd12R36jNvz2oiu&#x2B;Ub2FhefcpSM9FOy9lUxWY0LbcpjTBsCgMGxbtJaw4kSNiZ5&#x2B;0D3Obfkw6nW/lnoomcTGDDYllpgnmirVBQ9e89sHgB7cIjSz6Vrmb1WtfDDeo7fcuPikbXqWbdz8g4CU/CKxuxWVUjSft&#x2B;j9lPJkCjK2RZG0AdgClQMc/9zH3TXFpFZa7cyoGiO0kpeIYpXIRa14obUv25V6QvdpVzwzANAikwNlisStykyRaupui23mzV05Y8NsGBro/9b98PWXsw/BlzlpE2ezXWVIp&#x2B;U3kPHx5X24QxsZ29JI2gDYtFzU4e3ivlWDX8rT6v6AKYOF30MmLxb69PlzdZQlmJkRsKkSXjsKW/7RXjDxjC28cVC2ANhTXfawW/Xbfb91Z4y87dA0vW/zDwIjqd2XYTnnqfv5tz9mH0gEH&#x2B;vl3euHfulX5pmvEI7sbSEkbQCgy7B5Vzu72gbDzvBy0a8lrBJpz4p9SSWT2FrKh1Sxxn0EwObyGVJmwclNtL9f5lRFcf&#x2B;FSWRsUspP3fjJeXysoa5hm/JXxyMkbQCgGo203gafYXoiSrx986Z9AUlWidxK6spSVX72O8jwmen3BLAPd&#x2B;WraImaL2Z3m5jV4/3efgRWhbuyub/Z7WxgN5q/3gqXjjwSi70fx/EvX//b&#x2B;cOsNSTd4kvzxzpMdFHHrnFXOH3NOwDCtlWQtAGACqwYOZFgM7hu7yU&#x2B;dEGsErmbJfpGBx8kXXsAtlVdAHoxiflSdLd8sbfrCzNlpMv5ou5LhxEgIIvvVYtUKfFff/y3F7aNjAz5TG91irvcUI1EbXVfzD4AAMD/c&#x2B;7Qdv3s/QApY1q/56fJx9fuCrduZ7m9ffMmlYR9&#x2B;vz5/M97cPTxjx6MKQqvLLUXoGz5sE&#x2B;/MACkeKvmVlf26oZMrcu7GZXcR87T23KSLUnNoRz/Rcp8dnxSEKe8zqlzQtuFS3IJqbgrnOvWKDp5TvYlMBJJGwBgL2HDoGtTgbytzhlrlYRbgpmZ9&#x2B;Ajm95BP4XtWAoEAFAluvrulCOZqPoth3nbhmdPPz4UtFB7mSuP0x75jz&#x2B;/vX7&#x2B;rz/&#x2B;&#x2B;/rZ0ntczpi4K/MqH1/en/8NOAwIYvVIAFBKSRV2XeHiLRPXdcmMbOWDTsnkYfkHHOpXiWzfhQ6FlKyjOOwY3J1yBr80AMwVXQ6xcJJW&#x2B;YMNyKxXX3fTVDiuZTwl9Q2PwkPCWnRmbBn6o6lUgfkff377f/7yyf2N/vcCIETSBgAqhM0znQ22tWQStVkb43mHxEfs&#x2B;fT5c2p2mvdD6s&#x2B;93xCwWTVlHxQAgE4iadlWWyZ7b1bqrrpz&#x2B;8V77xoqKjt/HGinP2a7sqiff/tjuVwqLCL&#x2B;/9/&#x2B;v/OH//izulONHrwJbR9f3l&#x2B;/Ybe2dZG0AYAWYWNsqwZ/J5mzN6sB7G1Xzud76zagepqZDc7Yoi9H6tZOQx9WNcEjD&#x2B;exAcBW3NKvvWa1VVna8majkwiPvdsv7tdPyReJtgZEKP8WrRKzlQwKUX6q0SkAI1czg6QNgE1L9MAucZC2zarIErZleNPaMolU9J80T2JjyzdZi5afIw&#x2B;bsgXAhh7Nb9OWiwzQ2ADxzuqGJzBP4XmgrYFG1Wvzavbzb394v5kb1&#x2B;ksOqK/X/2jV&#x2B;iK2dxpbVgUSRsAs5aoAYQrRoaPoXW0kPJhvOSsGRXzvTRPYiNgG0lzl1/0kNqL98zTcvsAsLOSMvCquaVmaJnU8mYLg8x9bkBqvzm0NSAi9UVa&#x2B;hoPY7Zj6hKUei7V62PVc0iqMPMMt0jaAGCaMJXR3EeMciKbhaCEqoAtfEUytn7CQlLz5VYyJlRquS3vPkJxBGAT7enRlbdtIjxjj95&#x2B;9P6ybRdt5o1PuRGHr7V0LoIprF7O0ZhNibkX6dV2oKyITiybErMxxW05JG0A7FO&#x2B;W0D08K6xY2oPGyX4ELtK5VgEbLuJdidNOZJyJROaG5/TQ7MZgG1uKeduYFle9O1ZbZOaWh0dO7gD9&#x2B;3nB00OuBHn57FRE8BT0RUjDW&#x2B;CMGxam8JTlyk6rGaujzCbDYVI2gDsQmFtxhWOJ9V8tHjkdiir8i/nQuauEtn75RC1VswWDdhELv9wehwAbKJllbzwb/fM28qlulw3n0LtfW20dUwbjkbQT2rC69ILk&#x2B;qZ0KZqfY7owaz7KYvTMJuNqG8VJG0A7LhtGGtrWmQWPb8eMPaI0Jf7yVJzFcQktt2kLh&#x2B;1l1WPGWzhk7NvOQBcyuta0VDkbDVoazvokbn17BxVeo24ifsCpL66e34uaMTXRkrmxqTnJOs5kumGhVvvXj8QpJlB0gbAmrVad/kBjzTvl1M4glVtHrAWAjZc9LdaT52O83a9FwAwzJ2vU/0kmalaFKQZmYGDO5&#x2B;36BS3iRjkh2rTv72F3MlqY1aAlKLqDJuZvNhofO6V34&#x2B;NHG4hJG0AbPJWzFdeRcjvoa2q7qWZ90FPPHVPR7DyEbdjlchtLREyjT/I6Hpoek4IAHRVXvNXvujfEvQ3tbrSP72PjQlQIb/h3/mDki9VuCBkars1DUtHKjlpUV0X4UDo48v7fMB2PWzAwUAKSRsAy9Yal7rWbkMoMXHRGAO8NCuMu8LHiOs0iS36XlCupFNPbVF/SjVlGw/bG4jqPTkAICoshJXfRLS57ss7R5X5oZPHpC8V32TIWuXqToVtCK3ymZqUD9vI2FZE0gYAetE0aqQnWM10eSs5QlWigdb5Szej6hezdZrERsA2jObLyj02kZZtKqVTMpQeAHoTHFjgLkT51799RxEayg8N4bzlp7gNODPuaKSdPwhIUb7nn4ZpatP1WDmT&#x2B;G2A8oztfCTB2xJI2gBsR0/6AllLLL&#x2B;p6mBW9PbNm655FZPYDFB7lYlnbCm0jQHsKQw51N4RDOAkn1Kj6Caels3X84QI91sUDt5SctXnY7aKaW3LTYMrXzmzxNVz4hYgTPUeLIzT3EDu&#x2B;pnUTS2SNgB2lA9o1Za&#x2B;oKvpHzczSx65Dbd6hG0EbMsJe5E0X2IltyeRdSOjz6/5zACAiMY7QrQIpf5WiFDHE40lBp8lvrfohK&#x2B;WHqmg8WnYFqaqmOI2PCvZ1A3TkbQBMGjnHQKgFv01JcK92VIrSYqEWJ1WiYw&#x2B;M8StdTWlbknt7&#x2B;JsHpOxAcClfJRVOEsjzNsoS120swp53xy&#x2B;RViOtxKptiFurBs5wPRPeROZjC2Vrr17/cC0Np1I2gCYJbhnA1bkDc6imriWK6lKhW1Sz38aHLD1XgMT2nSNwcjYAGyucf1wbxVEVt4rkcrbdrv7hGusub&#x2B;hAYLVXd/qWfsOjqRh6cjysyobNEZvfJmVJCEoFZgxg21RJG0A7NMw9NJrw9urmCpEL4kxZzTVGInNncTWIzLEirqW/9xcAGzLq/OX1Le9XORwSlENLQjlvHGNO9&#x2B;A&#x2B;NrAKr7MY0w/z14Bvkm8Old1xsZsNs1I2gDsQkmzJ7OxMLqiXriowvUkb02fxCbyclhadKa1VLnU9ckBYCGNk9JY9K8CZ8lzfQlpgGBp&#x2B;bJ0ua/3D19/mZoKNmtC2/TuqZCxD30hBGw2kLQB2MusakGqzU9NBQjl46tHYRsBGzTIrGbcfhfo&#x2B;uQAsKLGnIPCE4VYaxSGeYO33IHCS3zto&#x2B;FZNGybErO1nMN&#x2B;e9Qt8cnaw0KRlpC0ATBF81j&#x2B;cD7&#x2B;9YO2QwXmurYxSyVVt0HX3FUiMy/H9mw769p2pWEMYFvVaYe7ujulKFqEDTq&#x2B;VDDDWGeFG7aNz9g0Fwv5rTc1H/nS8jHbx5f35HBrIWkDYJby5Rnd1pfyQ7WB07uWcNHIwj9UO4mNjE1cvjWozciYzR1uzGAOAOZFh6/JriEJ3Jr4ndE82BRQSNskNg3BfLQ1gd5SKRoLRa6LpA2AHdNrJ5grtYQa1cQdzJ3E9ihgOx9M8NZo3fV4uw4O1f/2AaCr60ZQUsBGOzc19HhiIZk9AsYcwP9l7/5ZLsnyO8GHGlnzHgRDI9H0GAVrbFJO2UMKCtYsaJKiap1dmtmFNcdZZgX7AhYEclRFkTSUn0axdjlFrlfGiB4JIRhLb2BMaY1Qx4Tiz4m4ESfO38&#x2B;HNDKffO698cQTN&#x2B;75xTfO7yxeyB2cxLU&#x2B;luazgZNvzlm51l1bCwds879nvElOWp/FZsy2l7HJ3mohaQMaN45UqhgOVnGNuAp2Y2MOl22b/7PYSWzWbItosxpczBIeSjoVFLhJAK2Sk5HYOmzLfhCqK7lp7xjOfmw3o8x3aJlb1QkZWxskbUD75sPBwquOwjcPnvbTx4/n&#x2B;0bO/ytijvXQJDaeVvXJ804UJ8YDOnd&#x2B;Etse147PM2VqUwlTIRf3Hqkr6VY5E9oWphNF4L15/217&#x2B;ccPvLRy42nitGZI2gCAgrzaVrHGSWxaR8YSaGhTvvUkvCeoh4FO7OVtkqEnuOo6CX&#x2B;IZ9k/JcR&#x2B;1G7ezHDYOpKzv/e//uyTb378efPr6Tfm0OEdIRnfs4cv7Xwymfd7jJiNbT7V9FpCuLpI2oAG7a3XNX0x&#x2B;7iQrty/1ZpNUTK26AHbq99MPx5doW3BCQfowbqZ8F4VsDf&#x2B;L7DvX10EmXPTYZZ9h2TfANpWyAG2DtsKjNnO7KuInztx98Biwwr5veeyWFbt7fsPT2Rg68XbHnohHiJpA4D41qPSzgemBTKJrW0FvuOmC3B75XSUbXaNGOjHPCdbZGnn73MyAeglm7ur27xtc1ecaRAHlSrtqC4wWnvV5vrTYQ/N5wuXKqX96hNbB2BD7Axs8yWeeCEeJWkDelTstLYyt4qX7M2kHP/iV5xd3kls03fK3i4rsE3TeY8WrusnL3xvADztZN62/jbnz4Bwo86hy723F0B2uCtoxuKodjBHdP/2jojz&#x2B;Rb3rOx9z7Unb0MgA7tvjNAOX0LYVgtJG9Cgzaqm/PtVOx&#x2B;&#x2B;tOFMl3O/6FwyTmKLtZgcjYlyNtj7dHOqAXpwZoQfPh&#x2B;6lHxNIMXsc0ZX&#x2B;cUmvCq8Kkdv7/H7wmeJV/fnFLY9OrHPb/m5mG1Kzh5N8khM0ga0qbo6xwimH31efYjlwpywQiaxwdzTZ4DpAqhTDdC8Oye6k8u5safzeOnwx3dE0YCe3&#x2B;PJXDtRxMrYNk9lixWmncoesheznZzrRmkkbUA7Oq/0qIvR6nnXwqpiAzZ9I2/aO9VX0bRqsW2xcvf1M/g0BLjGCO0ytdhovlQb1M6RHFexPTkPq4k&#x2B;bxdeBF0/vPs8cfSV/hW5SdIG9KL8MWKfY5eWLI6xxV1gm9/v1/2ElBnbne8kovLP8IcnhFjK3xUAhVjcojFfqMYI7ZqTC&#x2B;O1Z33MZAzbFJXEslneOlXeFM60StilgXOXX3pc2ZM8opO0AU2p9/7BzQGrMqle62J76PK6Q0q1TGIbv1PwFsX6tvEyT5jhVS6icHoBuGn&#x2B;geJi4h197rpCPojnx/CwGoH0&#x2B;avhmr0Bdr2XXMpRbCsOv9mMpmXbqJqkDWhNAyM/tf1J4WbiBVrnbX7XC&#x2B;EU6qePHzcDregZ20NdIq3Z9oRaltiRsQGUZl01NFBH0JvpoN0cAi3uSSp2mETJ9o6ZeY7ruDqv2KsBh0u1pd2c9s2nr4nZmiFpAxq0uRBO4BsKtJjZVv4Gp1dvP0YXcWKpaxIbyRR413bit/w81K/irAhQDuO0sAI/ZMtU5lHkF8d9i3mTvGRzp5UQhwcWwpi&#x2B;4je&#x2B;IB5jTdIGtK/SMUGN21yCKi4rlzCY7oFJbK2quh3rozeHOpkAXGAw9ip5W1j6O2ym22vC3wAnFdvesD3jB1DeN&#x2B;mZVvzOIcNjs9ACT2XZtupI2oAulDZAVM8/KtfuVcTG8umbN3eWMSt5Epvl2SKq7h330HnJpwnAfdPosa5PlrzsqyHJUqxRjKMmRSivWq8iz2WLQCvK/vzmx5/n//z6s0/uPJvzw0npZ7OZP1cLSRtAauFbDuequ46czOFuyV5GHm6AX&#x2B;5JU2p1JqPKHpvJ2BILvI&#x2B;ynwTmMm5JOTsBoHAGZlwwjTc204hkn8KHObHDm5csxtiB48dQ84JYO20Rs41fuRm2bTLHMQsT2mokaQPI5jBr0WDwvHVxa6f1wyQ2RtUF2A&#x2B;do&#x2B;raCQAZVffBkV0g0em2peTiB8&#x2B;7BxzSRLe3tFj6LenB&#x2B;R27jtmmr18L2/SNPCnN9LKHOlXyNEkbQB6Bmx&#x2B;nbzCmuSDvEmiLVx/OjZWFgmvhFc7G&#x2B;OrM95x5QpPYmlTse&#x2B;pwvfGITw7Aob3oqNvc6IxACdPtfitnzsfmBigtiSX7Ed6evO/N83Nh/eqHZ0Kvt&#x2B;8/yNKaIWkDSCqwTvXmF1VEZyz2Xt6wbSH7BrRhSq0O4yuT2CjZ5hXJKKcItxsD3LEXHRnIbZritEBO2e1&#x2B;y5s1BvZ8t78RonD8RHfnas/ehLZYNm8Ef/QVy/TDu8&#x2B;nuWWPhmGBsE0IVxdJG0DRxuFXn8OaOzKGlCdfWoa66aePH8Mz1QIPXHzFJDZK89C7/qUbOAAIO1zvqnOLpZvmXTr63GnhOZGDj2MqtziAHdh3TBcKihq9H27V0PevO1nQtRm2idmqI2kDKF3Pw5o7ig3b3CAWtg7bwgmWSWxUIWWLYKcUgJt6jo4uC7SUbJ7l62hP&#x2B;KB1N3B091doe4hfdC5ithpJ2gBoVsZBoc6fd5zMrupdie3TN2/kc4/qsyDs86cGeI7z6qHxavsiTOp2v5W8fN18k7r9BfEqy3SlMT91fPbb/2H&#x2B;X19/9kmOLRoGv&#x2B;7nzVtTbv5vyo0hFkkbQB7uAmuesC2ZWiaxXWuMSdjijVbmeXXeaSf6aaHMHxmAhm1&#x2B;nKluJnnnRPpFEEWgJ&#x2B;r0z6KOtHGmV8Zo6lC4t81XX3z3J5/96h9&#x2B;/m/jP//tJ/9mGIZvfvw5wU8U&#x2B;D1mv0ugbeuwTcBWO0kbADzlzJDUsPWyuiaxXXsgLymt4AeAVrml7FA57TSzbwDNKLOz7rybYvl522hds/zJZ7&#x2B;a//Mffv5vKcO2hdJ&#x2B;xQ1bR2vriW7it4pI2gCSmhelLgq3anNguvm7dgBcYxIbNdpbUh6AXIzGScAxRtUKj9U3Fy3Lkk6dtD4hjLPZsmzMWsm/6&#x2B;btNZN8&#x2B;/6DsK0WkjYAiGlvbDpvH5dwc5rSwCQ2y7M9wXsKgMu0xrpgnlDOl2qTXOa194uYJyV&#x2B;QZxRywGzGbMV6/xdd&#x2B;NstmuuRYwCtuwCa7YNwrZ6SNoAUjOtrWFnRqh&#x2B;6a96KDZLPIlNxsbmez/B2aCWayUAGcnbTip8dksa1Q3m/cpoUl0x29ziLTmf0HYnY7vMKSK7cMxGRSRtAPm5DPqq2ov86urzXBqYxHbnOWlP4hNX1edJgPSMyQ/N7xfMuyV5FRvNLqa1LX5NBW4wVZgfV/Mv5tuiY2U2kNw7c/7bT/7NP/z83xJvzJ5y1pjshJitJZI2gAwW09qmrwtgril2vwUSwWK3uRDnuy&#x2B;axEa9HjoJqIoBbio2R6EohUezYjYuK78lbL0T2ha&#x2B;/f7L9c8ypm4X5rfdDBcXv&#x2B;va72&#x2B;uwjpmW3SJlMPVRdIGkMfeqKXYsSyHNqvZwB1hftcvMYmNegVuKo97Htgrhp1qANbWMcniLCpvO8ml2KIOlc0ys5Bto0abb3BH1AXhGYFTrnY4ue3rzz7ZDBovx2x7v03n9sSsxNYASRtANptVvTFrG/ZWY1pfwfEbD2tsEtv0cGlcb84vgX6NjA3gPvfvH9JVbNgZ1Q9lTHGTsZGAg&#x2B;qm9Q6c0rWT89jWYVv0Vpk9n&#x2B;STmW8xLrMAACAASURBVM9XE7O1QdIGVKmxfKKlnyWZxaWQWg4JV3BOujkvreSMjc6lydiqOB8C5GVUdsE05N5Mm7r69NnL24Z8U9wCGzN09tvhIY6i6L764rs/&#x2B;exXgW/Yi9AeXYXOh2NiYrZmSNqAWhXVo4MswmFbsdlbpRlhRm1MYoM0JavzCcCr5oOxaZwWyFE6N98/PnQCSitXRW5cVuMx82gQFcXe58uF5dlicQPfpmnmWdw87NoCbA9tDLFI2oCarO88La2AIa9aejO6h/qMViex6RvZocQZm0tpALE4ke7xWTNsLQFQyAg/3LO62BKJAjlUIprOErVkbNN/9XwYXMvDXhLIzOa5WoIt4T5JG1CZvcWu5v9LPw4jq5RZrPwsos2YKk3AFnjam5PYZGyM4i5ys5jLO/&#x2B;vzgtjgEPT4G0aMRrLvcqNj8Psxy8qb5t0/tvhMkdOXIEzw17GlmZmXmmnrHIswq237z/kmkkmZquFpA2o0t5lSpVeh84UtOkvNx&#x2B;&#x2B;oks5L9nMqKJPGnuuUaSM7Wm1nPwf3UKnFIAzAh8ZTqSH9gbetXwQp5F9nO/XwX1VHz/lt44cjTv5mx9/zr0h/0rcmwLrlT3cyr4BXCBpA&#x2B;oWmOJW9dCQV2UvaO8w72TPSwFVrkls9x/OHbW88Z9&#x2B;j&#x2B;/tB6cXgE3T6bHqMWQuZc7cSm8&#x2B;J7LAT9sytwoYVmnWn3z2q/W0tvR54eKM4fNxLdm0tnDMZpG2YknagBZoKUlYsmNgPhhV3N4RyKjGWGv&#x2B;DSaxMZR9qn965sT6qRTGAOetS4mSP1PKIW8LKOSDWD1CAqUdZsVOaAssoPhff/z9MPxqmLWRTPlT7P36SjiJZbS5NNoTEdcivZOxVU3SBrRDS0nmSviNl1Z1NGAeblU6iW2dFHLZXveqUcnvvocK10Ku6wHUqORPjZL56BkZ9tOhjO/9rz/7ZLPpYrEx29zmfvuvP/5&#x2B;GIb/67elnEac2NeeS7kOG0UK2Grxi9wbABDft99/ua5zvvriO2MFEljfqrZ54Dkas/j0zZvxz/q/fvr48TD9ivLw81tLk577MHKBD&#x2B;AMK9DcsbnTet6l8w/f&#x2B;Ud89l3R8y&#x2B;FpxV7aaXemK0oxf5&#x2B;05vnW7myrh/efS5mq4g5bUCzLOHWuaJuLF0ceIvDspztbFj2SWwkUPiEtvDVybhPG/H5ARoWOIU6f&#x2B;5RTy0sZvWVcIXab4cnlHBsz1WRq51RzgoUD1UrDXgi69rsTvn0i/I0SRvQuM1swxJuPGqvi05pxUkP8q7EJmNLqeT31962PfcZVPLeAMhOw8P71FNzhRxRgc2Qj3JH&#x2B;qFsAvPmk8lCu8CezHsOafJXHEWWjpEytnpJ2oBemOJGStnHyjwUkt2cA0ca5Z/Vy99CgLYZqsVS&#x2B;ITyp03l5GaxWcgOKWS6DNVpeNbvYo238Z8pJ8kV9RlkKls5ZGy1k7QBfZG3dSVvMbl5sO19G7GYxNa5wt9Qj27e&#x2B;oxX&#x2B;N4AyGtxodM584yT49veLPK27PaKoEI2jyo0nL4sYrZkzkwFLmEPl7ANvRGwNUPSBvQokLdBXOHrEUaxa5thVd6QTMZWi5LfUOm3reS9AVCIclbHqYu8bVOxt28WNXuGShV4YF8TiNm&#x2B;&#x2B;fHnXGu/lfAOtah8FjK2xkjagH7tjSRoSfqLJpsD082DzZh1bS&#x2B;vGr&#x2B;&#x2B;mXjdTMgCzyBgq0vJb6hHt23z8lnJewOgKMK2y&#x2B;Rtm8pcwa6ojaEiiyNHMfuE7GfR8JUxn4wPkbE1SdIGoKUk0azHpouBqSPqjkWsZRIbjOaXiadPNGcbgJOEbXd0Pl8qEDcWUk5m3wAqNU9fmonVc/WNPCnvu7WB3y9kJ2kD&#x2B;BfhlpJKlHplv2KSfQMq9dPHj6&#x2B;mWbVMYju5neyprg5M8FGyfuZCLvABVEHYdkfnYdtQUq&#x2B;U9c03cNn8eD68o5Tzitp148ZsNubJfkKD6kjaAP6VvTLJJUsOBUaiRQ2mCzdPoca/nwm3qpjEJmB7VOfdbDr/8QHuE7adt5fl2G8lhI4lbAMNK/MAm09W21trragJbSX0freWPEQnaQPYpqUkD3EUBWxmUYG8LcEktsDDz1u80Kdv3kjdLiuwts9OzA8QRZlXkEuznubig2auhLkgfiPcV8vJcJ2fffPjz3thW16Bj5jL79n1j3/hZ9&#x2B;7ecJnIrzqF7k3AKBo337/5WZLLgOO8s1/cel/X&#x2B;sjZ68xKSeto6nDsOrTN2/GP5vPdufhJ42vMn&#x2B;hm0/IGcVeXUq2YdI1gMucP8MCC5IN9h60qMaWpEVNXwubrhtcuMp058c881ouWcCrzGkDOLbZUrK64Sbphe8CczX8VefngZXWKFK6FlH4bVXme&#x2B;rRrVIDA8TlLv5ryvwITiPX3D5zCnna3krAm/&#x2B;VXkWJ2mhzp137xNn72V&#x2B;d0jd95JXwC2XT2/cfhmH44d3nuTeEY5I2gBdoKVmvXLGWsC2l7AHb&#x2B;oVkbMl4K7k0DBCLz5RD6zsR&#x2B;xzWlnAjZp97nkftDSmLGmqGY7YLPSQT95wsYWcGTh0lbB7DH2K2xd&#x2B;lbsWStAG8TN5Wi8TXnQ9fThn8nOwZ2/mAzQpt0XlbAUBK809e93msjWP&#x2B;lLvlTMinXIVC3D853JzMt9cHeLOZE4WYR24US9IGcFEgbxvUMOxbFN7itzuyB2zrF5KxJaDJyZ5pz/gwAuA5i&#x2B;GrsG0tzQh/vec3X1fpwR3z46ecQXj0vpFpJrQVfqosfPOYvH3/wbS2MknaAG7Zu&#x2B;unkAEoZXI9Ioq9TCvLJLab20N0LiQBQGK9ffgu7ms5E3pBFdY3bw2zixsO7Gs2rwBsnj3CUq5O53edkUlsNZK0AcShpWSBMpa7h68lbIvuZKClUWQDDk&#x2B;t80sDzZ&#x2B;BNy&#x2B;FTP&#x2B;VY4sAgEQsmEdi9R5dX3/2yV5GlXiFttHmzODE02EDVyTq/UU/IeUcssOAzWy2kknaAGLSUrIcWXKszfxMqPa00hpFCtgowXjm8bkDQESJLwdXqqi9tChDsm8PNWr7sEkcs5W/M8vfwsTG6CtB2BbO2ARsVZC0AcSnpWS3rIKQUq5JbIHnlLGVpof34N5UNgE/AI9S2hR7O91Yhpjszh21Hy2b&#x2B;dl6WlvKmO2wIUf4exKo/ZceXbL&#x2B;jRpFNkPSBvAgLSU7dzJsk8mdN0Vch5lWyklsZ7aHWMq8pFWI9Zlkc3UNALhsEeH4XB62BvPZQzhT2WBTlkaRBZpfqnJ&#x2B;2LROv56Y1nY4j00IVxdJG8Dj5G1plDmNo7TtqdRLsZlJbJ1YXNUq5FbQXBY/tTMPAM/Zi5H6/AgeFfvJ2/MvBcoX/dTxUpTo/PCquGFbIEXTK7JSkjaARCzhlkYgbythJ5u&#x2B;dsHJ5KyKSWzn5&#x2B;RxxvSG6vnGbRkbAOmVeYtbenuhY/o9o10kTKqYuOYNy6bNjE3wVgtJG0BSlnBLY72fy9m3ewsncFnKjO1yQhZlIxnOtWMq8I2fwN4dBs42ADykq8/Z83J98q7n&#x2B;rvJD0qzd36I8latImKsxWbnxkcntMnYGiBpA8hDS8m49nZd4p25l6Qu9Dz/JmyMo/bSrJ8&#x2B;flzkVeU3ihSwPc27aTg64QjbAIjFJIy1Mj9np61SYNKbYtOmwIliujrkrVqy50IvcVozJG0AOWkpGcW0x8oZm56M3LjjZoiVrFFklGfjUCHv/fT2LnrOT4yptwmAbsw/Zbr9LN7rpZl3h8wjQAUmUZRzIH392Sff/Pjz5tfTb8xlm/NQ1/&#x2B;10MbPXoVpWluWJCzjS3OZpA0gPy0lbyq5jLSIRWmensT2xBOycP5tVU76nsb8hx1PjE4&#x2B;APCcddBYVDGyHjL1NjTiIWUeSBVFTYd7L7yH12FbxJ9dy5C5BEFX&#x2B;CXkbXWRtAEUREvJy9ZtW4q6wTYwxS37thXo0zdvngilck1iu/yEhAWaNZXZx&#x2B;lRizNJbz8&#x2B;ABSiwLF9h&#x2B;Mioig8cakoV5tb78Zrb88nfvzNLSkzVW3eYhW3t&#x2B;8/CNuqIGkDKI6WkufNh32BGrKcfMuv71VTfHUnrNIosjddXU46k7E58wAQxXq87SNmIeNdkoGXnn5xfl&#x2B;ctB5SjqV3gQs31OL8jXEZTyAkNjWonH8l18Zwn6QNoFBaSp50MmwLPCr69kwb88Tzc97TjSJNYivKYhprh6dKGRsACaxXA&#x2B;32sybQOrLAvM3MNqJwIN1XWsY2iNlyGBO1Rcw2mL5WOUkbQOm0lNwTuKycawGnxSoI803iJWMDycvBWMmT2MbHiuKe1tX7TsYGQGKmtswVsjDz5trVw2xI0PmviWtEaxFV0fo&#x2B;sPIFARcSsnXMNpmeKvA9FEjSBlAHedtCeNh3stxNc12g51/THfM0a8qlwgHV05PYbj5hIPAjot7ea&#x2B;V0xwWgeXvNJAx3N6XPIDev1xe1fDVVcM9oMiXs4b1TRFH5X&#x2B;HkYYwkbQA1sYTbWuCnnv9XYAm3NPttfQGi81/cpsA8tsMHzv&#x2B;ZbBLbmScUsKXU&#x2B;bup8x8fgARceJ3sXYbOe3k6fMehCYhQiMU7sYQ3ZgnbwKCBZM0kbQD1sYTbBefXH77sZMvKze0h4KV5bAU2ioy1JYR1/p7au6zW&#x2B;W4BgAQKjK/O3HEIJ03hsfmRdxR&#x2B;KWC9VU4dj5pPg9tbs43qSNoAKtZtS8n7Y74n9s9Lt68atu4ZU6gzi5mdzNiKahQpY3tC26e7Q5ZSAIDsFp/CRXVdW6RuBeaClGYerTla4FGmr7VE0gZQPS0lC/TSbaQKmLXziVQtjSJlbE/wxploEgVAAosAycSpPcXuDaMCXrXXIjX9lvCEQBEx/sXvOiziRLQf3n1uWlvtJG0AjdBSsljhxRJGfk0XmMQGo82mkcVe4wOgavOPmPkIts9x7PoD10cwzevzzR5L&#x2B;XvPGeykBKmY4K06kjaA1oSnuPGowLj5TIc3edtNMjYmfd6G6eoeAAksPm46nz9dzoevUoJHObRuKnMHbi7CN//f5FtUAQEYeyRtAG06M4&#x2B;KLPxqnqBRJHN9vr9UwgA8Z5HiCNvmivrZO/9d8IQmj6hvfvx5/s&#x2B;vP/sk15ZsKuGNPJ3ns29JURYx27jKWvTsbfNVKJ&#x2B;kDaBlZ&#x2B;ZR1a6EMegFgbtfK/2J0pjyrTHNMomNtb31Y1oVPr33sAcASGY&#x2B;ZXxx91i3I9j1wKPP/UCTWj2YFzHb&#x2B;JVCwrZCLt1sLsPZ6vFwjfSLNUkbQBfMo0rp1cYL5fScqUvceWwyNlrilAJAGp2PY62QTcNaPZLXMVsJMp49FheLAtvQ7R0Vc9EDtrfvP4Qnxon0KiJpA&#x2B;hIM6Oikkv6wEy1Yf9X0MPsw7zKaRQ5Pptw7iG9TWgDgDQCw&#x2B;&#x2B;SR&#x2B;ZZuBhNA1o9hgMxW65pbYWcPxe/8UK2qgrXWkf&#x2B;8O7z6YGBZxCz1UXSBkD1yqlmD8ejh7eqFfKDtKScSWyBxA6e4HwCQESBJhl9hm2BH7mc8gSYFDWbLXDvQuItWejwZH5Z9OXZFvZitmkaHKWRtAFAamPtnX0M3babE9FkbLXr8P21uKjX4R4AIIHDDg0d2lzQKGPYJufjaY6xO8qMsgJb1ee9FGEZM7ZHX5ebJG0AVGkx2qturF/dBlektEaR8KjN0nf64vwvGTYOADrjkjTNm8fJg0HmK8qcx3amM7Az2yTWamovPY&#x2B;ArRaSNgCIYzH03Ly5dfH9ypKAC&#x2B;uZld8o0vJscS0W7j6zjneTFqXv4ckHALhv79Lz9HXT2mhYCdM3X5K9deTe6SL9lhza3KoyN7UQUXo5ytgaIGkDoFYlT2srZ0uqs8iopn8GMqoqGkXK2KJbvP0D/9vD&#x2B;3H6GfcW0SnqDAkALSnzQ3Y936jM7aQibuGKaPFmLGSC4GIDsm9PsX549/mUgd2P2WRszZC0AVCxQNhWZiVZcjpYgkBm9umbN&#x2B;uw6olJbCcf/uizcUfnvU0qulsWAJqxXi21kNHIYjMKuZpPdcpse1ipMvtP&#x2B;FWeNKZij8Zs4Ywtyvw5HiJpA6ApY5U7NWwZyhsyllN4V2dvutucSWwE&#x2B;ri2TcYGAIUoYbQfKDrc7cdJgSPZIfSqzUlsJfCrfFWsmE3G1h5JGwB1W9eQ63&#x2B;WNnacb3OBm1eCKaYKzBXbe0iAjK03nby5yinUAaArm2lWIZ/Li24feTeGGoWXIWzP1599kuaFWt2BnZiHYYtg7KUkbPHNMrY2SNoAqN7eukSTNGlWw1VHMuuMavzKQyuxnXz4&#x2B;Sc8fLYzy87BTYenRAAglgJLgPUmLcYGndyKxB3ro9phc1NpJwoKcWY9trfvPwjbqiBpA4D4DrO9Amvykv308eM63KprEtv5yXlc023xPz&#x2B;TLFaIybE5ANCRMpvV71GAcM3iCG/yQEo2oW3BxNOencnYqIukDYDG1VL6EvZqNlZIxiZge868yPc2H&#x2B;wEAMhkL2/L/tG8vvkv&#x2B;yZRl/UBIxCKYu&#x2B;daGmJ8k1zy27mZHsPn89dE8VVR9IGQJuyj1DPj5KNpyMqsFFklM1gkzcOAFAINwDRsGQB2zc//jz/Z8SpZl9/9sniyZ94lUOHnW&#x2B;SbQmXrQOwWK0dF8/zw7vPhW11kbQBQDSLThoitJTSTGI784QyNtJzqgGA9Dbb6CVuKbmuOMw6IqJcGdv0xadjsGQxW&#x2B;CcUOB71kJ9exbR10MZG5WStAHQsvRrJzTZtr5whTSKjL4lcIaiFwAyGj&#x2B;Ic&#x2B;Vt46u4vY/oxqo2UNgmO&#x2B;oihm3raW25lmebK&#x2B;3qwd72OM8sRMzGxGzNkLQB0KbF3LKhsOvR880rasMqolEknFTgORAAWrKXt0GlNg/m524q3evrGF0J0dpcaSeN8PYI24aok9h0hmyPpA2AXmx2VnlipBioQEobSTdGo0hYcM4BgGRKy9tcEyeK&#x2B;YH0RNiWLGYrx16QmX5L5jY7RpZzQmvMFLMFojtRXHUkbQB0pISwjSdoFMmCWVxOQQCQRcpCYPO1eh7/ENf6WJqON4fZNXsnh&#x2B;z7c7Fh0/aUdgNBIc7kZBFpL1kLSRsAfZmitWmw&#x2B;FzYFvHbGE351hRoFdIo8vKW8Kg&#x2B;O5yohAEgjXJGGj79iWvvwC7kgK9ROGPLe5vgXszGpvlUs/HvTyRhJrTVSNIGQHeSzWzjUReSLY0iaVuxN8kCQKtM8aEfTxztHbaOnASmDG7&#x2B;bwKBhFWcP0oTgInZKiVpA6BNi7Fg3qHhNGDNPnTulkaRtE3GBgB56VxNP9yoelNRe0&#x2B;EdtJm&#x2B;nV/Ntvb9x/mT7J&#x2B;Fa0jKyJpA6ALi&#x2B;Hjo6PJwPrGRQ2pOyFja1747dz8hYDOf3wAKMqUt6W5eD2fY7Sud4wBuMl9otGF57Etvp54nwdeThr3UMwWePK4L0EakjYA2nQ4FnyoAA4MlAf1SVrRF2MTsBUoEGz3WRBuzqAFAGKZj&#x2B;r3hhyJR/7rxvjTX1QfXOZ2rrj23qeU79GYLWDzJZ5bGY77JG0A9Ct62Hb4bPK2BEqexDY9v9AuisA7rs/a1bkFANI4mbel/Gje3AxxCNcEjufEw&#x2B;yvP/sk&#x2B;nOuF4d74lX2BHZgxvsFnSg25crYNl/F4m3l&#x2B;0XuDQCAOL79/stXR4fzIWzK4WyfGUACn755sxmV/fTx45l5bJcfe2fbeMh0Nmi&#x2B;aAz/pM3/&#x2B;ACQ0VdffDfv37j5sTt&#x2B;T7Lx/2IzjAS4qb1DaB2z7X0xur1TQcadfObUND/LPbw5BXn7/sOjMVv4eRb/u7cxlMacNgCacrJz2hNjxPUrBubMub10z7VZZdEbRZ557EkCtsT6ydhGknsAyGs9v23I/QHdySiIp7V3IKVJ1Dadz9iK2u0d1hrJVk374d3n69daZ2wRX5GnSdoAaFOg8cLeyDVu&#x2B;nVYbAvb1gKh1Kdv3qyjrzs5WbJGkQ89PwR0WBIDQBp7w/vFtI8E43wf9zyknEMrZVPHb378OeXLLU4R5V8ZKH8Lo9hLth7qGBl42mSBHxFJ2gBowd76Z&#x2B;Hh4GLOWfSYbf0VCyfcsciu9po9vvo8Lz32DBlbRt5QD53TAICFvfYVi8Ik&#x2B;srQkNj8GE7ZSDB67pVxQtvcfNeV05gxfGki&#x2B;&#x2B;ZllD7WkrHVS9IGQPUW4/6XRoGJS1&#x2B;V9nk/ffz4Ut/FkhtFLp5/c34eFzwXltfIuQUAyrHZUhKqEE6R4/r6s082A7CU08vSWJwHNifFpj9X5IpRi5U3ypKx1U7SBkD1FpXAq4PU8eH3R5MnU7T11vY8kF2bR1DT38ORW/ZGkSdfwoJtT/D22Tvz2DMA8Kj1VenEd724h4&#x2B;n7R1gcceZ67CtvZhtoaJ3rpoigfBibDK2ikjaAGjBus58aaZL4uGjqnjPXvS1Ob&#x2B;tokaRMjZSUg8DQBaBhaIf5dY9UnriYEsQrRXSOnIoPmZzMpkbM7Dnsi4ZW2MkbQA0IhBfLb6eZn1yI9S4xuxqjKxkbDC3WOxB4xcASCAwrbzwK&#x2B;lwjbHlfZuXJub9G7M0kFxvGOEM7Onnl7FVStIGQDtOlrXP9UA/X1erwK&#x2B;pazG2Rzejc7lWMijcemqvXQQAT8v4gTvVFD70eZSjK4q9vjslXBzYW0auz1/90zFbgIytapI2AJpy/oassRyNe73&#x2B;2gJsCuMoClmMbe/bBGw8LXt9DgCMSrhuDlFs1tdNVq8pF4eraAe6WJEs&#x2B;pKxNUDSBkCDTuZt8y4NwwPjXaPSNApvFLn5bYK3O0xoWwv0zrWjAOAhe1PKUsZsprXxkEBN7WC7I7Drcu3VHpLU8wIT2hb/FSsbWz/P9ELit7pI2gBoVq5yd04k8Jy6GkVasI3nrM9vbqUHgMRKGPZP&#x2B;UcJG0PVrN0VXWBnFrifVRNrT8RsiydZh3zjV&#x2B;RttZC0AdCFvbbjiy8&#x2B;VI6ua929Fu3cUUijyEHGRiZKYgBIbPHhm&#x2B;WDeL4N17rZw1r4Xq7Gjq6UrSMXso/e1xsw/nJVFo86zNiokaQNgB49NN0tPBg1Tn2OjK0f3kd7WrrYAQAVKeF6dAnbQMOmcaYjLa6ibsD1yw14qG/k5pNvfoNpbVWQtAHAf3f/1rzp4QapD1msc1Zgo8jAtxHR3oIo2WvUxMKnmt72BgBksdlqL9en8HS53DCAy84nQLVMbvv6s0&#x2B;&#x2B;&#x2B;fHnvf9KuSWLLq&#x2B;FqOKX2CSz2VoiaQOARxQ4em7APMEqMGMTsCVWZplaAjsEABJY3OhTzqXqcraE2u0dSzXOf9oM27L0jdzszJl&#x2B;Mza35Mx/9ebRCW2bxpcQwlVH0gZA78Yi4aGh7ZkYwD2nucjY2rB5y223U9wAgPSM52nS&#x2B;pDeXBGwIvOwLXHGFsgmCzx1VPr7fULGvpE/vPtc2FaXX&#x2B;TeAADI7&#x2B;mh7bie8GHbDcPZZD5982YzG/vp48dFfnb4bXvfw0MW76PNd838i/28rcq5NxYA&#x2B;jSO58dP5PRje03siWXvEGrj0Pr6s0/GP7k3ZBj&#x2B;cKFgyHc1YFEvrMsHBcXcozGbldgaYE4bAKRzOMXNRJxHWYytYXtvrm7fSo/O1gUAArJcMV/faWQYwE2HrdodYy/Z3F2F5JeFbEbJHk3CxGxtkLQBQGpWltozZVfrxow3V2Urp1FkrOXlerZovbJ3B3cnlf9mI5rpi&#x2B;dXswcArgmM7d31Qo3mw0sZ23PKvyDgtzx6OgYTszVD0gZAHdq7MVODlzOmWOvTN2&#x2B;uZVQytiYd9pBs6VxxaH41pKsfHADymn/s7uVtWaoY4wGe4&#x2B;i6r/wrAA/9lmu8M/KhGMwCbE2StAFQk8CQtIpR2iZT3E56NeiSsfVg841T79ngsvmP7GQCAGmsU7QSBvYdDoRIwHF1XxWj9HVZEeVXH15du&#x2B;ejK5DkSeOqI2kDoA6bHdLmau/NUkJZ3oZyFmMTsD2t86lsa04gAJDeZt7mQ5lmdD7AjiXQh3PeqzPj3n7o1j0nw/u0l6yFpA2AajQftg3KmGEYbgRUMraedf7eCS&#x2B;hob4FgKdtTv6Yr5yaa6zSQIlELoH1DhxUN23uwFx79bn2GI6cy0xoq5GkDYCaWNuMTRU1ihyfXxQXhTpt2O&#x2B;f6SQJAE9bf&#x2B;BOedv0X8mGK5upXvacj0qpu59T2psx5e&#x2B;6tJ99NGVa5Uwdm8ds5WwVhyRtAFRpMUQrpN8CUXz65s06iPrp48fNDKy6jA0eVdTtsQDQvM3p41nCifmLboZ8CiVeFTiSHU6vKnl3PXTKWjzt&#x2B;T2Q6&#x2B;h6&#x2B;/7DZqy1mF4m&#x2B;mKPpA2ABhn3t2GKpsYQawrbxn9uBlfpG0Wun21BwPaExDeJV2HdrirXlgBAb8pv12xyG6/a7PtX8kFer1w7NmX/&#x2B;VfPPP2Ue3vx3kiqVxdJGwCtUUY24GRCFvivEhZju/BTwAWBlRWcBgHgafOOkcP&#x2B;/LaUbSTnfxeNcMH8sJkfRY6ouHLtzHDGNv39zuZdfmzifXK4HFqCCW3jS6yfWcxWHUkbAM0StnWiokaRMrYo&#x2B;rnD8QyraABALuuGjUMB89vSZ3s0zFH0kAKH7nsrdER/5mIdJlspo6/xtRZryO1lchRC0gZAy4RtDdhLp9Zfl7HRrb1K2DkQABIbP3zTf/6uJ6CshwFGBcTiWLqswIyN0eH8toh&#x2B;ePd54OXWWVrKbeMySRsADcrY1MI9pHdMK7HNv3L4qEB4lj1j25tvJ3jjOdlvpQeAHgQ&#x2B;aucRV8rCZDHTXczGTetjxgjzjtL23rxqKOT8kH4XLaaOHX5ngo05FF7ajYwkbQA0LuWUjkADGU56KYJKsBjb4Sal2QYIWCykkXFLAKBDm52cF2Fbrk0aLKzF6wLNEhJvSUs2997i7JHs2sVh//kSrmaUU9c8FGsdPq15bNWRtAHQoKJqgKLuEWvJS3PILojVKFLGFtf07l4UoiVUg9n1/LMDQHbFTis3QiAuR9R9pe3DqbbKewbLslvCgVaW2WMFbhJnSNoAII7wkHSdt0ng4sreKPLkNugb&#x2B;YQCL2klE44YnWEAIBerpVKpaR6kNqRPCOzAvOs7rkuqDn/X4eXTEpCxVU3Svq35tgAAIABJREFUBkALwk1RyqlyN/O2QratXjK2bnn77Ok5egSANPYKEN0aaVhLY&#x2B;9vfvx5/MvXn32S4OUCu67MM8ad33WZP9Ge80u1PUrG1gBJGwDtS9br/OSAsq5xZ7FSLsa29/wnt0HGFtHijbZ4N7VU/AMAVch7648G2iQzX9yr6uNtytimf6YJ29aKvTJQ9e/3moxRVvaQj1gkbQAQ3&#x2B;byUTyk5MXYZGzJdFgNbpqfcOwTAEhjETwkm9a2uP3IRz&#x2B;xLI7hecaWaYuiWcRs0xcTh23ltGqcL882/d1SF5O37z9Mk96eSOMCMVv2Vpa8StIGAM86XFjYKPaaEhpFnv82Itq7etX5Pd0NXPgAgLosljjKnkYoK4ioyZtHN2O26b/ShG17OzNvWL551cIpZfRQ3BXO2J54RZ4maQOgcSnHhYeLGx/mbeEn6co8wYqbWj2asQnY0jh8Q/UjsEhM&#x2B;o0BgJ4VMjIxuY2ICjmq21Dyzix52xLLO5NsnbFJ3SoiaQOgWQVWmNlvdK3FIsSKlbpFydhMYqN8UxJZ4GkQAFqSrFHk4WaMfylhY2hDe8dSYEJbAoF74zanxlatkBPjZeuwLXrctQ7zNl9CzFYXSRsAbcoyQj3fbL32oWdGY9D1aqx1LWPTKJIqTOcTV9kAIL2iBvbjxjRzvZ5c9mKh9jKhXLKs7Lhn8zpGsk0q8Fh6OmZbEKc1Q9IGQLNKGLFd2IYSNrsZFmPrRzlXuLKQsQFAeov274tP4VxD&#x2B;uxX7WlMUZlQA0or9vd&#x2B;oWl&#x2B;1&#x2B;NLlLyURq4YbJ72ieJqIWkDoGUlLOF7mJxZcWrPlGPtBV1nHrtHxkZjnEMAIJcSio65craEqtVyIM3bQn792SeH35NFYGcWkjM9F63tXRJRvwxbKdq6seTb9x&#x2B;EbVWQtAHQvjSzxALDxDMbYEpKwJll0ja/edOdjE3AVr5arghEdPPkAwBEUVreBpftHcaFZEJziwjtmx9/3gvbClRy7Z9&#x2B;2wo5qNZBF5wkaQOgC&#x2B;Vcbp4q8L2pbIVsZzk&#x2B;ffNmnm8Fsq4oGZtJbNRl7xxSct0OAG3YnAIib6NVBQ4vN2eqVRG2lXYdIPGrl/bj5zVme&#x2B;OsNTlf1SRtADRiUejmLQPWV7oXUd/0z54HlIfON42UscGwdT5xhgGAR&#x2B;3d4FJI3lbO7YbUq9hQJG5DyGThXFGB5d7GRJ&#x2B;8OD8XFXtEJXYYrf3w7nPBW10kbQDwlHCjc3XvnsQB2/lvo3zdvqe6/cEBoAQlTyhXdHBZIIbJflCFY7Yyp7Xt7c/sO/MJ64shXf34hzZjtvk/LcxWI0kbAI04rGwXd1GlGc8J215yPmMbjmIwGRud2DuHOLcAQGLp87ap1giXFYoOXlVmbFy1zV2a/Y05P4ds/u/Tr/7o8xfOfLX2SNoA6FT0gjMcqj3xij24kHjJ2Lrl/TWsimT7BAASm4oCn8K0ZNH6L29tG7dv5JCwdeRk3UqxtDOGmG309v2HBNPLzGBrwy9ybwAApDaNZbPcqbcYULpbMODV0OvTN28287OfPn5crMe2/rbxe8RsVM35BABS&#x2B;uqL78LtKxJvzN5/1XJFmwJ9&#x2B;/2X45/cG/KgxDHb3v4saiQf5TfezGHz9v2HR&#x2B;efrWM2wVulzGkDoGtZ7sU7nP3WuZ8&#x2B;fnypjeRwboKaSWxta6aQu2zzrGIqLQA8bT2DLeVof/5a8xcdt8cwgMsaO3i&#x2B;/uyT6DPhXlLsJLb5OWSxkfe3sKX7jONObtM6skmSNgB698SV6MPnFLZtujCJ7czzyNhonvMJAOQ1vzCd&#x2B;HN580XdbcMdh5Ouajy61mFb&#x2B;qaR831Yzpt0nQLO/1nIRibzw7vPN2Owh&#x2B;aZTU&#x2B;7flFpXHUkbQD05dG6dzM/E6pdcJiBydiY6638W3DaAYBCZPz8XX/6l3MdnwbUNbbci9DSR2tzm/twnpTnfc9G/xW3EdTlauQ4j9k0k6yFpA2AvqxL0IgjvzLvUGuMjI2Jt9iCgA0AUsoygy1gPjHFMIkoAuEQ95XzVn3uPHYybyutqebcGHqF4664vSWp1C9ybwAAPGI9Ppu&#x2B;kmzodnK0Wk5xXrhP37zZzM9&#x2B;&#x2B;vhxsR7bmW&#x2B;Dxmye2QqsVAGgMd9&#x2B;/&#x2B;X4J/eGDF998d34J/eG0IK9Y6mEQ71GJffeXN&#x2B;LfH8LXzoRLW5ZvvnScU1zy/Z6Ob59/2H8r1jNHheJnQCvIua0AdCszaV91//1qNKGiZU6M0HNJDY2tdG0JMBJBgByWcxHWUxxSzz82FxgKf1m0IaqM7a8LSIPBXZjlj28FwFGvGYS/rme6zl0zZ3A7PLMNkuytUHSBkDLDkdp6Qvg7APHimgUyU3dplDd/uAAkNj6np7SRvslz6ShFo6cRxUydPdbDptHaFMw9sO7z3949/nNcO7MK1IFSRsAnco1jhzDtkIG08WSscF9qmUA6NB8tbbFf7ntj5csjpYqUtvCJ7StFXtlIEsToGKPq82YbXhgLtr0QmK2GknaACCa&#x2B;bgwMDCtZTRZFBkbAYfvqR6uK/XwMwIA5y26WY4MGDgjbyvUyyqK2dZ33&#x2B;bdyYFU9b7N0876JYo9zPZitsC30adf5N4AAGhTIeuiN&#x2B;Cnjx8X67FtxmyLb4Oh4GotgZ5/dgBIo4pP27EqUZvwqnkQsjk/Mu3m/CubiVrhMdt8sun4J&#x2B;/2jA434/J5Y3HOee6FHjU2h5z&#x2B;uY7Zxm&#x2B;4kLFtPkRWVztz2gDgQZt3knLSmXls0jXWurpZe7MbbT8/PgDkVddnbl1bS0aB1qOF1LY3c7Vvfvw54rPdV/57c70mZUQF/viL0GtzKtv8e&#x2B;6HZGK2BkjaACCavdFnUTVJFRaT2A6/Bxa6ervNw7YCy1QAAIjr17/87ebX/&#x2B;bv//LwsYuYbfxKrrBtfq1gGtUnG9JPr7j5uoFFHyNuwEPPfNk68TqM2WK9ELWTtAFAZOG8baiw330uMjZu6uct1s9PCgCcpOjgvs32CXntZWzT/4bDtnXMlsaZLhTT92Rv0bHI/649SfjIqeK89FDGRqskbQDwiMCotIoxZV4yNu7zRgMAurVYZMu4iPOKzWjDGdv82/bCtkDMlnJa22LHlpZlDg9sUmnH0hliNl4laQOgTYm7LhS&#x2B;GQ2QsRGwuNnWOw4AYE7YRhS5QriTGdv8&#x2B;8&#x2B;0kUzvZMaWcvcuKqnNTbq2PQVOiDxjM2AbidkIk7QB0LLFwG6xXlqy8au87Q4ZG2Gbb3MAAOCC9U1s86W8Ens1YwvI1TdyVGDGtnjRr774zlS2vZhNxsYZkraaFHtHBkAtFgPHxLd2FtuFo0wCNi7w5gLqpdwDYtm8XG5aG68aj5kzC4xFFzFgK00gzcr1Di0q9iuNjI3zJG2VGT9pFGAAsWQpOE1xOyRm4yRNI/c4z0CNhG3Afevp/jU2cKMQ6WO2WBnb4iM174S2UaAxY8Z7gg&#x2B;3ajqHPLpJhdyXLFfjDklbleRtAIem8dlhYRlrFLtXhOxtgOvgEJG30sTVNKiaWg&#x2B;IaBwgCdt41d4x8&#x2B;iQ&#x2B;3LG9n9&#x2B;/3/P//mfvviPMTbncYudGb56kMbm73fapOfyv8VCcZudNpV7lE/SVjE3PAKccbIf&#x2B;nMvKm&#x2B;Dh7hmtGCHQDPkbcB9SgwuC09li564xMrYpi8WHrat994YbWZ8z2a5bLL5Wns7wZUTyidpq5sCDKAWZ/K2wcARuCrLEhrAo5R7wHnzSUiBS9WGB7zk6QCmnPXYvv7sk0eff&#x2B;/tmf1WuZPbc&#x2B;3Ucf9CR8a&#x2B;mvAqSVsLFGAA5y36YCQepR12bnGjFlzWc2J98lZQoEZ6mQAnGQAQ1/kVGS64n7FtTmirSPr&#x2B;nGFxM7bhqCfk5osexn7OcpRM0tYOeRvASXkXKjjz6m7UAs7LePcAkIZaD4CUCs/YhqOYrfAGktnnsa09vUliNnogaWuNGx4BznhiiHY&#x2B;wLMmOfAExSe0Td4GXKYA4VWHvViujTzLaRc593TryGG2nEQVU9nCi1888bqLhQD3NglK9ovcG0B8v/7lb8v83AJ4VFHtzl96dUNG4LKee2ZCn9R6wDUJLp3TjIeijlgfYTX2jQxkbEUN4&#x2B;fbk2zbxGy0wZy2ZrnhESCv8F1&#x2B;e8vFKX3hGu&#x2B;dBYs&#x2B;QsPUesA1BgZcMD9spjJ2XsCePK7y3iny9WeffPPjz3v/lXhjRqW9H&#x2B;Nuz8n&#x2B;9jI2WiJpa5xmkkDP0q92dr8ri1tNgZucQKAT8jYAHrWupufjzJfGnNditk/fvFl85aePHy88T0CWmG2z6s8bKe21CLq8VYdXNmRstEf3yJr88O7zC4/STBLoxObgrIoeklb6hYh6fvvsNaUBGqbcAyC6vbaB09dzjTnX2dum//TFf1x/cR2qpY/Zxh24OWgvcxh//07i9YG0&#x2B;KKYjWaY01aZH959/vb9hwsPdMMj0K3EM9sW09o0cIPoyqxCc5nOOTJ7qN14Y&#x2B;Xlck&#x2B;tB8DTro3D494R8umbN//&#x2B;//ifrj02V6PIofgFI042e7xpb&#x2B;Zc4HugIpK2&#x2B;twswAZ5G8DD1j0k13lbmcNroA0KVKjX5XJPrQfAc/YK2DvDzgTNIUuzeW/c9MX0618MO0tg3F8X45DbBGmPpK1WbngECMs7YN0cmD5RnABzHb6bilrgAYhFLxPgVffXVYJNNyce7U1o2&#x2B;wD&#x2B;embN82HbZNpHyaItQI2L1xMXS7TvKizVhR/8Y9/PgzDXw//lHtD&#x2B;iVpq5sCDGBP9kljeYfL0Cpvqz2bHWlUrVAvvUyAlywaShsDcNOj94kGlls7E7b95//vb/7d//jrvf/dXKStBIWP0pNdwRCzPWGM2cjrF7k3gLt&#x2B;ePf5WINdYPVsoB9Zrs4bMkJ0gbdVn&#x2B;&#x2B;48YbTvcJYMAm1u1nuxd0YoCJfffHd&#x2B;Cf3hlClWDHb5idRIGbrxN5uzFjOJHtpMVt0f/GPfy5mK4Q5bY3QTBKgBOsbSMe/B0pcI0t4VeHLiWcxb5abd0uAJ&#x2B;hlApyxWXroKklE92dMPh2zlT&#x2B;hbb33imodeea/YgkfSKbnHhKwlcactqZcvuHR5DaAiNZ3j44zTtbfadQIsfT8bpKuQQ/0MgEOjWXIXulhwMAFWY6lKY376ePH8c/iG/7rj7/ffGCxMVt1yjldmJu7yTy2MpnT1iA3PAJ9Km1dtL35bQBPK&#x2B;18CMSilwmwZz7BfR62zYcE439l2DhqE&#x2B;U4Wd/kcXlC208fPx4&#x2B;ttKYLe&#x2B;gfVE1rIuIuGeMwleqq4KArWSStjZZPRvo016rxoxjOB0PIAFvsVFRZz/gOZfLPbUedGgRuQnbeEk4hsmo0lxtoZzkqZzf7KicPVMOGVv5JG0tc8Mj0KcCx2FWR4C4ZNiT&#x2B;emltAoZeJReJsCmvQGSgROvWqcddwace5PSzsxXa8mYdj86dSyW&#x2B;VapvzKSsdVC0tY&#x2B;BRhAMnuT6iaGp0ACIjfohF4mADxkb1JR3GJ2XIOtw7At9yYcWGdsZCFjq8svcm8AL3j7/sO1Isrq2QAp7S1CPrGoLwCwcK3WG26Xe9ceCEDD0vTuG2O2TgQmmx7esJvSYpXHEraqkM1IT8xWHXPa6vP2/YdrdZQbHgFSMr8NHuK9s2ndRtIuguqMxdrlck&#x2B;tB13xcU8CYraIFk0jF2soZnc4jy3l2aao9DE9GVulJG1VylKADRZvA3idvA1IzykFqna53HNvJbAwrzXUHVStjQ6TizdgOUlSOPZz3khGxlY13SMrppkkQC3GDgyB4Wm3/RCAmxYnFmUwNEMzSSBsys/26ojp6/NvUHRwXsSBZQMhWVzlXAGYt68Us2X0F//452K22pnTVj3NJAEqEp7iNm/&#x2B;lm6boCpmiAYsOtIMfe8NaIBmksB50zBgPVgyHuCCRw&#x2B;bdevIwylrzWR1hQRscwVu0lDqVj1BwNYMSVsLbhZgw428TQEGsLA3HJwXKmdaSqqHIWzxNumnEls7vKUdqJpmksBJ4SpjfUcO7MlejX765k17C7mV&#x2B;Qbcy&#x2B;YTb234psnsB&#x2B;RDZGyNkbTVJFwpueERILuXZtt0vsYv3DeFbd5HgZmyrdal0J7Dck8vEyBg&#x2B;tAPfPQbFUAu4caM04TUvG/SxfWKZEXWotXt/FTWaqEnY2uSddrqE267n6ubv4b&#x2B;AGds3i&#x2B;m4oXz1quIz99W3k0j&#x2B;wHqFa71LN4GzC1WgzbBHWpR4HWAQrZnvQp1IRsWkZitVea01SowCy1jM8nBDY8ARza7IrR9uxak0V4NdpJTBzRGLxPggvU6bd0OjXiIQ&#x2B;u&#x2B;8K4rasemn9DWAxlb28xpq9jh5LY7Nzxe3Sg3PAL9emnt8b3eEU3esQVxeY/ssWegJXqZAK/anPrf1VVsnrA&#x2B;kBxUFwQq/RL2Z646YvGzN1zO/MU//rmYrXmStppshmcP5W0KMICbpt7iFwaLDY8vIQqZ9NrmDrGXoCKbhVuZzSSVe1CszY9&#x2B;kRuXOWyeVuYeTjN/sZOYTcbWD0lbffbytvBDrr2WAgzgmjNjxDKH1FCRxZLd4196u5a0&#x2B;ZP28&#x2B;NDY1LeWznoZQKNCvTJMELgJYEDJvGx9OmbNylfLo0SapZpA&#x2B;Z/SbNVPcRsMrbeSNpqpQADqNG6o0uuLYEGrN9B3lNAA67lbddey72V0DCt6bljHYQkPpwC6dpPHz8m24wnbKZZWd6q8xddb1X4fx/ajDbI2Pr0x7k3gOs2l8J&#x2B;aPXs8NOGWT0bYG5aqxyIyztrob2SFbqyV&#x2B;5Fr/UG5R60bjH13wiBQ/Nx9RMHzKdv3qzTsp8&#x2B;flyna43NZtsrWAp8Vy5itgSv0gYBW8/MaaueZpIA1UkzZoWetVezHXIygSbpZQJEZIobr4p1wFybhdZSzLY3J6zMd&#x2B;W4SU/PYyvwB79JzNY5SVtNXuoW8mgBJm8DWGtvmAgVefrG2&#x2B;rYCdAMzSSBM0pY84l&#x2B;GGreV0jUtNiGcaucT16lXSSD7pHVebVbyEPNJMNbcujXv/yt7iJA2w67sughCQ8poV5NaX0y6W0PQDMu1G6aSQILmkMS0fpYiljDbjaQPKP2RdqG8obrh013StvgogjYmEja6hO3ABsfogADABrQZxE4dXcZet0D0JLDci/lvZWBZw5T7gHUay9Oe/pW0TO9ImuP2Uoeq7sV&#x2B;FUyNhZ0j6zVq91CNJMESODaAmxGtHBfId1XMur8x4fGvFq7WbwNgOcsegleG3auQ7JP37wZ07XpLw0ruVqpaw25EugVySZJW002C6rANyvAAPISoUECKkCgSRdqt3BR5t5KAM6YhtZjAPN0o/LzGVvtE9rK9FzGtnn8hL/55ismIGMjQNJWmSjhmQIM4Dmu&#x2B;EMyMjagJVFqN71MAHjOuELwlIi8mo7cicr6idnyZk7zCivWlhw&#x2B;yeUjKiUZG4es01afvZXYBt38Af4g7yq&#x2B;Y/kR/p5ih49AXaaTidAR2hCldnu03Luc1f36l79V6wHU69paCQs/ffz4aqPIrjK2jK8e5fd7/xkKLGoEbJwkaavVXkHVRgE2yNuAGwILOGcftOWNAAGA8sWq3cJF2TrSO8m9lVC4EqoeajceQmP1ehjAvHTIvRSzydjSiJuxhZ9/rfC7kMVsnKd7ZN1abSY5WLwNeEayMZziFgC4QzNJAPKK3kjwpSXZOonZsvdLjN4r8iVPrwJ4h3aRvMqctuppJgnwkmT3eBY1RgTa5oQDrWq7meSg3INnrKciwWV76cuZRRMu6CRgG4I7tpAtSfy65ZyyBGxcI2lrxGbrj6KaSQaeOUwBBrxkPUZ8qACIpZzRJFAj5xBoXsPNJAeLt8GTFnmb&#x2B;I1XBeroCwfS4YQ2GVuWt&#x2B;fmJZTNr998icVPV2bMJmPjDklbOwovwA6fOUzeBkSUfumCRX27/joAQECU2s29ldChRQFiFTfOODmPLdaxtMjYvnv/u8U3fPnuN1FeKLuiMra1&#x2B;WbcvGX5pbiuhB9fxsZ9krbWNNxMcnDDI1C8wyCthBEkNEBoDfSp/GaSgWcOk7dBdHsXyoVtvOq5A&#x2B;YwY5t/veq8raKMrYfXnZOxEYukrU2aSQLM5WogqUMLPGH9dvZeA/rRfC8TtR5ENB8dldxRn2I9evPoPGbby9jmvnv/u6rDtoVCipe9zUhwxsi&#x2B;B2RsxPWL3BvAU96&#x2B;/7Aub35493mgXtp7yKuvctLlym0Yhl//8rdj5AZwTco686svvlPWAgARXavd1t//anl4UviZw9R6cNPhxevsV7epwrfff/noofJqzPbqd5Zs2rfjtYICrxhE2Z5wo9HsJyIxG9FJ2hp3LW976fs3H3LSnQJs&#x2B;MP8NoBChAej69FzaYNpqMKiYJv/ybhVAFnEurdS3gY9MFjivJRHy6vhWdVh2yJjm/9XOdcHnliKryh/8Y9/LmbjCZK2LmyWRgowoEnrgWA5A9ZhNZ4u8OY1AKAiyXqZXN5CvUwgl3Wh4eYkSlN1bPaSQMZWjrjbVuAJR8bGoyRtvdBMEuBpi0FkYExZ8tgaalFa2QaQUcPNJAe9TOBFCg1q0U/MVr7NaxRRCq69vC3xmUrGRgKStr4kKMA2H3LS/QJMDQYMZUxrG7ehwHu4AIBWaSYJQC3uxGz1RnThmaZZYvK9jC3ZpYwENyLL2EhD0tajhguwwQ2PwDkPjRo3n/ZwkGqKG5zhnQJwSDNJAAr308eP/&#x2B;t/&#x2B;N/D3/Plu998&#x2B;e43abYnmSpqmcS3C0/7pIqdA2F/nHsDyGMsjRZFzvjPvaop1kNOCj9z2Fh9/c3f/&#x2B;WFxwJt&#x2B;Pb7LwMDtUcHjntPPvVk33vg&#x2B;F/mwAEAN&#x2B;3VboHy6u37D1XUeoNyD05TWVCUnz5&#x2B;PPyeRbo2/rPeGWx79q5X5H3Pbk6te3STkr0QpCFp61qUAuzaQ04KP3OYAgw6V&#x2B;ZA7UzeVuaWQ2kUZgBhUcKzkvM2tR5sMi7iUfdX89pLzvYmsX357jcthW0FvkMD7SvjXqAoM2KEWCRtKMAAYloMHPf6Sa6/E7hMRA2wKWIvk/C9leuHnKSXCUCB0teq7fWKXDhsb5NL9qsT6jiaYZ02hiFqN/8CF2/TzR9IJsrwVAIHEXlDAURZie2wIrN4GxRiXNrWEIgybc5Oaz5mC&#x2B;j8rSpmoyWSNv67WEthK8AAXpJ4zWHox1i4utgEMLwenlV0b&#x2B;Xwh/ltwJzxD1U4E7P1EMVlvCZwvyMoMEjaWGu&#x2B;AFODAQ&#x2B;5WcrK2wCAR0XsZfLqq5yklwnENVUobjziJWNxuihR1195VUvLrV1W2kJle2eGBJvkAgiNkbSxoe1mkoMbHoEkFqPGqYvLVOXuLeFmuAmbDmv79bts/tjnNxCgDlEak2gmCTUStnFf3GF2D5PV1sosVQrZDKiXpI1dmkkCXDYOUqeh6rqmncI2w1l4iGtJAHt6uLdSuQcQ3Z2IaD2hrauYbW9fFXtB4IliSoFG2yRtHFCAATzEKBOu2Zzc5g0F8Kq2m0kOepnAzOJGQLigzJlYVRv3YQmFjN8m3Cdp45gbHgEeUsKQGhp2fzEJgOZpJgmN2Rz5jHWH6oNYDLAvmK9&#x2B;NxUp03szy9tz70Wnrz/3i3YI0R5JG2dV0UzSDY9AgRS0kIXiDeAk91ZCYxaX8iGuKMdVV60j11wlgPZI2nhN4QXY4IZHIJ&#x2B;T9cai4jXChie4rgTwKs0koQ3j5JjFFBlDI2K5diytF2nr0/y9WdSlgM1JdY&#x2B;eN4r68Zvx13/1T7k3oWuSNl7mhkcAAIAmVdFM8nK5p9ajN65lc5O12SLafD/O78RN/4YN/ELT/K437wyASknauChWZ8gyC7DBDY/APYfDRCUKPMf7C&#x2B;CO8u&#x2B;tHPQygdPm6y0ZI/ESMdvTio2XksVsiV8RHvXHuTeAio110aLCGf&#x2B;5VzLFesh5P7z7/HL9NlZff/P3f3nt4UB6idsdhH31xXfffv&#x2B;l4gQS8y4DiCJiuReoyO6Ue&#x2B;GNOaTcAwh4tJJ9dZG2xppPri8UZDTfmFyVlAqONpjTxl3l3/ComST0Yz0&#x2B;Szx&#x2B;XWzAyVcvZ5ANVXOnNkB0bTeTHPQyoQ/6s/Gqwm8YfTWoK8GZNCtj0JWmktp8idKOrnpZpC07c9qI4&#x2B;37D&#x2B;vy5vDuxQsPGdzwCAD8a8ozgOfoZQJVGIdDsjTi2juuDL8j6vlt60CiJea0EU2ayW3D7RseLz92cMMj1CnvtLaT/wVckOzuSwD2arcEDzlJLxMYdqb4GyxxzdhXMHsO1FjryIXsuzc7M25phqSNyDSTBPIqoYwMb4NxJABQqSg3ShbeTFK5RwOmu5Gm4K2EKom6hNcSy1jP1tg6cq2ot2SuCxTXVt9gk9aRJZC08Ygo3fzPPETeBpTppTtJixpkAwAElH9v5aCXCWzRCYDzNmO2LIdQexPa9m69zfX2zJtvzV/dCYraSdp4Si3NJK2eDe1Zj89y3Z&#x2B;1uJMUSGkqYt0dCRCdZpIA/Yhe0p7Mz1qK2cI7MDyDsFViNhrzx7k3gMZZPRsAeNRYoanNANJ7&#x2B;/7DS4VbrIecd/jkYco9yrR5Rd5YiIiKjUDaaB05N&#x2B;7e&#x2B;Q5vuLrpME1MQ&#x2B;vIQkjaSGGzNArnW9ceMlzN2xRg0JhpVFrgSG5xt1qTA2hI4&#x2B;TSEd5lAM&#x2B;p5d7KwJMf&#x2B;vUvf6vWoyib01&#x2B;&#x2B;&#x2B;uI7Yx6i2zuo0hxs81yt9vltZ9pF5rp8kffU4cR1k5itHJI2EklTgA1ueAT&#x2B;tTIHbWVuFTSjwIgdoG17tdurN0o&#x2B;d2/l4ZOHqfUozbygmEY&#x2B;wjbiejQK&#x2B;u79716aoNbSbLbFjt3cq8nezmI2iMU6bSRl9WwA4AljgWpVNoCMoqy6feYhFm&#x2B;DOZeqiWtvOB19mF37NLVrFjF5t8WL9eyjMKGtKJI2Mtisi14twM48RAEGAP2wZglAdmnurRxudCI58&#x2B;Rhyj0KtDnFDR4ScYDdW9h2&#x2B;FZVvHCemK00ukeSh2aSAMCjlKkAuURsJjk8uXjbnbjO4m2UScxGRNPhNB9XXxtjf/nuNy&#x2B;FaotvbqB15Jk4XP3CeWK2ApnTRk57dy9eeIhmkgDRcP8cAAAgAElEQVTAMOtD0nMzFoASxJqpppcJvMoQiDv28p4n2v0tIrTv3v9u/LP4ts0v1mizQtncq1I3AsRsZTKnjfzW086uzVR7bvVsk9sAAABepZcJQO2mm9jWX7xpHbOFv/&#x2B;797&#x2B;rd3LbmV6RMnLOELMVy5w2iqCbPwAQhQIVoDSxZqrpZQLnGRFxx3z6WqxGEYGQ7PyUtTZmtg2rCYJNzmAbj5yTB8/0zc5dAX/9V/8kZiuZpI2C1NJMUt4GACVTngGUJuKNkppJAqQRiH&#x2B;ujbfnYdv092bCs5PWTTibj5cOf7q2f/xYZGzlk7RRnPILsMMnP6QAA4C4Nu8JbfLmUIB66WUCyRgFcd9zHSPvxGyVJnNjwHYmY3tiPbz05j9X&#x2B;Md54jBrjKlstbBOGyXSzR8AuEOFBlCsWKtuX6gQz1PuAZ3bTEq&#x2B;/f7L&#x2B;9OPup3NNndm2TYQsNXFnDbKpZkkAHCSliMAFamimeThkx9S65HSPAtxvZ6bzk9IuuxOzFZ1RNfwPLYLTGjbYx5bjSRtlK6TAkwNBgAAdEUzSYhoumDt9iMi2ks&#x2B;JCIXyNgWxGx7ZGyV0j2SCqRsJrl&#x2B;1Ek3u4sMw/DrX/5WdxEAuEmFBlAXzSQByrQeV8fKcQOT0qbekme&#x2B;uSKbGVuWLUlv/NnXa9TN/9nP3giTsVVN0kY10hRgey90kgIMADKaV2hT8aZsAyhcxMLtQoV4XvjJDyn3SMPIh5v24rSnY7Z1xtaq6U2aoEtnLuOPc/KYaexnv0bG1gDdI6lJP938NRgBgFep0ACq1kMzycHibUD9nhh1B2K2xhK4KYJapFB99n3tuXnmxJJszTCnjfpoJgkALCzumlSwAVRKM0mAQmwOrW8OszcntDWWpW3a7L3RM/XaSMbWEnPaqFWsmWol3/Bochu8anOFYaAHi7e/UwFAvfQyAchoLwJ5aPrRmZitpSiunzql4d6YUZjK1h5JGxWrqACTt0Ea8z4MUjcAgHppJgn3KYiIJUqVvbdCWz/We2&#x2B;eX3rDdkLG1ipJG9VLWYC54RGqY6gK3RpLVrdPXmbgAZQgTS8T91bSpLEUUhBxwWII/dyKYi1NVjvU25vRGmxrMra2SdpoRA/NJAfXvADgHDHbHa75AkXRywResp541Nv1faIIxyQOqjsC/TkTb0kC8rZJURmbUccTJG20QwEGbFIDAJxkmAEUSy8TuMxlbq5ZlNI3D6R168iuJrQR1vYiIEVNZTPSeI6kjdYowKBzykjAeeAaQwugfHqZwKHFQMi4iGvmgcc0LcnhdNm0P9f7sMls6SXhPVB1CCdj64qkjTYpwACgT&#x2B;r/CxRdQEX0MoFDYy6iaRuXLWK2J17ChLZRjelRXOGpk8&#x2B;tEfi0ojK2wTXkJCRtNEsBBt1yjxh0y&#x2B;WkVxlIAJXaK/cuPEQvE9pT6eQPCmR0nUyTu7rbE1FpGZuxRBqSNhqnmSQA9GAsTbut5a4xeABqF6tw08sE4IxAC8Sw9SJtzDUZs43CjR9fmtC2/oYCFTWVzeXixP449wZACm/ff1jXNj&#x2B;8&#x2B;zxQL43/tXjU&#x2B;M/woy4XUYdPfmg8e/7N3//l5WeAZpQ//AIe8tUX3zkDHFJxAc2IWLhdqBDPu1nuqfW4wKCImxw/TwhkTtO9g23s&#x2B;cMepIGYrdKMLfcm/CsqvvTMaaMXnTSTHJxJAYB9bmwEmpRyoW69TIC2HU4/up95vLpIW8NT4sb1FMd9O8396qFRR0sxW1Hz2AajhXzMaaMvF254vHyP5PpR57nhEQCIS7kFtC1i4aaXCcBcacHPq0FdCaY4bfHFLBtTmmk/bB5phe&#x2B;l0jK23JvQNXPa6FHKGx4vbN7JTTrkFgYAYGRIAHRCLxMoLRShOvPYY73CVuGxR8nmu26cyjbM5rHtfWfbpv0w7ExlK3lXFDWVzUXgEpjTRqc66eY/uOERgD64qLRHxQV0KOVC3etHnaeXCWmMw6SSL1hTiyxHUUutI8M9EtffU6/DRdoOd0XJ&#x2B;6GcgG2k4iuEpI2uddJMchiGX//ytwowAOiKigvoWS3NJIejCPCQvI0904yZ8Z9fffFdyVeuKdzicMp4LNXYOnKtumzpVeGZavN/JpjS99d/9U//8/8Sp7GfjI0ASRvUdMOjAgwAwloqUO&#x2B;4WXTd7GkGUIiuepmo9YBYplztzBysR7U0oW3UWyuORc/Mxf/W1Zu0qJjtfsam4otO0gbDkLAA23vUSZpJAgBhMjaAhYrurQw/f5haj7npgvW333&#x2B;peyTXBKYlpdFYzBaYx9Zb/DYkmcoWUVEZ26DiK5WkDf67TgqwwQ2PADSq5PIsATc2AuzRTJKuLEZEnQ&#x2B;QuOOhBOi797&#x2B;71gSyjdaRo/Bkr7ZVNJVNxsZ5kjb4VxIXYOtHnacAAwBGMjaAM7pqJjko94AbwhlbmmX/plytscltJQdLCWSJ2S4s1dZYxjao&#x2B;J4XZzFAaMzb9x/WVc0P7z4Pn5I2C6HDs9id8ulwkw79&#x2B;pe/tXgmAG3otmS9f2OjogvoyoXC7XKFmL3cu/NwKtXtiIiINjv7jX&#x2B;ybM&#x2B;X734z/sny6lFMu9Q7dK7YvdFYzKbiS0PSBru6KsDUYAA0pofVDm5&#x2B;gqu4gG5FLNyu3ZF5nloPyGsesEWMi757/7vGZqpxxrxGSxyznQzP/vqv/qmomE3FVxFJG4QkLsCy5213Hg4AGe3VaV998V2Tkdv9K6cqLoBkvUxKqPWUe8CrEkxiE7aRUjhCayxjG1R8yVmnDY4l6&#x2B;a/96jzLN4GAJMpY0uzkkQyKi6AiGItw5Zgoe7w8x9S7gEn7Y2cL4&#x2B;ov3z3G6HaUHCzxDRO3gH56EJumwu2FRWwDZZkq5akDc5SgAFApZqpaWVsAE&#x2B;IWLhVUe6p9XrT2C1HpLe5bFuWLanX4R7r7X0aaEmy/kr0sC3is0Wn4quXpA1eoAADgFp8&#x2B;/2XLfWNdGMjwNP0MqFJ43Cot4v4RPToiPrLd79ZfCUw9W39zc2Y7&#x2B;Tx732&#x2B;YVsq3y6QsdXOOm3wsmTd/PcedZ5u/gB0a6pRGyhT7xdd6i6Ak2Itw1bFQt3KPSAgsODxhURknZMtvvLd&#x2B;9&#x2B;FO0w233&#x2B;y1RWm72t&#x2B;t1iSrQ3mtMFFmkkCQBZ7t3lOBdj4Xw0EbIMbGwFy0MuEqs0vSbcxHKIQcTtGrGO2M4/67v3v2pvZtrlXO5yHul6erfmAbaTia4Y5bXBdxFsX3fAICbhBDFqyeDu39&#x2B;7OfmPjzYn1ALXTy4QGdHixnlgWkW2UW9n2QrLmJ6sFtFfFPKTJHXXz8/fmxV7lXnSSNrirnwJsiLFIDGS3ztskcFCRw3drA5eTomRsN4sudRfASDNJmqHk4bzDmZHjFy&#x2B;U0mPYNkVuhx0j15qJ5Tb3XgO1DGe4q7JJukdCHJpJQl3c3QlNauB9reICKE1vzSQH5V7lGhgOUY7F4TQlQ3eC23nMdvlJqra393p&#x2B;865bRw6NNpC8f1OLiq9Y5rRBNJpJQuHWRUJ7gzZoXqD&#x2B;rL00dWMjQMn0MgF6U&#x2B;zout6I7uQ8tqldJ43RuaRtkjaILG4BduFR50XJ2&#x2B;48HNJbD1iFbdCGqmtR7SIBaqGZJMWaxkL60XHTXo28&#x2B;fXLR1e9adk1exnbZsyWaqMqU/XVG3dV9kD3SHhErGaSlx91Xvj5D&#x2B;kuQo2mnvK5NwSIoPZaVMUFUBfNJCnTvLoZ/z4fI9U&#x2B;XiKLac2FuBnbcBSzTe0lD7&#x2B;zXou95x0619je0C6yH5I2eIoCDAonb4NKTW/e2muwwouu&#x2B;83HABq2d2/lcFS4vXpv5d6jzotS7qn1oB/zxbGiZ2xh84xt&#x2B;kp7Ydt8B057uPbS5iG1L9XmrsquSNrgWZeTs2tl2/q1zpO30bz1rZ1D/eM26FbVtWjhGdv95wfoQcSuJE/XeodbdUitV5Gqx0gULsrRtZecrWO26evNhG2BLq8N3Ed42XxvhHdCRXup8IpPufcESRukkKyZ5N5rnXezABvc8EjxNvM2gDQKr7juPz9Ab/QyAXrwdAW9F7M1Y3MeG01S8XXrF7k3AHoRcR1sq2fDfYa2QHqFF133BwAA3do8wR6eVCM&#x2B;6jzlHvCSb7//MmLMtjk77TBmaymHcy3ijvLvmb7fLvLOZ/ThBWEV36PMaYOkNJOEjBYLs5ncBiRTeMZ2//kBqGhy26CXCXBCmmK5pRTt0CJmWzSTrKg1YkSHrSPHJT/K3zOFV3zKvQQkbZBBb80kB3kbJVkszOaGMuBRhVdce8//L4/6s1/deWmADlWUt7m3sjFTmVPFJWkK99AhtJ7Q1lXMNudN&#x2B;pLCd1fFFZ9yLypJG&#x2B;TRVQE2uOGRMgjVgMTuNw&#x2B;5uQHXbmy8&#x2B;aEPwIV7K&#x2B;M&#x2B;6jx5WzPWdxMWfm0aejO9Sb03J4cT2gpXccbGA6zTBjnt9eU/XIbt2qMs3gYAadz/1LtfdF2I2W6OFgCYVLRQ9xDj3g7lXhZfffGduwnJ684R2O2Etj01Rk09E7OxYE4bZHatLWTGZpKDGx4BYJ&#x2B;KC4CJXiYksGgX6WI9abyasa1bR3YlMKGt27y83gltKj42SdqgCBUVYIPVs6nWfIW2uoZx0IY/&#x2B;u7vc2/C47SLBGAtcTPJweJtfVPy8LRuk6En2Jl1kbERoHskFEQzSXjaVG0azkJKf/Td3zcfs2kXCUBAymaSw&#x2B;1rasq9Nih5iC5iw1KtI4eaJ3XdV&#x2B;PPfr/cE7O1zZw2KItmkvCcaWHw8S&#x2B;LLivAE5oP2IZ2b2y8P8EOgAW9TIhr3rRj/UXFDhHtBWwOs8tk4RVpteIjLkkblKjDAmyQt3HP&#x2B;dhsPpwVtsFz9jK2//zZD4m35DnZK67hmaJLxgbwKM0kiW5xyV6NQ0RRMrbOF2mb29yfPb9nC//Zs1d87qqsiKQNyrVXSg1Hydm1Rw1ZC7DBDY/ccGeOmrANnrAZs7WUsQ2KLgBuSHlv5aCXCXCJeWxp9Lw/S/7Zs5d7g7sqa/NH//zP/5x7GzjlT//sV3/3t7/PvRXkEfFKWYLra/fnJivAuOB8j&#x2B;8Oq4XP//3/M/7lw//7v0V82n/349vxL//85S8jPi21k7GdUUvG9h9&#x2B;&#x2B;i/Gn5CGcq9nFZV7UfpQKffi2uwemWVLyOWJci/Q2PD8ATYfMy/mtL26SNt6StyZZyjtbBOYzdZJx9eKzledVHz/4af/MgyDIWgs5rRBBTSThJeEB6nzgSwQkYztDDc2ArDQVTPJQS&#x2B;T2MZV2TYXbIOIijrGXg3qCjHfh9P1inL2anplxmzZK74yb7XhDEkbVCNuATZoJklb1uP&#x2B;9RB28f1D34NaiKiHJdmGzoquf3nUn/3q7MYBcINmktyxqHc2u33omc9ljpyI5juz88sRBR5X2cu9IX3Fp9yLStIGNYk7Te1aSneeAozE9m6yC0Ru8ja4z1S2M&#x2B;rL2ABITi8T7jicciRs41WFHDDr1pG16/wSRCHH1YKKj/us01aNP/1DyKx3KqOKuvmfeYlDCjBOOjlmLXNs9xDrtPEQGdsZ9d3YOGPhKEhmLPe84xglvpqWffE2tV5ci4Koq1Wg&#x2B;vRQubf26lEUa522a4u0DUWeWw6vV3iTppe94rt8VfbCAgHrcm8w/oxH0laNP51N5/QGYBQ3NrN6Ni05k7f1M4SVtBGdjO2k2m9slLRBMso91txbSUSbLSVpQ8akLZy9RUnaLsdsQ3lnlc3LFIvZqN6eKWXP2IbcFZ&#x2B;kLS5JW2UUYKwpwGCP&#x2B;8VGkjYisiTbSbVnbCNJGySmkQlryj1icTW/VVmStjOHk6Rtbn11Yr6M4uIrJKDiGyRtsUna6iNsY5MCDPaGp&#x2B;G8rYexrKSNWExlO6P2GxvnJG2QnnKPNb1MiELS1qrESdvahaRtOBeYba7Q1kDStnfJwhszjewVX8Z2kQuStrgkbbVSgLGmAKNzh6XjXq&#x2B;GB7epDJI27pOxndTAjY1zkjbIxeQ21txbyU2StlblTdoCx9LNpO1mzDYUdhqxVmIJsmdsQ2EVn6QtLklbxYRtbOpt9eyhsMETGQW6MYS/s/nBrqSNO3rI2IYCiq5ybmyck7RBRso91uLeJSlv65PL/e1JkLRdu2n1TtK2GbMdPmrBCYSJuyo3SdrikrRVTwHGJjc80qHzSdviUc3XmZI2rrEk20mN3dg4J2mD7ExuY00vE2Du0aTt1Y6Rc&#x2B;GkbdiPzaLEbINTB3&#x2B;QveJLeVflmZebSNrikrS1QNjGJgUYveltptp5kjZeJWM7qeGMbSRpgxIo99jk3kpg9FC5dydjGx0mbcNWeBYrZhucN1DxHZG0xSVpa4cCjE2aSdIPSdseSRsv0S7ypFZvbJyTtEE5TG5jTTNJYHim3IuyxvmZpG2YRWiB7xkkbbxIu8gzJG1xSdqaImxjjxse6YGkbY&#x2B;kjZNkbCe1fWPjnKQNiqLcY5NeJtC5BEnbteJ6MeoOB2lhF2K2wbmiY9krvsSfwpc/WyVtcUnaGuRuRzbVVYCdeYlDBlW9kbTtkbRxSMZ2Uj8Z20jSBgVS7rGpt3srB&#x2B;Ue/MGjSdtUVl8ot2MlbdditsFZoksqvpdI2uKStLXJ3Y7s0UyShkna9kjaCLAk23md3Ng4J2mDMin32KSZJPTpoaRtL2MbJUvaLsdsg1NEZ2RsF0ja4pK0tczdjmzqsAAbDLD6IGnbI2ljj6lsJ3VYdI0kbVAy5R6b9DKB3jxU7o02Y7bRYcW9HoS/GrZtxmyfvnkzDMNPHz8ePtzJoRPuqrxM0haXpK1x7nZkjwKM2s1vspu&#x2B;Mv&#x2B;npG0iaWNNxnZStxnbSNIGhVPusUcvE&#x2B;jHc0lbIGYbnk/aAjHbIGnjD1R8d0ja4pK0dcHdjuxRgFGvcdA/H9wHkrb1N3dF0sacjO28Pm9snJO0QfmEbezRywQ68VC5t47ZxoJ6vYTbns0B&#x2B;cmwbR2zTRnbSNKGjO0&#x2B;SVtckrZeKMDYowCjRvNB/&#x2B;ESzZvf3BVJG6NOlmQbFF3xSNqgFso99uhlAs17aJ226e/ffv/l/NbVm0nbcBS2HWZsI0lbz9xVGYukLS5JW19MbmOPAoy6bIZq4dYWi2/uiqQNGdt5MrY5SRtURNhGgF4m0LBHk7Z5rb3&#x2B;e1hgZL4Ztp3M2EaStm6p&#x2B;CKStMX1x7k3gKT&#x2B;7m9/P76FvJFYGE/ci3P6&#x2B;M/AOX3zUeNXwp8Eew887/AlDo2fzQZeHVov8AZt0y7yPDc2AvUaizvlHpvevv8Qq2o7LBL3Xu68My9xSLkHTzh5e&#x2B;uhzTXY5gIZG93qLWM780CKYk5bp0xuY49mklThzpy2&#x2B;UM6YU5bt2Rs59VVdCWruMxpgxqZ3EaAXibQnufmtO2t1DDcntMWcDJjM6etKyVUfJendJdc8bk3Ky5JW78UYAR0WIANBmG1WXeHl7TtkbR1SLvI8&#x2B;rK2M48MCJJG9RLuUeAZpLQkujl3mGtfbKafnWg/tI8NklbJ0rI2IZG76ocJG2xSdp6Z3IbAXUVYCdfJcw4rC7h&#x2B;&#x2B;wCE926itkGSVtnZGwv0S4yTNIGVRO2ERC3anNvJWTURtJ2PmY7k7GNvOVr567Kp0na4pK0oQAjRDNJijUf62&#x2B;Gar3FaQGStn5oF3leXUVXrgb9kjZogHKPAL1MoAHPdY8cffv9l&#x2B;vq&#x2B;4yTg/boU9km3uz1KqHia7Jd5IKkLS5JG//C5DYCFGAUaJ2rSdr2SNp60EnGNrixMS1JG7RB2EaYXiZQtZRJ20tV9uG4/aWMbSRpa14JGdvQx12Vg6Qttl/k3gBKMb2p/vTPfjWvxGAYhrfvP6zP&#x2B;z&#x2B;8&#x2B;zz80bX5qOHEB97eA8873LYzfv3L30b5gAd41B999/edxGxRTsv3b2xMXHRlrLuAZvzd3/5euUdAxKrtTCF2/6NNrQfpTY1kXloffc&#x2B;nb95ciNmGS&#x2B;EcFYlS7j1d8e29RHUxG9GZ08aSyW0EpF9vxurZBAQ6WgzmtM2Y09YqS7K9xI2NF5jTBo0xuY0wvUygRg&#x2B;Ve&#x2B;HV2s6U25tj&#x2B;ChR2cmZbd7dFSmh4uuhXeSCOW1xSdrYoAAjTAFGOeajf0nbHklbkzqZxzY03S7yzgPTkLRBk5R7BFR3b&#x2B;XJVwlT61G1h8q9yVdffLdeGf1C0hZxOpqkrSUlZGxDl3dVDpK22CRt7DK5jbAOu/kPBmrlGcf663H/IGmbkbQ1RsZ2XprPjiaLrpGkDVolbCMs8R0kaj244&#x2B;k5baML97ZeS9oWKdreo86Ebd7U5aui4kt/D0oykra4JG2EKMAIS38Lv2aSBGyO&#x2B;6f773omaWuGjO0lbmy8T9IGbVPuEaaXCVQhTdI2rO5wfSJp28zPNh8oaatdCRVf53dVDpK22CRtHDO5jTAFGIUIrMzcedgmaWuAJdle4sbGWCRt0DxhG2F9NpMclHtU5Ylyb7O4fjRpCydn68dK2upVdcX3XJ2YhaQtrj/OvQFU4O/&#x2B;9vfjG8/bj03jp8Xis2T8Z&#x2B;CDZPNR41fCHz97DzzvcNvOGEcGxm21MLONevWTsQ2VNA/Ze5XGMjagE2Nxp9xjT9yq7Uwh9vb9h5uf5ofbdsavf/lbtR4MW00jozu56BoNqDpju/xAFV8/JG2csijAVF&#x2B;sbVZEjxZg6we&#x2B;RN7WG2EbNdIu8iV1NQ85&#x2B;YoACUz3Vg7KPbbEjc0u35R5nloPoni6gpaxdcVdlTRP90heo7sIhzSTJJfDW&#x2B;26Tdp0j6yRjO0lbmx8iAvu0BvlHmGaSUKBopd7i/6Q83&#x2B;ebx05BLtHXsjYFg0kdY&#x2B;sSNUVX9t3VepnEJekjSus3EaYAowsFknbos1FtzHbIGmrjXaRL3Fj46MkbdAhYRuH4lZtyj246emkbdi6q/Vy0nZ5HpukrUZVZ2yXH1hRxSdpi0vSxkUKMA4pwEhsnbTl2pLSSNpqIWN7lXaRT5O0QbeUexzSywQK8US5tzmPbXKy1o4y4J9I2qrjrsrySdrikrRxi8ltHFKAkYykbY&#x2B;krQo320VWNIOzhIxtcGPjOZI26JmwjUN6mUAJHk3a1ua1xvhte9WHpK1bVVd8j84QKI2kLS5JG3cpwDikACOZisKGlCRthbu/JFstMXMtFdfeq3SVsY0kbYByj0N6mUBeKZO2zX6SkjYmtVR87qocSdrikrQRh8ltHFKAkUAteUNikrZixWoXWcWRX0LRlf5Dp96iayRpAwZhG&#x2B;foZQK5pEnaLqzZFjFpuxCzDd6haZVQ7g3uqnyRpC0uSRvRKMA4o88CbDDCS&#x2B;Jy&#x2B;/jmSdoKdD9jW6&#x2B;dMP9LjG2Mppaiy42Na5I2YKLc45BeJpDF00lbIGMbgqXHE0nbyYxt5L2ZTNUVX7d3VQ6SttgkbURmchuHFGA85NVxfz8kbaWJ2y6y5KStlopr71V6zthGkjZgTtjGGXqZQGLPJW2XM7ZR3O6RF3hXJlBLxeeuyk2StrgkbcSnAOMMBRjRHbaS75akrRz3M7Zhq1fkV198J2bbpF3kTZI2YE25xxl6mUAyDyVtY1lx535WSVvbSij3huR3VZ58xVpI2uKStPEUk9s4o7oC7MyrnGHA94S9pG0oKXvIQtJWgpsZ22GvyDNrkidTS9HlxsZDkjZgk7CNM/QygTQeKveG/QUa5jncE90jF6uyDS82jZx4Mz6n6orPXZUTSVtckjYepADjDAUYsWxO9Jn&#x2B;nmOLSiFpyyvikmxzZSZttVRce6/ixsYFSRv/P3t3jytJcp4LOCjMSghSBLWAxuxAGIO&#x2B;HEGQTUiLkRZwQdC5/hiCbDnE7GA0g7uVvkZKxZzKn4qMjIiMn&#x2B;cxiObpk5Ul8XRlvueNLxJOWFtJDHuZQGmln9P2cjTldpQ&#x2B;EqLBtmNbu9q3&#x2B;WdYQi&#x2B;Jz6rKGJq2vDRtFCeAEUMA475t0/b6uqZt&#x2B;YOmrbL7HdviZF4z/DLZPriBZK7NYWwX2RRNG3DO2koi2csEyqnQtG0Tx9Hfrl0NCOc12&#x2B;JS2eYfYF69dGxHZ7GqckvTlpemjRoEMCLVvxbq20ZyEgYmp2l7RJbtIt9GMz8&#x2B;JuGppq2X0GVh41WaNiCGtZXEsJcJFFK0aTvv2MJp9IjPCDEd20t82eZfX0ZdJz6rKo9o2vL65uk3wBSWf7HLv16/suHEd3/&#x2B;fnttW75ycnlb/mr3wI8Xxd0zXhJzlo&#x2B;WWxZ3gTCGmx3brpO9Ih&#x2B;cYwv9JK6js1jYCHDfzz/9&#x2B;Mp6we9rOJCc2nYP/BgST84YL&#x2B;YsH8l6dOpOx3bJpZqN&#x2B;npJfFZV8jgzbVRluI1INpMkgZm2I2baqrm5XWTMHNvRZFvYtHGl9ZK4js5iYWMMC6SASwy3EclmkpBRobi3OIkeH4&#x2B;NyQtpNVvkWJt/cTcNn/isqrRGKq&#x2B;/efoNMJeff/rx9a933brBm&#x2B;/&#x2B;/P32wvYf//iHj1fo3cth5IE3L6UxZ/no97/&#x2B;Y65nHQE1/epP/&#x2B;9olO3mNNuR//N//&#x2B;kt354/zi2vXkLX0Sdz2oH3rxQAY1tnPXGPE0ep7eNReQ&#x2B;8JEtdJ&#x2B;7Rl4&#x2B;PZPvnf/jTnQximq1ZuT6sGk98u0dJfCQz08YzDLcRadrd/IPlV9eZaTtipq20XNtFHkXZo91aiu7icqSXxHV0FgsbLzHTBqQx3EYke5nAfYXiXnw2OQog58HhTs1mpq2oXhKf7SLvM9OWl&#x2B;e08QxPbiPStLv5Bxv6Qw9udmzbJ42fbA555G23yUvHXtJL4jo6i&#x2B;0iAarx5DYipT2oO/uBl3h4GzM4WcaaEFgSLF3aURv37ZcvkWUbl0h8cIeZNh5muI149acTLHjsS/zautmYaSvh5iPZwi9/YtePWNv9&#x2B;vav1t8TecY7egldFjbmZTkUcJPhNiJNO9wWxD1uKxH3jlbyXQrdJwniZKBtW6HtfnNM0&#x2B;YfV7xG4l6Q&#x2B;OqyIiovM208zHAb8dLWLZ5MxZ0feHTGSyx4hPHc79jCpmZ7&#x2B;9ttqfZgbdxI6LKwEaBHhtuIlHdLEnuZQBbrDFJhzd9RefaXH37wRLeihk98HhBAHZo2miCAESnvZpJ3Drzk41liCOnzIdkAACAASURBVGAJXkNCT78RBpGlY3uzW7PdOTyj3hNXzLE6NoDSrK0k3iObSYZm&#x2B;jZZjzZl79iSZ9TIrvfEZ1UlTdG00QoBjHh31i0KYECaXI9kC798Klv8G6jZHGdJXKHD7SJjDgQggbWVRKq/tjLYywQOVHge20LNVl8jHVuwXSQD0bTRFgGMeDaTvPMiU/nnf/iTsTbuuN&#x2B;xHf0EHj3/4OQ7K2gkdFnYCDAYayuJ1&#x2B;NmksFeJoxuvcV9csreDrTF1Gw2kMyoo1WVR2exqpI2adpojgBGPJtJCmAntk&#x2B;6gqvubxe5/BDm&#x2B;lEs3Rn33rHFHKtjA3iWtZXEs5nkzReBXNZ7ckjZXes98VlVScs0bTRKACPe5AEs6NuOGWUjWaFHsp3n0t2fWNtFRp7FwkaAXlhbSTybScp6PCtvGEkbaCOLRjq2YLtIxqVpo10CGPGS94QcYDPJYMHjgfh9&#x2B;eDNze0i4726t2dXhjYSuixsBJiKtZXEs5mkuMcjTqK0lN0RqyqhDk0brRPAiGczSQEMbrr/SLblD&#x2B;fJs50dV3rv2GKO1bEBNMvaSi6xl4m4RzW7cSZ7ijHQVkHvic&#x2B;qSjryq69fvz79HiDKEsCCso0IeX8hG3PgybHxct0HTB7Adu/&#x2B;J19w94e//7flD9//579mfNm/&#x2B;6/vlj98/adfZ3zZp&#x2B;R6JNvL8lO3flT4bg&#x2B;3PqrmD6qFjcTwi2&#x2B;gjlfWC&#x2B;IeEer/NrbOhmkxJs967CoU997shp1zb4nj5taRb4fHHDv5v5dGOrZgu8iGGWvJS9NGTwQwLsmeo5JvDi4RwLLY9m0zl22atnNZHsm2&#x2B;yO3fPGtaXv7UazftM3Qsd05kDVNG1CTtZVc0mPfZm0lJZRu2pLD9XnTdnWgTdMWT&#x2B;IjkqYtL7tH0hO7i3BJ9k35q20m&#x2B;fEdfjTh7iLryaGwGid67h3Rh1zbRb68CrZLR1XTyMJG20UCsOXBAVxiM8mp4h5PsYa1O70nPh0b/dK00R8BjEt6DGDBw9suWu7&#x2B;38q2IANw6mbHtuvkR&#x2B;7x3tfCRgDaZ20ll9R/UHc4yImXZOzbZsh6PKXl5zJ4wNuuRjq2UH27yJgDoQK7R9Ixu4twycybSYYJ&#x2B;ranHnbVBbtHvsmyXeRi6Xd3t4UMv9wucvvnl9I/sTo2kvk1N/AUDw7gqh43k4w80UfDZz3OlYh7WUbZ1jGk/kPawkz/NCQ&#x2B;0hhiyctMGx0z3MYlM28mGSZb8HhUe0DGji0cj6ltfwJf3/n6q9dXuqjZetwuMvKkALTJcBtX2ctknrhHZSUWC5YYSlvauNnG3XRs0A5NG30TwLhKABs1gG0fjqVvYy1vx7a2/sGL3yKywk9mIx1bELoASGVtJZfYTDKMG/d4REePP9/OzM2go8RnVSUzsHskg7C7CFfV30zy5Nh4NpM8d5IBZq7c7B5Z4pFsYW/P0revvJ4daLvIq2fRsTXCMiagER4cwFU2k2QeheLe4k7EPtk98urk2frwt2NPXnngfwsSH1lYyZSXpo2hCGBcNXMAC4Ped35ccDdh5TZz01ZulC18atpeX&#x2B;&#x2B;xZrNdJAtNG9AOayu56pE7DWsrqa9c07YNMpeej56raTs6dneObfimTcdGRpq2vDRtjEYA4yoBLMvrtEbftjZn01aiY9uOrK3/68dvm6RjC0LXQDRtQGusreQqayuzvA4tKxT3PoadB5u2k70ix27aOkp8VlV2QdOWl&#x2B;e0MRpPbuOqErv5h083Afcf3mY3/3PbQaI36239pmrdZlB0ji1NFx1bsLARgOZ5chtX7Sav5MhW80HdH08U4/e//uN4WY/Kns3L21It8pFsg/3kd9SxHZ1I4mN4ZtoYluE2EljwmOV1mnLet70KubHLtqlm2ko8km2pY3f3TtmOrPW4V2SwXSQHLFoCmmW4javsZZLldWhQibh3MrgWn6CzzLRF9mrbVx7mZ37mxCfulWbdUl6aNgYngHFVpwEs8kQfDXMzujXzfpKTNG2FOrblD&#x2B;tSdl2wHU1Pvr7tztk/srCR0jRtQMusrSTBIzck&#x2B;jaKqtm0XdoY/6RpC3Fl29WaLYzVtLXTsQXbRQ5K05aXpo3xCWAkyD6jZsFjO04qt1HLtuGbtkLbRZ48lW399bD3Q9VFxxZsF8knmjagfdZWclX2yNbX2sowetybULmm7ahm2/7VrptNm5rt/otYVck5TVtemjZmIYCRwGaSWV6nWSfFyWAGbtrKPZJtd6/I7be9fmCuxs5kA3RsMcda2NgITRvQBWsrSWAvk/svQiOyx70sA23hXtOWvGnkouufcInv40nJRdOWl6aNiQhgJJg8gIXO71AjVetInjJq01Zuu8ijp7Jtv7/yD4yFjVSmaQM6Ym0lCexlkuV1eFa5pi38Mu9cfcZ5ctN2qWbbfZ1Of7bb6djCE7/1kvjq07TlpWljOgIYCQSwLK/TLE1bmgebthId2&#x2B;KtaVv/4e17FtV&#x2B;YNoJXRY2TkXTBvTF2koS2Exy&#x2B;Lg3vKLPaVu89sy/FH/eIkxk2aZmu8OqSi7RtOX1zdNvAGr7&#x2B;acfl88RnybEW676bzcEy389vyHYPXD5ysc7ie/&#x2B;/P3Nm6SYdxhjueHr9G71qqvhgcqKPpJt93/6V9l2dQlnLpN0bEfHCl0AxFvC3SvuyXrEOIlsISLuJR&#x2B;4e9JLxD3qu7qB5Llvv3xZV2X3O7ZOTZL4rKpkeGbamJfhNhLYTHLUADb2WNsYM233O7bd/5Xfvrj9nqP9JEP5H5V2ElewsHFWfk8NdMpwG2nsZZLldais9Exb8qOpP860pTnv2Pr6MW4n8VlVOSdTKHlp2piaAEYaASzL61BN701b3o5tcdScRTZtFerYSUKXhY2N07QBXbO2kgQ2kxT3ulMo7i3WQ2y7W0qe2Caam2Xbxzm2jn5624l7warKiWna8rJ7JFOzuwhpsm8SYjNJOHLzkWzbOi3e0Vai84yyWdgIQNc8OIAE2SObzSTpVORqxTpG2isyTJP4rKpkNmbaIATDbaSymaQA1oVOZ9qyj7KtZ9Tevv42uJawYDOLdhJXsLCREIJ1SMAoDLeRxl4mWV6H0grFvaPN8&#x2B;Mf1babbhLG2iJrti5&#x2B;YttJfFZVEixFys1MG4RguI1UyQsebz52e/fYSyx4pGX3O7atoxzYzmP5JgldFjYCUJ/hNtLYyyTIerN6anbtTfwoW/s/qO3EvWBVJZShaYO/EsBI02kAizxRjN//&#x2B;o/t39fShVxzbCf92YN7nhxpJ3RZ2AjAqKytJI3NJPVtk8uYni5Ns13aLrL9n89JEp9VlUxO0wa/IICR5uaMmgAG4fYj2e5bZ8hXV1e0lmsncQULGwGYgLWVpNlNXjfXViYfe4m4xx3b9YvxW0cmu/pItsZ/LNtJfJGfAxIfJNO0wQ4BjDQ2kxTASPN4x7ZVYe4tS&#x2B;h6tmOLOdbCRgCaYm0lyexlYi&#x2B;TSWwfWb18pUJEGmmUrZ2OLTyxqjLyWBiJpg32CWAkeyqA7R57iQBGfdkfyfZxcWVCPsy&#x2B;YLOd0GW7SADmZG0laWwmaW0lhYzUsQWJT&#x2B;JjSr/6&#x2B;vXr0&#x2B;8BmrZEr4UAxiWPjIBUW&#x2B;4Uo/3b30n84e//bfnD9//5rxlf9u/&#x2B;67vlD1//6dcJh2fv2Bbr57T98z/86bUA8203yLevb3dB2d1J8r52ElewsJEIFhsBw3vFPR93XPXIbZK4x1aJuLfOR9ulipH56C37HD2nzXaRu2wXSQXWG&#x2B;Vlpg0&#x2B;MNxGMptJWvDIrqId29F/PbfNigPPsQULGwHgfxluI5nNJO1lMoPkmi2Gjm2XVZXQKU0bRBHASGYzSX0bazcfyVZo1Ky0dkKXhY0A8MbaSpLZTFLWm8p6/4/7WWyk7SLbiXvBqkp4jqYNYglgJHskgB0de0muABYseCTHKNvumNqlmFfhId5vxghdFjYCMDxrK0m2G/durq1MPvYSfRuR1oHrfqQaqWMLLSU&#x2B;qyrhWZ7TBpd5cht32M2//Rvl8Tz&#x2B;nLYs20WeJLq3Z62FXz6GreiGJyfaSVzBwkZSWVoETMiT20j2yN1UU1kviHtPKPqctnDjUdbb57TZLnKXVZU8xeqivMy0wWWG27ij680kP77JGBY8TqXEI9l2y7NLhycfG6&#x2B;d0GVhIwBcYriNZDaTDPYyGctux5ZspFG2duJesKoSmmGmDdIZbuMOw22h&#x2B;bvnYTw103bzkWxrr2j39myA1&#x2B;BaiJtpq1CzjRG6LGxkYUURMDPDbSQrEdm6i3uyXjWFZtq2IetNwlhbjPZ/ctpJfFZVcpNFRXlp2uAuAYw79G3t30YPoH7Tln2Ubd2oHX1927S9fb10zdZO4goWNpKJpg2YnLWV3PHUvZa4N5tCce/jHFv2pq39n5Z5Ep9VlZPQtOWlaYMMBDDuEMBCD7fUXavZtJXYLjLsNW3bSbWnnscW8iWuYGEjjdG0AQRrK7nH2sog7hVW&#x2B;jlti&#x2B;1OkpFpKzIrNf5DMk/HdnSsxDckTVtemjbIRgDjDgEsNH9v3a86TVuhjm1xNLu2eLZpGyN02S6SXZo2gIW1ldxhM8kg65VUumnbXe8YH7U&#x2B;xqXGfzasqow/L93RtOWlaYOcBDBu0rc1fpPdqQpNW8ZHsm2t49zuHiYnX8/yBo6M0bHdOVbiGp6mDWDN2krusJdJEPfKKNq0vUWqtJ35j3JT&#x2B;z8P8yQ&#x2B;HducNG15adogPwGMOwSw0MMNd19KN227ctVs4dNAW9hr2nrp2IKFjbRN0wbwxtpKbrK2Moh7uRVq2qptxd&#x2B;meTq2o2PFvRlo2vLStEERAhg3CWBBAMunctOW5ZFsYfMkgKPVlLuKxsJ5QpeODU0bwC5rK7nDZpJB1suqUNx7U3lp44Osqow/L73TtOWlaYOCBDDuEMAWMth91Zq2&#x2B;I5ttzxb/1U4feb2yV6RJ6983zwd29GxEtdsNG0AR6yt5CZ7mQRZL5PSTdsjG/U/ReKT&#x2B;KaiactL0wZlCWDcJIAFAey2Ck3b1Tm2XE3bsm/kyXfmYmFj/HkZiaYN4Jy1ldxkL5Mg7t1WtGk72UpksLJNxybuTUjTlpemDWoQwLip3wAWea4YAliyok1b2l6RR49eO&#x2B;/ewi8fybb95hJNW1MdWxC6qEvTBvCRtZXcZC&#x2B;ThbiXrFzT9uCO/TU1lfisqqQmTVtemjaoRADjJgFsIYAlqLNx/yWvpm0b3j6WbSfflp2FjRLX5DRtAJGsreQme5kEWS9Vobh3FMHK7SPyCIlP4puZpi2vb55&#x2B;AzCL5WNr&#x2B;QjzeysSLHc/2xuj5Svn90Ynx368qTo69pKYNxnp97/&#x2B;owBGhVDXXeI6OpeFjQBQwc8//fjKesEvrbjuZmRLy4lHx14V8yZjLHfg4l5rdtdHDqC7xKdjg8aZaYPaDLdx31O/T7fgsVNNzbTtbgV5vifk&#x2B;sCOOrYgdNE/a4MArjLcxk32MlmIe/FKxL23dLbd/L/rgbamEp9VlTzI8qC8NG3wDAGMmwSwhQAWo52m7W0tZPzukdVY2ChxsaZpA0hgbSX32UwyyHrRajZtvW8d2VTHFiQ&#x2B;nqZpy0vTBo8RwLhPAFvIYOeabdq2Hlwm2V3HdnQuCxvJSNMGkMzaSu575GYvy91s5LliyHoflWvaXomstfWRabpLfE8tsGYemra8NG3wJGUbWdhMMghgpxpp2tbrH3ej2nbirc4bs7Ax8kAmpGkDuEPc4z57mSzEvRPZ4952cO2ppJZLdx3b0bl0bOSlactL0wbPE8C4TwBbCGC76jRtbw9g235x/Vfbb35qmWR3ocvCRmrStAHcZ7iN&#x2B;7LvR9Lj2sog7h3QtJ2wqjLyQOakactL0wZNULaRhc0kFwLYmwpN22702t0rcvevXgNt6z8Ueqsv3XVsR&#x2B;fSsVGOpg0gC3GPLGwmGWS9PeWatsXb7iMT1mz9dmyRx5749suXEMJffvjhzovQLE1bXpo2aIgARhY2k1zIYC&#x2B;lm7aPT19bOynhQm9zbKHn0KVjI4amDSAjw23cZy&#x2B;Thay3Vu45bYt109ZLzdZdx3Z0rgrHHlk6toWmbVSatrw0bdAWZRtZdB3AIs8VQwBbFG3a3kLX7mja0V6R9VdH6tjij4WgaQPITdwjC5tJLsS9RZ2mbbaOLfSc&#x2B;O7/K1vXbAtl25A0bXlp2qBFAhhZ2ExyIYBVaNq2uSuyaXt9c0c128wLG5mNpg2gBMNtZGEvkyDrhRCKxb1p59hCJ4mv3KrKbc22ULaNR9OWl6YNGqVsIxcBbDFzBmutaauf2XoMXQ0ubGRCmjaAQsQ9suh6LxNZL5cKj&#x2B;Vun1WV8cd&#x2B;dNS0BWXbcDRteWnaoGkCGFl0HcAizxVj2gBWv2nb3VJyq6M5ttBzxxZ5LGxp2gCKMtxGFjaTXIh7czZtEl/kgfFOmragbBuLpi0vTRu0TtlGLjaTXEwYwMpFr6PptI9NW51pNgsb44&#x2B;FN375C1CHuEcWDy7VEvceN23T1mPHdnSuplZVnjdtLyq33kl82WnaoA8CGLnYTHIxVQAr3bQd1Wzhob0iQ5&#x2B;hq/GFjUxF6AKozAcvWdjLZDFV1guzNm3DrKqMPLxy4osp2zRt/fJL5kI0bdANn4PkIoC9TJLBajZtD24UueixYzs6V1MLG5mEmw2Ap/gEJhebSS4myXphvqatx8TX4wMCPpZtmrZOud8oR9MGnfGBSC4C2GKGAFa/aVuPsi08ku3SuWwXySNMVAA8zkcxWdhM8kXcG8lsie/ZVZWatvH4lXJpmjboj09GMrKZ5GLsAFbzOW27TZua7dKJ2g9djMetBUA7fCaTi71MXsS9AdguMv68uZyXbZq2vri7qEDTBr3yEUkuAtjLqAGsWtPmkWxh9IWNDMn8BECDfDiTi71MFqNmvTBB09Zj4ut9VaXntI3EL5Cr0bRBx3xWklGJENVj3zZkAKvQtK15JFvauXpZ2MhI3EgAtMynNLnYTPJF3OvLSImvl44txNVsQdPWCfcSNWnaoHs&#x2B;NMlFAHsZLIAVjV7bsq1O09bU5iFhjoWNDMb9A0AXDLeRi71MXsS99o3UsUUe3sKqysiObaFpa59biMo0bTACvywjI33byzABrGbT5pFsl86lY&#x2B;MRbhsA&#x2B;uJzm4xsJrkYJuuFEZu2HhPfAKsq42s2HVv73Dk8QtMG4/AxSkY2k3wZIIMNE716TFwn5&#x2B;plYSODcbcA0Ckr08nF2sqXAbJeGCjuhbESX4Vjc9GxDcYNw1M0bTAUvz4jIwHspfcANkb0sl1k/LGwy00CQO98kpORzSRfxL0WjNSxRR7eV8cW1Gw9cJ/wLE0bDMgHKxnp2176DWC9R6&#x2B;RQldHCxsZjHsDgGFYq05GXW8mGX&#x2B;6GOLeg6yqjD82I6Nsg3F78DhNG4zJL9TIy2aSLz0GsH6j10gdW&#x2B;ThOjayc0sAMB6f7WRkbeVLj1kv9Bz3wliJr6NVlUbZBuOuoBGaNhiZj1oyEsDW&#x2B;spgPUav1hJXmGZhI4NxJwAwMKvXychmki99Zb3QZ9wL7SW&#x2B;B1cSN1uz6di64GagHZo2GJxfsZGXvu2lowDWXfQaKXR1tLCRwbgBAJiBT3vyspnki7hXTmtxL0yzqlLHNhj3AK3RtMEUfPiSl80kX7oIYB1Fr9ZC1zwLGxmM6z7AVKxnJyNrK1&#x2B;6yHqhq7gXxkp8Ha2qtF3keFz6G6Rpg1n4pRt59R7A4k8Xo/EM1kX0ai1xhWkWNjIYl3uAOfn8J6/e4948WS90EvdCe4lvnlWVRtkG44rfLE0bzMXHMXkJYC8tB7D2o9dIoaujhY2Mx1UeYGauAmRnM8kXce&#x2B;O1uJemGZVpVG28Rhla5mmDaYjgJGdzSRf2gxgLUev1kLXPAsbGY/QBUAQ98jN2so1cS/BSImvu1WVkU2bjq0Lru/t07TBpHxAk1fvASz&#x2B;dDFaC2BtRq/WEleYZmEj43FNB2DNdYHseo97A2e90GrcC&#x2B;0lvglXVX5s2nRsvbCqsguaNpiXAEZ2AthaOxmsteiVMXGFBkJXdwsbGYzQBcAucY/sbCb50k7WC&#x2B;3FvdBexxae&#x2B;6XEs4nvvGlTs3XB1bwjmjaYnY9ssrOZ5EsjAayp6NVa6JpwYSPDcAUH4JwrBdn1vrYy/nQxxL0tqyqvHlvUUdN2tWNbv45&#x2B;riarKvuiaQMEMPITwNYeD2CNRK/WOrYw68JGxiB0ARBJ3CO7p9ZWnhx&#x2B;yWB7mTQS90J7ic&#x2B;qyt2mLb4qy1XUkcC1u0eaNuB/&#x2B;BAnu977tmEC2OPRy8LGq8fCCddrAK5y7SC7B5ejWVv55vG4F9rr2IJVlSGETVV2Z5TtjbKtKKsqO6VpA/5KAKMEm0m&#x2B;PBXAno1erYUuCxvpmtAFQDJxj&#x2B;x6X1sZf7oY4t59El9er6osrRjzmLf6XKm7pmkD3vlYJzsBbK1&#x2B;AHsqerXWsQULG&#x2B;mZqzMA97maUILNJNfmiXuhvcSnY3uzVGXJlZimrTKrKnunaQN2CGCUoG9bqxnA6kev1hJXELronNAFQEbiHtnZTHKtctn2SNPWaeKzqvISTVs1rstj0LQBh3zQU4LNJNfqZLDK0au10KVjo2uuxQCU4PpCCdZWrlXr2/qNe0Hia5umrQ5X5GFo2oAzPu4pQQBbqxDAqkWv1jq2YGEjnTPKBkBR4h4l2ExybaS4F9pLfDq2ojRtpbkKD0bTBnzmo58S9G1rRQNYhejVWuIKQhedc&#x2B;UFoA5XHEoolNfsZbKrTtM2WOIbYFXlzWewxZ/iiKbtJtff8WjagCguAJTwYAA7OfySLgJY0ehl85CEU8M5o2wAVCbuUYK1lWvlyrbSTdtgHVvk4e0nvm0Nlr36epV5u5Wbpi2Za&#x2B;6oNG3ABS4GlCCArZUIYOWiV6ehy3aRNMt1FoCnuAZRSO&#x2B;bScafLsa0cS9Mv6ryray6X1NVbr8qFHuTcLUdmKYNuMYlgUL0bWt5A1iJ6NVpx3ZyujEWNtI1o2wAPE7cowSbSb5pP&#x2B;6F4RLfg6sqj/ZgvNNUlXjNq2fUtF3lCjs8TRuQwuWBEmwm&#x2B;SZXAMsbvSxsTDg1nHNVBaAdrkoUYm3lWsayLXvTNljHFnl4nVG2teSmqsRrJpxU03aJa&#x2B;sMNG1AIhcJChHA3tzPYBmj12Chy3aRtMAoGwANEvcoxGaSa1n6tjbjXuhnVeXR4ff/hz6pxEJSU3W0Y&#x2B;Tr67uvmaUk07Qlcz2dh6YNuMUFg0IEsLWbASxL9BqsY4s83CgbRbmGAtAy1ykKsZfJmxbiXhgu8dX5cTpx9GC281Ys8tXeXvboNc&#x2B;rvkvvQdOWxpV0Kpo24C6XDQoZIIDFny5GcgC7Gb0sbEw4Fj5y9QSgCy5YFGIvkzdPxb0wXMcWeXjRVZVHNVtIatp2W67lizebtvi3oWm7ytVzQpo2IA&#x2B;XEAoRwN4kBLDk6NVgxxY6X9gIwRUTgN64clGOvUzW0sq2O01bg4lvjFWVJ3XapabtaLvI11&#x2B;tt47cvmZM0xbzZtRsV7luzknTBmTjQkI5AtibSxksLXpZ2JhwavjItRKATrmEUcgAe5k8u7by8bgX2kh87ayqPKm&#x2B;wpWm7bzf&#x2B;vbLl7eBtu1rxjdtJ&#x2B;/npO1jy7VyZpo2IDMXFQoZIIDFny5GfAC7Gr0aDF1jLGxkcq6PAPTOtYxy7GXyplzcC1ZVJp06XsxA2&#x2B;7fHn3n7vdvZ9rOTxcpsqvTtO1ylZycpg3Iz6WFcgSwNzEBLD56NdixhVEWNjI5V0YAhuGiRjn2MnmTN&#x2B;6FJhPfeKsqY56admmg7fx11g9sO3mReK&#x2B;XUrNd8ro4ujJOS9MGlCKAUY4A9uY8gEVGLwsbE04NH7kaAjAeVzfKsZfJm49lW/24F9pIfM2uqjyqvhKato9jalcH47LQtL1xTWShaQMKcrGhHAHszUkA&#x2B;xi9Ggxd4y1sZE6ugwAMzGWOcuxl8uZO3AtWVSadOtnHmba0pur8eWm7zVyJpk3N9sYoGy&#x2B;aNqA4AYxyBLA3uwHsJHo12LGFQRc2MhvXPgBm4HpHOdZWbl2Ne6HJxNf1qspvv3xZqqaYPRuPnqyWcNLtF3f3eCzdtKnZ1lwBeaNpA2pw&#x2B;aEom0m&#x2B;eQtgR9HLwsaEU0MMVz0ApuLCRzn6tjfbsq1C3AttJL7HV1WeN15H33azndqedP2C5&#x2B;faPfZO/aZpezHKxpamDajHdYhyBLCtVwbbRq85O7ajw3VsZORXjQDMyRWQouxl8mbdt&#x2B;02bRJfwrEf3WnaEuq3&#x2B;FG2o5c9aekS&#x2B;jY128L1jiOaNqAqFySKGiCAxZ8xxhLA1tHLwsa0wyGGaxwAk3MppBxrK7e2cS80Ocr27P9GlWu27XcejZGdF1eXRtki38nHFzmhZlsYIeCEpg14gCsTRdlM8k2Jf3EtdGw3D9exkZFfLALAwjWRovRtW4V&#x2B;wdJR4munYzs/5M4rXBplO3kbaQ9yU7MFVzciaNqAZ7hEUZQAtpY3enWUuO4fDjFc0QDgjYsjRQ2wl0nGPJK9aRsg8WX8f2/k9FjksfGv8zo2rWM7OiRy9C3y9edhYIAYmjbgSa5VFPXssrh2MljGf2gdhS4dG3W4kAHALmUbRVlb&#x2B;TJn3Lt/&#x2B;EdH/VNk&#x2B;XTUcm0rtKPDE7aLjHwPMd&#x2B;sY1u4lhFP0wY8zEWL0mwmmSV6DRC6dGzk5foFAB&#x2B;5XFKUvi3ka9o6SnxPbRe5fD2hadvdszG5sbtzrP7sEqsquUTTBjTB1YuiJg9gN/99dZS47h8OkVy2ACCSso3SBthMMv6MW/fvSwdIfHW2i4xvyD7WbAmvsz3qbe7t6uGccOUigaYNaIXLGKVNu5nknejVUejSsVGHqxUAJHABpaiZ11ZOEvfuHx4jVzV1UqfF7x65/eL2mW0VmrYJd5W0qpI0mjagLa5nFDVnAEv7ZzVA6NKxkZ2LFAAkU7ZRmrh36cCOEl&#x2B;dVZW5KqXzGiytJDt6ZlvRpu3oSXVXX6cjrlPcoWkDmuPCRmmzBbCr0aujxHX/cIjk2gQAWbikiwuMaAAAH&#x2B;1JREFUUtoAD&#x2B;qOP2NIatoGSHwl4l7Mlo/bvzp5nZOBto&#x2B;vs/udV5uz5KbtpGO79Dp9saqSmzRtQKNc4Shtns0kL/1r6ih06dioxiUJADJStlHaVGsrR4179w&#x2B;/KktDFvk6kS9yNMoW&#x2B;WYSmraPHVv8S3XEVYksNG1Au1zqKG2MAPbxjJHRa4DQpWMjO1ciACjERZbSxoh7H08X37R1lPgeWVUZ2bTtfsP2m2/WdSdnv/pOIr8/vmOLOXVHXIzIRdMGtM4kAaUNH8A&#x2B;/iPqKHHdPxziuQABQFF&#x2B;v0kFD24mefIKV92Je3XeRszpGk98J0NjN5u25CfA3dzFMb5pu1qzfTx1F1yDyEvTBnTAxY8KBt5M8jx6dRS6dGxU47oDANW47FLa2Gsrh4l79w&#x2B;/6aht2j4mLbLfSmjpzt9P8js5OXtCxxZz6va59JCdpg3ohtkCShsjgG3PePRvR&#x2B;iCXS43AFCZ33hSwRhxb3u6k3vXARJf5bh3/iy05H5r&#x2B;1IJ72R3SO7SO8lYs308dctccShE0wb0xOWQCsYLYNvoNUDiij8c4rnKAMCDXIipYLzNJHebNokvTdGmLfnZbCcNWfw7yVuzfTx1s1xoKEfTBvTHtAEVPLscL28uevsnM0Do0rFRgosLADzO70CpYIy1laGNuHd0xu46trDppbZt1p2m7W0nyY811cl3nvdn2&#x2B;&#x2B;82bHt7oH58dQNcn2hNE0b0CUXSCoYJoD9y1/&#x2B;e/nDv3/7t1lecLaFjQzPNQUAmuLSTAVjxL3v/vz9ummzqvKOo&#x2B;erXS3JwkEZlvzAto&#x2B;vnPwK53b3q7x59qe4rFCBpg3omPkDKhgggGVs2nRsjMelBAAa5Lei1DHAZpJ5F1bOnPjOh9guNW3nr5/8Otlf4UjMGFwvTZurCdVo2oC&#x2B;uWRSR4ndIKsFsFzRa86FjQzMFQQAGudiTQW9r62sHPfC0/VkOSdN21p8w3S0HeXV1zl6J7leJOYFO23aXESoSdMGjMBEAhX0G8DuR6&#x2B;ZFzYyKhcOAOiC35NSx8xxL1hVGUKIa9rSarbd10x&#x2B;qbT3c/46H1&#x2B;tu6bNtYP6NG3AIFxEqaPHAHYnelnYyHhcLwCgOy7fVPD4wsH6cS88nWSbSnxXm7blb3cLp/NhuJMDI18nb1338XXUbBBD0wYMxYwCdfS1mWRy9LKwkfEIXQDQKRdx6uhubWXpuBemWVUZP/L1ti1k5OtcbdqSe76Ylzp62chjm23aXCl4kKYNGI3LKnU8vqYvPoMlRC8LGxmPqwMADMAFnTo66tvSmjaJbytyk8aPj1s7ejzb8p2R42gxNdvHFzl5tcjD1WwQT9MGjMlwG3V0EcAuRS8LGxmS0AUAw3BZp47HS6YScS/&#x2B;DTz&#x2B;f/4jIvuto294&#x2B;7bdai2haft4inN5a7bIk1bmukALNG3AsFxoqabxzSTjo5fQxXhcCwBgSC7x1NH&#x2B;2srsce/kvDGv0G/cu1qzHRVOJ9XaeX928iJH7/POw94Sjoo8Y2UuBzRC0wYMznAbdTxePp1ksJjopWNjSEIXAAzMhZ5qWu7bIps2ie&#x2B;jowbralP19gS1vBswfty78vz77xwVeWxlfulHOzRtwPgEMKppM4CdR686CxuPDu8icdEjn/wAMAkXfep4vIJKi3vxp3j8/8DHbcfI7tRUafNwke8w/kWunvqkY4s8YzU&#x2B;/GmNpg2YhXUu1FEoQd05/CR6CV0MSegCgKm49FNNg2sr78e9Qm&#x2B;su7gXM4sWrgyEve0eGf8KJ6956UVmqNl85tMOTRswEQGMah6vptavsBu9dGwMyec8AEzLbQDVNNW3HTVtEl&#x2B;y88Ip5Oirvv3y5e0Pl14wsvRKeLbciUaaNh/1NEvTBkzHyheqaSSAvUUvCxsZldAFAJNzM0A1jxdUR3Gv2nsYsmMLx&#x2B;3U0VPcYl5hfeClHSlvPuMtsmnrsWbzCU&#x2B;DNG3AjAQwqim3HX98/llHL6GLIflUBwBe/CqWah7PTWlx7/6ph1xV&#x2B;bHW2j7ILf6lEp79dn/byY/PdYvp2BLOW4LER/s0bcC8BDCqeTaAXfpRfzwrwlVCFwDwxu0BNXUU9&#x2B;6fbuDEF99LXZ1p263rIs8Vc8aEdxLZsSWfOi&#x2B;/vqMLmjZgagIYNT0VaeLvSi1spC8&#x2B;wwGAE345SzUP1lfPxr34w9t3vj9k2kDb2zenPThtvX3lna0jEzxes0l8dETTBiCAUc8jm0nG/IQLXXRH6AIAPnLDQE2PpKrIX2hIfB9lb9rOR9liBuO2I2jVmrbHO7bgl3X0RtMGEIIARl2VQ8757anERY&#x2B;ELgAgnjsHamoq7tV/P/06abPOS7jdb/64T&#x2B;OlKqty0/Z4zeZ3dPRI0wbwVwIYNVULPCc/2EIX3RG6AIAEbiGoqWbOEvdyOWqzLtVsR6&#x2B;51WzT1k7N5rOavmjaAH5BAKOmOptJ7t6nCl30SOgCAO5wL0FNdTLX0U&#x2B;1xHdVzK6P27&#x2B;KedDa&#x2B;vCEzuzovcUfFamdji34lKZDmjaAHQIYNZWOQG8/zxIXPRK6AIAs3FRQ2W6Ayri2cvvrC4kvzbbN&#x2B;lizhYN26upT2RLe26WjYrRTs/lkplOaNoB9AhiVlYtD6xtWoYseCV0AQF7uLqipaArLGPeOzjVJ3DvvpWLqt6OXul9iFW3a2unYgs9keqZpAzgjgFFToVz0L3/57&#x2B;UP//7t3ya/uI6NRwhdAEAhbjOorFDfdh737r/&#x2B;PIkv5plqMcNqJ891O99wMua9ZXxQXNo7yc6v3RiGpg3gAwGMyrIHsKPoZWEjjRO6AIDS3G9QWfbNJE&#x2B;aNh3bJUel1FJHHT137eR1LvVzke/tTkt35w2U4LdtDEbTBhBFAKOyjH3bbvQSumiZ0AUAVOPGg8ryrq28E/eO3sy0ce9o18dLVdlbK3Ze4MW/sRa6sYx88DIeTRtALPcBVJZrM8m36KVjo3FWNgAA9bkDobJcfdu2aZP4MkoYCFs3bTE7Us7G79YYlaYN4BoBjMruB7BX9Ir/obWwkUcIXQDAg9yKUFmWtZXrpk3HllHypouvh7HtTsLd2QdyAD5mGZimDeAydwbUdycLXaqHhS6eYh0DANAC9yRUdjOCXf2Jlfhi3Hmy2rLT49ErTNu0&#x2B;U0aw9O0ASQSwKgsORFF/qxKXDxF6AIAmuLmhPpKx707p5hK8ihb/Iu8ht6uv7te&#x2B;VBlBpo2gHTuFagvIR3FRC&#x2B;hi6dYtQAAtMldCpWlhTJxL6M7o2znrxNmnWnzezPmoWkDuEsAo75Lz1E7/xEVuniK0AUANM7tCvVdDWgffyMh8UU6qdku1WPr19k&#x2B;mG2qps1HKFPRtAFk4O6B&#x2B;uLz0lH0krh4kDUKAEAv3LdQ3/24d&#x2B;lFCJuGbPvFt7/6&#x2B;Dq71dokTZvfkjGhb55&#x2B;AwAjWO4bljuJ3/z2d24jqGBJR9vstHzlY3YSuniK0AUA9OXnn358Zb3gBoYqvvvz97uR7T/&#x2B;8Q8xkU3cu&#x2B;OtEstIzQYDM9MGkJP7Cer7GKLeFjkKXTzIhyQA0C/DbdR3Ne7FHMKub798ORllWzvvyZZjz19q1KZN3GNmmjaA/AQw6jtJU68fyH//9m&#x2B;PvqfU24L/JXQBAANwS8MjYuLezz/9qGPLYnfHyN29JU8Ov7P/ZKd8PDI5TRtAEe4weMRusvqXv/z38ofdpk3oogIfiQDASKytpL6jFk3cy&#x2B;ukGIvc&#x2B;/HowWwxx3ZK3IPgOW0AhXhyG4842s3/6JuLvhkIQhcAMCJPbqO&#x2B;owd1fzyEp5R40luDJD5YaNoAChLAqC8mgElc1CF0AQCjsraSR0T2bRJfmrctIrNXZYMNtIl7sPY3T78BgMH9/NOPrxuO9V0IFPXdn78/CldCFxX85re/W&#x2B;&#x2B;qJHcBAENaZz1xj2rOM53Ed9&#x2B;2EovcOvLkBdVsMDYzbQA1GG7jEW&#x2B;bSUpc1CF0AQDzMNzGI3aH2yS&#x2B;O252aUd2n9aW/SyVeVYlbP3q69evT78HgIm4HaE&#x2B;P3VUo2MDAKblRohHiHu5bJu25Stv20hebciOtqDstGnzQQdH7B4JUJXdRYBRCV0AwMw8OACGVKJm65QHBMAJTRtAbQIYMBhPZQMAWFhbCSxG2jHyLfE9&#x2B;2agTZo2gGcIYMAYjLIBAKxZWwlDutSTvdVsf/nhh5PDGx99s6oSYnzz9BsAmJdHZwNd07EBABz5&#x2B;acfX1kvuFmCfrwez7b&#x2B;4utpbevHtkV2b&#x2B;tve3vqWy8dW/AhBp&#x2B;YaQN4mOE2oEdCFwDAOcNtMIZ1VRbTk5082q3Hms0oG8TQtAE8b33LIoABjfNUNgCAeNZWQtdOBtc&#x2B;zrR1umOkp7JBgl99/fr16fcAwP8wI0IJbpHJyMcUAEAat&#x2B;WU4Ocqo6NZtN1W7KhFO9lb8qhdu/QEuNL8REEaz2kDaMhrK//gyW1AY3RsAAB3eHIbNG79MLbXF7f1WFoxdqmue4TEB3do2gDastzNCGBAU4QuAID73uKe2ypoTfIo2/m3dVSz&#x2B;VyCNJo2gBYZbgPaIXQBAGRkuA3al/E5armm4gqxqhKy&#x2B;Jun3wAA&#x2B;37&#x2B;6UePzgae5VHYAAAlvMW9Z98MsPbtly/3u7HXK/RSs60/lIAEZtoAmma4DXiKjg0AoCjDbdCa82LsUknWS8cWfPhADmbaAFpnuA2ozCgbAEAdhtugHRlrti01G4zNTBtAHwy3AXXo2AAAKjPcBo97q9neirHX3yYUZjo2mIGmDaAbyz2QAAYUInQBADzlLe65GYMHrbux7aBb8ks9TuKDcuweCdCZ9c2Q3UWAXDwKGwDgcR4cAI87r9nii7e//PBDOzXb2wMCJD7ITtMG0B9PbgMy8lQ2AIB2eHIbDKCdji0YZYMqNG0AvTLcBtxnYSMAQIOsrYSnfPvlyzK4th5fi2/OjLLBnDRtAB0z3AYkM8oGANAyw23QiHaas0uMskFNmjaA7hluA66ysBEAoAvWVkIdndZpu4yyQX2aNoARGG4DIhllAwDoi&#x2B;E2IJ5RNniEpg1gHIbbgHMWNgIAdMraSijq7als6/&#x2B;6/tuWR9&#x2B;MssGDNG0AQzHcBuwyygYA0DvDbVDBW5e2bd3aZJQNnqVpAxiQ4TZgTegCABiGtZXAmlE2aME3T78BAIpYbq2Wm63lP91swYR0bAAA43mLe27zoI4Gt46U&#x2B;KARZtoARma4DWYmdAEADMxwG9TUWs1mlA2aYqYNYHCG22BCOjYAgBkYboMS3h7M1lrHFiQ&#x2B;aI&#x2B;ZNoApGG6DeQhdAABTMdwGGa1rtjY7NqNs0CAzbQCzMNwGw9OxAQDMyXAbzEDig2aZaQOYi&#x2B;E2GJXQBQAwOcNtkFFrA21G2aBlv/r69evT7wGAB/il/DzWt&#x2B;PPvhMK8c8ZAIAXN4dTEfcyanbfSP&#x2B;ooX2aNoB5uVebhOg1Nv&#x2B;QAQDYcpc4CXFveP4nhi54ThvAvDy5DbrmtycAABz5&#x2B;acfX7eLntwGPZL4oCOe0wYwO09ugx4JXQAAnFs/zMmT26AvnsoGfTHTBoDhNuiJjg0AgHiG26AvEh/0yEwbAP/DcBu0T&#x2B;gCAOAqw23QC6Ns0CkzbQD8leE2aJaODQCAOwy3QcskPuiamTYA3hlug9YIXQAA3Ge4DdpklA16Z6YNgB2G26AROjYAAPIy3AbtkPhgDGbaADhkuA2eJXQBAFCC4TZogVE2GIamDYAzAhg8RegCAKAoayvhKetfsIh7MABNGwCfCWBQk9AFAEAd1lZCfVZVwng0bQBEEcCgDqELAIDKrK2EOqyqhFFp2gC4QACDcoQuAACeYm0llOY53DCwb55&#x2B;AwB0ZrkdXG4Ql/90gwj36dgAAHjczz/9&#x2B;Lov/c1vf&#x2B;fWFLLQscHwzLQBkMJwG&#x2B;RilA0AgHYYboO81GwwAzNtACQy3Ab36dgAAGiQ4Ta4T8cG8zDTBsAthtsgjVE2AABaZrgN7lCzwVTMtAFwl&#x2B;E2uErHBgBAFwy3wVU6NpiQmTYA8jDcBjGMsgEA0BfDbRBPzQZzMtMGQDaG2&#x2B;Ccjg0AgE4ZboNzOjaYmZk2ADIz3AZbRtkAAOid4TY4omaDyWnaAMhPAIM1oQsAgGFYWwlrb6sqJT6Yk6YNgFIEMBC6AAAYj7WVsLCqElho2gAoSABjZkIXAAADs7aSmVlVCaxp2gAoTgBjNkIXAAAzsLaSOVlVCbzRtAFQgwDGPIQuAACmYm0l87CqEtilaQOgHgGMsQldAADMydpKZmBVJXBE0wZAVQIYoxK6AACYnLWVjMqqSuCcpg2ABwhgjEToAgCAhbWVjMeqSuAjTRsAzxDAGIPQBQAAb6ytZAxWVQKRNG0APEkAo19CFwAAHLG2kt5ZVQnE07QB8DABjB4JXQAA8JG1lXTKqkrgkm&#x2B;efgMAEEIIP//04&#x2B;tG9je//Z0bWZqlYwMAgHjLPfNyF738p7toWibxAQnMtAHQCsNttE/oAgCABIbb6IJRNiCNmTYA2mK4jTbp2AAA4A7DbbRM4gPuMNMGQHMMt9EaoQsAALIw3EaDjLIBN5lpA6BRhttogY4NAADyMtxGOyQ&#x2B;IAszbQC0y3AbzxK6AACgEMNtPM4oG5CLmTYAWme4jfp0bAAAUJrhNp4i8QF5mWkDoAOG26hJ6AIAgGoMt1GZUTYgOzNtAHTDcBul6dgAAKA&#x2B;w23UIfEBhZhpA6AnhtsoR&#x2B;gCAIAHGW6jKIkPKMdMGwD9MdxGduv9Q559JwAAMC3DbZSgYwNKM9MGQJcMt5HL&#x2B;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&#x2B;GE0IXAABwibWVHbGqEuiRpg0A/spqx8YJXQAAQALDbV2wqhLolKYNAH7BcFubjLIBAAA3GW5r1lvie/bNAFylaQOAHVY7NsUoGwAAkIXhtgZZVQn0TtMGAPsMt7XAKBsAAJCd4bZGGGUDxqBpA4AzVjs&#x2B;yCgbAABQiOG2x1lVCQxD0wYAHxhuq88oGwAAUIHhtkcYZQMGo2kDgChWO1ZjlA0AAKjGcFtlVlUC49G0AUAsw22lGWUDAAAeYbitAqNswKg0bQBwjdWOhRhlAwAAHmS4rSirKoGBadoA4DLDbXkZZQMAABphuC07o2zA8DRtAJDIascsjLIBAABNMdyWkcQHzEDTBgDpDLfdZJQNAABok&#x2B;G2m2xeAsxD0wYAd1ntmMD&#x2B;IQAAQOMMtyUzygZMRdMGABkYbrvEwkYAAKAXhtsuMcoGTEjTBgDZWO34kVE2AACgO4bbIhllA&#x2B;akaQOAnAy3nbCwEQAA6JfhthNG2YCZadoAID&#x2B;rHd8YZQMAAAZguG2XUTZgcpo2ACjCcNuLhY0AAMBIDLe9GGUDCJo2AChq8tWORtkAAIAhGW4LRtkA/pemDQDKmna4TegCAADGNu1wm1E2gLVvnn4DADCFn3/6cckhy3&#x2B;OnUN0bAAAwCSWyDNP3AsSH8CGmTYAqGSS4TahCwAAmM0kw21G2QB2mWkDgKoGHm7TsQEAANMafrhN4gM4YqYNAGobcrhN6AIAABhyuM0oG8A5M20A8Ixhhtt0bAAAAC&#x2B;DDbdJfAAfmWkDgMcMMNwmdAEAAGwNMNxmlA0gkpk2AHhYp8NtOjYAAIATXQ&#x2B;3SXwA8cy0AcDzuhtuE7oAAABidDfcZpQN4CozbQDQii6G23RsAAAAl3Q03CbxASQw0wYADWl8taPQBQAAkKb9uGeUDSCNmTYAaEubqx11bAAAADe9xb12spXEB3CHmTYAaFFTqx2FLgAAgFzWT&#x2B;l&#x2B;PO6FVeIzygaQxkwbADSqheE2HRsAAEB2jQy3SXwAWZhpA4CmPTjcJnQBAACU8&#x2B;xwm1E2gFzMtAFA6&#x2B;oPt&#x2B;nYAAAAKnhkuE3iA8jLTBsA9KHacJvQBQAAUFPN4TajbADZmWkDgG6UHm7TsQEAADyiwnCbxAdQiJk2AOhMoeE2oQsAAOBZ5YbbjLIBlGOmDQD6k3e4TccGAADQiOzDbRIfQGlm2gCgV1mG24QuAACA1uQabpP4ACow0wYAHbsz3CZxAQAANOvmcJvEB1CNmTYA6F7CcJvQBQAA0L604TaJD6AmM20AMIJLw23rR2FXeXcAAAAkujTcpmMDqM9MGwCM4&#x2B;Nw23oVpNAFAADQi5jhNjUbwCN&#x2B;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&#x2B;3Z8cCAAAAAIP8reewuzQCAOAwbQAAAAAAAHCYNgAAAAAAADhMGwAAAAAAABymDQAAAAAAAA7TBgAAAAAAAIdpAwAAAAAAgMO0AQAAAAAAwGHaAAAAAAAA4DBtAAAAAAAAcJg2AAAAAAAAOEwbAAAAAAAAHKYNAAAAAAAADtMGAAAAAAAAh2kDAAAAAACAw7QBAAAAAADAYdoAAAAAAADgMG0AAAAAAABwmDYAAAAAAAA4TBsAAAAAAAAcpg0AAAAAAAAO0wYAAAAAAACHaQMAAAAAAIAjqqF7zjVkSUEAAAAASUVORK5CYII=" />
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>